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Abstract 
Gliomas are among the most difficult of tumours to treat. Their highly invasive 
nature leads to recurrence even after aggressive therapy including surgery, 
radiotherapy and chemotherapy. A promising target for new therapies are tyrosine 
kinases, because they regulate a large range of proteins involved in growth, 
metabolism and differentiation. The receptor tyrosine kinases, epidermal growth 
factor receptor (EGFR), platelet derived growth factor receptor (PDGFR) and C-Kit, 
as well as the non-receptor tyrosine kinase C-Abl are often amplified, 
overexpressed, and/or mutated in gliomas and play an important role in glioma 
development. A number of tyrosine kinase inhibitors (TKIs) have been developed 
and tested in clinical trials with mixed results. 
In collaboration with Beaumont hospital 31 glioma cell cultures were 
established to identify molecular markers indicative of responsiveness to EGFR and 
PDGFR blockade. Each culture was characterised with regard to their protein 
expression profile, their proliferative and invasive behaviour and their 
responsiveness to three TKIs, erlotinib, gefitinib and imatinib, and two 
chemotherapy drugs, docetaxel and temozolomide.  
All data of 26 high-grade gliomas (20 primary glioblastomas, 2 secondary 
glioblastomas, and 4 grade III astrocytomas including medical history of the patients 
were analysed using hierarchical clustering analysis (HCA) and principal component 
analysis (PCA) employing multivariate statistics.  
Two distinct clusters of samples were found, which separated by the 
expression of PTEN and PDGFR-α in cluster 1 and predominately PDGFR-β, 
EGFR, phosphorylated C-Kit (p-C-Kit) and phosphorylated C-Abl (p-C-Abl) 
expression in cluster 2. Principal components analysis of the culture data captured 
55% of the variance in the dataset showing PTEN, PGDFR-α and PGDFR-β loading 
vectors in approximately the same direction.  
Imatinib responsiveness was strongly correlated with high expression levels 
of PTEN and PDGFR-α. Responsiveness to erlotinib was correlated with the lack of 
expression of all proteins tested, while non-responders showed higher expression of 
PTEN and PDGFR-α. Responders to gefitinib fit into two groups, the majority 
(group 1) were influenced by the expression of the proteins tested, while the second 
smaller group correlated with the lack of protein expression. Non-responders to 
 14 
erlotinib and gefitinib showed higher expression of PTEN and PDGFR-α; in 
contrast, these markers were highly expressed in imatinib responders. While 
influenced by the proteins; erlotinib response may be characterised by lack of 
expression of those markers. 
 In a panel of 2 glioma cell lines and 2 glioma cultures tested, the 
combination effect of imatinib and docetaxel was tested and a strongly synergistic 
inhibition of the drug combination on proliferation and invasion was seen.     
According to their proliferative and invasion characteristics two pools of 
glioblastoma cultures were chosen and analysed for their microRNA expression. 
MiR-93 was upregulated in highly proliferative glioblastoma cultures, 
downregulation of miR-93 reduced proliferation by 13.2%. Validation of miR-93 
expression profile in 12 primary glioma cultures, one established glioblastoma 
culture and normal human astrocytes suggested that miR-93 played a role in the 
regulation of glioma proliferation and invasion. MiR-23b was upregulated in slowly 
proliferating glioblastoma cultures. Increased expression of miR-23b in a glioma 
cell line decreased proliferation by up to 40% and resulted in a 65% knockdown of 
the X-linked inhibitor of apoptosis gene (XIAP), which has been identified as the 
most potent member of the inhibitor of apoptosis (IAP) gene family. XIAP protects 
cancer cells against irradiation and anti-cancer drugs by binding to and inhibiting 
caspase-3, 7 and 9, caspases are enzymes involved in apoptosis, this makes XIAP an 
ideal target in the battle against cancer. 
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1.1 Background 
The majority of brain tumours occur in adults from the age of 35 and older. Each 
year in the United States about 180,000 adults are found to have a brain tumour. In 
Ireland there were 302 malignant and 39 begnin registered cases of brain tumours in 
2007 . 
High-grade gliomas are the most common primary central nervous system 
neoplasms in adults. They are considered to be among the deadliest of human 
cancers (Jemal et al. 2005). Glioblastoma is the most common and aggressive 
primary malignant cancer of the central nervous system. Despite current therapies 
the average survival rate of a patient with a glioblastoma is 14 months (Stupp et al. 
2005). The lethality of a glioblastoma is due to characteristics such as high growth 
rate, extreme invasiveness, and intrinsic resistance to current therapies. Even novel 
treatments have not substantially improved the survival rate of glioblastoma patients 
so far. The use of personalized medicine, by targeting essential molecular 
mechanisms involved in the survival of the tumour, provides new hope. 
Glioblastomas commonly express molecular or genetic abnormalities that influence 
signal pathways which regulate cell proliferation. Overexpression of EGFR and/or 
mutations of tumour suppressor genes such as phosphatase and tensin homolog 
(PTEN) (Frederick et al. 2000) are the most common oncogenic alteration in 
glioblastomas. These gains or losses may promote cancerous behaviour but also may 
be targets for new treatments.                     
The increasing knowledge of cell-growth signalling pathways and the role of 
oncogenes and tumour suppressor genes in tumorigenesis are critical for the 
development of new molecular-based approaches for the treatment of brain tumours. 
These new therapies may lead to improved prognosis for patients with brain 
tumours. 
 MicroRNAs (miRs), although known for several years, are lately gaining 
increasing importance in cancer research. Every type of tumour analysed has shown 
significantly different miR profiles, compared to normal cells from the same tissue. 
MiRs are small non-coding regulatory RNA fragments of 20-22 nucleotides. They 
regulate a variety of cellular pathways through the control of target gene expression. 
They bind mRNA through partial homology and, in doing so, can  potentially 
regulate the expression of multiple targets (Zhu et al. 2007), most of which are still 
largely unknown. There are indications that miRs might regulate the expression of 
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up to 30% of the genome (Lewis et al. 2005). MiRs are now emerging as master 
regulators, which can act as oncogenes or tumour suppressors. 
 
1.2 Glial Cells and Gliomas 
There are over 100 different types of brain tumour. Primary brain tumours are 
classified by histology and location. Primary brain tumours arise from the brain 
itself, in contrast to metastases, which are derived from tumours developed in other 
organs and parts of the body. Primary brain tumours can be benign or malignant. 
Benign brain tumours (e.g. meningiomas, acoustic neuromas, pituitary gland 
tumours) usually grow slowly and can often be removed by surgery depending upon 
their specific location in the brain. Malignant brain tumours tend to grow rapidly 
spreading into the surrounding brain tissue and often cannot be entirely removed 
surgically. Any cell type in the central nervous system (CNS) has the potential to 
become neoplastic, often resulting in mixed cell types within a single tumour. Brain 
tumours are named after their cell type of origin. A schematic drawing of glial cell 
types present in the CNS is seen in figure 1.1. Astrocytes are stellate cells with 
numerous processes contacting several cell types in the CNS. These star-shaped 
cells provide structural and physiological support for neurons in the CNS. 
Astrocytes are named after the greek word "astro" meaning "star". Oligodendrocytes 
form the myelin sheets around axons and have an insulating function; they can 
myelinate up to 50 axonal segments. A number of interactions between glial cells, 
particularly between astrocytes in the mature CNS, are regulated by gap junctions, 
forming a glial network (Baumann and Pham-Dinh 2001). 
 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1 Different types of glial cells in the CNS and their interactions (Baumann 
and Pham-Dinh 2001). Neurons conduct electrical impulses in the brain, astrocytes 
provide structural support, oligodendrocytes form myelin sheaths around axons, 
microglia are involved in the immune response in the brain. 
 
1.2.1 Gliomas 
Gliomas are formed from the glial component of the nervous system. These are the 
most common primary brain tumours. Gliomas are very heterogenous with an 
infiltrative growth pattern with the majority being resistant to both radiotherapy and 
chemotherapy. It is thought that a small population of cancer stem-like cells is 
responsible for resistance to therapy in gliomas (Auger et al. 2006; Kolenda et al. 
2010). Brain tumours have been classified by the World Health Organisation 
(WHO) according to their cell type and malignancy. Gliomas are comprised of 
astrocytomas, oligodendrogliomas, oligoastrocytomas, and ependymomas. These 
tumours are graded according to their malignancy: astrocytomas I-IV, the latter also 
being known as glioblastoma; oligodendrogliomas and oligoastrocytomas grade II 
(low-grade) and grade III (anaplastic) lesions (Francis Ali-Osman 2005). 
1.2.2 Astrocytomas 
Astrocytomas usually occur in the cerebral hemispheres, however they can be found 
in any location in the CNS. They are derived from astrocytes, show diffuse 
 
Different types of glial cells in the CNS 
and their interactions
←Myelin sheath 
containing axons
←Axon 
terminal
←Blood vessel
(Baumann, 2001)
 19 
infiltration of brain structures, and low-grades tend to progress to more malignant 
phenotypes. Malignant astrocytomas are the most frequent intracranial neoplasms, 
and comprise more than 60% of all primary brain tumours. Table 1.1 gives the 
WHO classification of astrocytomas, based on histological criteria and molecular 
changes. The mean age of occurrence for low grade astrocytomas is 34, whereas 
higher grade astrocytomas typically occur within the age range of 40-70 years. Some 
low-grade astrocytomas progress rapidly to higher grades (1-2 years), while some 
may show no change in histological grade over more than 10 years. Grade II 
astrocytomas and higher grades exhibit diffuse invasion and a high rate of 
transformation, in addition primary glioblastomas are angiogenic, with a higher 
proliferation rate and increased cellular necrosis than lower grade gliomas (Fig. 1.2). 
Progression to a higher grade astrocytoma is associated with an increase in multiple 
genetic alterations. Tumour p53 mutations and overexpression of platelet derived 
growth factor (PDGFR) are associated with low-grade diffuse astrocytomas. Loss of 
heterozygosity (LOH) on chromosome 19q is associated with anaplastic 
astrocytomas. LOH on chromosome 10/MMAC1/PTEN, PDGFR amplification, and 
loss of DCC (deleted in colorectal cancer) are characteristic of glioblastoma (Table 
1.1). Most gene amplification events in high-grade astrocytomas involve the gene 
for the receptor tyrosine kinase, EGFR. Half of all glioblastoma cases have receptor 
amplification associated with gene rearrangement. The most common mutation is 
EGFRvIII. The DCC gene encodes a protein involved in neural cell adhesion. Loss 
of DCC expression is increased during transformation from low-grade astrocytoma 
to glioblastoma. Primary glioblastomas usually occur in older patients who do not 
have a prior history of lower-grade astrocytoma, typically affecting older patients 
with an average age of 55 years (Paul Kleihues 1997). These primary glioblastomas 
generally overexpress EGFR, a tyrosine kinase receptor with downstream effects 
resulting in cell proliferation and invasion. Secondary glioblastomas are thought to 
arise from lower-grade astrocytomas and usually occur in younger age groups 
(Nagane et al. 2001). These glioblastomas generally do not overexpress EGFR; 
instead, they commonly have mutations in tumour suppressor gene p53 (Frederick et 
al. 2000), which is responsible for cell-cycle control, DNA repair after radiation 
damage, and induction of apoptosis, p53 is mutated in approximately 50% of 
cancers and in 30% of gliomas (Frankel et al. 1992) resulting in decreased 
apoptosis, and predisposition towards neoplastic transformation. There is an 
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increased risk of developing an astrocytoma when exposed to irradiation of the 
CNS. There is also a genetic susceptibility including Li-Fraumeni syndrome, p53 
germline mutations, Turcot syndrome and the NF1 syndrome (Paul Kleihues 1997).
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Table 1.1 WHO classification of diffuse astrocytomas (Paul Kleihues 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2 Pathways to glioblastoma formation (Maher et al. 2001). There are two 
types of glioblastoma, (1) a secondary glioblastoma which is derived from a low 
grade astrocytoma and progresses to a glioblastoma over a number of years; (2) a 
primary glioblastoma occurs spontaneously. There are large differences in clinical 
features between primary and secondary glioblastomas. 
WHO 
Grade 
WHO 
Designation 
Histological Criteria Molecular 
Characteristics 
II Astrocytoma 
(low-grade 
diffuse) 
Zero criterion 
nuclear atypia 
P53 mutations 
Overexpression of PDGFR 
III Anaplastic 
astrocytoma 
Nuclear atypia and mitotic 
activity 
LOH on chromosome 19 
IV Primary 
Glioblastoma 
Nuclear atypia, mitoses, 
endothelial proliferation 
and/or necrosis 
EGFR overexpression 
LOH on chromosome 
19/MMAC1/PTEN 
Loss of DCC 
IV Secondary 
Glioblastoma  
 
Nuclear atypia, mitoses, 
endothelial proliferation 
and/or necrosis 
P53 mutations 
LOH on chromosome 
19/MMAC1/PTEN 
Loss of DCC 
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1.2.3 Oligodendrogliomas 
Oligodendrogliomas are derived from oligodendrocytes and account for 5-12% of all 
glial tumours. They are usually found in the cerebrum, especially in the frontal or 
temporal lobes, and at the optic nerve. They are more common in adults than in 
children, with a mean occurrence age of 40-49 years. Survival rates range from 3-10 
years. They appear as grade II and III (anaplastic). Oligodendrogliomas with 1p19q 
respond well to treatment with a combination of procarbazine, CCNU, and 
vincristine (PCV) (Paul Kleihues 1997). Loss of 1p19q are associated with 
sensitivity of brain tumours to chemotherapy and radiotherapy, improved outcome 
with temozolomide treatment has been associated with promoter methylation of 
MGMT and  loss of heterozygosity (LOH) of 1p and 19q in glioma patients (Rivera 
et al. 2010). Oligodendrogliomas are clinically less aggressive than astrocytomas, 
and tend to have a better prognosis than other gliomas. EGFR amplification and 
LOH on chromosomal region 19q are predictors of shorter progression-free survival 
giving a more aggressive form of tumour, and LOH on chromosomal region 1p is 
associated with longer survival. Mutations in p53 are found in about 10-15% of 
cases. Half of all oligodendrogliomas have EGFR overexpression (Paul Kleihues 
1997). 
1.2.4 Mixed Gliomas 
Mixed gliomas are made up of two or more neoplastic cell types. The most common 
mixed gliomas are oligoastrocytomas (Paul Kleihues 1997) which consist of 
oligodendrocytes and astrocytes; the cell types may be mixed or found in two 
separate areas, resembling oligodendroglioma or an astrocytoma. Oligoastrocytomas 
appear as WHO grade II and III. The mean age of occurrence is 45 years. 
Oligoastrocytomas are usually found in the cerebral hemisphere, the frontal lobes 
are typically more affected, than the temporal lobes. Some oligoastrocytomas 
respond well to treatment with PCV. 30-50% of oligoastrocytomas have LOH of 1p 
and 19q, 30% also have mutations of the p53 gene and/or LOH on 17p. The survival 
ranges from 5 to 10 years (Paul Kleihues 1997). 
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Table 1.2 Mutations found in gliomas (Paul Kleihues 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tumour grade Mutations 
 
Oligoastrocytomas   Loss of genetic information on 1p and 19q (30-50%) 
  TP53 and/or LOH 17p (~30%) 
 
Oligodendrogliomas   EGFR amplification, overexpression (~50%) 
  LOH 19q and 1p 
  TP53 (10-15%) 
 
Anaplastic 
Oligodendroglioma 
  Deletions 9p/or 10p 
  LOH 19q and 1p 
  EGFR overexpression and amplification 
 
Anaplastic 
Astrocytoma 
  LOH 19q (~50%) 
 
 24 
1.3 Tyrosine Kinases in High-Grade Astrocytic Tumours 
The protein tyrosine kinases (PTKs) regulate a large range of proteins involved in 
processes including growth, metabolism and differentiation. They are divided into 
receptor and non-receptor tyrosine kinases, which initiate signalling processes by 
phosphorylation (activation) and dephosphorylation (deactivation) of a variety of 
downstream proteins including PI3K/Akt and members of the RAS/RAF/MAPK 
pathway (Schlessinger 2000). As previously mentioned progression to a higher 
grade astrocytoma is associated with an increase in multiple genetic alterations. The 
identification of genetic mutations in high-grade astrocytic tumours opened a whole 
field for possible new therapies, shifting away from the deregulated cell cycle 
control as the only target. The most prevalent mutations in high grade astrocytomas 
include the receptor tyrosine kinases (RTKs) EGFR, PDGFR, and the vascular 
endothelial growth factor receptor (VEGFR). Overexpression or gene loss results in 
increased downstream neoplastic signalling, and may promote neoplastic cell 
behaviour. Recent advances in our understanding of the signalling pathways of these 
growth factor receptors involving their downstream effectors, e.g. phosphoinositol3 
kinase (PI3K)-AKT, RAS-mitogen-activated protein kinase (MAPK), made these 
available as targets and novel treatments have been developed, which resulted in 
some improvements, particularly in quality of life (Haas-Kogan et al. 2005).  
 
1.3.1 Epidermal Growth Factor and its Receptor  
EGFR is a receptor tyrosine kinase which plays an important role in normal tissue 
development and carcinogenesis. EGFR signalling promotes proliferation, 
migration, and invasion, and inhibits glioma cell apoptosis (Hynes and Lane 2005). 
EGFR is abnormally activated in 70% of solid cancers, and is amplified or 
overexpressed in up to 60% of primary glioblastomas (Omuro et al. 2007). EGFR 
amplification is the most common genetic abnormality in high-grade gliomas 
(Ziegler et al. 2008). EGFR is a type I cell surface receptor kinase and a member of 
the ErbB family which has 4 receptor members: EGFR/ERBB1, ERBB2, ERBB3 
and ERBB4. EGFR is a highly glycosylated 170 kDa membrane spanning protein, 
with a single polypeptide chain of 1186 amino acids. The extracellular domain of 
EGFR has four subdomains designated I, II, III and IV. The domains I, II and III 
form the ligand-binding pocket (Fig. 1.3) (Ogiso et al. 2002). ERBB2 is the 
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heterodimerization partner of the other ligand-bound family members. Without the 
presence of a ligand EGFR exists as monomers on the cell surface. All have an 
extracellular ligand binding region, a single membrane spanning region and a 
cytoplasmic tyrosine kinase containing domain. The receptors are expressed in 
epithelial, mesenchymal and neuronal tissue. The EGF ligands are specific for each 
receptor (Fig. 1.4). Ligand binding to EGFR results in the formation of receptor 
homo- and heterodimers, depending on dimerization with itself or with another ErbB 
family member, and to phosphorylation of specific tyrosine residues in the 
cytoplasmic tail. These phosphorylated residues serve as docking sites for a number 
of proteins, resulting in the activation of intracellular signalling pathways (Fig. 1.5). 
The main pathways activated in response to EGFR and ERBB2 phosphorylation 
include MAPK, PI3K-AKT, signal transducer and activator of transcription (STAT) 
and SRC tyrosine kinase (Fig. 1.8) (Hynes and Lane 2005). 
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Fig. 1.3 EGFR structure and ligand binding (Zandi et al. 2007). The extracellular 
domain of EGFR has 4 subdomains I, II, III and IV, the domains I, II and III form 
the ligand binding pocket (A). Ligand binding to EGFR results in the formation of 
receptor homo- and heterodimers and to phosphorylation of specific tyrosine 
residues in the cytoplasmic tail; these phosphorylated residues serve as docking 
sites for a number of proteins, resulting in the activation of intracellular signalling 
pathways (B). 
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Fig. 1.4 Schematic diagram of EGFR receptors and their ligands. There are four 
types of EGFR receptors, ERBB1, ERBB2, ERBB3 and ERBB4. Each receptor has 
specific ligands. 
 
1.3.1.1 EGFR and Cancer 
Gene amplification causing EGFR overexpression is commonly found in cancers. 
Many EGF-related growth factors are produced by the tumour cells or the 
surrounding stromal cells giving rise to constitutive EGFR activation. EGFR 
amplification can be caused by structural rearrangements resulting in in-frame 
deletions in the extracellular domain of the receptor, e.g. EGFRVIII variant. The 
resulting mutant protein is ligand independent and constitutively phosphorylated. 
This variant has been found in glioma, breast, lung and ovarian carcinomas. Mutant 
EGFR activates the pro-survival pathways PI3K-AKT and STAT (Hynes and Lane 
2005). Mammalian target of rapamycin (MTOR), a serine/threoine kinase, a 
downstream activator of the PI3K-AKT pathway, plays a very important role in 
tumour cell growth and proliferation, by sensing the availability of nutrients/energy. 
MTOR can also be activated by stimuli other than RTKs (Hynes and Lane 2005).  
Mechanisms by which EGFR signalling becomes oncogenic include: (1) 
overexpression of EGFR, (2) autocrine and/or paracrine growth factor loops, (3)  
Growth factors 
RTKs 
 
 
EGFR/ERBB1 ERBB2 ERBB3 ERBB4 
Betacellulin 
Heparin-binding EGF 
Epiregulin 
 
EGF 
TGF-α 
Amphiregulin Muca4 NRG1 NRG2 
NRG1 
NRG2 
NRG3 
 
Betacellulin 
HB-EGF 
Epiregulin 
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heterodimerization with other EGFR family members and cross-talk with 
heterologous receptor systems, (4) failure in receptor downregulation and (5) 
activating EGFR mutations (Fig. 1.5). 
 
 
Fig. 1.5 Mechanisms leading to EGFR oncogenic signalling: (1) overexpression of 
EGFR, (2) autocrine and/or paracrine growth factor loops, (3) heterodimerization 
with other EGFR family members and cross-talk with heterologous receptor 
systems, (4) failure in receptor downregulation and (5) activating EGFR mutations 
(Zandi et al. 2007). 
 
1.3.1.2 EGFR as a Target for Cancer Therapy 
EGFR receptor overexpression has been found in many human tumours, providing 
an ideal candidate for selective therapy. Many monoclonal antibodies targeting 
EGFRs, are already in clinical trials e.g.: Trastuzumab (Herceptin), Pertuzumab 
(Omnitarg), Cetuximab (Erbitux), Matuzumab, and Panitumumab. However, 
monoclonal antibodies are of limited use in glioma therapy, because of the restricted 
passage through the blood brain barrier (BBB). An alternative treatment option is 
the use of tyrosine kinase inhibitors. They are small molecules preventing 
phosphorylation of tyrosine kinases, which results in the inhibition of downstream 
signalling pathways. Examples of TKIs are Gefitinib (Iressa), Erlotinib (Tarceva), 
Lapatinib,AEE788,CI-
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1033, EKB-569 and EXEL 7647/EXEL 0999, some of which are multifunctional 
inhibitors targeting several TKs. 
It is important to consider that by targeting multiple EGFR receptors this 
may also increase toxicity. Clinical trials have shown that patients with amplified 
EGFR gene and/or elevated EGFR mRNA expression, have a higher response rate to 
TKIs and improved survival, than those with low EGFR copy number and/or mRNA 
expression level (Hirsch et al. 2005; Dziadziuszko et al. 2006). Tumour cells 
containing mutated EGFR have constitutively activated pro-survival pathways 
PI3K-AKT and STAT, and are responsive to TKI treatment resulting in cell 
apoptosis. A subgroup of non small cell lung cancer patients with mutated EGFR 
showed tumour regression to treatment with gefitinib (Paez et al. 2004).  
Another treatment option is a recombinant toxin, TP-38, which consists of 
the EGFR ligand TGF-α. This has been tested in a phase I toxicity trial for the 
treatment of glioblastoma patients with promising results: one patient showed a 
complete response and 3 out of 15 had a partial response, while no toxicity was seen 
(Sampson et al. 2003).  
During development cancer cells typically have acquired multiple mutations, 
causing malignancy; therefore it is unlikely that targeting one specific mutation will 
kill these cells. The benefit of targeting EGFR as a treatment is still under 
discussion; it is not known whether treatment failure is due to ineffective agents, or 
inefficient drug delivery. Resistance to TKIs has become a clinical problem, e.g. 
chronic myelogenous leukemia (CML) patients expressing the oncoprotein BCR-
ABL, usually have complete recovery with imatinib treatment; however, resistance 
to imatinib has been seen more and more, which is due to acquired mutations in the 
BCR-ABL kinase domain (Hynes and Lane 2005).  
Another possibility for the ineffectiveness of TKI treatment could be the 
involvement of compensatory growth pathways. Activation of other RTKs has been 
found, e.g. insulin like growth factor-1 receptor (IGF1R), fibroblast growth factor 
receptor (Adnane et al. 1991; Laban et al. 2003). Therefore, a combination treatment 
targeting ERBB2 and IGF1R has shown reduced cell growth in MCF-7 breast cancer 
cells (Hynes and Lane 2005). 
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1.3.1.4 EGFR in Gliomas 
EGFR is overexpressed in 50-60% of glioblastomas and EGFRvIII is present in 24-
67% (Heimberger et al. 2005). Amplification and overexpression of EGFR is a 
characteristic of glioblastomas. EGFRvIII overexpression in the presence of EGFR 
amplification is a strong indicator of poor survival in glioblastoma patients 
(Shinojima et al. 2003). The role of EGFR is to mediate cell growth and 
proliferation signals via the PI3K-AKT pathway, which is negatively regulated by 
PTEN (Hesselager and Holland 2003). Mutations in the PTEN gene can further 
predispose the cells toward cancerous proliferation, and are found in 45% of 
glioblastomas (Pan E 2004).  
Following promising results in patients with lung cancer, EGFR blockade 
was tested in recurrent glioblastomas and was successful in a sub-group. About 20% 
of patients responded to erlotinib and gefitinib, as determined by a reduction in 
tumour size measured by MRI. Response was correlated with co-expression of the 
mutated form EGFRvIII and PTEN; however, the detailed mechanism of action is 
still unknown (Mellinghoff et al. 2005). Sordella et al. have shown in lung cancer 
cells that EGFRvIII activates PI3K/AKT signalling and can sensitise cells to the 
EGFR inhibitor, gefitinib (Sordella et al. 2004). It has not been established whether 
this is true for glioblastomas. The loss of PTEN might promote resistance to EGFR 
kinase inhibitors (Bianco et al. 2003).  
 
1.3.2 Platelet Derived Growth Factor and its Receptor  
The overexpression of PDGF and its receptor PDGFR plays an important role in the 
development of cancer through an autocrine stimulation of cancer cells and 
angiogenesis. The PDGF family consists of 4 ligands, PDGF-A, -B, -C, and –D and 
2 receptor tyrosine kinases, PDGFR-α and PDGFR-β (Fig. 1.6). The ligands form 
disulfide-linked homodimers, PDGF-AA, -BB, -CC, -DD, and the heterodimer 
PDGF-AB. PDGFR-α and PDGFR-β, are transmembrane glycoproteins and have 
tyrosine kinase activity (Kanakaraj et al. 1991). PDGFR-α binds A, B and C chains 
with high affinity, while PDGFR-β only binds the B and D chains  (Lokker et al. 
2002; Zhuo et al. 2004) (Fig. 1.6). Ligand binding leads to receptor homo- or 
heterodimerization and autophosphorylation of the tyrosine kinase residues which 
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initiates intracellular signalling cascades (Kanakaraj et al. 1991). Two most 
significant PDGFR signalling pathways are the RAS/MAPK pathway, which 
mediates an increase in proliferation, migration and differentiation (Schlessinger 
1993), and the PI3K-AKT pathway promoting cell survival (Franke et al. 1995). 
PDGF-BB had a more important role than PDGF-AA in normal and tumour 
angiogenesis (Risau et al. 1992). The α–granules of platelets are the main site of 
PDGF formation; other cell types producing PDGF include macrophages, epithelial 
and endothelial cells (Lindroos et al. 1997; Mondy et al. 1997; Demayo et al. 2002). 
Expression of PDGF initiates organ development (Pinzani et al. 1996; Ponten et al. 
2003), and diseases such as fibrosis and atherosclerosis (Wilcox et al. 1988).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.6 A schematic diagram of PDGF receptors and actions. The ligands form 
disulfide-linked homodimers, PDGF-AA, -BB, -CC, -DD, and the heterodimer 
PDGF-AB. PDGFR-α and PDGFR-β, are transmembrane glycoproteins and have 
tyrosine kinase activity PDGFR-α binds A, B and C chains with high affinity, while 
PDGFR-β only binds the B and D chains.  
 
 
1.3.2.1 PDGFR in Glioma 
PDGFR and PDGF are commonly overexpressed in glioma, especially in secondary 
glioblastoma. The overexpression is associated with p53 tumour suppressor gene 
PDGF-A
PDGF-A PDGF-C
PDGF-C
PDGF-D
PDGF-D
PDGF-α PDGF-β
PDGF-B
PDGF-B
PDGF-A
PDGF-B
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loss (Omuro et al. 2007). One of the most common cellular signalling defects found 
in brain tumours, is the presence of a PDGF/PDGFR autocrine loop. The activation 
of the PDGF/PDGFR autocrine loop is thought to be an early event in the 
pathogenesis of malignant astrocytomas, and continues to play a role in late stage 
tumour maintenance (Guha et al. 1995). This occurs in all brain tumour grades, 
including low-grade and anaplastic astrocytomas, and glioblastomas (Maher et al. 
2001). In addition to PDGF-A and –B, Lokker et al. identified the ligands –C and –
D. They also found that PDGF-C was ubiquitously expressed in glioblastoma cells 
and tissue, but its expression was low or absent in normal adult and foetal brain. 
PDGF-D was expressed in 10 of 11 glioblastoma cell lines and in 3 of 5 primary 
brain tumour samples (Lokker et al. 2002). Looking for PDGFR expression in a 
series of 101 glioblastoma tissue samples Haberler et al, found 25.8% expressed the 
α form and 24.8% expressed the β form (Haberler et al. 2006). Nister et al, 1991 
found three different phenotypes in 12 out of 13 glioma cell lines, those that 
expressed PDGFR-α or PDGFR-β only, and those that expressed both receptors 
(Nister et al. 1991).  
 
1.3.3 C-Kit 
KIT, a receptor tyrosine kinase, and its ligand stem cell factor (SCF), are highly 
expressed in embryonic and adult mouse brain, and play an important role in 
proliferation, differentiation, as well as in cancer cell metastasis, and glioma 
development (Stanulla et al. 1995). SCF induces angiogenesis in the normal brain, 
and probably in brain tumours since it is found in human gliomas. Expression of C-
Kit protein was found only in a small number of tissue samples of low and high-
grade gliomas (Blom et al. 2008) and in 4 out of 101 glioblastomas (Haberler et al. 
2006). While in cell lines, C-Kit mRNA or protein was detected in about 50% 
(Hamel et al. 1992) to 100% (Stanulla et al. 1995). The coexpression of the receptor 
kinase C-kit and its ligand SCF was found in the cytoplasm of glioma cell lines, 
suggesting its involvement in the autocrine growth regulation of glioma cells 
(Stanulla et al. 1995). 
SCF signalling includes the PI3-kinase-AKT, the phospholipase C, the 
STAT and the RAS/MAPK pathways leading to proliferation, differentiation, cell 
cycle regulation and apoptosis. It is suggested that KIT plays a role in altering cell 
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growth and size, and might be responsible for the transformation of astrocytes to 
gliomas (Blom et al. 2008).  
 
1.3.4 C-Abl 
C-Abl is a ubiquitously expressed non-receptor tyrosine kinase, which is activated 
by a number of signals including DNA damage and cell adhesion interactions. 
Expression of C-Abl is found in the nucleus and the cytoplasm and is involved in 
two cell responses, cell cycle arrest and apoptosis. C-Abl activates p53 (a cellular 
tumour suppressor). Under cellular stress p53 is negatively regulated by Mdm2, 
upon C-Abl phosphorylation p53 is dissociated from Mdm2 resulting in active p53, 
on recovery from damage p53 reassociates with Mdm2 to form a stable complex 
(Fig 1.7) (Levav-Cohen et al. 2005). Haberler et al, found C-Abl expression in just 7 
out of 101 glioblastoma tissue samples (Haberler et al. 2006). Using tissue samples 
on a protein lysate array, Jiang et al. found overexpression of C-Abl in 
glioblastomas compared to lower grade gliomas, and suggested an association with 
poor survival (Jiang et al. 2006). 
The oncogenic form of C-Abl occurs when the N-terminal portion of C-Abl 
is replaced with fragments of genes such as bcr, tel or the viral gag, forming the 
fusion tyrosine kinases Bcr-Abl, Tel-abl, and v-Abl (Shteper and Ben-Yehuda 2001; 
Wong and Witte 2004). The most important oncogenic form is Bcr-Abl; it is a 
cytoplasmic protein that triggers mitogenic and anti-apoptotic signals. Bcr-Abl 
promotes cell proliferation and counteracts p53-mediated apoptosis, by causing 
constitutive anti-apoptotic signals. Bcr-Abl is present in over 95% of CML patients 
(Levav-Cohen et al. 2005). 
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Fig. 1.7 The p53/ Mdm2 negative auto-regulatory loop (Levav-Cohen et al. 2005). 
With cellular stress p53 is negatively regulated by Mdm2, upon C-Abl 
phosphorylation p53 is dissociated from Mdm2 resulting in active p53, on recovery 
from damage p53 reassociates with Mdm2 to form a stable complex. 
 
1.4 Signal Transduction Pathways 
There are a number of different signal transduction pathways associated with the 
various receptors mentioned above. In the following paragraphs two of the pathways 
will be discussed in detail: the RAS/MAPK pathway, and the PI3K/AKT/MTOR 
pathway. These cellular signalling pathways are required for normal cell physiology 
(Schlessinger 2000). In gliomas, however, these pathways are overactive due to the 
overexpression and constitutively activated RTKs (Ali et al. 1999). The 
RAS/MAPK and the PI3K/AKT/MTOR pathway, in particular, are involved in 
tumour resistance to radiotherapy and chemotherapy.  
 
1.4.1 RAS/MAPK Pathway 
In normal cellular proliferation RAS proteins control signalling pathways which are 
key regulators of cell growth. Overactivation of the RAS/MAPK pathway can 
increase cellular proliferation, migration and differentiation in several types of 
cancers including gliomas (Schlessinger 1993). RAS is a membrane-bound G-
protein; it exists in an inactive GDP-bound form and an active GTP-bound form. 
RAS is activated by RTKs, including EGFR, PDGFR, other growth factor receptors 
and cytokines (Gullick 2008). Activated RAS recruits Raf to the cell membrane. Raf 
activation requires phosphorylation of a tyrosine residue by a SRC kinase, and/ or 
phosphorylation of serine/threonine residues by PKC. Activated Raf 
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activates/phosphorylates mek kinases and subsequently MAPK and ERK, causing 
ERK translocation to the nucleus. ERK-2 activates nuclear targets such as 
topoisomerase II-α, a cell cycle progression mediator, and transcription factors 
including cyclic AMP response element binding protein (CREB), oestrogen 
receptor-α (ER-α), Iκ-B/NF-κB, and C-Fos. Activation of these transcription factors 
results in the expression of oncogenes involved in cell cycle progression, cell 
growth, neoangiogenesis, and anti-apoptosis (Fig. 1.8) (Wong et al. 2007). MAPK 
activation is partially influenced by the level of EGFR expression. MAPK activity is 
involved in cell migration by interacting with the cytoskeletal machinery; 
phosphorylation of the myosin light chain kinase results in the phosphorylation of 
myosin light chains which generate the force to move the cell forward (Wong et al. 
2007).  
Increased activity of RAS-GTP has been found in high-grade astrocytomas. 
Ras mutations in gliomas are rare in comparison with other cancers (Woods et al. 
2002). It is thought that activation of Ras in malignant gliomas may be due to the 
overactivity of membrane tyrosine kinase receptors (Newton 2003). Ras inhibitors 
such as R111577 (tipifarnib) and SCH66336 (lonafarnib) are being tested in clinical 
trials (Brunner et al. 2003). Both of these demonstrated positive results in preclinical 
studies (Glass et al. 2000). 
 
1.4.2 PI3K/AKT/MTOR Pathway 
The PI3K/AKT pathway promotes cell survival. Phosphoinositide 3-kinase (PI3K) 
regulates EGF-driven cell motility and invasion of glioma, breast, and bladder 
cancer cell lines (Schlessinger 2000). The activation of this pathway is stimulated by 
the growth factor receptors, EGFR, PDGFR, fibroblast growth factor receptor 
(FGFR) and insulin-like growth factor receptor (IGFR). PI3Ks are a family of kinase 
heterodimers with separate p85 regulatory subunits which are phosphoprotein 
substrates for RTKs, such as VEGFR, EGFR and PDGFR and p110 catalytic 
subunits. This pathway is activated either directly through the p85-p110 complex or 
indirectly through RAS. Accumulation of phosphoinositol 3,4,5-triphosphate (PIP3), 
a product of PI3K, is involved in directional movement. This is involved in the role 
of p85-p110α PI3K isoform in localising actin polymerization and lamellipodia 
extension in response to EGF. The accumulation of PIP3 is recognised by Akt which 
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stimulates cell cycle progression and inhibits apoptosis. Akt promotes cell growth 
via the mammalian target of rapamycin (MTOR) signalling. MTOR is a central 
growth regulator. MTOR plays an important role in regulating protein translation 
through phosphorylation of p70 S6 kinase 1 (S6K1), a protein involved in ribosome 
biogenesis, and 4E-BP1 (eIF-4E binding protein), a translation repressor. It has been 
shown that MTOR has a direct linkage to the phosphatidylinositol-3'-kinase 
(PI3K)/PTEN-Akt survival pathway (Endersby and Baker 2008). Phosphatase and 
tension homolog (PTEN) is a major tumour suppressor gene which inhibits cell 
growth. PTEN inhibits PI3K by depleting levels of PIP3. PTEN loss is correlated 
with aggressive phenotypes, indicating it plays a role in tumour cell invasion 
(Schlessinger 2000). PTEN mutations are found in up to 65% of high-grade gliomas, 
and 15% to 40% of primary glioblastomas (Omuro et al. 2007). In glioblastoma, the 
reduced level of PTEN and increased Akt activity has been correlated with more 
aggressive tumour behaviour and reduced survival time in patients (Wong et al. 
2007). 
PTEN mutations are found in 20-40% of malignant gliomas (Cai et al. 2005). 
The loss of function of the PTEN is more commonly found in high-grade gliomas, 
which are extremely invasive. Furukawa et al. introduced the wild-type PTEN gene 
into malignant glioma cell lines, which inactivated Rac and cdc42 (two Rho-family 
GTP-binding proteins), inhibited MMP-2 and 9 enzyme activity and decreased 
MMP-2 mRNA expression. This resulted in a significant reduction of migration and 
invasion activities of the transfected cells (Furukawa et al. 2006).  
Direct inhibitors of Akt have been difficult to develop, and have not been 
tested in glioma clinical trials. As an alternative agents have been developed that are 
directed at the mammalian target of rapamycin (MTOR) pathway (Schmelzle and 
Hall 2000). The classic MTOR inhibitor is rapamycin, initially developed as an 
immunosuppressant for patients undergoing transplantation. This agent works by 
forming a complex that binds to MTOR and inhibits its kinase activity, resulting in 
G1 cell-cycle arrest (Neshat et al. 2001). Preclinical studies have shown that 
rapamycin is cytostatic against xenografts of glioblastoma and medulloblastoma 
(Geoerger et al. 2001). Compared with PTEN-positive tumours, PTEN-negative 
tumours appear to be more sensitive to inhibition by rapamycin (Neshat et al. 2001). 
Rapamycin is unstable in solution and has not been used in many clinical trials. 
Instead, more soluble ester analogs of rapamycin (e.g., CCI-779) have been studied. 
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CCI-779 has been shown to inhibit glioblastoma proliferation in vitro and is 
currently being tested in several clinical trials (Geoerger et al. 2001). 
 
Fig. 1.8 Signalling pathways in malignant glioma. The activation of receptor 
tyrosine kinase by growth factors (GF) leads to the activation of PI3K/Akt and 
RAS/MAPK pathways downstream. Various functions are then activated such as 
growth, differentiation, and apoptosis. A number of targeted therapies are also listed 
at their site of action (Wong et al. 2007). 
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1.5 Tyrosine Kinase Inhibitors 
Tyrosine kinase inhibitors inhibit the phosphorylation and dephosphorylation of a 
variety of downstream proteins. In addition to the primary effect on growth factor 
signalling, TKIs seem to reduce matrix metalloproteinase (MMP) expression and 
activity, which has a negative effect on the invasion and infiltration abilities of 
tumour cells (Newton 2004). 
Clinical trials using TKI as monotherapy on high-grade astrocytic tumours 
have revealed only modest response rates, confirming in vitro studies, which have 
shown that e.g. effective siRNA silencing of EGFR in receptor-positive cell lines did 
not inhibit proliferation, migration and activation status of EGFR-coupled signalling 
cascades in these cells; suggesting single agent treatment not being sufficient 
(Vollmann et al. 2006). Glioblastoma, as with most epithelial cancers, has multiple 
interactive and dysregulated cell signalling pathways, that will require a multipotent 
combination of targeted therapies for effective invasion blockage and tumour cell 
killing. 
Although there are several combination therapies currently in clinical trial 
phase, very little data are available on the interaction between TKIs directed at 
EGFR and PDGFR/C-Kit/C-Abl, and conventional, cytotoxic drugs.  
 
1.5.1 Imatinib  
A promising TKI is Imatinib (GLEEVECTM, STI1571, Novartis), it was specifically 
developed to treat chronic myeloid leukaemia (CML), many CML patients have 
shown a full recovery with imatinib treatment. It specifically inhibits BCR-ABL, 
created as a consequence of a (9:22) chromosomal translocation: known as the 
Philadelphia chromosome and used as a diagnostic marker for CML (Druker 2001). 
The chromosomal translocation causes the fusion of two broken genes, the BCR 
gene on chromosome 9, and the ABL gene on chromosome 22, to give a new gene 
called BCR-ABL. The ABL gene produces a tyrosine kinase, which controls growth 
and division. The fusion protein BCR-ABL contains unregulated tyrosine kinase 
activity, and is the target for imatinib (le Coutre et al. 2004). The development of 
imatinib began in the late 1980s, when several pharmaceutical companies initiated 
screens, to identify compounds that would interact with the BCR-ABL tyrosine 
kinase. The drug was approved in 2001.  
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Imatinib is a small molecule belonging to the group of 
phenylaminopyrimidines which have been shown to interact with and inhibit 
tyrosine kinases. Its main metabolite is N-desmethyl-imatinib. Imatinib itself 
specifically targets the BCR-ABL tyrosine kinase, blocks any growth signals, which 
the abnormal protein generates and prevents cell proliferation (le Coutre et al. 2004). 
Imatinib also inhibits the tyrosine kinases PDGFR-α, PDGFR-β, the stem 
cell factor receptor C-Kit, the non-receptor protein tyrosine kinase C-Abl, and 
BCRP expression. PDGFR expression status is directly correlated with imatinib 
sensitivity (Kilic et al. 2000; Hagerstrand et al. 2006). However, Haberler et al. 
showed no correlation between the expression of these proteins and the response to 
imatinib in glioblastoma patients (Haberler et al. 2006). Imatinib inhibits growth by 
cell cycle arrest by selectively disrupting the PDGF receptor autocrine loop (Kilic et 
al. 2000). Clinical trials using imatinib as a single agent resulted in increased 
progression free survival after 6 months for a small number of patients with 
recurrent glioblastoma (Katz et al. 2004; Raymond et al. 2008). The low treatment 
response could be due to the limited permeability of imatinib into the brain. In mice 
only 20% of imatinib was shown to cross the BBB, as the other 80% is effluxed by 
BCRP and Pgp (Bihorel et al. 2007). Le Coutre et al. have reported a mean peak 
plasma concentration (PPC) for imatinib of 4-5 µg/ml of a 600 mg dose, and 2-3 
µg/ml for a 400 mg dose, 4 hours after oral administration and for the metabolite N-
desmethyl-imatinib 531 ng/ml. The average cerebrospinal fluid (CSF) concentration 
for imatinib was 38 ng/ml, and for N-desmethyl-imatinib it was less than 10 ng/ml 
showing that only a small amount of drug crosses the BBB (le Coutre et al. 2004). 
High-grade glioma patients have a disrupted BBB, which would allow a higher 
concentration of imatinib in the CNS; however, it still might not reach an effective 
concentration. Inhibition of PDGFR alone seems not to be sufficient to stop glioma 
growth, since other pathways might compensate (Wen et al. 2006). 
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Fig. 1.9 Structure of imatinib, molecular formula C29H31N7O·CH4SO3, molecular 
weight 589.7 (Boddy et al. 2007). 
 
1.5.2 Erlotinib 
Erlotinib (TARCEVA®, OSI-774, OSI Pharmaceuticals) is an EGFR-specific TKI. It 
inhibits autophosphorylation of EGFR, resulting in inhibition of EGFR-dependent 
cell proliferation. In combination with temozolomide it has shown antitumour 
activity, in a small group of patients with glioblastoma, resulting in an increased 
survival time (Prados et al. 2009). Responsiveness to erlotinib in patients with 
glioblastomas seemed to be dependent on the co-expression of mutated EGFR 
(EGFRvIII) and the tumour suppressor gene PTEN (Mellinghoff et al. 2005).  
The average PPC of 67 ng/ml erlotinib has been seen in patients who 
received escalating doses ranging from 50 mg/ml to 150 mg/ml of erlotinib 
(Yamamoto et al. 2008). A 75 mg erlotinib dose resulted in an average peak plasma 
concentration for erlotinib and its active metabolite OSI-420 of 30.3 µg/ml and 2.5 
µg/ml, respectively, and in the CSF of 2.1 µg/ml and 0.2 µg/ml, respectively 
(Broniscer et al. 2007). 
 
 
 
 
 
Fig. 1.10 Structure of erlotinib, chemical formula C22H23N3O4·HCL, molecular 
weight 429.90 (rxlist). 
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1.5.3 Gefitinib 
Gefitinib (IRESSA®, ZD1839, AstraZeneca) is a specific inhibitor of EGFR; it 
inhibits the intracellular phosphorylation of Akt and PI3K. This results in inhibition 
of proliferation, angiogenesis and induction of apoptosis. Patients with 
phosphorylated Akt have been shown to be better responders to gefitinib; suggesting 
patients with Akt activation may be more sensitive to gefitinib (Cappuzzo et al. 
2004). An average PPC of a 250 mg oral dose of gefitinib measured 5 hours after 
administration was 85 ng/ml (Swaisland et al. 2005).  
              
 
 
 
 
Fig. 1.11 Structure of gefitinib, chemical formula C22H24ClFN4O3, molecular weight  
446.9 (rxlist). 
 
1.5.4 Elacridar 
Elacridar (GF120918) N-[4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-
yl)ethyl] phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide], a second 
generation Pgp antagonist  is a potent and selective inhibitor of P-gp and BCRP 
which affect drug efflux at nanomolar concentration (Stokvis et al. 2004).  
It has been shown in mice that blockade of both Pgp and BCRP by elacridar 
produced significantly greater brain penetration of imatinib and docetaxel (Kemper 
et al. 2004; Bihorel et al. 2007); this effect has also been seen in glioma cell lines 
with imatinib (Decleves et al. 2008), and with docetaxel in lung cancer cell lines 
(Myer et al. 1999). 
 
 
 
 
 
 
 
 
Fig. 1.12 Structure of elacridar, molecular formula C34H33N3O5, molecular weight 
563.64 (www.chemblink.com). 
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1.6 Mechanisms of Drug Resistance  
Multidrug resistance in tumour cells is due to an ATP-dependent decrease in drug 
accumulation, caused by the overexpression of specific ATP-binding cassette (ABC) 
transporter proteins. Some of the most significant ABC proteins involved in this 
process include P-glycoprotein (MDR1/Multidrug resistance 1/Pgp/ABCB1), the 
multidrug resistance protein 1 (MRP1/ABCC1), MRP2 (ABCC2), and the breast 
cancer resistance protein (BCRP/MXR/ABCP/ABCG2). As well as being involved 
in drug resistance, these proteins also play a role in tissue defence by forming an 
essential barrier in specific tissues (e.g. BBB, blood-CSF barrier, blood-testis barrier 
and maternal-fetal barrier or placenta) and are found in tissues involved in 
absorption (e.g. lung and gut), metabolism and elimination (e.g. liver and kidney) 
(Leslie et al. 2005).  
 
1.6.1 The ATP-binding Cassette Transporter Superfamily 
The ABC protein superfamily is very large and widely expressed throughout the 
body and in tumours. Most of its members actively transport a large range of 
compounds including phospholipids, ions, peptides, steroids, polysaccharides, amino 
acids, organic anions, bile acids, drugs and other xenobiotics. There are 48 ABC 
genes with 7 superfamilies (A-G) that have been identified in humans. Many of the 
ABC transporters require ATP binding and hydrolysis at their nuclear binding 
domain (NBD), to give them the energy to move their substrates across membranes. 
In each NBD three sequences Walker A, Walker B, and a sequence located between 
A and B called the ABC signature motif (or C motif), are conserved among all ABC 
transporter family members and other ATP binding proteins (Leslie et al. 2005). 
Pgp was the first drug transporter to be associated with multiple drug 
resistance, followed by the detection of MRP1, MRP2, MRP3, MRP4, and MRP5. 
BCRP, another important transporter was originally found in a breast cancer cell 
line. BCRP is highly expressed in placenta, and is possibly regulated by sex 
hormones (Allikmets et al. 1998). The role of BCRP and MRP2-5 in drug resistance 
is not fully understood. All of the ABC proteins mentioned are also expressed in 
non-malignant tissue where they protect against xenobiotic accumulation. MRP1 is 
usually located in the basolateral cellular surface, and high levels are found in the 
lung, testis, kidneys, skeletal muscle and peripheral blood mononuclear cells. 
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MRP1, in certain tissues effluxes substrates into the blood. MRP2, BCRP, and Pgp 
are found in the apical surface of epithelial cells and are highly expressed in areas 
that need protection from xenobiotics, including the BBB, the placenta, liver, gut 
and kidneys (Leslie et al. 2005). 
BCRP is activated by hypoxia-inducible transcription factor (HIF-1α), which 
is over-expressed in many primary and metastatic cancers, due to hypoxia or loss of 
Hif-1α-inactivating tumour suppressor genes such as VHL or PTEN (Semenza 
2003). BCRP expression has been correlated with drug resistance in several studies 
about acute myeloid leukaemia (Nakanishi et al. 2003), and a subpopulation of 
tumour cells called a side population. This side population shows high expression 
levels of BCRP; it was hypothesised that this side population represents cells with 
stem-like characteristics (Hirschmann-Jax et al. 2004). Cancer stem cells are 
undifferentiated and have the potential for self-renewal and long term proliferation, 
they can differentiate into many different cell types. This side population has been 
found in a number of human solid cancers, e.g. ovarian carcinoma, small-cell lung 
carcinoma, Ewing sarcoma, and prostate cancer. BCRP has a significant role to play 
in clinical drug resistance and may also have prognostic value. Yoh et al. have 
shown that BCRP -negative non small-cell lung carcinomas had a better rate of 
response to therapy (44%) than BCRP-positive tumours (24%) (Yoh et al. 2004).  
 
1.6.1.1 Specificity for Anticancer Drugs 
Pgp is a primary active transporter of bulky amphipathic natural product type drugs 
e.g. taxanes, vinca alkaloids, anthracyclines, camptothecans, epipodophyllatoxins 
and TKIs. Besides the common substrates transported by Pgp, MRP1 and MRP2, 
they also transport uncharged drugs, like methotrexate, cisplatin, and anthracyclins 
Overexpression of MRP2 is associated with cisplatin resistance. MRP1 and MRP2 
also transport metabolites of alkylating anticancer agents including chlorambucil 
and cyclophosphamide. BCRP causes resistance to a smaller range of anticancer 
agents, including anthracyclines, mitoxantrone, toptotecan, and the topoisomerase I 
inhibitor camptothecin, but does not transport vinca alkaloids, epipodophyllatoxins, 
paclitaxel or cisplatin. BCRP gives resistance to anthracyclines. The MRPs cause 
resistance to methotrexate after short-term exposure, whereas BCRP causes 
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resistance to methotrexate after long-term exposure to methotrexate (Leslie et al. 
2005). 
 
1.6.1.2 Expression of ABC Transporters in the BBB/CSF Barrier/ Brain 
Parenchyma 
The BBB and the blood cerebro spinal fluid barrier (BCB) act as an interface 
between the circulatory systems. The BBB is made up of a monolayer of brain 
capillary cells, fused together by zonulae occulents and tight junctions to give a 
continuous cellular barrier, which is impermeable to almost everything except the 
smallest lipid soluble compounds. BBB capillaries are covered with a continuous 
basement membrane enclosing pericytes and a cell layer. An astrocytic foot is in 
contact with the basement membrane and plays a role in the establishment and 
maintenance of the brain endothelial cell phenotype. Drug metabolising enzymes 
including cytochrome P450 haemoproteins and UDP-glucoronosyltransferases 
provide an enzymatic barrier (Fig 1.12) (Leslie et al. 2005). 
The BCB forms a barrier between the ventricular and the blood systems. It is 
located in the choroid plexus and is formed by highly vascularised cells located in 
the ventricular system of the brain, which produce cerebrospinal fluid. While the 
capillaries in the choroid plexus do not have tight junctions and are leakier than in 
the BBB, the choroid epithelial cells do have tight junctions and prevent the passage 
of compounds from the blood to the CSF. The brain parenchymal cells (glial cells 
and neurons) give additional protection to the brain by preventing toxin 
permeability. Pgp expression is found in many cell types in the brain including the 
choroid plexus, astrocytes, microglia and capillary endothelium. Most importantly 
Pgp is found in the luminal plasma membrane of the capillary endothelium, where it 
inhibits drugs and toxins from crossing the capillary membrane into the brain. Pgp is 
also present in the apical membrane of the choroid plexus, where it probably 
facilitates the transport of compounds from the blood into the CSF (Fig. 1.12(b)) 
(Leslie et al. 2005). 
BCRP is mainly expressed at the luminal surface of brain capillaries. MRP1 
is expressed at high levels in the choroid plexus, where it regulates the drug 
concentration in the CSF. MRP1 also functions in brain glial cells. MRP1 is found in 
the apical side of brain microvessel endothelial cells and in brain capillaries. MRP4 
 45 
is located in the basolateral surface of the choroid plexus and the apical side of brain 
microvessel endothelial cells, where it protects against topotecan and other 
xenobiotics. MRP2 is located in the apical membranes of brain capillary 
endothelium where it effluxes xenobiotics (Leslie et al. 2005). 
 
 
Fig. 1.13 A Schematic diagram showing the membrane localization of MRP1, 
MRP2, Pgp and BCRP in (A) blood–brain barrier and (B) blood–cerebral spinal 
fluid barrier. CP, choroid plexus; TJ, tight junctions (Leslie et al. 2005). 
 
1.6.1.3 Drug Resistance in Gliomas 
Increased expression of resistance genes was not correlated with overall survival of 
patients with medulloblastomas/PNET and high grade gliomas (Valera et al. 2007). 
Pgp is expressed in newly formed capillaries in human gliomas and might contribute 
to the resistant behaviour of these tumours (Toth et al. 1996). Pgp expression is 
upregulated in gliomas (Calatozzolo et al. 2005; Valera et al. 2007; Nakagawa et al. 
2009). BCRP expression is upregulated in gliomas (Valera et al. 2007; Gilg et al. 
2008). Pgp possibly inhibits the delivery of anticancer drugs to brain tumours. 
MRP1 and MRP3 are present in glioma capillaries; MRP1 is also present in glioma 
cells. MRP4 is present in astrocytes, glioma cells of astrocytic tumours and tumour 
capillaries. MRP4 may be the sole transporter for astrocytic glutathione release: 
glutathione is an intracellular reductant which protects cells from free radicals and 
other compounds. MRP5 is present in astrocytes, glioma capillaries and tumour 
cells. BCRP expression has not been detected in astrocytes or neurons, but has been 
found in glioma tumour capillaries, though not in the tumour cells (Nies 2007). 
Pgp inhibitors are known as chemosensitizers or reversal agents. They inhibit 
Pgp drug transport and increase cellular concentrations of therapeutic agents, 
therefore they are co-administered. Reversal agents include calcium channel 
blockers like verapamil, calmodulin antagonists such as phenothiazines, quinolines, 
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immunosuppressive agents such as cyclosporin A, antibiotics such as cefoperazone, 
and rifampicin, steroid and hormonal analogs, reserpine, and surfactants. 
Unfortunately some of these agents have severe side effects. Verapamil and 
cyclosporin A cause cardiotoxicity and increase hepatic, renal, myeloid and 
neurotoxicity. Second generation analogs to verapamil and cyclosporin A have 
reduced the side effects (Leslie et al. 2005).  
Alternative methods of overcoming Pgp mediated drug resistance are 
monoclonal antibodies against Pgp, anticancer drug containing liposomes which can 
bypass the Pgp in the lipid bilayer. MDR-1-specific antisense oligonucleotides have 
also been used to decrease the expression of Pgp mRNA l. As Pgp is expressed in 
other tissues such as the liver and kidneys, Pgp inhibitors co-administered with 
anticancer drugs could, however, lead to altered drug metabolism and excretion, and 
to unwanted side effects (Leslie et al. 2005).  
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1.7 Current Chemotherapy Drugs for Malignant Gliomas 
 
1.7.1 Temozolomide 
The first line drug for treatment of high-grade astrocytomas and recurrent 
glioblastomas is temozolomide (Temodar, Temodal – Shering Plough), an 
alkylating drug, which causes DNA methylation at the O6 position of guanine and 
crosslinks between strands of DNA, which results in cell death. Temozolomide 
induces autophagy, or programmed cell death type II in glioma cells (Aoki et al. 
2007). The active metabolite of temozolomide is 5-(3-methyltriazeno)-imidazole-4-
carboxamide (MTIC) (Rudek et al. 2004). The DNA repair protein O6-
methylguanine-DNA methyltransferase (MGMT) reverses the alkylating effect of 
temozolomide, giving increased resistance to temozolomide. The allelic losses of 1p 
and 19q are associated with sensitivity of brain tumours to radiotherapy and 
chemotherapy. Improved outcome after treatment with temozolomide has been 
associated with promoter methylation of MGMT (or loss of MGMT) and Loss of 
heterozygosity (LOH) of 1p and 19q in patients with glioblastoma, anaplastic 
astrocytoma, oligoastrocytomas and, in particular, oligodendrogliomas. In particular, 
LOH in 1p and promoter methylation of MGMT was associated with longer 
progression free survival (Ishii et al. 2007). In malignant glioma patients 
temozolomide concentrations range between 0.10 µg/ml and 13.99 µg/ml in the 
plasma and between 0.16 µg/ml to 1.93 µg/ml in the CSF (Ostermann et al. 2004). 
Up to only 6 months progression free survival is reported for glioblastoma patients 
(Perry et al. 2010). A subcutaneous human xenograft glioma model gel matrix-
temozolomide was placed directly at the tumour site, resulting in minimal 
cytotoxicity toward normal brain tissue, and high levels of oncolytic activity toward 
glioma cells were seen, this may offer an alternative treatment method (Akbar et al. 
2009). 
 
 
 
 
Fig. 1.14 Structural formula of temozolomide molecular formula of C6H6N6O2 and a 
molecular weight of 194.15 . 
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1.7.2 Docetaxel 
Docetaxel (Taxotere, Aventis) is a cytotoxic taxane that inhibits depolymerisation 
of microtubules, thereby interrupting cell proliferation and inhibiting cell motility 
(Bissery et al. 1995). Docetaxel is a hemisynthetic product derived from the 
European yew tree; it is used to treat various forms of cancer and is one of the most 
active chemotherapeutic agents for non-small cell lung cancer (Burris et al. 1995). 
As second line treatment in phase II trials for recurrent glioblastoma, docetaxel 
showed very little response in glioblastoma, which is probably due to the poor 
penetration of docetaxel through the BBB (Forsyth et al. 1996; Kemper et al. 2003; 
Kemper et al. 2004). This problem can be addressed by convection-enhanced 
delivery (CED), which is been used with paclitaxol in an ongoing clinical trial to 
patients with recurrent gliomas and is showing promising results. CED is a drug 
application method in which the drug is injected directly into the tumour avoiding 
the blockage through the BBB (Chamberlain 2006). PPCs for docetaxel have been 
reported to be 0.5 nM and 0.050 nM for CSF (Fracasso et al. 2004). 
 
 
 
 
 
 
 
 
 
 
Fig. 1.15 structure of docetaxel, molecular formula of C43H53NO14•3H2O and a 
molecular weight of 861.9 (rxlist).  
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1.8 MicroRNA 
 
1.8.1 Introduction 
Micro (mi) RNAs are highly conserved noncoding RNAs that control gene 
expression post-transcriptionally, by degradation of target mRNAs or the inhibition 
of protein translation. The discovery of Let-7 in Caenorhabditis elegans as a 
regulator of developmental cellular fate (Reinhart et al. 2000) and discovery of let-
7-related genes in multiple species indicated the importance of these miRNAs 
(Pasquinelli et al. 2000). This led to the understanding that miRNAs act as key 
participants in cellular differentiation. MiRNAs have also been found to play a key 
role in neuronal patterning (Johnston and Hobert 2003), tissue homeostasis (Cui et 
al. 2006), and apoptosis (Baehrecke 2003). There are currently 678 mature human 
miRNA sequences listed in the miRNA registry (Sanger) with about 1000 predicted 
miRNAs, each possibly targeting 200 genes (Lewis et al. 2003). Lewis et al. also 
identified miRNA target sites in 5300 of 17850 genes in their data set, indicating 
that >30% of the human genome may be under the translational regulation of 
miRNAs (Lewis et al. 2005).  
MiRNAs are now emerging as master regulators which either act as an 
oncogene or a tumour suppressor, or even affect both phases of tumourigenesis, e.g. 
the loss of let-7 causes tumour progression by modulating both apoptotic and cell 
cycle pathways. Each miRNA is thought to control the expression of multiple 
mRNA targets and have been shown to be involved in the initiation and progression 
of human cancer. As they control important processes such as differentiation, cell 
growth and cell death, miRNAs hold great promise for targeted cancer therapy. As 
miRNA biology evolves we will need to understand miRNA function more on a 
systems level, where relationships between miRNAs and target genes are less 
important, than changes in overall gene expression pattern induced by altered 
miRNA levels (Pasquinelli et al. 2000). 
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1.8.2 MicroRNA Transcription and Function   
 
1. Transcription 
These small non-coding RNAs are generated in vivo within the chromosome regions 
once called “junk DNA”, which are the introns within protein coding genes. 
MiRNAs are encoded by specific genes (Nelson et al. 2003). MiRNAs are small 
molecules consisting of about 21 nucleotides; they mediate expression of the target 
genes by base pairing with complementary regions within target messenger RNA 
(mRNA). A perfect match causes destruction in a similar way to small interfering 
RNAs (siRNAs), and mismatches cause inhibition of translation (Nelson et al. 2003; 
Krol et al. 2004).  
 
2. Hairpin Release in the Nucleus 
MiRNAs are similar in size to siRNAs, but have distinct transcription units in the 
genome. MiRNAs expressed within introns are expressed with their host mRNA 
which is derived from introns within the same precursor mRNA (pre-mRNA) 
transcript. Whereas siRNAs, which are used therapeutically, have exogenous origins 
and are either directly introduced into cells as ~21-bp double stranded RNA 
molecules, or are generated in vivo from introduced expression vector systems. 
   All miRNA gene products originate in the nucleus. A primary precursor 
miRNA (pri-miRNA) is transcribed from noncoding transcription units, or spliced 
off from introns of pre-mRNA. MiRNAs are expressed as part of pri-miRNAs (Lee 
et al. 2002) and transcribed by RNA Polymerase II, that include 5' caps and 3' 
poly(A) tails (Smalheiser 2003). The miRNA portion of the pri-miRNA transcript 
forms a hairpin which signals for double stranded RNA-specific nuclease cleavage.  
 
3. Export to the Cytoplasm 
The double stranded RNA-specific ribonuclease Drosha digests the pri-miRNA in 
the nucleus to release hairpin, pre-miRNA (Lee et al. 2003). This Pri-miRNA is 
processed by Drosha-type endonucleases following the so called pre-miRNA, which 
is exported from the nucleus by the receptor exportin-5. Exportin-5 binds directly to 
correctly processed pre-miRNAs, which is a requirement for miRNA biogenesis and 
a probable role in coordination of nuclear and cytoplasmic processing steps (Yi et al. 
2003; Lund et al. 2004). Pre-miRNAs are 70 nucleotide RNAs with 1–4 nucleotide 
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3' overhangs, 25–30 base pair stems, and relatively small loops. Drosha also 
generates either the 5' or 3' end of the mature miRNA, depending on which strand of 
the pre-miRNA is selected by RNA induced silencing complex (RISC) (Lee et al. 
2003; Yi et al. 2003).  
 
4. Dicer Processing 
When the pre-miRNA reaches the cytoplasm it is cleaved by Dicer-type nucleases to 
form mature, fully processed miRNA. Dicer is a member of the RNase III 
superfamily of bidentate nucleases, and is involved in RNA interference in 
nematodes, insects, and plants (Lee et al. 2003; Yi et al. 2003). The resulting 
double-stranded RNA has 1–4 nucleotide 3' overhangs at either end (Lund et al. 
2004). Only one of the two strands is the mature miRNA; some mature miRNAs 
derive from the leading strand of the pri-miRNA transcript, and with other miRNAs 
the lagging strand is the mature miRNA.  
 
5. Strand Selection by RISC 
Selection of the active strand from the double stranded RNA is based on the stability 
of the termini of the two ends of the double stranded RNA (Khvorova et al. 2003; 
Schwarz et al. 2003). The strand with lower stability base pairing of the 2–4 
nucleotide at the 5' end of the duplex associates with the RNA-induced silencing 
complex (RISC) and thus becomes the active miRNA (Schwarz et al. 2003) (Fig. 
1.15). 
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Fig. 1.15 MiRNA transcription. The excision and activation of active single-
stranded miRNAs from precursor transcripts occurs through a multi-step process. A 
primary precursor miRNA (pri-miRNA) is transcribed from noncoding transcription 
units, or spliced off from introns of pre-mRNA. MiRNAs are expressed as part of 
pri-miRNAs and transcribed by RNA Polymerase II, that include 5' caps and 3' 
poly(A) tails. The miRNA portion of the pri-miRNA transcript forms a hairpin 
which signals for double stranded RNA-specific nuclease cleavage. The double 
stranded RNA-specific ribonuclease Drosha digests the pri-miRNA in the nucleus to 
release hairpin, pre-miRNA. This Pri-miRNA is processed by Drosha-type 
endonucleases following the so called pre-miRNA, which is exported from the 
nucleus by the receptor exportin-5. Exportin-5 binds directly to correctly processed 
pre-miRNAs, which is a requirement for miRNA biogenesis and a probable role in 
coordination of nuclear and cytoplasmic processing steps. The strand with lower 
stability base pairing of the 2–4 nucleotide at the 5' end of the duplex associates with 
the RNA-induced silencing complex (RISC) and thus becomes the active miRNA 
(Ambion).  
 
1.8.3 MiRNA Expression in Gliomas 
Oncogenic signalling is central to the development of most cancers, including the 
most common class of primary brain tumour, glioma. MicroRNAs are small non-
coding RNA molecules that regulate protein expression by targeting the mRNA of 
protein-coding genes, for either cleavage or repression of translation. MiRNAs are 
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effective post-transcriptional regulators of gene expression and are important in 
many biological processes. Although the oncogenic and tumour suppressive 
functions of several miRNAs have been characterized, the involvement of miRNAs 
in tumour invasion and migration remains largely unexplored. Increased 
understanding of the molecular and cellular mechanisms that drive glioblastoma 
formation are required to improve patient outcome.  
 
1.8.3.1 miRNAs Involved in the Proliferation and Invasion of Gliomas 
Several miRNAs have been implicated in regulating the development of gliomas 
through their targeting of mRNA involved in processes including growth and 
invasion. Knockdown of miR-221/222 in glioma cells and xenograft tumours 
reduced growth, invasion ability, cell cycle was blocked at G(0)/G(1) phase of the 
cell cycle, and apoptotic cell number increased (Zhang et al. 2009), which resulted 
in the downregulation of the anti-apoptotic gene bcl-2 and the upregulation of 
negative regulators of the cell cycle including connexin43, p27, p57, PUMA, 
caspase-3, PTEN, TIMP3 and Bax (Gillies and Lorimer 2007; Medina et al. 2008; 
Zhang et al. 2009; Zhang et al. 2009). It is known that P27 is expressed at low levels 
in high-grade astrocytomas (Piva et al. 1997). It seems likely that miR-221/222 play 
a crucial role in enhancing proliferation in gliomas. 
Very little is known about miRNA interactions with cellular pathways. 
MiRNAs have been associated with the Notch pathway, which plays key roles in 
nervous system development and in brain tumours (Kefas et al. 2009). Neuronally 
expressed miR-326 was upregulated following Notch-1 knockdown, and was not 
only suppressed by Notch but also inhibited Notch proteins and activity, indicating a 
feedback loop (Kefas et al. 2009). Transfection of miR-326 into both established 
and stem cell-like glioma lines and in vivo was cytotoxic, and rescue was obtained 
with Notch restoration (Kefas et al. 2009). MiR-326 partially mediated the toxic 
effects of Notch knockdown (Kefas et al. 2009).  
MiR-34a is a transcriptional target of p53, and is down-regulated in some 
cancer cell lines (Li et al. 2009). Transfection of miR-34a down-regulated c-Met in 
human glioma and medulloblastoma cells and Notch-1, Notch-2, and CDK6 protein 
expressions in glioma cells and stem cells, and strongly inhibited in vivo glioma 
xenograft growth (Li et al. 2009). MiR-34a expression is down-regulated in 
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glioblastoma tissues in comparison to normal brain and in mutant p53 gliomas as 
compared with wild-type p53 gliomas. MiR-34a in glioma and medulloblastoma cell 
lines strongly inhibited cell proliferation, cell cycle progression, survival, and 
invasion (Li et al. 2009). In human astrocytes transfection with miR-34a did not 
affect cell survival or cell cycle status (Li et al. 2009). MiR-34a suppresses brain 
tumour growth by targeting c-Met and Notch in glioma cells and stem cells (Li et al. 
2009).  
Overexpression of miR-125b promotes human glioma cell proliferation and 
inhibits all-trans retinoic acid (ATRA)-induced cell apoptosis and low expression of 
miR-125b sensitizes cells to ATRA-induced apoptosis (Xia et al. 2009). Bcl-2 
modifying factor (BMF) may play an important role in the process of miR-125b 
influencing cell apoptosis (Xia et al. 2009). 
MiR-21 up-regulation has been reported for the majority of cancers profiled 
to date; the mechanism of action of miR-21 is poorly understood, although it is 
known to  contribute to proliferation and apoptosis (Chen et al. 2008). MiR-21 
expression plays a key role in regulating cellular processes in glioblastomas, and 
appears to function as an anti-apoptosis factor in glioblastomas (Chan et al. 2005; 
Chen et al. 2008; Ohno et al. 2009); however the functional target genes of miR-21 
are largely unknown. Increased miR-21 levels have been found in human 
glioblastoma tumour tissues, early-passage glioblastoma cultures, and in established 
glioblastoma cell lines in comparison with non-neoplastic fetal and adult brain 
tissues, and in comparison with cultured nonneoplastic glial cells (Chan et al. 2005). 
In addition to increasing apoptosis, inhibiting miR-21 expression has also led to 
glioma cell growth suppression, invasion reduction, caspase-3 activity elevation and 
caspase-9 activation, but has not affected PTEN and caspase-8 expression (Shi et al. 
2008). Inhibiting miR-21 expression could induce glioma cell apoptosis via caspase-
9 and 3 activation, but not PTEN activation (Shi et al. 2008). MiR-21 is an 
important oncogene that targets a network of p53, TGF-beta, and tumour suppressor 
genes in glioblastoma cells (Zhu et al. 2007; Papagiannakopoulos et al. 2008). 
Downregulation of miR-21 contributes to the antitumour effects of IFN-beta and 
miR-21 expression is negatively regulated by STAT3 activation (Ohno et al. 2009), 
it also inhibits the EGFR pathway independently of PTEN status (Zhou et al.).  
Over-expression of miR-15b resulted in cell cycle arrest at G0/G1 phase 
while suppression of miR-15b expression resulted in a decrease of cell populations 
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in G0/G1 phase, and a corresponding increase of cell populations in S phase (Xia et 
al. 2009). MiR-15b regulates cell cycle progression in glioma cells by targeting cell 
cycle-related molecules including CCNE1 (encoding cyclin E1) (Xia et al. 2009). 
MiR-181a and miR-181b function as tumour suppressors leading to growth 
inhibition, apoptosis and inhibited invasion in glioma cells (Shi et al. 2008). Down-
regulated miR-181a and miR-181b may be critical factors that contribute to 
malignancy in human gliomas (Ciafre et al. 2005; Shi et al. 2008). 
Control of cell proliferation by Polycomb group proteins (PcG) is important 
in cellular homeostasis, and its disruption can promote tumorigenesis (Chao et al. 
2008). Chromobox protein homologue 7 protein (CBX7) is a novel PcG protein 
controlling the growth of normal cells (Chao et al. 2008). The protein level of CBX7 
was reduced in glioma tissues and cell lines in comparison to normal brain tissue 
and the up-regulation of miR-9 in glioma tissues and cell lines, was associated with 
down-regulation of CBX7 (Chao et al. 2008). 
MiRNA-128 is significantly down-regulated in glioblastoma cell lines in 
comparison to normal brain tissue (Ciafre et al. 2005; Godlewski et al. 2008); 
increased expression of miR-128 in glioblastoma cells reduced proliferation 
(Godlewski et al. 2008; Zhang et al. 2009). MiR-128 targets angiopoietin-related 
growth factor protein 5 (ARP5/ANGPTL6), Bmi-1 and E2F-3a, key regulators of 
brain cell proliferation. ARP5/ ANGPTL6 is a transcription suppressor that 
promotes stem cell renewal, and inhibits the expression of known tumour suppressor 
genes involved in senescence and differentiation; Bmi-1, a transcription factor 
critical for the control of cell-cycle progression, and E2F-3a, were found to be up-
regulated in glioblastoma (Cui et al. 2009; Zhang et al. 2009). Addition of miRNA-
128 into glioblastoma cell lines restored ARP5 (ANGPTL6), Bmi-1 and E2F-3a 
expression, and significantly decreased proliferation. Down-regulation of miR-128 
may contribute to glioma proliferation by up-regulating ARP5 (ANGPTL6), Bmi-1 
and E2F-3a (Cui et al. 2009; Zhang et al. 2009). 
The most common genetic alterations found in glioblastoma include EGFR 
activation and AKT pathways (Wong et al. 1987; Haas-Kogan et al. 1998). Low 
expression levels of miR-7 were found in glioblastoma in comparison to normal 
brain (Kefas et al. 2008). In glioblastoma cells transfection of miR-7 decreased the 
level of EGFR and upstream regulators of the AKT pathway, insulin receptor 
substrate 1 (IRS1) and insulin receptor substrate 2 (IRS2); these cells had increased 
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apoptosis and reduced invasion (Kefas et al. 2008). This would suggest that miR-7 
regulates the EGFR and AKT pathways. MiR-7 is a potential tumour suppressor in 
glioblastoma targeting critical cancer pathways. MiR-7 decreased viability and 
invasiveness of primary glioblastoma lines and is a regulator of major cancer 
pathways and suggests that it has therapeutic potential for glioblastoma (Kefas et al. 
2008). 
MiR-10b was initially identified as a miRNA highly expressed in metastatic 
breast cancer, promoting cell migration and invasion (Sasayama et al. 2009). MiR-
10b expression was found to be upregulated in glioma in comparison to normal 
brain tissue (Sasayama et al. 2009). The expression levels of miR-10b were 
associated with higher grade glioma. mRNA expressions of Ras homolog gene 
family, member C (RhoC) and urokinase-type plasminogen activator receptor 
(uPAR) were significantly correlated with the expression of miR-10b. MiR-10b 
might play some role in the invasion of glioma cells (Sasayama et al. 2009).  
MiR-146b significantly reduced the migration and invasion of glioma cells, 
by targeting a matrix metalloproteinase gene, MMP16. This implicates miR-146b as 
a metastasis-inhibiting miRNA in glioma (Xia et al. 2009).  
The Akt pathway, which is regulated by the tumour suppressor gene PTEN 
(phosphatase and tensin homolog), plays a crucial role in the process of 
gliomagenesis (Huse et al. 2009). MiR-26a is a direct regulator of PTEN expression. 
miR-26a is frequently amplified in human glioma, most often in association with 
monoallelic PTEN loss (Huse et al. 2009). MiR-26a-mediated PTEN repression in a 
murine glioma model enhanced de novo tumour formation (Huse et al. 2009).  
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1.9 Plan of Investigation 
 
Characterisation of a Panel of Newly Developed Glioma Cultures 
 To establish new glioma low passage cultures, derived from brain tumour 
biopsy samples. 
 To compare these low passage cultures with established glioma cell lines and 
early passage cultures from other laboratories; to identify potential cellular or 
molecular therapeutic targets. 
 To examine invasion, migration, proliferation and apoptosis in the presence 
of tyrosine kinase inhibitors imatinib, erlotinib, and gefitinib and 
chemotherapeutic drugs docetaxel and temozolomide, as single agents and in 
various combinations. 
 To examine the expression of EGFR in the glioma cultures in relation to the 
responsiveness to tyrosine kinase inhibitors, as erlotinib and gefitinib are 
tyrosine kinase inhibitors which specifically target EGFR, to determine if 
EGFR expression is indicative of a responder or non-responder to TKIs 
which target EGFR in  glioma. 
 To compare the expression of specific targets of imatinib including PDGFR-
β, C-Kit and C-Abl in relation to responsiveness to imatinib in the cultures, 
to see if these targets are indicative of responsiveness to imatinib in glioma. 
 To see if the expression levels of ABC transporter proteins, Pgp and BCRP 
indicated sensitivity or responsiveness to TKIs or chemotherapeutic drugs. 
 To correlate responsiveness to TKIs with their target expression including 
PDGFR-α, PDGFR-β, C-Abl, C-Kit, (specific targets of imatinib); EGFR 
and EGFRvIII (specific targets of erlotinib and gefitinib), and downstream 
targets of the EGFR and PDGFR signalling pathway, e.g. phosphorylated 
Akt, PTEN and p70S6K in the cultures. 
 To measure the accumulation of tyrosine kinase inhibitor gefitinib in a panel 
of these cultures, to determine if the amount of drug within the cell is related 
to responsiveness to gefitinib in glioma cells.
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Identification of Key MiRNAs 
 Identification of key miRNAs, which are correlated with tumour 
proliferation and invasion, in fully characterized primary cell cultures 
developed from brain tumour tissue, in order to identify novel markers and 
increase our understanding on the pathways involved in glioblastoma 
proliferation and invasion. 
 Validation of identified key miRNAs in selected established cell lines and 
primary glioma cultures and in normal human astrocytes. To identify 
miRNAs associated with proliferation/ invasion in malignant glioma. 
 Functional validation of identified key miRNAs in selected glioma cultures, 
to demonstrate that these miRNAs have a significant role to play in the 
progression of malignant glioma. 
 
 
1.10 Overall Thesis Hypothesis 
To develop a cohort of early passage glioma cultures from tumour biopsy samples 
and determine their response to the TKIs, erlotinib, gefitinib and imatinib and 
correlate this with expression of specific targeted proteins of the TKIs, EGFR, 
PDGFR, C-Abl, C-Kit and downstream targets of the EGFR and PDGFR signalling 
pathway, PTEN, Akt and p70S6K to see if expression of these proteins is indicative 
of TKI response in glioma. 
 To characterise the glioma cultures in relation to their invasion and 
proliferation rate, and look at the effect of TKIs and chemotherapeutic drugs on these 
characteristics. To examine the expression of drug efflux pumps in these cultures, 
and to correlate this with drug sensitivity. 
 To identify key miRNAs which play a role in the malignant progression of 
glioma, i.e. that are directly involved in the regulation of proliferation and/ or 
invasion in glioma. 
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Section 2.0 Materials and Methods 
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2.1 Cell Culture 
All cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 10% 
fetal calf serum (Harlan 5-0001AE), and 4% non-essential amino acids (NEAA) 
100x (GIBCO 11140).  
  Normal human cerebral and foetal astrocytes were purchased from Lonza 
(CC-2565) and cultured in an astrocyte bullet kit (CC-3186) containing 500 mls of 
Astrocyte Basal Medium (no growth factors) and Supplements for a complete 
growth medium, developed especially for NHA. 
 
2.1.1 Origin of Cell Cultures 
Primary cell cultures were established from brain tumour biopsy samples from 
Beaumont Hospital, Dublin. Approved by the Ethics (Medical Research) (ERC/IRB) 
Committee in Beaumount Hospital, Dublin9, investigator: Professor Michael Farrell, 
protocol number: 04/05, title: Cellular Investigation of Drug Effect on the Invasive 
Behaviour of Malignant Astrocytoma, final approval date 31st August 2005. 
 
All newly established glioma cultures were below passage 10. The passage numbers 
of other cell cultures used during this study are listed in table 2.1. 
 
          Table 2.1 Passage numbers of cell cultures used in this study. 
 
 
 
 
 
 
 
 
*: SNB-19 has the same origin as the cell line U251 and there is a possibility that 
they are the same cell line (Lorenzi et al. 2009). 
 
 
 
 
 
Cell Culture Passage Numbers 
 
CLOM002 11 to 40 
UPHHJA 9 to 25 
SNB-19* +9 to +31 
IPSB-18 52 to 72 
NHA Below 6 
SNB-19- Tem +40 
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          Table 2.2 Origin of cell cultures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
Tem:temozolomide. Prev res: previous resection. Later res: later resection. 
1: Geoff Pilkington’s laboratory, University of Portsmouth, UK. 
2: The German cell bank Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 
(DSMZ), Germany (German Collection of Microorganisms and Cell Cultures). 
3: Lonza biologics, Cambridge, UK (CC-2565). 
4: The National Institute for Cellular Biotechnology, Dublin City University, Ireland. 
Cell Culture Origin Source 
 
CLOM002 Primary Glioblastoma 1 
UPHHJA Primary Glioblastoma 1 
 SNB-19 Primary Glioblastoma 2 
  IPSB-18 Grade III Astrocytoma 1 
  NHA Cerebral & Foetal Astrocytes 3 
SNB-19-Tem Primary Glioblastoma 4 
N070055 Grade III Oligoastrocytoma  4 
N070126 Primary Glioblastoma  (later res) 4 
N070152 Primary Glioblastoma 4 
N070201 Grade III Astrocytoma  4 
N070219 Grade II Oligodendroglioma  4 
N070314 Grade II Oligodendroglioma 4 
N070788 Grade III Astrocutoma (prev res) 4 
N070859 Primary Glioblastoma 4 
N070865 Primary Glioblastoma 4 
N080501 Primary Glioblastoma 4 
N080533 Primary Glioblastoma 4 
N080540 Primary Glioblastoma 4 
N080869 Primary Glioblastoma 4 
N080923 Primary Glioblastoma 4 
N080943 Primary Glioblastoma 4 
N070229 Grade III Astrocytoma 4 
N070237 Grade III Astrocytoma (prev res) 4 
N070440 Secondary Glioblastoma (prev res) 4 
N070450 Grade II Astrocytoma 4 
N070780 Secondary Glioblastoma (prev res) 4 
N070934 Primary Glioblastoma 4 
N071155 Grade III Oligodendroglioma 4 
N060893 Secondary Glioblastoma (prev res) 4 
N060913 Primary Glioblastoma 4 
N060950 Grade III Oligoastrocytoma 4 
N060978 Primary Glioblastoma 4 
N061007 Primary Glioblastoma 4 
N061092 Primary Glioblastoma 4 
      N070454* Primary Glioblastoma 4 
N070701 Secondary Glioblastoma (prev res) 4 
N070293 Primary Glioblastoma 4 
N071026 Primary Glioblastoma 4 
N071057 Primary Glioblastoma 4 
N071060 
      Primary Glioblastoma 4 
N071144 
      Primary Glioblastoma 4 
N071271 
      Primary Glioblastoma 4 
N080558 
      Primary Glioblastoma 4 
N080749 
      Primary Glioblastoma 4 
N080805 
      Primary Glioblastoma 4 
N081185 Secondary Glioblastoma  prev res) 4 
N070215 Grade III Astrocytoma (prev res) 4 
N070950 Grade III Oligoastrocytoma 4 
N070311 Secondary Glioblastoma 4 
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Table 2.3 Preparation of Drugs 
Drug Dilution Source 
 
Erlotinib (Tarceva) 10 mg/ml Sequoia Research Products Ltd 
 
Gefitinib (Iressa) 10 mg/ml Sequoia Research Products Ltd 
 
Elacridar (GF120918) 10 mg/ml Sequoia Research Products Ltd 
 
Imatinib (Glivec) 10 mg/ml Novartis 
 
Docetaxel (Taxotere) 10 mg/ml Sanofi Aventis 
 
Temozolomide (Temodal) 20 mg/ml Donated from the National 
Cancer Institute, USA 
 
Drugs were diluted in DMSO, Docetaxel was in liquid form. 
 
2.2 Generation of Cultures from Biopsy Samples 
The tissue sample was placed into a petri dish, with cold DMEM media containing 
10% fetal calf serum and 4% NEAA. Each tissue sample was dissected into very 
small pieces using a scalpel and tweezers (to hold the tissue in place). The dissected 
tissue sample was pipetted up and down 3-4 times to further break up the sample. 
The media containing the dissected tissue sample was then pipetted into vented 
25cm2 flasks. After 2 days the media was removed and placed into fresh vented 
25cm2 flasks. Fresh media was placed onto the original vented 25cm2 flasks, where 
attached cells were left to proliferate. All flasks were continuously given media 
changes to generate primary cultures. Generation of each primary culture ranged 
from one to four months. 
 
2.3 Proliferation Assays 
Cells in the exponential phase of growth were harvested by trypsinisation. Cell 
suspensions containing 2x104 cells/ml were prepared in cell culture medium. 100 
µl/well of the cell suspension was added to 96-well plates (Costar, 3599). Plates 
were agitated gently in order to ensure even dispersion of cells over the surface of 
the wells. Cells were then incubated overnight. Drug dilutions were prepared at 2X 
their final concentration in cell culture medium, as 100 µl of cells was already on the 
plate this allowed for a 1 in 2 dilution of the drug. 100 µl of the drug dilutions were 
then added to each well. Plates were then mixed gently as above. Cells were 
incubated for a further 7 days until the control wells had reached approximately 80-
90% confluency.  
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2.3.1 Assessment of Cell Number - Acid Phosphatase Assay 
 
A. Acid Phosphatase in 96-well plate format. 
Following an incubation period of 6-7 days, media was removed from the plates. 
Each well on the plate was washed with 100 µl PBS. This was removed and 100 µl 
of freshly prepared phosphatase substrate (10 mM p-nitrophenol phosphate (Sigma 
104-0) in 0.1 M sodium acetate (Sigma, S8625), 0.1% triton X-100 (BDH, 30632), 
pH 5.5) was added to each well. The plates were wrapped in tinfoil and incubated in 
the dark at 37°C for 1.5 hours. The enzymatic reaction was stopped by the addition 
of 50 µl of 1 M NaOH to each well. 
 
B. Acid Phosphatase in 6-well plate format. 
Following an incubation period of 72 hours, media was removed from the plates. 
Each well on the plate was washed with 1 ml PBS. This was removed and 2ml of 
freshly prepared phosphatase substrate in 0.1 M sodium acetate, 0.1% triton X-100 
(BDH, 30632), pH 5.5) was added to each well. The plates were wrapped   in   
tinfoil and incubated in the dark at 37°C for 2 hours. The enzymatic reaction was 
stopped by the addition of 1 ml of 1 M NaOH to each well. Plates were read in a 
dual beam plate reader at 405 nm with a reference wavelength of 620 nm. 
Assessment of cell survival in the presence of drug was determined by the acid 
phosphatase assay. Results were graphed as percentage survival (relative to the 
control cells) versus drug concentration, using excel software. 
2.3.2 Measurement of Doubling Time 
Cells were seeded in two 6 well plates at a concentration of 5000 cells/2ml/well and 
incubated approximately 72 hours before the first cell count. For each cell count 
cells of two wells were trypsinized, centrifuged and resuspended in 100 µl culture 
medium. Cells were counted using a haemocytometer. Cells were counted every 48 
or 72 hours and 6 times in total. The doubling time was calculated in three steps: 
The counted cell number was divided by the previous count resulting in a 
multiplication factor. Then the time period between two counts was divided by the 
multiplication factor and the resulting number was multiplied by 2. A series of 
doubling times was obtained for each cell line, which were then averaged. Trypan 
blue staining was used to check for viable cells. 
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2.4 Drug Scheduling for Proliferation Assays 
Cells were exposed to each drug/drug combination for 24 hrs in a consecutive way. 
For the proliferation assay each treatment schedule was performed with three 
different drug concentrations (IC10, IC25 and IC50) per drug, representing high, 
medium and low concentrations. The assay was done twice in triplicates. In the 
invasion assay we tested 4 different drug schedules individually with one set of drug 
concentrations. After the last incubation drug/drug combination containing medium 
was replaced with fresh medium and the cells were incubated for a further 3 days.  
 
2.5 Analysis of Drug Combination Effects  
The effect of the drug combination on cell kill was performed and analysed 
according to a protocol by Chou and Talalay (Chou and Talalay 1984). For each cell 
line the IC10, IC20, and IC30 of imatinib was combined with the IC10, IC20, and IC30 
of docetaxel, resulting in a total of nine value points per combination index (CI) 
plot. A range of IC values were tested to examine the combination effect at low and 
high toxicity. A CI value smaller than 1 indicates a synergistic action of the two 
drugs; a CI value equal 1 an additive effect and a CI value greater than 1 indicates 
an antagonistic effect.  
 
2.6 Apoptosis Assay 
On day 0 cells were set up at 1x104 cells/well in a 24-well plate. On day 3 the media 
was removed and drug was added. After 24 or 48 hrs cells were trypsinized and 
counted. After incubation, the supernatant was removed to eppendorfs, rinsed with 
300 µl sterile PBS, this PBS was added to the same eppendorf. During trypsinisation 
this was spun at 1000rpm for 5 minutes at RT. 300 µl trypsin was added to each 
well, the plate was covered with parafilm and incubated at 37oC and 5% CO2 with 
monitoring until the cells had detached. 600 µl of serum-supplemented medium was 
added to each well and this was added to the initial eppendorf, with previously 
removed supernatant containing centrifuged cells. Each well was washed with 300 
µl sterile PBS and this was also added to the same eppendorf. This was also spun at 
1000rpm for 5 minutes at RT. The supernatant was gently removed and resuspended 
in 150 µl serum-supplemented medium. 75 µl of sample was added to a well in a 96-
well round bottomed plate. A 75 µl sample of a positive control (cells exposed to 
drug) was included, and also a 75 µl sample that is a negative control (cells not 
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exposed to anything). These were used to adjust the settings on the Guava. 75 µl of 
nexin reagent was added; this was mixed and incubated for 20 minutes with gentle 
mixing in the dark (i.e. covered with tin foil). Cells were assessed for early and total 
apoptosis using the Guava Nexin® Assay and the Guava® EasyCyteTM Flow 
Cytometer according to manufacturer’s recommendations. At least 3 biological 
replicates in duplicate for each condition was used. 
 
The Guava Nexin® Annexin V Assay 
The Guava Nexin® Annexin V Assay offers detected early apoptosis. The assay 
relies on the translocation of phosphatidyl serine (PS) to the outer surface of the cell 
membrane, an event often associated with the onset of apoptosis. A mix-and-read 
assay for monitoring externalization of PS through the binding of Annexin V to the 
exposed PS, the automated single-cell analysis assay is the choice for monitoring 
apoptosis due to its sensitivity and reproducibility. Annexin V is a calcium-
dependent phospholipid binding protein with high affinity for phosphatidylserine 
(PS), a membrane component normally localized to the internal face of the cell 
membrane. Early in the apoptotic pathway, molecules of PS are translocated to the 
outer surface of the cell membrane where Annexin V can readily bind to them. 
The assay relies on a two-dye stategy: 1) Annexin V-PE to detect PS on the external 
membrane of apoptotic cells and 2) 7-AAD, a cell impermeant dye, as an indicator 
of membrane structural integrity. 7-AAD is excluded from live, healthy cells and 
early apoptotic cells, but permeates late-stage apoptotic and dead cells. 
 
2.7 3D Collagen Invasion Assay 
Cell spheroids were formed using the hanging drop method described by Del Duca 
(Del Duca et al. 2004). Briefly, after trypsinisation the cells were diluted with 
conditioned medium (CM) reaching a concentration of 1x106cells/ml. Drops (20 µl) 
of cell suspensions were placed onto the lids of 100 mm Petri dishes, which were 
inverted over dishes containing 10 ml sterile water. Hanging drop cultures were 
incubated for 24-48 hrs until cell aggregates were formed, which were transferred to 
a 100 mm dish coated with 4% agar and filled with 10 ml CM. The 
aggregates/spheroids were incubated for another 2 days, while they rounded up, and 
then implanted into collagen gel. Cold PureColTM (INAMED, USA) was mixed with 
cold 10-fold concentrated minimal essential medium (Sigma) and cold 0.1 M 
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sodium hydroxide at a ratio of 8:1:1 reaching a final concentration of 2.4 mg/ml 
collagen type I. The pH was neutralised by adding 1 M NaOH (Sigma). The 
collagen solution was distributed into 24-well plates (0.5 ml/well) and one spheroid 
was placed into each well. The plates were kept at 37°C for about 30-60 min. After 
solidification the gels were overlaid with 0.5 ml CM and kept at 37°C under 5% 
CO2. On day 4, the medium was replaced with fresh CM (control) or drug-
containing CM. Cell migration out of the spheroid was measured before drug 
addition (day 0) to 12 after drug addition.  
 
2.7.1 Spheroid Measurement 
Spheroid measurements were taken at 4X magnification using a graticule eye piece, 
with 10 mm line in 100 parts, each part = 0.1 mm. A spheroid measurement was 
taken from a central point in the spheroid. Each spheroid had 4 measurements per 
timepoint. Day 0 (post 4 day spheroid invasion) measurements were subtracted from 
the overall measurements. Each condition was done in duplicate per experiment, with 
3 biological repeats, in some cases 2 biological repeats. 
 
2.8 In vitro Invasion Assay 
Invasion assays were performed using the method of Albini et al.(Albini et al. 
1997). 100 µl of matrigel were placed into each insert (Falcon 3097) (8.0 µm pore 
size, 24 well format) and kept at 4 oC for 24 hours. 4 inserts per 24 well plate was 
used per assay, with 3 separate assays. The insert and the plate were then incubated 
for one hour at 37 oC to allow the proteins to polymerise. Cells were harvested and 
resuspended in culture media containing 5% FCS at 1 × 106 cells/ml. Excess 
media/PBS was removed from the inserts, and they were rinsed with culture media. 
100 µl of the cell suspension was added to each insert. A further 100 µl of culture 
media was added to each insert and 500 µl of culture media containing 5% FCS was 
added to the well underneath the insert. Cells were incubated for 24 hours. After this 
time period, the inside of the insert was wiped with a cotton swab dampened with 
PBS, while the outer side of the insert was stained with 0.25% crystal violet for 10 
minutes and then rinsed in distilled water (dH2O) and allowed to dry. The inserts 
were then viewed and photographed under the upright brightfield microscope. The 
invasion assays were quantified by counting cells in 10 random fields within a grid 
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at 20x objective and graphed as the total number of cells invading at 200x 
magnification. 
 
2.9 Drug Accumulation Assay 
On day 0 Cells were seeded at 5 x 104 cells/ml in T25 flasks (3 flasks per cell line 
per drug) and 3 control flasks also with no drug. On day 1 the medium was removed 
and 5mls of medium with drug was added. The flasks were incubated for 2 hours; 
the drug containing medium was then removed. The flasks were than washed with 4 
mls of cold PBS. The cells were than trypsinised with 2 mls of trypsin; this was 
stopped with 2mls of medium. The suspensions were transferred into extraction 
tubes, centrifuged at 1000rpm and the supernatant then removed leaving the pellet 
intact. The pellet was resuspended in 1ml of PBS. A small aliquot was removed for 
counting. This was then spun down, and the PBS was removed, the pellet was then 
frozen at -20oC. The samples were then analysed by mass spectrometry by a 
postgraduate student, Sandra Roche, in the National Institue for Cellular 
Biotechnology. 
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2.10 Western Blotting 
 
2.10.1 Whole Cell Extract Preparation 
Cells were grown to 80-90% confluency in cell culture grade petri dishes. Media 
was removed and cells were washed twice with 10 mls ice cold PBS. All procedures 
from this point forward were performed on ice. Cells were lysed with 150 µl of NP-
40 lysis buffer (425 ml dH2O water, 25 ml 1 M Tris-HCl (pH 7.5) 50 mM Tris-HCl 
(pH 7.5), 15 ml 5 M NaCl 150 mM NaCl, 2.5 ml NP-40 0.5% NP-40) 15 µl of the 
10X protease (100X Protease inhibitors 2.5 mg/ml leupeptin, 2.5 mg/ml aprotinin, 
15 mg/ml benzamidine and 1 mg/ml trypsin inhibitor in dH2O) and 1.5 µl 
phosphatase inhibitors (100 mM DTT 154 mg in 10 ml dH2O, 100 mM PMSF 174 
mg in 10 ml 100% ethanol) were also added to each petri dish and incubated on ice 
for 20 minutes. Cells were then removed with a cell scraper and further 
homogenised by passing through a 21 guage syringe. Sample lysates were 
centrifuged at 14,000 rpm for 10 minutes at 4 oC. Supernatant containing extracted 
protein was transferred to a fresh chilled eppendorf tube. Protein concentration was 
quantified using the Biorad assay. Samples were then stored in aliquots at -80°C. 
 
2.10.2 Protein Quantification 
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad, 500-
0006) according to maufacturers guidelines, with a 2 mg/ml bovine serum albumin 
(BSA) solution (Sigma, A9543). 
 
2.10.3 Gel Electrophoresis 
Proteins for analysis by Western blotting were resolved using SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE). PAGEr®duramide®Precast Gels with 7.5% Tris-
Glycine gels (Lonza, 59601) were used. The gels were run at 250V and 20mA until 
the bromophenol blue dye front was found to have reached the end of the gel, at 
which time sufficient resolution of the molecular weight markers was achieved. In 
advance of samples being loaded in to the relevant sample wells, 20 µg of protein 
was diluted in 5x loading buffer. Molecular weight markers (Sigma, C1992) were 
loaded alongside samples. Western Blotting was performed by the method of 
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Towbin et al, 1979. Once electrophoresis was complete, the SDS-PAGE gel was 
equilibrated in transfer buffer (25 mM Tris (Sigma, T8404), 192 mM glycine 
(Sigma, G7126), pH 8.3-8.5) for approximately 15 minutes. Five sheets of Whatman 
3 mm filter paper were soaked in freshly prepared transfer buffer. These were then 
placed on the cathode plate of a semidry blotting apparatus (Bio-rad). Air pockets 
were then removed from between the filter paper. Nitrocellulose membrane (GE 
Healthcare, RPN 3032D), which had been equilibrated in the same transfer buffer, 
was placed over the filter paper on the cathode plate. Air pockets were once again 
removed. The gels were then aligned onto the membrane. Five additional sheets of 
transfer buffer soaked filter paper were placed on top of the gel and all air pockets 
removed. The anode was carefully laid on top of the stack and the proteins were 
transferred from the gel to the membrane at a current of 275mA at 25 V for 30-40 
minutes, until all colour markers had transferred. Following protein transfer, 
membranes were stained using PonceauS (Sigma, P7170) to ensure efficient protein 
transfer. The membranes were then blocked for 2 hours at room temperature using 
5% blotting grade blocker (Bio-Rad 170-6404) in PBS with 0.1% tween 20 (Sigma 
P1379) at 4 °C. Membranes were incubated with primary antibody overnight at 4 
°C. Antibodies were prepared in 5% blotting grade blocker in PBS with 0.1% tween. 
Primary antibody was removed after this period and the membranes rinsed 3 times 
with PBS containing 0.5% Tween 20 for a total of 15-30 minutes. Secondary 
antibody (1 in 1,000 dilution of anti-mouse IgG peroxidase conjugate (Sigma, 
A4914)) in PBS, was added for 1.5 hours at room temperature. The membranes were 
washed thoroughly in PBS containing 0.5% Tween for 15 minutes. 
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       Table 2.4 Western Blot antibodies. 
Primary Antibody Dilution Source 
 
Pgp 1:200 Sc-13131, Santa Cruz  
EGFR 1:100 Ab-15, Lab Vision 
PDGFR-β 1:50 PR7212, Calbiochem  
PDGFR-α 1:500 Ab35765, Abcam 
BCRP 1:40 Ab3380, Abcam  
C-Abl 1:500 Tyr245, Cell signalling 
BCR-Abl 1:1000 3902, Cell Signalling 
C-Kit 1:1000 Ab32363, Abcam  
β-actin 1:10,000 A5441, Sigma  
Secondary 
Antibody 
Dilution Source 
Anti-mouse 
 
1:1000 A6782, Sigma 
Anti-rabbit 
 
1:500 18772, Sigma 
 
 
2.10.4 Enhanced Chemiluminescence (ECL) Detection 
Immunoblots were developed using Luminol (Sc-2048, Santa Cruz) and ECL 
AdvanceTM (Amersham, RPN2135) which facilitated the detection of bound 
peroxidase-conjugated secondary antibody. 
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2.11 Immunocytochemistry 
 
2.11.1 Primary Culture Preparation for Immunocytochemistry 
To ensure the cells were screened in their natural state, they were plated on chamber 
slides (Menzel Glaeser) at a concentration of 6.25x104 cells/ml in 80 µl  culture 
medium per well. Cells were incubated for 24hrs at 37oC, 5% CO2, and were then 
fixed with ice cold acetone, air dried and stored at -20oC. This work was carried out 
with my supervisor Dr. Verena Amberger Murphy. The slides were transported to 
Beaumont Hospital for staining by immunohistochemistry. The following 3 sections 
describe ICC carried out by Rachel Howley in Beaumont hospital. 
 
2.11.2 Automated Immunocytochemistry (ICC) 
To ensure all tissue microarrays (TMAs) and chamber slides were treated under the 
same conditions, where possible, antibodies were optimised for use on the 
automated Bond™maX system (Vision Biosystems™, Leica Microsystems, Milton 
Keynes, UK.) The procedure for automated immunocytochemistry on Bond™maX 
was set up as described in the user manual (Table 2.5).  
 
2.11.3 Manual Immunocytochemistry 
Both cultured chamber slides and formalin fixed paraffin embedded (FFPE) TMAs 
were immunohistochemically manually stained for phospho-AKT and phospho-
P70S6K. Culture chamber slides were treated with 3% hydrogen peroxide for 5 mins 
to block endogenous peroxidases. They were then washed for 5 mins (x2) in TBS-T, 
circled with the pap pen. All slides were blocked with 100-200 µl per slide of 
blocking buffer (5% Normal Goat Serum (Vector)) in TBST for 1 hour at room 
temperature, followed by an incubation with primary antibody overnight at 4oC. 
Both primary antibodies were diluted in blocking buffer; 1/60 and 1/30 for phospho-
AKT and phospho-P70S6K.  
      The following day all unbound primary antibody was removed using 5 min (x3) 
washes with TBS-T. The biotinylated anti-rabbit secondary antibody (Vector) was 
diluted 1/200 in blocking buffer and applied to each slide for 30 mins at room 
temperature. Again, all unbound antibody was removed by washing with TBS-T (5 
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min x3). The ABC complex (ABC vectastain kit, Vector) diluted 1/100 in TBS-T 
was applied to the slides for 30 mins at room temperature. (Note: the ABC complex 
was prepared 30 mins prior to use to allow the Avidin-Biotin Complex to form.) All 
unbound Avidin complex was removed by washing with TBS-T for 5 mins (x3) 
after which the chromagen Novared (Vector) was applied for 5-10 mins. This 
peroxidase labelled chromagen reacts with the Horseradish Peroxidase (HRP) 
labelled Avidin resulting in a red stain located wherever the primary antibody is 
bound. The reaction was stopped by immersing in a trough of running tap water 
before being Haematoxylin stained for 1 min. Excess Haematoxylin was rinsed in 
running tap water and the slides were dipped in acid alcohol once before allowing 
the haematoxylin to darken in running tap water for 5 mins. Finally, the slides were 
dehydrated by dipping once in three alcohol dips (95%, 100%, 100% ethanol) before 
being submerged in two xylene washes. Finally the slides were mounted with DPX 
(Fisher) and viewed under the microscope for manual scoring or image analysis 
(Table 2.5). 
 
2.11.4 Manual Scoring of Immunocytochemistry 
In order to quantify the amount of each protein present in ICC stained slides a 
manual scoring system was established. This scoring system took into consideration 
both the staining intensity and the percentage of cells that were stained as previously 
described by Riemenschneider (Riemenschneider et al. 2006). The staining intensity 
was recorded on a scale of 0-3 for each protein. The percentage of cells stained was 
divided into the four quartiles; 0, 1-25%, 26-50%, 51-75% and 76-100% which were 
assigned values of 0, 1, 2, 3 and 4 respectively. An overall score was determined by 
multiplying the score for staining intensity (0-3) by the score for the percentage of 
cells stained (0-4) for an overall score between 0-12. Manual scoring was carried out 
by a Ph.D student, Rachel Howley from Beaumont Hospital, Dublin and a 
neuropathologist, Professor Michael Farrell.  
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Table 2.5 Immunocytochemistry methods. 
 
       CST: Cell Signalling Technologies,      BPDS: Bond Polymer Detection System. 
 
Antibody Cat. No. Company Working 
Dilution 
IHC Method Technology Chromagen 
(staining) 
EGFR tot 4267S CST 1:50 Automated  BPDS DAB 
EGFR vIII 
Donated by Darell D. 
Bigner, Duke University 1:50 Automated  BPDS DAB 
PTEN  
(Clone 
6H2.1) ABM-2052 
Cascade 
Biosciences 1:300 Automated  BPDS DAB 
Phos-AKT 
(Pan) 
(Thr308) 9266L CST 1:60 Manual  
Vecastain 
ABC Biotin / 
Avidin  Novared 
Phos-
P70S6K 
(Thr389) Ab32359 Abcam 1:30 Manual  
Vecastain 
ABC Biotin / 
Avidin  Novared 
PDGFR α 3164 CST  1:100 Automated  BPDS DAB 
PDGFR β 3169 CST  1:50 Automated  BPDS DAB 
Phos-C-Abl  
(Thr245) Ab4479 Abcam 1:50 Automated  BPDS DAB 
Phos-C-KIT  
(Tyr 721) Ab5632 Abcam 1:/65 Automated  BPDS DAB 
GFAP Z0334  Dako 1:7000  Automated  BPDS DAB 
NESTIN  
(Clone 
10C2) MAB 5326  Millipore 1:500  Automated  BPDS DAB 
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2.12 Statistical Methods 
Statistical methods were used to analyse our immunocytochemistry (section 3.5) 
results in comparison to responsiveness to TKIs of the cell cultures; to test the 
dependency of the cultures with the PI3K/Akt pathway. The cohort included 26 
high-grade glioma cell cultures, this dataset was too small for supervised analysis, 
therefore unsupervised analysis was used, hierarchial clustering analysis and 
principal components analysis were chosen for multivariate statistics. 
 
2.12.1 Hierarchical Clustering Analysis 
Cluster analysis is the assignment of a set of observations into subsets (called 
clusters) so that observations in the same cluster are similar in some sense. This is an 
unsupervised analysis which is commonly used. Hierarchical clustering creates a 
hierarchy of clusters which can be depicted in a tree structure called a dendrogram. 
The root of the tree consists of a single cluster containing all observations, and the 
leaves correspond to individual observations. Any valid metric may be used as a 
measure of similarity between pairs of observations. The choice of which clusters to 
merge or split is determined by a linkage criterion, which is a function of the 
pairwise distances between observations. The results are in a dendrogram signifying 
a hierarchical clustering algorithm using Ward’s linkages in Euclidian space (Lomo 
et al. 2008). 
 
2.12.2 Principal Components Analysis 
Principal component analysis (PCA) involves a mathematical procedure that 
transforms a number of possibly correlated variables into a smaller number of 
uncorrelated variables called principal components. The first principal component 
accounts for as much of the variability in the data as possible, and each succeeding 
component accounts for as much of the remaining variability as possible. It is a 
popular technique in pattern recognition. It can be used to extract relevant 
information from confusing data sets. It can transform a complex data set to a lower 
dimension to reveal the sometimes hidden, simplified structures that often underlie it 
(Shlens 2009). 
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2.12.2 One Way Anova 
One-way analysis of variance is a technique used to compare means of two or more 
samples (using the F distribution). This generates a p value; a p value less than or 
equal to 0.05 is classified as statistically significant. 
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2.13 MicroRNA 
2.13.1 Taqman Low Density Array (TLDA)  
The TaqMan® Custom Array is a 384-well micro fluidic card that allows you to 
perform 384 simultaneous real-time PCR reactions without the need to use multi-
channel pipettors to fill the card. This card allows for 1-8 samples to be run in 
parallel against 12-384 TaqMan® Gene Expression Assay targets that are pre-loaded 
into each of the wells on the card.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(www.appliedbiosystems.com) 
 
Fig 2.1 TaqMan low density array workflow. 1:Isolate total RNA that contains small 
RNAs such as miRNA, siRNA, and snRNA. 2: convert miRNA to cDNA prior to 
real-time PCR quantitation.3: dilute RT product. 4: TaqMan® Universal Master Mix 
II is added to each sample and pipetted into the sample loading ports of a TaqMan® 
Array Card. 5: The Taqman arr card in run, performing real-time PCR.6: data 
analyzed.
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Materials for TLDA anaylsis 
Human Multiplex RT set (Pools 1-8) (P/N 4384791, Applied Biosystems) 
TaqMan® MicroRNA Reverse Transcription Kit (200 reactions) (Applied 
Biosystems P/N 4366596) 
TaqMan® 2X Universal PCR Master Mix, No AmpErase® UNG   (Applied 
Biosystems P/N 4324018) 
TaqMan® Array Human MicroRNA Panel V 1.0 (4 Arrays) (Applied Biosystems 
P/N 4384792) 
MirVanaTM miRNA isolation kit  (Applied Biosystems AM1560) 
 
Multiplex reverse transcription 
1. Prepare the RT master mix 
The taqman microRNA reverse transcription kit components were thawed on 
ice. The directions and volumes listed below were for a single sample and were 
scaled appropriately. 
a. The RT master mix for a total of eight multiplex RT reactions was prepared 
in a polypropylene tube (12.5% excess volume was allowed for pipetting 
losses). 
b. This was mixed gently and centrifuged at 1000 rpm for 30 seconds, then 
placed on ice. 
 
Table 2.6  Preparation of RT master mix 
 
Component Volume for one RT 
reaction (µl) 
Volume for one 
sample (8 RT 
reactions) with 25% 
excess (µl) 
100 mM dNTPs 0.2 2 
MultiScribe™ reverse 
transcriptase, 
50 U/µl 
 
2 20 
10x reverse transcription buffer 1 10 
RNase inhibitor, 20U/µl 0.125 1.25 
Nuclease-free water 2.675 26.75 
Total 6 60 
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Add the RNA template 
a. 2 µl of the 50 ng/µl total RNA template was dispensed into each well of the 
MicroAmpTM optical reaction plate. 
b. The MicroAmpTM optical reaction plate was placed on ice. 
 
2. Prepare the multiplex RT reaction 
a. 6 µl of RT master mix was dispensed into each well of the MicroAmpTM 
optical reaction plate. 
b. 1 µl of each multiplex RT human primer pool (5x) was transferred into the 
appropriate wells. A total of eight independent RT reactions were run per 
sample. The plate was sealed using MicroAmpTM optical adhesive film.  
c. This was mixed gently. The plate was placed on ice for 5 minutes before 
loading it into the thermal cycler. 
 
3. Perform multiplex reverse transcription 
a. The thermal cycler was set to the 9600 emulation mode as follows 
  
                         Table 2.7 Thermal cycle for RT reaction   
 
Step Type 
 
 
Time 
(min) 
 
Temperature 
( °C) 
HOLD 30 16 
HOLD 30 42 
HOLD 5 85 
HOLD ∞ 4 
   
The volume was set to 10 µl, the plate was put into the thermal cycler and the run 
was started. 
 
Taqman array 
1.  Preparing the RT reaction-specific PCR mix 
a. The RT reaction was diluted 62.5-fold by adding 615 µl of nuclease free 
water to each of the eight 10 µl RT reactions. For each RT reaction a 1.5 ml 
microcentrifuge tube was labelled. 
b. The Taqman Universal PCR Master Mix was thawed on ice. 
c. The following components were added to each 1.5 ml microcentrifuge tube 
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                  Table 2.8 Preparation of PCR master mix 
         
 
 
 
 
 
d.  The microcentrifuge tubes were capped and mixed gently. 
e. The tubes were centrifuged to eliminate air bubbles from the mixture, and    
placed on ice. 
 
2. Loading the RT reaction-specific PCR reaction mix into fill reservoirs 
a. When the TaqMan array had equilibrated to room temperature, the card was   
carefully removed from the packaging, and placed foil side down on the lab 
bench. 
b. 100 µl of the RT reaction-specific PCR reaction mix was loaded into the 
corresponding ports. This was dispensed so that it went in and around the fill 
reservoir toward the vent port; the entire 100 µl was pipetted into the fill 
reservoir. 
 
3. Centrifuge the TaqMan Array 
a. The TaqMan Arrays were centrifuged according to the user bulletin: Applied 
Biosystems TaqMan® Low Density Array (P/N 4371129). 
b. Centrifugation was repeated so that the arrays were centrifuged for a total of 
two consecutive, 1 minute spins to ensure complete distribution of the PCR 
reaction mix. 
c. When complete each array was examined to determine if filling was 
complete. 
 
4. Seal the TaqMan Array 
a. The array was sealed according to the user bulletin: Applied Biosystems 
TaqMan® Low Density Array (P/N 4371129). 
b. By using a scissors we trimmed the fill reservoirs from the array.  
 
Component Volume (µl) 
per fill reservoir 
Diluted RT reaction 50.0 
TaqMan 2x Universal PCR Master Mix     
(No AmpErase® UNG) 
50.0 
Total volume 100.0 
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5. Set up and run the plate document 
            Referred to the user bulletin: Applied Biosystems TaqMan® Low Density    
Array (P/N 4371129) and Applied Biosystems 7900HT Fast Real-Time PCR   
System and SDS Enterprise Database User Guide (P/N 4351684). 
 
6. Analyze the PCR reactions 
Referred to the SDS online help, 7900HT system user guide. 
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2.13.2 Relative quantity of miRs by qRT-PCR 
Total RNA was extracted as per section (2.14.2.1) and cDNA synthesised and 
experiments were performed in triplicate, according to the manufacturer’s 
instructions. Reverse transcriptase (RT) reactions were performed using 
micropipettes which were specifically allocated to this work. To form cDNA, a 
high-capacity cDNA reverse transcription kit (Applied Biosystems) was used. 
The number of copies of a mRNA transcript of a gene in a cell or tissue is 
determined by the rates of its expression and degradation. The Real-Time PCR 
system is based on the detection and quantitation of a fluorescent reporter (Livak et 
al. 1995). There are two conventional real time PCR methods SYBR Green and 
TaqMan probe based. The former was the first to be used in real-time PCR. It is a 
fluorescent dye that binds to double-stranded DNA and emits light when excited. 
Unfortunately, it binds to any double-stranded DNA which could result in a non-
specific signal, especially compared with the specificity found with TaqMan probe 
based method. This uses a fluorogenic probe which is a single stranded 
oligonuleotide of 20-26 nucleotides and is designed to bind only the DNA sequence 
between the two PCR primers. Cycle threshold is defined as Cycle number (in 
qPCR) at which the fluorescence generated within a reaction well exceeds a defined 
threshold. The threshold is defined by the software or user to reflect the point during 
the reaction at which the number of amplicons is doubling with each PCR cycle (Fig. 
2.14.2). 
 
 
 
 
 
 
 
 
 
 
 
www.appliedbiosystems.com)  
Fig 2.2 The PCR cycle at which the sample reaches a fluorescent intensity above 
background is the Cycle Threshold or Ct.  
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(www.appliedbiosystems.com)  
 
Fig 2.3 Gene expression analysis with Taqman probe-based assay chemistry, and 
SYBR GREEN I assay chemistry. 
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Materials for qRT-PCR 
TaqMan® MicroRNA Reverse Transcription Kit (200 reactions) (Applied 
Biosystems, P/N 4366596) 
TaqMan® 2X Universal PCR Master Mix, No AmpErase® UNG   (Applied 
Biosystems, P/N 4324018) 
Fast SyBr Green master mix  (Applied Biosystems, P/N 4385612 ) 
MirVanaTM miRNA isolation kit (Applied Biosystems, AM1560) 
MicroAmpTm Fast 96-well Reaction Plate with barcode (Applied Biosystems, PN 
4346906) 
MicroAmpTm optical adhesive film (100 covers) (Applied Biosystems, PN 4311971) 
Nuclease free water (Applied Biosystems, AM9930) 
RNU44 control (Applied Biosystems, PN4373384) 
MiR-93 TaqMan MicroRNA Assay (Applied Biosystems, PN4427975, ID2139) 
MiR-155 TaqMan MicroRNA Assay (Applied Biosystems, PN4427975, ID2623) 
MiR-23b TaqMan MicroRNA Assay (Applied Biosystems, PN4427975, ID400) 
 
2.13.2.1 Organic RNA Extraction using MirVana miRNA Isolation Kit 
Cells were cultured in vented 75cm2 flasks until they reached 80% confluency. The 
cells were then lysed and RNA was extracted from them using the MirVanaTM 
miRNA isolation kit (catalogue number 1560, 1561). 
 
Cell Lysis Prior to RNA Extraction 
Trypsinised cells were washed by gently re-suspending in 10 mls of 1X PBS and 
pelleted at low speed. The PBS was removed and the cells were resuspended in 600 
µl lysis/binding solution (from the MirVanaTM miRNA isolation kit). The sample 
was then vortexed vigorously to ensure complete lysis of the cells and to obtain a 
homogenous lysate. 
 
The MirVanaTM miRNA isolation kit designed for purification of RNA is suitable 
for studies of both siRNA and miRNA. The kit employs organic extraction followed 
by immobilization of RNA on glass-fibre filters to purify either total RNA, or RNA 
enriched for small species, from cells or tissue samples. The total RNA from cell 
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samples was isolated as per the manufacturer’s protocol a recommended 102-107 
cells were used for RNA extraction. 
2.13.2.2 Using the Nanodrop to Measure Nucleic Acids 
The NanoDrop is a cuvette free spectrophotometer. It uses just 1 µl to measure from 
5 ng/µl to 3000 ng/µl of nucleic acids in solution. Before applying the RNA sample 
the pedestal was wiped down using a lint free tissue dampened with UHP. 1 µl of 
UHP was then loaded onto the lower measurement pedestal. The upper sample arm 
was then brought down so as to be in contact with the solution. “Nucleic acid” was 
selected on the NanoDrop software to read the samples. After the equipment was 
initialised the “blank” option was chosen, and after a straight line appeared on the 
screen the “measure” option was selected. All sample readings were automatically 
saved as text files which could be viewed using Microsoft Excel. The upper and 
lower pedestals were cleaned with a clean dry wipe between samples. When 
finished, the pedestal was cleaned with a wipe dampened with UHP followed by 
drying with a dry wipe. The purity of the RNA extraction was determined by 
calculating the A260:A280 ratio. An A260:A280 ration of 2 is indicative of pure RNA. 
Only those samples with ratios between 1.7 and 2.1 were used in this study. 
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2.13.2.3 Two step RT-PCR 
In the reverse transcription (RT) step, cDNA (complemetary DNA) was reverse 
transcribed from total RNA samples using specific miRNA primers from the 
TaqMan MicroRNA Assays and reagents from the TaqMan® MicroRNA Reverse 
Transcription Kit and the TaqMan® 2x Universal PCR Master Mix, No AmpErase® 
UNG. PCR was carried out using the TaqMan® MicroRNA Assays, with the control 
RNU44. The following products were also used for PCR nuclease free water, 
MicroAmpTm fast optical 96-well reaction plate with barcode, 0.1ml E94 20 plates, 
and MicroAmpTm optical adhesive film 100 covers E215. RT-PCR was carried out 
according to TaqMan® microRNA Assay Protocol. The following reagents were 
thawed and mixed on ice in a 0.5 ml eppendorf (Eppendorf, 0030 121.023). 
 
 
               
(www.appliedbiosystems.com) 
    
Fig. 2.4 Two step RT-PCR The first step is reverse transcription (RT), in which RNA 
is reverse transcribed to cDNA using reverse transcriptase. This step is very 
important in order to perform PCR since DNA polymerase can act only on DNA 
templates. The RT step can be performed either in the same tube with PCR (one-step 
PCR) or in a separate one (two-step PCR) using a temperature between 40°C and 
50°C, depending on the properties of the reverse transcriptase used  
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                 Table 2.9 Preparation of RT master mix per 15 µl reaction. 
Components In 15 µl reaction 
 
dNTP mix (100mM) 0.15 µ l 
MultiscribeTM RT enzyme (50 U/ µ l) 1.00 µ l 
10 x RT Buffer 1.50 µ l 
RNase Inhibitor (20 U/ µ l) 0.19 µ l 
Nuclease free water 4.16 µ l 
Primer 3.00 µ l 
 
The master mix was placed on ice and mixed gently, cDNA reverse transcription 
reaction was prepared by adding 10 µl of the RT master mix into an individual tube, 
5 µl (10ng/ µl) of RNA was pipetted into master mix containing tubes, sealed, 
centrifuged briefly and loaded into the thermal cycler (Hybaid). The reaction volume 
was set to 15 µl. 
 
                                  Table 2.10 Thermal cycle for RT reaction. 
Temperature Hold (oC) Duration 
(minutes) 
16 30 
42 30 
85 5 
4 ∞ 
 
After completion of the reaction cDNA was ready for quantitative PCR. 
 
 
Table 2.11 Preparation of PCR master mix per 20 µl reaction 
Components Per reaction (20 
µl) 
2X PCR master mix 10.00 µ l 
Nuclease free water 7.67 µ l 
Primer 1.00 µ l 
cDNA 1.33 µ l 
 
The PCR reaction was carried out the Applied Biosystems 7900HT Fast Real-Time 
PCR system. 
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       Table 2.12 Thermal cycle for qRT-PCR 
Step Temperature 
Hold (oC) 
Duration Cycle 
Denature 95 10 minutes 1 
Denature 95 15 seconds 2 
Annealing & Extending 60 60 seconds X40 
 
 
2.13.2.4 High-Capacity cDNA Reverse Transcription with SyBr Green 
 
 
                 Table 2.13 Preparation of  2X RT master mix per 20 µl reaction. 
Components In 20 µl reaction 
 
10 x RT Buffer 2.0 µ l 
dNTP mix (100mM) 0.8 µ l 
10x RT Random Primers 2.0 µ l 
MultiscribeTM RT enzyme (50 U/ µ l) 1.0 µ l 
RNase Inhibitor (20 U/ µ l) 1.0 µ l 
Nuclease free water 3.2 µ l 
Total per Reaction 10.0 µ l 
 
The master mix was placed on ice and mixed gently, cDNA reverse transcription 
reaction was prepared by adding 10 µl of the RT master mix into an individual tube,  
10 µl (100ng/ µl) of RNA was pipetted into master mix containing tubes, sealed, 
centrifuged briefly and loaded into the thermal cycler (G-Storm). The reaction 
volume was set to 15 µl. 
 
 
                             Table 2.14 Thermal cycle for High-Capacity RT reaction. 
Temperature Hold (oC) Duration 
(minutes) 
25 10 
37 120 
85 5 sec 
4 ∞ 
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Table 2.15 Preparation of SyBr Green PCR master mix per 20 µl reaction. 
Components Per reaction (20 
µl) 
2X PCR master mix 10.0 µ l 
Nuclease free water 7.0 µ l 
Primer (10 µM F & R) 1.0 µ l 
cDNA 2.0 µ l 
                             F: forward, R: reverse. 
 
      Table 2.16 Thermal cycle for SyBr Green qRT-PCR 
Step Temperature 
Hold (oC) 
Duration 
(seconds) 
Cycle 
Denature 95 20 secs 1 
Denature 95 3 secs 2 
Annealing & Extending 60 30 secs X40 
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          Table 2.17 PCR Primers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             Tm: annealing temperature 
             s: sense, a.s: anti-sense 
 
 
 
Primer Name Sequence 5’ – 3’ Direction Tm 
(0C) 
 
SEMA6D.s 
 
SEMA6D.a.s 
 
TGCTTTCCATAACCACAGTGCTGAA   
 
TCGTACACCATGGCAGTCCCCT 
61.3 
 
64 
XIAP.s  
 
XIAP.s  
 
TGTCCTGGCGCGAAAAGGTGG 
 
ACCCTGCTCGTGCCAGTGTTG 
63.7 
 
63.7 
SMAD5.s 
 
SMAD5.a.s 
AGCCGGCTCGCGAAAAGGAA 
 
TGCTTCTTTCATTGGGTCAAGTCCTGT 
 
61.4 
 
63.2 
MAP4K4.s 
 
MAP4K4.a.s 
 
CGAGGTGCCTCCAAGGGTTCC 
 
TTCTGCTGCCCACTGCCCTG 
65.7 
 
63.5 
BCL2.s 
 
BCL2.a.s 
 
TGAACCGGCACCTGCACACC   
 
CAAAGGCATCCCAGCCTCCGT   
63.5 
 
63.7 
MET.s 
 
MET.a.s 
TGCTTTGCCAGTGGTGGGAGC   
 
AGAGCGATGTTGACATGCCACTG 
63.7 
 
62.4 
 
PDGFA.s 
 
PDGFA.a.s 
 
AGAGGACACGGATGTGAGGTGAGG 
 
CCATGTCCCAGGAAAGGGCTGC 
66.1 
 
65.8 
Actin.s 
 
Actin.a.s 
 
CAATGGCTCCGGCCTGGTGA 
 
CCATGACGCCCTGGTGTCGG 
63.5 
 
65.5 
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2.13.3 Transient Transfections with anti-miR and pre-miR 
Anti-miR was used to inhibit miRNA activity in the cells, and pre-miR was used to 
increase the copy number of miRNA in the cells. Anti-miR and pri-miR used were 
chemically synthesised (Ambion Inc). These miRNAs were 21-23 bps in length and 
were introduced to the cells via reverse transfection with the transfection agent 
siPORTTM NeoFXTM (Ambion Inc., 4511), or lipofectamineTM 2000 (Invitrogen, 
11668-019). 
 
 
                   Table 2.18 Synthetic miRNA Oligonucleotides 
 
 
 
 
 
2.13.3.1 Transfection Optimisation 
In order to determine the optimal conditions for miRNA transfection, optimisation 
with kinesin siRNA (Ambion Inc., Am4639) was carried out for each cell line. A 
protocol was optimised for the miRNA transfection of an established glioblastoma 
cell line, SNB-19. Cell suspensions were prepared at 2x104, 1x105, 3x105 and 5x105 
cells per ml. Solutions of negative control (Ambion Inc., 4390843) and kinesin 
(Ambion Inc., 4392420) siRNAs at a final concentration of 30 nM/ 50 nM were 
prepared in optiMEM (GibcoTM, 31985). Transfection reagent solutions at a range of 
concentrations were prepared in optiMEM in duplicate and incubated at room 
temperature for 10 minutes. After incubation, either negative control or kinesin 
siRNA solution was added to each neoFX concentration. These solutions were 
mixed well and incubated for a further 10 minutes at room temperature. 100 µl of 
the siRNA/transfection reagent solutions were added to each well of a 6-well plate. 1 
ml of the relevant cell concentrations were added to each well. The plates were 
mixed gently and incubated at 37°C for 24 hours. After 24 hours, the transfection 
mixture was removed from the cells and the plates were fed with fresh medium. The 
miRNA Catalogue No. Product ID 
 
Pre-hsa-miR-93 AM17100 PM10951 
Anti-hsa-miR-93 AM17000 AM10951 
Pre-hsa-miR-23b AM17100 PM10711 
Pre-miR-control AM17110 - 
Anti-miR-control AM17010 - 
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plates were assayed for changes in proliferation at 72 hours using the acid 
phosphatase assay. Optimal conditions for transfection were determined as the 
combination of conditions which gave the greatest reduction in cell number, after 
kinesin siRNA transfection, and the least cell kill in the presence of transfection 
reagent.  
2.13.3.2 Proliferation Assays on miRNA Transfected Cells 
Cells were seeded using 2 µl Neofx/lipofectamine 2000 to transfect 30 nM/ 50 nM 
miRNA in a cell density of 1x105 per well of a 6-well plate. After 24 hrs, 
transfection medium was replaced with fresh media and cells were allowed to grow 
until they reached 80-90% confluency, a total of 72 hours. Cell number was assessed 
using the acid phosphatase assay. All experiments were carried out independently at 
least three times. In the miRNA experiments, siRNA scrambled transfected cells 
were used as control compared to miRNA treated samples. This was to ensure no 
‘off-target’ effects of the transfection procedure. Non-treated controls were used to 
ensure scrambled siRNA was having no effects and to normalise data. Pre-miR 
negative control (AM17110) was used to ensure no ‘off-target’ effects of pri-miR-93 
with the transfection procedure. Cell number was assessed using the acid 
phosphatase assay described in section 2.4.1 B. Analysis of the difference of 
comparisons, as well as untreated versus miRNA treated mean percentage survival 
was calculated on Microsoft Excel. 
 
2.13.4 Agarose Gel Preparation 
5 g of agarose was weighed and added to 200 ml of TAE buffer (1X), this was 
placed in the microwave for 3 minutes at power 70. This was then left to stand for 
10-15 minutes to come to room temperature. 4 µl of ethidium bromide were added 
to the mixture in a fumehood. This was then poured into a mould (containing 
combs) to set, the gel was left to set for 1 hour. 
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Section 3.0 Results 
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3.1 Imatinib and Docetaxel in Combination can Effectively Inhibit Glioma 
Invasion in an in vitro 3D Invasion Assay 
The effect of the combination of imatinib and docetaxel was examined on 4 
established glioma cell cultures, with respect to proliferation and invasion. 
 
3.1.1 The Effect of Imatinib and Docetaxel on Glioma Proliferation  
The IC50 values were established for imatinib and docetaxel on four different glioma 
cell lines; CLOM002 and UPHHJA are primary cell lines, which were used at low 
passage numbers, and SNB-19 and IPSB-18 are established cell lines. The IC50 for 
imatinib was similar for all four cell lines, ranging between 15.7 µM and 18.7 µM 
(Table 3.1). Docetaxel inhibited cell proliferation at much lower concentrations. 
SNB-19 was the most sensitive cell line with an IC50 of 0.7 nM docetaxel, and 
UPHHJA was the least sensitive cell line with a 28-times higher IC50 value of 19.8 
nM. In addition, normal human astrocytes (NHAs) were tested, where an IC50 with 
imatinib of 17 µM was found, which is very similar to the value found with the 
glioma cell lines; with docetaxel the graph plateaued and 50 % inhibition could not 
be reached with a concentration up to 124 nM. 
 
 
Table 3.1 IC50 values for imatinib and docetaxel on cell proliferation of four 
different glioma cell cultures and normal human astrocytes. Data represents 3 
individual biological assays. Standard deviations were generated using Microsoft 
Excel software. 
 
 
 
 
Drug CLOM002 UPHHJA IPSB-18 SNB-19 NHA 
Imatinib (µM) 15.7 ± 1.3 17.7 ± 1.3 17.4 ± 2 18.7 ± 2 17 ± 0.2 
Docetaxel (nM) 11.8 ± 0.6 19.8 ± 2.5 8.2 ± 0.7 0.7 ± 0.02 >124 
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3.1.2 Combined Treatment with Imatinib and Docetaxel Synergistically 
Inhibited Cell Proliferation in 3 out of 4 Cell Cultures 
To investigate the drug combination effect three low kill concentrations of docetaxel 
and one low kill concentration for imatinib were chosen, which reduced cell 
proliferation of CLOM002, UPHHJA and IPSB-18 cells only up to 37% (Fig. 3.1.1). 
The combination of both drugs at low concentration resulted in up to 87% inhibition 
in these three cell lines compared to imatinib or docetaxel alone. On the other hand, 
the combined treatment of imatinib and docetaxel had no significant effect on SNB-
19 (Fig. 3.1.1).  
For each cell culture the combined effect of the IC10, IC20 and IC30 of 
imatinib and docetaxel revealed a synergistic effect for 3 out of 4 tested cultures 
analysed/, using the combination plot according to Chou and Talalay (Chou and 
Talalay 1984). An effect is synergistic when the combination of two drugs results in 
a higher toxicity than expected, based on pre-determined toxicity levels of either 
drug alone, an effect is additive when the combination of two drugs gives the 
expected toxicity. Highest synergism was seen in IPSB-18 cells with a combination 
index (CI) between 0.05 and 0.25; in UPHHJA the CI was between 0.1 and 0.4 and 
the weakest synergy was in CLOM002 cells with a CI between 0.1 and 0.7. The CI 
in SNB-19 cells was between 0.7 and 1.0 representing an additive effect.  
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      Table 3.1.2 The 
concentrations of docetaxel 
and imatinib used in the 
proliferation assay in figure 
3.1.1. 
 
 
 
 
 
 
 
 
                                                                                                            Do: Docetaxel, Im: Imatinib.                                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1.1 Combination effect of imatinib (Im) and docetaxel (Do) on cell 
proliferation. *: p <0.05. Data represents 3 individual biological assays. Standard 
deviations were generated using Microsoft Excel software. 
Cell 
Culture 
Docetaxel 
(nM) 
Do1  Do2   Do3 
CLOM002 0.5    0.9     1.2 
UPHHJA 1.2    2.5     3.7 
SNB-19 0.1    0.2     0.3 
IPSB-18 1.2    2.5     3.7 
 
Imatinib 
(µM) 
 
CLOM002 3.4 
UPHHJA 3.4 
SNB-19 1.7 
IPSB-18 3.4 
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3.1.3 Imatinib Combined with Docetaxel Induces Apoptosis in Glioma Cultures  
Total apoptosis was analysed in the presence of single drug and drug combinations. 
Over 24 to 48 hours between 2 and 3.4% apoptotic cells were measured in the 
controls (no drug) (Fig. 3.1.2(a)). Drug effects were low after 24 hours, but much 
more pronounced after 48 hours: imatinib alone induced apoptosis in 4.7-7% cells 
and docetaxel alone in 4.3-10% cells, while the combination of imatinib and 
docetaxel caused apoptosis in 13.8-40.1% cells, with CLOM002 cells being the most 
sensitive. In SNB-19, however, docetaxel alone caused 10% apoptotic cells and the 
drug combination increased this effect to 13.8% apoptotic cells (Fig. 3.1.2(a)). There 
was no major difference in early and late apoptosis (not shown). Neither drug alone 
had a significant effect on cell viability of CLOM002, IPSB-18, and UPHHJA cells; 
however, the combination significantly reduced cell viability by over 30% in all 
three cell lines (Fig. 3.1.2(b)). In SNB-19 cells, docetaxel alone caused 10% 
reduction in cell viability, which was similar to the effect of the combination (Fig. 
3.1.2(b)).  
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Fig. 3.1.2 (a) Percentage of total apoptotic cells measured after 24 and 48 hrs in the 
absence and presence of drug; imatinib 13.5 µM; docetaxel 14.9 nM. Im & Doc: 
imatinib and docetaxel. The first two bars in each set represent the controls for each 
cell culture, i.e. no drug added. *: P < 5E-3. Data represents 3 individual biological 
assays. Standard deviations were generated from Microsoft Excel software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1.2 (b) Percentage cell viability after 24 and 48 hrs in the absence and 
presence of drug; imatinib 13.5 µM; docetaxel 14.9 nM. Im & Doc: imatinib and 
docetaxel. The first two bars in each set represent the controls for each cell culture, 
i.e. no drug added. *: P < 5E-3. Data represents 3 individual biological assays. 
Standard deviations were generated from Microsoft Excel software. 
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3.1.4 Drug Scheduling Effect with Imatinib and Docetaxel on Cell Proliferation 
In order to increase the inhibitory effect on proliferation five different drug 
schedules were tested (Table 3.1.3). Each treatment was performed with three 
different drug concentrations; high, medium and low. The high drug concentrations 
were chosen just under the IC50 values, medium was the IC25 and the lowest was the 
IC10. Treatment 5 involving a combination of imatinib and docetaxel on day 1 and 2, 
followed by imatinib alone on day 3 and 4 was the most effective treatment (Fig. 
3.1.3). With treatment 5 survival of CLOM002, UPHHJA and IPSB-18 cells was 
less than 10% in the presence of both high and medium drug concentrations with all 
three cell lines showing similar sensitivity. SNB-19, however, was less responsive to 
the drug scheduling treatment, with 23% survival with the highest concentration, 
and 50% survival with the medium concentration with schedule 5 (Fig. 3.1.3). 
 
 
Table 3.1.3 Drug treatment schedules: Cells were treated with each drug/drug 
combination for 24 hrs. On day 5 medium was replaced with fresh medium without 
drugs. Cell proliferation was determined at day 8. 
Schedule Day 1 Day 2 Day 3 Day 4 
 
1 Imatinib Imatinib & 
Docetaxel 
Imatinib Imatinib 
 
 
2 Imatinib Docetaxel Imatinib Imatinib 
 
3 Docetaxel Imatinib Imatinib Imatinib 
 
4 Docetaxel Imatinib & 
Docetaxel 
Imatinib Imatinib 
 
 
5 Imatinib & 
Docetaxel 
Imatinib & 
Docetaxel 
Imatinib Imatinib 
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Fig. 3.1.3 Cell survival (%) after 5 different drug schedules using three different 
drug concentrations; high = closed bars, medium = hatched bars, low = open bars. 
Each drug treatment was measured against 100% cell survival of cells in the absence 
of drug. Data represents 2 individual biological assays. Standard deviations were 
generated from Microsoft Excel software. 
 
Table 3.1.4 Concentrations of docetaxel and imatinib for drug scheduling with 
CLOM002, UPHHJA, IPSB-18, and SNB-19. 
 
                      Do: Docetaxel, Im: Imatinib. 
 
Cell Line Docetaxel (nM) 
 
Do1    Do2   Do3 
Imatinib (µM) 
 
Im1   Im2   Im3 
CLOM002 12.4    6.2    2.5 13.5   6.8    0.2 
 
UPHHJA 12.4    6.2    2.5 13.5   6.8    1.7 
 
IPSB-18 12.4    6.2    2.5 13.5   6.8    1.7 
 
SNB-19 
 0.6     0.4    0.008 13.5   6.8    3.4 
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3.1.5 Effect of Imatinib and Docetaxel on Glioma Invasion  
In the absence of drug the cell lines UPHHJA, IPSB-18 and CLOM002 showed 
similar invasion activity reaching a distance between 1700 µm and 2000 µm from 
the spheroid within 11/12 days; SNB-19 cells invaded much less and reached only a 
distance of 760 µm within the specified time (Fig. 3.1.4). To investigate the effect of 
imatinib and docetaxel on actively invading cells, the drug was added 4 days after 
implanting the spheroids, when invasion had already started. Imatinib alone had 
little inhibitory effect (CLOM002, UPHHJA, and IPSB-18) or even a slightly 
increasing effect on invasion activity (SNB-19) compared to invasion in the absence 
of drug (Fig. 3.1.5). Docetaxel alone reduced the invasion distance reached after 
11/12 days up to 40% in CLOM002, IPSB-18 and UPHHJA and 50% in SNB-19. 
The combination of imatinib and docetaxel did not increase the inhibitory effect on 
SNB-19 invasion, in comparison to docetaxel alone; however, the combination of 
imatinib and docetaxel substantially decreased the invasion of IPSB-18 (87.7%), 
CLOM002 (63%), and UPHHJA (59%) in comparison to either single drug 
treatment and controls (Fig. 3.1.5 and 3.1.7). NHAs showed significant invasion 
activity, which was only inhibited up to 60% although treated with much higher 
concentrations of drug than glioma cell lines (imatinib 40.7 µM, docetaxel 29 nM). 
The combination of imatinib and docetaxel did not significantly increase the effect 
of docetaxel alone, a similar result to that obtained with SNB-19 (Fig. 3.1.6). 
 
 
 
 
 
 
 
 
Fig. 3.1.4 Invasion activity of four cell lines and NHAs in the absence of drug; 
UPHHJA (○), IPSB-18 (□), CLOM002 (▲), SNB-19 (×), cells were tested in 
biological triplicate assays. NHA (---♦---) NHAs were tested in duplicate in one 
experiment. Standard deviations were derived using Microsoft Excel software. 
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* 10 days   ** 11 days 
 
Fig. 3.1.5 Average invasion distance over 10-12 days in the absence (control) and 
presence of imatinib 13.5 µM and docetaxel 14.9 nM alone and in combination. 
Cells were tested in biologically triplicate assays. Standard deviations were derived 
using Microsoft Excel software. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1.6 Percentage of average invasion over 13 days with normal human 
astrocytes with imatinib (Imt) 40.7 µM and docetaxel (Doc) 29 nM in comparison to 
the control (Ctr). Cells were tested in duplicate of one experiment. Standard 
deviations were derived using Microsoft Excel software. 
 
 
 
 
 
 
 
Fig. 3.1.7 CLOM002 cell invasion on day 24 in the absence (a) and presence of the 
combination of imatinib 13.5 µM and docetaxel 14.9 nM (b). 
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3.1.6 Protein Expression Profile of Glioma Cell Cultures  
Using western blotting the protein expression of tyrosine kinases (PDGFR-β, 
PDGFR-α, C-Kit, C-Abl) of multidrug resistance pumps (Pgp, BCRP) and of glial 
fibrillary acidic protein (GFAP) were analysed. All four cultures were positive for 
GFAP proving their glial origin (Fig. 3.1.8). Low expression of PDGFR-β was seen 
in CLOM002, UPHHJA, and SNB-19, and higher expression was found in IPSB-18 
(Fig. 3.1.8). In addition low expression of PDGFR-β in NHAs was found (Fig. 
3.1.10). All cell cultures expressed low levels of PDGFR-α, but no C-Kit. C-Abl 
was expressed in cell cultures (Fig. 3.1.8) and in NHAs (Fig. 3.1.10). In SNB-19 
cells the C-Abl antibody recognized an additional band around 210 KDa which is 
similar to the pattern expressed in the positive control K562, a chronic myelogenous 
leukaemia cell line expressing both C-Abl and the mutated form Bcr-Abl (Fig. 
3.1.8). A Bcr-Abl-specific antibody recognized the same band in SNB-19 cells 
suggesting the expression of a mutated form of C-Abl in these cells (Fig. 3.1.9).  
The multidrug resistance protein BCRP (ABCG2, MXP) was found in all 
four cell cultures (Fig. 3.1.8); however, SNB-19 and IPSB-18 expressed much 
higher levels compared to CLOM002 and UPHHJA cells. Pgp (MDR-1, ABCB1) 
was only expressed in SNB-19 cells (Fig. 3.1.8). Higher expression of Pgp was 
found in the NHAs and low expression of BCRP (Fig. 3.1.10). In summary, SNB-19 
protein expression differed from the other cell cultures in a strong BCRP expression, 
the presence of Pgp, and a protein similar to the mutated tyrosine kinase Bcr-Abl.  
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Fig. 3.1.8 Western blot analysis of tyrosine kinases PDGFR-β, PDGFR-α, Bcr-Abl, 
and C-Abl, multidrug resistance pumps BCRP, Pgp and the astrocyte marker GFAP. 
CLOM002 (1), UPHHJA (2), SNB-19 (3) IPSB-18 (4). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1.9 Western blot analysis  
with Bcr-Abl specific antibody.  
Positive control (K562) (1),  
SNB-19 (2), IPSB-18 (3). 
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3.1.7 Effect of Elacridar in Combination with Imatinib and Docetaxel on 
Proliferation of Glioma Cell Lines 
SNB-19 was the only cell line expressing Pgp, and had the highest BCRP 
expression. Imatinib is a substrate for both Pgp and BCRP (Leslie et al. 2005), 
which has possibly led to a higher efflux of imatinib in SNB-19 cells. Docetaxel is 
also a substrate of Pgp. To test the functionality of Pgp and BCRP, a specific 
inhibitor of both pumps, elacridar, was added which should prevent the efflux of the 
substrates imatinib and docetaxel resulting in stronger inhibition of proliferation. 
Elacridar was tested on CLOM002 and SNB-19 using an IC10 of imatinib, an IC20 of 
docetaxel, and an IC20 of elacridar, a concentration which has been optimised 
previously in lung cancer cell lines. In CLOM002 the inhibition of Pgp did not result 
in inhibition of proliferation in the presence of imatinib and docetaxel (Fig. 3.1.11); 
however in SNB-19 the addition of elacridar resulted in a 17% increase in inhibition 
of proliferation in the presence of the drug combination (Fig. 3.1.12). This indicated 
that the efflux pumps Pgp and BCRP were active in SNB-19 cells and were 
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Fig. 3.1.11 The combined effect of imatinib 1.7 µM, docetaxel 0.12 nM and 
elacridar 0.25  µM on proliferation. 1: Elacridar (El), 2: Imatinib (Imt), 3: Imt and 
El, 4: Docetaxel (Doc), 5: Doc and El, 6: Imt and Doc, 7: Imt and Doc and El. Data 
represents 3 individual biological assays. Standard deviations were generated from 
Microsoft Excel software. 
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3.1 Discussion  
 
Imatinib and Docetaxel can Effectively Inhibit Invasion and Proliferation in 
Glioma 
 
Introduction 
In the present study the inhibitory effect of the TKI imatinib singly and in 
combination with the chemotherapeutic drug docetaxel has been examined in glioma 
cell cultures. Clinical trials using imatinib as a single agent for the treatment of 
recurrent glioblastoma resulted in increased progression free survival after 6 months 
for only a small number of patients (Katz et al. 2004; Raymond et al. 2008). A 
similar result was seen in primary cultures of glioma specimen; out of 15 specimens 
Hägerstrand et al, 2006 identified a small subgroup of high-grade human glioma 
cultures, which were imatinib-sensitive (Hagerstrand et al. 2006). In this subgroup 
the PDGFR expression and phosphorylation status was significantly correlated with 
imatinib sensitivity, indicating a dependency on the PDGFR signalling (Hagerstrand 
et al. 2006).  
TKs regulate a large range of proteins involved in processes including 
growth, metabolism and differentiation. A number of small molecule inhibitors were 
developed to target tyrosine kinases; some of these inhibitors are highly effective in 
the treatment of specific types of cancer, e.g. imatinib. Imatinib for example had 
been designed to target Bcr-Abl, a mutated form of the non-receptor kinase C-Abl 
found in Philadelphia chromosome positive chronic myeloid leukaemia (CML) 
(Sherbenou and Druker 2007). The success of this compound in the treatment of 
CML triggered the hope that imatinib could also be effective against other tumour 
types. Besides BCR-Abl imatinib targets PDGFR, stem cell factor C-Kit and C-Abl, 
causing cell cycle arrest and/or apoptosis (Kilic et al. 2000; Nagar 2007).  
There are various possible reasons for the ineffectiveness of imatinib 
monotherapy on the majority of gliomas: inhibition of C-Kit and PDGFR by 
imatinib may lead to induction of vascular epithelial growth factor (VEGF) resulting 
in angiogenesis; inhibition of a single tyrosine kinase might be insufficient to impact 
downstream signalling cascades, and the molecular targets of imatinib may not play 
a key role in glioma growth and spread. Higher levels of VEGF are found in high-
grade glioma, making this an ideal therapeutic target (Takano et al. 2010); an 
antibody targeting VEGF, bevacizumab, showed promising results in glioma, 
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initially, however the development of resistance emerged (Norden et al. 2008; 
Narayana et al. 2009). A more promising treatment in glioma is currently being 
examined by combining temozolomide with radiotherapy and bevacizumab 
(Narayana et al. 2008).   
The main problem in the treatment of malignant gliomas is their invasive 
behaviour. Successful resection of the main tumour mass cannot prevent recurrence 
due to single cells invading the surrounding brain parenchyma at the time of 
diagnosis. The clinical effectiveness of combination therapy PCV (Procarbazine, 
CCNU and Vincristine), which was used for over 30 years in the treatment of 
malignant astrocytomas and glioblastomas, is still doubtful. The development of 
new treatment strategies is urgently needed. 
Another possibility for increasing the response and effectiveness of TKIs 
could be a combination treatment consisting of a TKI and a cytotoxic drug, e.g. 
docetaxel. Docetaxel is a hemisynthetic product derived from the European yew 
tree, which promotes the assembly and inhibits the depolymerisation of 
microtubules in the cells (Bissery et al. 1995). This drug is widely used as 
chemotherapeutics and is particularly effective in the treatment of non-small cell 
lung cancer (Plosker and Hurst 2001). The use of docetaxel alone for the treatment 
of glioblastomas has shown little or no significant response possibly due to the BBB 
limiting drug flow into the brain (Forsyth et al. 1996; Sanson et al. 2000). However, 
docetaxel combined with radiotherapy resulted in a partial response (Koukourakis et 
al. 1999), and local delivery of docetaxel in vivo in an animal model significantly 
improved survival (Sampath et al. 2006). 
The combined treatment of imatinib and docetaxel was tested on four glioma 
cell cultures. Two of the cell cultures (CLOM002 and UPHHJA) derived from 
primary glioblastomas were used at low passage numbers (CLOM002 passage 11 to 
40, UPHHJA passage 9 to 25) and were developed in Professor Geoffrey 
Pilkington’s laboratory in Portsmouth, UK. A cell line IPSB-18 also from Professor 
Geoffrey Pilkington’s laboratory was derived from a grade III astrocytoma, was 
used at passages 57 to 72. A second cell line SNB-19 is an established and 
commercially available cell line and was used between passages +9 to +31 (after 
purchase). The cell lines IPSB-18 and SNB-19 appeared as homogeneous 
populations possibly due to higher passage number; while the primary glioblastoma 
cell cultures CLOM002 and UPHHJA presented as heterogeneous cell populations. 
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All cell cultures had fast proliferation rates and were highly invasive. The effect of 
imatinib and docetaxel singly and in combination on proliferation, invasion and 
apoptosis was examined. 
 
Effect of Imatinib and Docetaxel on Proliferation and Invasion of Glioma Cell 
Cultures CLOM002, UPHHJA and IPSB-18 
To examine if the combination of the TKI imatinib and the chemotherapeutic drug 
docetaxel decreases proliferation activity of glioma cells the IC50 concentration for 
each drug was determined in a monolayer proliferation assay (Table 3.1). The IC50 
values for imatinib were in the micromolar range (15.7 µM to 17.4 µM), which is 
consistent with published data where Servidei et al, 2006 showed IC50 values 
ranging from 18.6 µM to 32.6 µM in U87 glioma cells (Servidei et al. 2006). IC50 
values for docetaxel ranged from 8.2 nM (IPSB-18) to 19.8 nM (UPHHJA) (Table 
3.1).  
The combination of both drugs at low concentration (Fig. 3.1.1) (Table 3.1.2) 
resulted in up to 87% inhibition of proliferation in CLOM002, UPHHJA and IPSB-
18. For each cell culture the combined effect of the IC10, IC20 and IC30 of imatinib 
and docetaxel was analysed using the Chou and Talalay plot (Chou and Talalay 
1984). This revealed a synergistic effect of imatinib together with docetaxel in these 
3 glioma cell cultures. The highest synergism was seen in IPSB-18 cells followed by 
UPHHJA and CLOM002 cells. Gucluler and Baran et al, have shown that the 
combined treatment of imatinib and docetaxel decreased cellular proliferation in 
chronic myeloid leukaemia cell lines (Gucluler and Baran 2009). They increased the 
chemosensitivity of human K562 cells to imatinib in combination with docetaxel, 
and showed that the combination of both drugs decreased cellular proliferation and 
increased apoptosis as compared to any drug alone. Apoptosis was reduced through 
caspase-3 enzyme activity (Gucluler and Baran 2009).  
It has been reported that small amounts of imatinib in the plasma can cross 
the blood–brain barrier (BBB). Bihorel et al, have shown that in mice only 20% of 
imatinib is crossing the BBB, while 80% is effluxed by BCRP and Pgp (Bihorel et 
al. 2007). Le Coutre et al, found a mean plasma concentration with imatinib in 
leukaemia patients of 2–5 µg/ml and 531 ng/ml for the metabolite N-desmethyl-
imatinib (le Coutre et al. 2004). They also found that the average CSF concentration 
for imatinib was 38 ng/ml, and less than 10 ng/ml for N-desmethyl-imatinib (le 
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Coutre et al. 2004). High-grade glioma patients have a disrupted BBB in the tumour 
centre, which would allow a higher concentration of imatinib in the CNS; however, 
it is not clear if an effective concentration can be reached. 
A similar problem exists with docetaxel. Docetaxel as a substrate of Pgp 
probably does not reach a sufficient concentration in the brain, which might explain 
the poor response seen in recurrent glioblastoma treated with docetaxel 
systemicallypo (Forsyth et al. 1996; Kemper et al. 2003; Kemper et al. 2004). 
Plasma concentrations for docetaxel are around 0.5 nM, while concentrations in the 
cerebrospinal fluid (CSF) are ten times lower (0.05 nM) (Fracasso et al. 2004). This 
issue has been addressed recently by using convection-enhanced delivery (CED), for 
the treatment of recurrent gliomas with some promising results, where direct 
regional administration of protein toxins is achieved through stereotactically 
implanted catheters by using CED (Chen et al. 1999; Debinski 2002). The 
concentrations of docetaxel in the proliferation assays with SNB-19 and CLOM002 
(0.1 nM to 0.5 nM) (Table 3.1.2), were within the reported plasma concentration 
reported by Fracasso et al, for docetaxel (Fracasso et al. 2004), and over 4 times 
higher for UPHHJA and IPSB-18 (1.2 nM) (Table 3.1.2); and the concentrations for 
imatinib are lower than the plasma concentrations reportedly found by Le Coutre et 
al, for imatinib (up to 8 µM) (le Coutre et al. 2004). It is possible that the 
concentrations of imatinib and docetaxel currently achievable in the CSF are 
inactive concentrations and have no toxic effect on glioma. 
The synergistic effect of imatinib and docetaxel in combination was caused 
by apoptosis, while single drugs had little apoptotic effect (Fig. 3.1.2). Docetaxel 
causes G2/M cell cycle arrest (Gucluler and Baran 2009) and imatinib induces cell 
cycle arrest at the G0-G1 or G2/M phase in glioma cells (Ren et al. 2009). Increased 
apoptosis through combination of imatinib and docetaxel has also been found in 
human K562 chronic myeloid leukaemia cells, and this effect was induced by 
caspase-3 enzyme activity (Gucluler and Baran 2009).  
A variety of drug scheduling assays were carried out to increase the 
combination effect of imatinib and docetaxel (Fig. 3.1.3). A combination of imatinib 
and docetaxel on day 1 and 2, followed by imatinib alone on day 3 and 4 was the 
most effective treatment, resulting in 90% cell kill in CLOM002, UPHHJA and 
IPSB-18 cells (Fig. 3.1.3).  
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UPHHJA, IPSB-18 and CLOM002 show similar invasion activity reaching a 
distance between 1700 and 2000 µm from the spheroid within 11/12 days (Fig. 
3.1.4). Imatinib alone had little or no effect on glioma invasion activity while 
docetaxel slightly inhibited invasion in these 3 cell cultures (Fig. 3.1.5). The drug 
combination, however, reduced invasion activity between 63% in CLOM002, 59% 
in UPHHJA and 87.7% in IPSB-18, and was much more effective compared to 
single drugs. It is also possible that the 3D invasion assay allowed some cells to 
invade and some to proliferate, therefore the drugs may have had an effect on both 
invasion and proliferation. In figure 3.1.7 the image of the invasion assay with 
CLOM002 after 24 days invasion shows cells with an elongated structure, these may 
have been invasive, and cells with a round structure, which may have been involved 
in proliferation, possibly indicating a difference in function for each cell type (Fig. 
3.1.7). Golembieski et al, have shown migrating U87MG glioma cells maintain an 
elongated morphology on a fibronectin substrate, migration was correlated with 
decreased proliferation, they found an increase in the number of rounded cells with 
proliferative function (Golembieski et al. 2008). It is possible that docetaxel 
inhibited both proliferation and invasion, as it specifically targets microtubules, 
which are involved in cell division and motility. 
All cell cultures expressed GFAP proving their glial origin (Fig. 3.1.8). C-
Abl, PDGFR-α and PDGFR-β were expressed at low levels in all cell cultures, 
while C-Kit expression was absent. Low expression or absence of these imatinib 
targets could explain the low sensitivity to imatinib. C-Kit and C-Abl are frequently 
mutated or overexpressed in glioblastomas (Haberler et al. 2006), and are associated 
with glioma progression (Stanulla et al. 1995; Jiang et al. 2006), Overexpression of 
C-Kit and C-Abl was not found in the tested glioma cells. Other growth factors such 
as EGFR, tumour growth factor (TGF), insulin growth factor (IGF) may play a more 
significant role in proliferation of these cell lines. EGFR which signals through the 
PI3K/Akt pathway (Hynes and Lane 2005) is commonly overexpressed in gliomas 
(Heimberger et al. 2005).  
IPSB-18 had the highest expression of PDGFR-β, which is not surprising as 
the activation of the PDGF autocrine loop is thought to be an early event in the 
pathogenesis of malignant astrocytomas (Guha et al. 1995) and IPSB-18 is derived 
from a grade 3 astrocytoma. Secondary glioblastomas are usually associated with 
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overexpression of platelet derived growth factor (PDGF) and its receptor tyrosine 
kinase PDGFR forming an autocrine loop, which contributes to tumour growth, and 
the transformation process to a more malignant phenotype (Hermanson et al. 1992; 
Westermark et al. 1995).  
 
Effect of Imatinib and Docetaxel on Proliferation and Invasion of Normal 
Human Astrocytes 
As a control cell line normal human astrocytes (NHAs) were included. Their IC50 for 
imatinib was 17 µM, which is similar to the value found in glioma cell cultures, 
suggesting the possibility of side effects on normal cells. Bartolovic et al, found a 
reversible effect with normal hematologic (CD34 positive) progenitor cells at IC50s 
ranging from 0.3 µM to 1.8 µM (Bartolovic et al. 2004). This effect was 
independent of C-Kit signalling and could not be seen with stem cells (Bartolovic et 
al. 2004).  
With the NHAs an IC50 concentration with docetaxel could not be achieved, 
the highest concentration tested was 124 nM (Table 3.1), which resulted in an IC20; 
this is
 
a very low toxicity in comparison to that seen with the glioma cells. It appears 
from this result that docetaxel is more toxic to cancerous cells, making docetaxel an 
ideal therapy for glioma, with low-toxicity to normal astrocytes. Docetaxel is a 
known substrate of Pgp, the NHAs had very high expression of Pgp (Fig. 3.1.10) in 
comparison to the glioma cells (Fig. 3.1.8). Pgp expression is known to be expressed 
in the BBB (Leslie et al. 2005) and in human astrocytes (Marroni et al. 2003). It is 
possible that Pgp effluxes docetaxel in NHAs and that there is a loss of function of 
Pgp in glioma cells. 
Rabi and Bishayee et al, have shown that d –limonene, a non-nutrient dietary 
component, enhanced the antitumor effect of docetaxel against human prostate 
cancer cells without being toxic to normal prostate epithelial cells (Rabi and 
Bishayee 2009). Cells have a complex defence system for protection against free 
radical-induced damage resulting in the generation of glutathione (GSH), cysteine 
and antioxidant enzymes, including GSH peroxidase, superoxide dismutase and 
catalase (www.benbest.com/nutrceut/AntiOxidants.html). Hydrogen peroxide (H
 2 O 
2) has been identified as a major cytotoxic molecule of reactive oxygen species 
(ROS) in docetaxel-induced cell death (Bauer 2000; Bohler et al. 2000; Komatsu et 
al. 2001). Rabi and Bishayee et al, 2009 have shown that docetaxel induced certain 
 112 
amounts of ROS with cell death and suggested that the different effects of docetaxel 
on the prostate cancer cells in comparison to the normal prostate epithelial cells, 
may be due to the presence of more effective endogenous antioxidant mechanisms in 
the normal cells than in the malignant ones (Rabi and Bishayee 2009).  
To our surprise, NHAs invaded collagen gel from the spheroid up to a 
distance of 1193 µm within 10 days (Fig. 3.1.4). NHAs used in this project are of 
cerebral and foetal origin suggesting the presence of a mixture of astrocytes and 
oligodendrocyte-type 2 astrocyte progenitor cells (O2A). Rat O2A cells have been 
shown to spread and migrate on myelin coated dishes, and on spinal cord sections 
(Amberger et al. 1997). 
NHA invasion activity was only inhibited up to 60% although treated with 
much higher drug concentrations than the glioma cultures, mainly due to the 
docetaxel effect (imatinib 40.7 µM, docetaxel 29 nM) (Fig. 3.1.6). As NHAs had 
high Pgp expression and both imatinib and docetaxel are substrates for Pgp, it is 
possible that they were effluxed, which could explain why high concentrations were 
necessary to show an effect on invasion. The combination of imatinib and docetaxel 
did not significantly increase the effect of docetaxel alone, a similar result to that 
obtained with SNB-19 (Fig. 3.1.6).  
NHAs also had low expression of PDGFR-β, BCRP and C-Abl (Fig 3.1.10). 
The 2 low passage primary cultures CLOM002 and UPHHJA had similar expression 
of BCRP to the NHAs, again possibly indicating that BCRP expression is correlated 
with increased passage number (Figs 3.1.8 and 3.1.10). 
 
 
Effect of Imatinib and Docetaxel on Proliferation and Invasion with the 
Established Glioma Cell Line SNB-19 
The established cell line SNB-19, derived from a glioblastoma, had an IC50 for 
imatinib of 18.7 µM, and for docetaxel an IC50 of 0.7 nM was found (Table. 3.1). 
The combination of both drugs resulted in an additive effect in contrast to the results 
obtained with the other glioma cells (Fig. 3.1.1). With drug scheduling a cell kill of 
77% could be reached in SNB-19 (Fig. 3.1.3), showing their lower responsiveness to 
the drug combination. 
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SNB-19 appear as a homogeneous population and seem to have the potential 
to revert to a cancer stem cell-like genotype when exposed to chemotherapeutic drug 
(Auger et al. 2006). Stem cells seem to be responsible for resistance to 
chemotherapy, which might explain the lower cell kill effect of drug combination on 
SNB-19. Auger et al, developed temozolomide resistant variants of SNB-19 which 
did not show increased MGMT expression (Auger et al. 2006). Ma et al, also found 
MGMT expression not to be correlated with resistance in glioma; but some loss of 
chromosome 2p no amplification of chromosome 4 and 16q (Ma et al. 2002). Drug 
resistance in glioma is due to chromosome recombination (Duesberg et al. 2001); 
however, Auger et al, found that SNB-19 temozolomide-resistant variants had less 
rearranged chromosomes than the parental population, these cells were possibly 
derived form a pre-existent population in the parental cell line (Auger et al. 2006). 
They used microarray analysis to compare gene expression profiles of SNB-19-
temozolomide resistant variants in comparison to the parental cell line. They found a 
number of genes known to be involved in developmental pathways to be 
overexpressed in the resistant variants, including frizzled-2 (FZD2) (Galceran et al. 
2004) which is involved in the Wnt pathway or in stem cell self-renewal, and genes 
involved in proliferation such as leukaemia inhibitory factor (LIF) (Pitman et al. 
2004), RNA polymerase II elongation factor (ELL) (Kanda et al. 1998), and Co-
purified with NNF1 protein 1 (CNN1) (Xie et al. 2004). If following temozolomide 
treatment gliomas have the ability to revert back to senescent drug resistant stem 
cell-like cells it could explain why tumours relapse over time.  
Invasion activity of SNB-19 cells was slow and the cells reached a distance 
of only 760 µm within 10 days (Fig. 3.1.4). Invasion was strongly inhibited in the 
presence of docetaxel alone, and the drug combination did not significantly increase 
this effect (Fig. 3.1.5). Western blot analysis revealed an additional band similar to 
that found in K562, a CML cell line, representing the fusion protein Bcr-Abl at 210 
kDa (Fig. 3.1.8 and 3.1.9). Bcr-Abl is a specific target for imatinib; however SNB-
19 did not show higher sensitivity to imatinib suggesting that the band does not 
represent Bcr-Abl. Several BCR-Abl kinase domain point mutations have been 
identified, in CML tumour cells after imatinib treatment, it is more common to find 
these mutations in patients with acquired resistance to imatinib, than patients with 
primary resistance (Qin et al. 2010; Sherbenou et al. 2010). It is possible that SNB-
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19 has a mutated form of Bcr-Abl, which can be examined by specifically looking at 
single nucleotide polymorphisms using PCR. 
SNB-19 cells expressed both efflux pumps, Pgp and BCRP which might 
explain why the drug combination was not as effective as it was on the other tested 
cultures. Using elacridar, a specific Pgp and BCRP inhibitor (Evers et al. 2000), 
suggested the functionality of these pumps in SNB-19 cells (Fig. 3.1.11). It has been 
shown in mice that blockade of both Pgp and BCRP by elacridar produced 
significantly greater brain penetration of imatinib and docetaxel (Kemper et al. 
2004; Bihorel et al. 2007); this effect has also been seen in glioma cell lines with 
imatinib (Decleves et al. 2008), and in lung cancer cell lines with docetaxel (Myer et 
al. 1999). 
Co-expression of Pgp and BCRP has also been found in an imatinib resistant 
subgroup of acute myeloid leukaemia patients (van den Heuvel-Eibrink et al. 2007).  
It is also possible that the more established cell lines SNB-19 and IPSB-18, 
have developed into more resistant cell lines over time, as they have undergone 
more passages, possibly allowing for clonal selection, resulting in higher expression 
of BCRP and Pgp expression in SNB-19 in comparison to the two cell cultures 
which have less passages, CLOM002 and UPHHJA. 
 
3.1 Summary and Conclusion  
 
The Effect of Imatinib and Docetaxel on Glioma 
The combined effect of the TKI, imatinib and the chemotherapeutic drug, docetaxel 
had a synergistic antitumourigenic effect on glioma cells. The drug combination 
strongly inhibited both proliferation and invasion, and had a pro-apoptotic effect in 3 
out of 4 glioma cell cultures. The combined treatment of imatinib and docetaxel is a 
promising treatment for glioma patients. 
 SNB-19 cells express a mutation of the Abl protein, which might prevent 
imatinib binding. Out of 4 cell cultures only SNB-19 expressed both BCRP and Pgp, 
which might lead to higher efflux of imatinib explaining the low sensitivity of SNB-
19 cells to the drug combination.   
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3.2 Development of Drug Resistant Cell Lines 
To study drug resistance in glioma it was necessary to develop drug resistant glioma 
cells. Two glioma cultures were chosen to develop resistant variants, SNB-19 an 
established glioma cell line bought in from DSMZ, and CLOM002 cells which 
originated from a glioblastoma and was developed in Professor Geoffrey 
Pilkington’s laboratory in University House, Winston Churchill Avenue, 
Portsmouth, Hampshire, PO1 2UP, UK. Both cell cultures were exposed for 4 hours 
once a week over 10 weeks, separately to imatinib (169 µM), docetaxel (4.96 nM 
and 1.24 nM), and temozolomide (257.5 µM). Neither SNB-19 nor CLOM002 
developed resistance to imatinib or docetaxel, only CLOM002 did not develop 
resistance to temozolomide. However, SNB-19 became strongly resistant (15 fold) 
to temozolomide in comparison to the parental population (temozolomide IC50 561.4 
µM ±  45.8 µM versus 37 µM ± 4.1 µM). The parental cell line was used at passage 
P+16, and were temozolimide resistant at passage P+40. Figure 3.2.1 shows cell 
morphology at 10 and 20 times magnification of the parental cell line ((a) and (c)), 
and the temozolomide resistant variant ((b) and (d)). The latter appeared rounder and 
with a more flattened structure. 
 
 
Table 3.2.1 Temozolomide IC50 values SNB-19 and SNB-19 temozolomide 
resistant cell line. 
Cell Line IC50 
 
Parental SNB-19 P+16 37 µM ± 4.1 µM 
 
Temozolomide resistant 
SNB-19 P+40 
561.4 µM ±  45.8 µM 
                           Standard deviations represent the result of 3 biologically individual assays. 
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Fig. 3.2.1 (a) and (c) show the parental cell line SNB-19 without drug exposure; (b) 
and (d) show the SNB-19 after 10 weeks exposure to temozolomide. 
 
 
 
 
SNB-19 Parental cell line SNB-19 Temozolomide resistant cell line
(a) (b)
(c) (d)
200 µm 200 µm
200 µm 200 µm
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3.2 Discussion 
 
Development of Drug Resistant Cell Lines 
 
Introduction 
Development of resistance in glioma to current therapies over time ultimately results 
in treatment failure in glioma patients. Exploration of resistance mechanisms in 
glioma cells should increase our understanding of resistance in glioma, and enable 
identification of new targets for treatment. In order to study resistance in glioma it 
was necessary to firstly make a resistance model; an established glioma cell line 
SNB-19, and the glioma culture CLOM002 were chosen, both were derived from 
glioblastomas.  
Both cultures were separatley pulse selected with imatinib, docetaxel and 
temozolomide four 4 hours once a week over 10 weeks. Toxic concentrations of 
drug were chosen; the concentrations used were 169 µM imatinib, 4.96 nM and 1.24 
nM of docetaxel, and 257.5 µM of temozolomide. With either culture there was no 
change in resistance to imatinib and docetaxel in comparison to the parental cells, 
when the IC50 values were tested. CLOM002 did not develop resistance to 
temozolomide; however SNB-19 developed strong resistance to temozolomide (15-
fold). The parental cell line SNB-19 had an IC50 with temozolomide of 37 µM, while 
the SNB-19 temozolomide resistant cell line had a much higher IC50 of 561.4 µM 
(Table 3.2.1). Auger et al. used an incremental concentration of 3-150 µM of 
temozolomide with SNB-19 and created two resistant variants, SNB-19A4 and 
SNB-19C1 which had a 100-fold and 55-fold resistance to temozolomide in 
comparison to the parental SNB-19 cell line (Auger et al. 2006). They initially used 
a low concentration of temozolomide (3 µM) and selected out the more resistant 
clones, then they incremented the concentration of temozolomide over time, this 
appears to be a more effective way of developing resistant variants (Auger et al. 
2006). 
The parental cell line had a homogeneous population, with elongated cells, 
while the SNB-19 temozolomide resistant cell line had a mixed population of 
elongated, flattened and rounded cell types (Fig. 3.2.1). There were much larger 
nuclei present in the resistant cell line, possibly indicating the presence of a stem 
cell-like population, as stem cells tend to have larger nuclei with less defined 
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structures (Li and Xie 2005). Strong staining for stem cell markers such as CD133 in 
these temozolomide resistant cells and the parental cells would be interesting to see 
if there are stem cells present and if there is a higher population of stem cells in the 
resistant cells. If there are stem cells in the resistant cells they could be isolated by 
fluorescently activated cell sorting (FACS) analysis, and further testing of 
temozlomide resistance could be examined to see if these cells are more resitant than 
the original mixed population. 
The induction of O6-G-methylation by temozolomide is reversed by the 
DNA repair gene MGMT. Increased levels of MGMT leads to resistance to 
temozolomide in some glioblatomas, however Auger et al, found that the levels of 
temozolomide resistance did not correlate with MGMT expression levels (Auger et 
al. 2006). Very few gliomas actually overexpress O6-G-methylation-DNA 
methyltransferase, suggesting dependence on other resistance mechanisms. Some 
tumours develop resistance independently to MGMT status, with mechanisms such 
as loss of p53 function, which causes cell cycle arrest and apoptosis (Auger et al. 
2006); or the Akt pathway which prevents senescence and mitosis (van den Bent et 
al. 2009). Ulasov et al, found that glioma CD133 positive stem cells which were 
resistant to temozlomide treatment had more active Notch and Sonic hedgehog 
(SHH) pathways, the pathway activity was further enhanced after exposure to 
temozolomide (Ulasov et al. 2010). The SHH pathway is involved in prenatal brain 
development where it regulates proliferation (Dahmane et al. 2001). The Notch 
pathway is associated with proliferation differentiation and apoptosis (Miele and 
Osborne 1999). The activationof these pathways in the temozolomide resistant cells 
from the present study could be examined by using westrn blotting and looking at 
phosphorylated proteins of these pathways. 
Kitange et al, have identified CD74 as a potential modulator of 
temozolomide responsiveness; CD74 is a membrane receptor for the 
proinflammatory cytokine macrophage migratory inhibitory factor (MIF) on 
immune cells, which promotes cell proliferation through the MAPK and Akt 
pathways (Kitange et al. 2010). They found overexpression of CD74 in glioblastoma 
(Kitange et al. 2010). The levels of CD74 in the SNB-19 temozolomide resistant 
cells from the present study could be examined  to see if CD74 expression correlates 
with resistance in these cells. 
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Schaich et al, examined MDR1 nucleotide polymorhisms of glioblastoma 
patients treated with temozolomide (Schaich et al. 2009). They found that response 
to temozolomide treatment was dependent on MDR1 expression, analysis of MDR1 
genotypes showed that the C/C variant of the exon12 C1236T SNP was associated 
with higher survival for patients treated with temozolomide, the effect was 
independent of MGMT methylation status (Schaich et al. 2009). The overexpression 
of MDR1 has been found in most brain tumours (Demeule et al. 2001). It has been 
suggested temozolomide resistant clones of SNB-19 develop resistance due to less 
differentiated pre-existent cells possibly of stem cell origin (Auger et al. 2006). 
Tumour stem cells are thought to be naturally resistant to chemotherapy due to their 
quiescence, their ability to repair DNA, and their increased ABC transporter 
expression (Auger et al. 2006). In a previous section it was shown that SNB-19 have 
high expression of Pgp and express BCRP (Kinsella et al. 2011), BCRP is known to 
be a stem cell marker (Wang et al. 2008). It would be interesting to check the levels 
of Pgp and BCRP expression in the temozolomide resistant cell line developed to 
see if the levels have increased in comparison to the parental population. 
 
3.2 Summary and Conclusion  
A temozolomide resistant variant (15-fold) was developed from exposure of SNB-19 
cells to temozolomide. There was a change in morphology, resistant cells were 
larger with a flattend elongated structure. 
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3.3 Glioma Cell Cultures Generated from Biopsy Samples from Beaumont 
Hospital 
31 cell cultures were generated from biopsy samples from 44 glioma patients. 15 of 
the cultures had good growth. The cultures were grown in DMEM with 20% fetal 
calf serum, and 4% non-essential amino acids. Reasons for unsuccessful 
development were non-adherence to the bottom of the flask, bacterial contamination, 
and cell division arrest. The age range of the patient cohort was 22 to 78 years, 
35.5% of the patients were between 24-49 years, and 64.5% of the patients were 50-
78 years. The cohort included 31 male and 12 female patients. Malignant gliomas 
are more frequently found in older male patients (Paul Kleihues 1997), which is 
consistent with our findings. The survival time was determined in months from the 
point of enrollement. 26 of these patients passed away during the course of this 
study, patient survival did not correlate with cell growth rate (Table 3.3.3); this is 
not surprising as benign meningioma cultures usually grow rapidly for ten passages 
and then senesce (Rooprai et al. 2003; Ragel et al. 2008). Patients with a 
glioblastoma had an average age of 58 years and an average survival time of 16.5 
months, in comparison to the lower grade tumours where the average age was lower 
at 40 years with more than a 2-fold increase in an averge survival time of 34 months 
(Fig 3.3.1).  
Of the 39 biopsy samples which formed cell cultures, 25 originated from 
glioblastomas, 5 secondary glioblastomas, other samples included 4 grade III 
astrocytomas, 1 grade II astrocytoma, 1 grade III oligoastrocytoma, 1 grade III 
oliogodendroglioma and 2 grade II oliogodendrogliomas II (Table 3.3.2). Fig. 3.3.2 
shows representative morphologies of the different cell lines. Figures 3.3.3 to 3.3.8 
are images of each cell culture, showing the vast range of differences in morphology 
with each culture. The cultures with fast growth had a more elongated structure 
(Figs 3.3.3 and 3.3.4), the slow growing cell lines had more of a mixture of 
elongated and rounded cells (Figs 3.3.5, 3.3.6 and 3.3.7). 
In total 15 cultures were established with fast growth rates; 7 with slow 
growth, and 18 samples were slow initially and slowed down even further after less 
than 10 passages (Table 3.3.2). One grade III astrocytoma sample (N070215) 
stopped growing completely (Table 3.3.2). A grade III oligoastrocytoma and a 
secondary glioblastoma (N070950 and N070311) failed to attach to the bottom of 
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the flask (Table 3.3.2), and one glioblastoma sample (N070948) became 
contaminated with bacteria (Table 3.3.2).  
Figure 3.3.3 contains images of the glioma cultures with a fast growth rate 
N070055 has a typical oligoastrocytoma structure, with clusters of cells forming 
networks with each other typical of an oligodendroglioma, with a typical star shaped 
astrocytic cell to the right hand side of the image, these cell types had large nuclei 
and represent a mixed cell population of oligodendrocytes and astrocytes. The 
glioblastoma images (N070126, N070152, and N070859) showed mixed cell types 
of mostly elongated cells and some rounded cells, with small nuclei; N070126 
shows a low confluency population of cells. The grade III astrocytomas (N070201 
and N070788) shows typical astrocytic cellular networks between clusters of cells. 
Both grade II oligodendrogliomas (N070219 and N070314) have elongated cells 
typical of oligodendrocytes, in addition there are a few smaller more rounded shaped 
cells. 
In figure 3.3.4 all of the images are of glioblastoma cell cultures with a fast 
growth rate, and show mixed cell type populations, of mostly elongated cells and 
rounded cells, typical of the heterogeneity of a glioblastoma. However there are 
differences in cell size between samples, N080501 has much larger cells with larger 
nuclei, while N080923 has smaller cells and small nuclei in comparison. There is 
also a difference in confluency beween the images, N080533 and N080869 have low 
confluency, while N080943 is the most confluent. 
Figure 3.3.5 shows images of glioma cultures with a slow growth rate. The 
astrocytomas (N070229, N070237, and N070450) have a typical star-like structure 
of an astrocyte, however N070229 has larger cells and N070237 has a higher 
confluency. The secondary glioblastoma N070440 has a very low confluency in this 
image, showing small rounded cells, the other secondary glioblastoma N070780, has 
larger flattened cells, these are very different in cell types of the glioblastomas with 
fast growth rates from figures 3.3.3 and 3.3.4. The glioblastoma N070934 has very 
small cells which are a mixture of thin elongated and rounded cells, again they are 
very different in structure to the glioblastoma cells with fast growth in figures 3.3.3 
and 3.3.4. N071155 represents a typical oligodendroglioma structure, flattened and 
elongated with a rounded center.  
Figure 3.3.6 shows images of glioma cultures whose growth rate slowed 
down in culture below passage 10. The secondary glioblastoma N060893 had a 
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typical mixed cell type population of elongated and rounded cells, however in 
comparison to glioblastomas, there is a higher population of small rounded cells. 
The other secondary glioblastoma shown here N070701, has large flattened cells. 
Figure 3.3.7 also shows glioma cultures which slowed down in culture with fewer 
than 10 passages. These were all derived from a glioblastoma and all slowed down 
in culture. Figure 3.3.8 shows a glioblastoma with large flattened cells with a 
rounded centre, more typical of an oligodendroglioma, it also shows a secondary 
glioblastoma with large flattened cells. Figure 3.3.9 is an image of a grade III 
astrocytoma culture which stopped growing, it mainly has small rounded cells with 
one cell containing thin elongated processes. 
Fast growing cultures originated from patients with an average survival time 
of 22 months, the cultures with slow growth originated from patients with an 
average survival time of 25 months, while the cultures which slowed down in 
growth (with the exception of the outlier N06893 with greater than 138 months 
survival) had a much lower average patient survival time of 13 months (Table 3.3.3 
(a)). All biopsy samples were taken prior to treatment (Table 3.3.3 (b)). 
 
 
        Table 3.3.1 Brain tumour types of glioma cell cultures. 
 
                
              
 
 
 
 
 
Tumour Type Number of  samples which formed 
cultures 
 
Primary Glioblastoma 25 out of 26 
Secondary Glioblastoma 5 out of 6 
Grade III Astrocytoma  4 out of 5 
Grade II Astrocytoma  1 out of 1 
Grade III Oligoastrocytoma  1 out of 3 
Grade III Oliogodendroglioma  1 out of 1 
Grade II Oliogodendroglioma II 2 out of 2 
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Table 3.3.2 The take rate of glioma cultures. 
 
Tumour Type Fast 
Growth 
Slow 
Growth 
Slowed 
Down 
Stopped 
Growing 
Never 
Attached 
Cont 
Primary 
Glioblastoma 
(26 samples) 
 
10 1 14 - - 1 
Secondary 
Glioblastoma 
(6 samples) 
 
- 2 3 - 1 - 
Grade III 
Astrocytoma  
(5 samples) 
 
2 2 - 1 - - 
Grade II 
Astrocytoma  
(1 sample) 
 
- 1 - - - - 
Grade III 
Oligoastrocytoma  
(3 samples) 
 
1 - 1 - 1 - 
Grade III 
Oligodendroglioma  
(1 sample) 
 
- 1 - - - - 
Grade II 
Oligodendroglioma  
(2 samples) 
 
2 - - - - - 
Never attached: never attached to the bottom of the flask. Cont: contaminated. 
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Table 3.3.3 (a) Establishment of glioma cell cultures. 
 
* Only cell line which initially had fast growth and then slowed down.  
PR: Previous resection. LR: Later resection. ?: patient emigrated and contact details were lost 
Cell 
Culture 
Tumour Type Growth 
Rate 
 
Age Survival Time 
(months) 
 
N070055 Grade III Oligoastrocytoma Fast       32 >38 
N070126 Primary Glioblastoma (LR) Fast 56 28 
N070152 Primary Glioblastoma Fast 52 5 
N070201 Grade III Astrocytoma Fast 42 >36 
N070219 Grade II Oligodendroglioma Fast 66 >36 
N070314 Grade II Oligodendroglioma Fast 33 >36 
N070788 Grade III Astrocytoma (PR) Fast 38 >31 
N070859 Primary Glioblastoma Fast 55 12 
N070865 Primary Glioblastoma Fast 70 5 
N080501 Primary Glioblastoma Fast 60 18 
N080533 Primary Glioblastoma Fast 55 15 
N080540 Primary Glioblastoma Fast 51 ?>12 
N080869 Primary Glioblastoma Fast 54 >20 
N080923 Primary Glioblastoma Fast 61 15 
N080943 Primary Glioblastoma Fast 62 >19 
N070229 Grade III Astrocytoma Slow 22 >36 
N070237 Grade III Astrocytoma (PR) Slow 33 55 
N070440 Secondary Glioblastoma  (PR) Slow 45 7 
N070450 Grade II Astrocytoma Slow 35 >34 
N070780 Secondary Glioblastoma  (PR) Slow 60 4 
N070934 Primary Glioblastoma Slow 52 10 
N071155 Grade III Oligodendroglioma Slow 36 >28 
N060893 Secondary Glioblastoma  (PR) Slowed down 40 >138 
N060913 Primary Glioblastoma Slowed down 67 10 
N060950 Grade III Oligoastrocytoma Slowed down 50 >30 
N060978 Primary Glioblastoma Slowed down 54 3 
N061007 Primary Glioblastoma Slowed down 75 1 
N061092 Primary Glioblastoma Slowed down 78 6 
N070454* Primary Glioblastoma Slowed down 73 3 
N070701 Secondary Glioblastoma  (PR) Slowed down 39 >56 
N070293 Primary Glioblastoma Slowed down 38 >36 
N071026 Primary Glioblastoma Slowed down 46 10 
N071057 Primary Glioblastoma Slowed down 73 7 
N071060 Primary Glioblastoma Slowed down 58 >29 
N071144 Primary Glioblastoma Slowed down 53 8 
N071271 Primary Glioblastoma Slowed down 59 11 
N080558 Primary Glioblastoma Slowed down 64 5 
N080749 Primary Glioblastoma Slowed down 74 4 
N080805 Primary Glioblastoma Slowed down 75 6 
N081185 Secondary  Glioblastoma  (PR) Slowed down 55 4 
N070215 Grade III Astrocytoma (PR) Stopped 
growing 
58 >36 
N070950 Grade III Oligoastrocytoma Cells failed to 
attach to flask 
52 14 
N070311 Secondary Glioblastoma Cells failed to 
attach to flask 
57 6 
N070948 Primary Glioblastoma Bacterial 
contamination 
51 5 
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Table 3.3.3 (b) Patient treatment during the course of the study. 
Sample 
Number 
Tumour Type Radiation 
Treatment 
Temozolomide Gliadel PCV 
N070126 Primary Glioblastoma 60Gy (30fr) Yes Yes No 
N070152 Primary Glioblastoma 56Gy (28fr) Yes No No 
N070201 Grade III Astrocytoma 55Gy (30fr) No No Yes 
N070788 Grade III Astrocytoma Yes amt? No No No 
N070859 Primary Glioblastoma 45Gy (20fr) Yes No No 
N070865 Primary Glioblastoma 60Gy (30fr) Yes No No 
N080501 Primary Glioblastoma Unknown Unknown No No 
N080533 Primary Glioblastoma Yes amt? Yes No No 
N080540 Primary Glioblastoma 58Gy (28fr) Yes No No 
N080869 Primary Glioblastoma 60Gy (30fr) Yes No No 
N080923 Primary Glioblastoma 60Gy (30fr) Yes No No 
N080943 Primary Glioblastoma 58Gy (29fr) Yes No No 
N070229 Grade III Astrocytoma Unknown Unknown No No 
N070237 Grade III Astrocytoma 55Gy (30fr) No No No 
N070440 
Secondary 
Glioblastoma No No yes No 
N070780 
Secondary 
Glioblastoma No No No No 
N070934 Primary Glioblastoma 56Gy (28fr) Yes Yes No 
N060893 
Secondary 
Glioblastoma 60Gy (30fr) Yes No No 
N060913 Primary Glioblastoma 66Gy (30fr) No No No 
N060978 Primary Glioblastoma 20 Gy (5fr) No No No 
N061007 Primary Glioblastoma No No No No 
N061092 Primary Glioblastoma 45Gy (20Fr) No No No 
N070454 Primary Glioblastoma 40Gy (60fr) No No No 
N070701 
Secondary 
Glioblastoma 60Gy (30fr) Yes No No 
N070293 Primary Glioblastoma 60Gy (30fr) Yes No No 
N071026 Primary Glioblastoma Unknown Unknown No No 
 
 
    
N071057 Primary Glioblastoma Unknown Unknown No No 
N071060 Primary Glioblastoma 30Gy (60Fr) Yes No No 
N071144 Primary Glioblastoma Unknown Unknown No No 
N07-
1271 
Primary Glioblastoma 
60Gy (30fr) Yes No No 
N080558 Primary Glioblastoma 30Gy (30Fr) Yes No No 
N080749 Primary Glioblastoma Unknown Unknown No No 
N080805 Primary Glioblastoma Unknown Unknown No No 
N081185 
Secondary 
Glioblastoma No No No No 
N070215 Grade III Astrocytoma No Yes No No 
N070311 
Secondary 
Glioblastoma 55Gy (30fr) Yes No No 
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*: Patient still alive. N060893 was an outlier with >138 months survival. 2o: Secondary Glioblastoma. 
 
Fig 3.3.1 (a) Survival and age of patients with a glioblastoma (b) survival and age of patients with a lower grade glioma
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Fig. 3.3.2 Images of glioma cell cultures. (a) Glioblastoma, (b) Grade III 
Oligoastrocytoma (c) Grade III Astrocytoma (d) Grade III Oligodendroglioma. 
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     Fig. 3.3.3 Images (10x) of glioma cell cultures with fast growth rate.  
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Fig. 3.3.4 Images (10x) of glioma cell cultures with fast growth rate.  
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Fig. 3.3.5 Images (10x) of glioma cell cultures with slow growth rate.  
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Fig. 3.3.6 Images (10x) of glioma cell cultures which slowed down in growth. 
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Fig. 3.3.7 Images (10x) of glioma cell cultures which slowed down in growth.  
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Fig. 3.3.8 Image (10x) of glioma cell cultures which slowed down in growth.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3.9 Image (10x) of glioma cell culture which stopped growing.  
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3.3.1 Characterization of Newly Developed Glioma Cell Cultures 
The newly developed glioma cell cultures were characterised in relation to invasion, 
proliferation, sensitivity to TKIs and chemotherapeutic drugs, and protein 
expression. 
 
3.3.1.1 Invasion and Proliferation  
Invasion and proliferation was tested with my supervisor, Dr. Verena Amberger-
Murphy. The 3D spheroid collagen invasion assay was used because it is a better 
model for tumour invasion in vivo. One cell culture was additionally tested in the 
Boyden Chamber assay, which resulted in similar invasion activity. 65% of all cell 
cultures tested were invasive. Out of 19 glioblastomas, 4 were non-invasive, and 15 
were invasive, 5 cell cultures showed invasive behaviour with biospheres produced 
from segments of the biopsy sample, the other cell cultures showed invasive 
behaviour from spheroids produced from the cell cultures (see section 2.8). Within 
the lower grade tumours invasive behaviour was independent of the tumour type and 
grade of malignancy. The overall invasion rate per day ranged from 5.23 µm to 
50.69 µm (Fig. 3.3.10). 
Proliferation activity was determined by measuring the doubling time, which 
ranged from 37.3 to more than 168 hours (Figs. 3.3.11 and 3.3.12). Again 
proliferation rate was independent of tumour type and grade. Invasion did not 
correlate with proliferation rate in glioblastomas or the lower grade tumours (Fig. 
3.3.13). The ICC for GFAP and Nestin with 17 of the cultures was carried out a 
Ph.D student, Rachel Howley. ICC of GFAP and nestin was correlated with 
doubling time for the cultures, a low amount of GFAP was detected overall, there 
was an increase in nestin expression with slower proliferating cultures (Fig. 3.3.14). 
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Fig. 3.3.10 Invasion rate per day for 19 invasive cultures. Data represents 3 individual 
biological assays. Standard deviations were generated from Microsoft excel software. 
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Grade II Astrocytoma, Grade III Oligoastrocytoma. * Biosphere
0
10
20
30
40
50
60
70
N
06
09
13
N
06
09
78
N
06
10
07
N
06
10
92
N
07
01
52
N
07
02
93
N
07
08
59
N
07
08
65
N
07
10
26
N
07
11
44
N
07
12
71
N
08
08
69
N
08
09
43
N
07
04
54
N
06
08
93
N
07
07
01
N
07
02
29
N
07
04
50
N
07
00
55
av
er
ag
e
 
m
igr
at
io
n
/d
ay
 
(um
)
* * * * *
 136 
 
 
 
 
 
 
 
      *: Doubling time greater than 168 hours. Blue bars represent secondary glioblastomas. 
Fig. 3.3.11 Doubling time of glioblastoma cell cultures measured in hours. Data represents 3 individual biological assays. Standard 
deviations were generated from Microsoft excel software. 
 
 
 
 
 
 
 
 
                                                        *: Doubling time greater than 168 hours. ** repeat astrocytoma III. 
Fig. 3.3.12 Doubling time of cell cultures derived from other tumour types measured in hours. Data represents 3 individual 
biological assays. Standard deviations were generated from Microsoft excel software. A: astrocytoma, OA: grade II 
oligoastrocytoma, OD: oligodendroglioma
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     Biosphere, ** Doubling Time greater than 168 hours.  
 
Figure 3.3.13 The invasion and proliferation rate of glioblastoma cultures (a) and 
the invasive lower grade cultures, a grade III oligoastrocytoma (N070055), a grade 
II astrocytoma (N070450), and a grade III astrocytoma (N070229) (b). Invasion was 
measured in micrometres per day, doubling time was measured in hours. Data 
represents 3 individual biological assays. Standard deviations were generated from 
Microsoft Excel software. 
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Figure 3.3.14 Doubling time of cultures tested for ICC of GFAP and nestin. GFAP 
and nestin were graded 1 to 12.  
* * ** 
* * 
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3.3.1.2 Sensitivity to Tyrosine Kinase Inhibitors 
31 glioma cell cultures were tested for sensitivity to three TKIs, erlotinib, gefitinib, 
and imatinib. Using a cut-off concentration based on data published in the literature 
each cell culture was classified as a responder or non-responder to the TKIs (Table 
3.3.4). The cut off concentration for Erlotinib was 10 µM based on Mellinghoff et 
al, (Mellinghoff et al. 2005) and Zerbe et al, who reported a concentration of 
erlotinib of up to 9 µM found in tumours of an animal model (Zerbe et al. 2008). 
The cut off concentration for gefitinib was 20 µM, based on Hofer and Frei, (Hofer 
and Frei 2007); they found gefitinib concentrations of up to 24 µM in human 
glioblastoma tissue. Cemeus et al, (Cemeus et al. 2008) classified glioblastoma cell 
lines as responsive, if they were inhibited by gefitinib at a concentration of 20 µM. 
The cut off concentration for imatinib was 20 µM which is consistent with data 
published by Servidei et al, (Servidei et al. 2006).  
8 out of 23 glioblastomas, 1 out of 5 astrocytomas III, and 1 out of 2 
oligoastrocytomas III were responsive to erlotinib (Table 3.3.5). Responders to 
gefitinib included 13 out of 23 glioblastomas (Table 3.3.6). 6 out of 23 
glioblastomas, 2 out of 5 astrocytomas, and 1 out of 2 oligoastrocytomas III, and the 
only oligodendroglioma II responded to imatinib (Table 3.3.6). Overall there were 
more imatinib responders found in astrocytomas and mixed tumours than in 
glioblastoma. 
Figure 3.4.4 represents the glioblastoma responder profile. 7 glioblastomas 
responded to 2 TKIs. One grade III astrocytoma responded to both erlotinib and 
imatinib (N070201), and one grade III oligoastrocytoma (N070055) responded to 
both erlotinib and imatinib (Tables 3.3.7 to 3.3.9). Only one secondary glioblastoma 
culture was sensitive to all three TKIs tested (N070701) (Tables 3.3.7 to 3.3.9). 
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Fig. 3.3.15 Glioblastoma cultures which responded to the tyrosine kinase inhibitors, 
erlotinib, gefitinib and imatinib. 
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Table 3.3.4 Classification of glioma cultures as responders and non-responders to 
erlotinib, gefitinib and imatinib. 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Responder: +        Non-responder:- 
 
 
Cell 
Culture 
Tumour Type Erlotinib Gefitinib Imatinib 
 
 
N070701 Secondary 
Glioblastoma 
+ + + 
N060978 Primary Glioblastoma + +  - 
N070152 Primary Glioblastoma + +  - 
N071144 Primary Glioblastoma + +  - 
N080923 Primary Glioblastoma + +  - 
N080540 Primary Glioblastoma  - + + 
N071057 Primary Glioblastoma  - + + 
N070055 Grade III 
Oligoastrocytoma 
+ - + 
N070201 Grade III 
Astrocytoma 
+ - + 
N060913 Primary Glioblastoma + -  - 
N061007 Primary Glioblastoma + -  - 
N061092 Glioblastoma + -  - 
N060893 Secondary 
Glioblastoma 
- +  - 
N070126 Primary Glioblastoma - +  - 
N070293 Primary Glioblastoma - +  - 
N071271 Primary Glioblastoma - +  - 
N080501 Primary Glioblastoma - +  - 
N080533 Primary Glioblastoma - +  - 
N070454 Primary Glioblastoma - - + 
N071026 Primary Glioblastoma - - + 
N080869 Primary Glioblastoma - - + 
N070450 Grade II 
Astrocytoma 
- - + 
N070314 Grade II 
Oligodendroglioma 
- - + 
N070788 
Grade III 
Astrocytoma 
- -  - 
N070859 Primary Glioblastoma - -  - 
N070865 Primary Glioblastoma - - - 
N080558 Primary Glioblastoma - - - 
N080943 Primary Glioblastoma - - - 
N070229 Grade III 
Astrocytoma 
- - - 
N070237 Grade III 
Astrocytoma 
- - - 
N060950 Grade III 
Oligoastrocytoma 
- - - 
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Table 3.3.5  IC50 values of glioma cell cultures responsive to erlotinib.  
 
 
 
 
 
 
 
        
 
 
 
 
Standard deviations are from 3 biologically individual assays. *: 2 biologically 
individual assays. 
 
 
Table 3.3.6 IC50 values of glioma cell cultures responsive to gefitinib.  
 
 
 
 
 
 
 
 
 
 
                  
Standard deviations are from 3 biologically individual assays. *: 2 biologically    individual assays. 
Cell 
Culture 
Tumour 
Type 
Erlotinib   
(µM) 
 
N070152 Glioblastoma 
  6.5 ± 0.9 * 
N060913 Glioblastoma 
  7.2 ± 0.2 * 
N080923 Glioblastoma 7.2 ± 0.5 
N070701 Secondary 
Glioblastoma 
7.9 ± 0.7 
N061007 Glioblastoma 
  9.1 ± 1.2 * 
N071144 Glioblastoma 9.3 ± 0.5 
N060978 Glioblastoma 9.5 ± 1.4 
N061092 Glioblastoma 9.3 ± 1.4 
N070201 Grade III      
Astrocytoma 
  8.4 ± 0.1 * 
N070055 Grade III 
Oligoastrocytoma 
9.3 ± 0.7 
     Cell Culture Tumour   Type Gefitinib 
(µM) 
 
N080923    Primary Glioblastoma 15.2 ± 0.7 
N071271    Primary Glioblastoma 16.7 ± 1.3 
N080533    Primary Glioblastoma 16.7 ± 1.1 
N070701 Secondary Glioblastoma 16.7 ± 1.1 
N060893 Secondary Glioblastoma 
  16.8 ± 1.6 * 
N080501 
   Primary Glioblastoma 16.9 ± 0.9 
N070152    Primary Glioblastoma 17.0 ± 0.9 
N060978    Primary Glioblastoma 17.2 ± 2 * 
N070293    Primary Glioblastoma 18.3 ± 2.2 
N080540    Primary Glioblastoma 18.5 ± 1.8 
N070126    Primary Glioblastoma 
   20.0 ± 1.1 * 
N071144    Primary Glioblastoma 19.5 ± 2 * 
N071057    Primary Glioblastoma 
   17.2 ± 0.9 * 
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Table 3.3.7 IC50 values of glioma cell cultures responsive to imatinib.  
 
 
  
 
 
 
 
  
Standard deviations are from 3 biologically individual assays. *: 2 biologically 
individual assays. 
 
 
Overall, the IC50 values for each drug were relatively high and no cell culture 
showed particular sensitivity to any TKI. 
Cell Culture Tumour  Type Imatinib  
(µM) 
 
N080869    Primary Glioblastoma 14.0 ± 4 * 
N070701 Secondary Glioblastoma 14.4 ± 0.7 
N080540    Primary Glioblastoma 15.8 ± 1.7 
N070454    Primary Glioblastoma 
  16.7 ± 1.5 * 
N071026    Primary Glioblastoma 
  19.6 ± 2.4 * 
N071057    Primary Glioblastoma 
  14.0 ± 1.7 * 
N070201 Grade III Astrocytoma 
  20.0 ± 0.7 * 
N070450 Grade II Astrocytoma 
  15.8 ± 3.2 * 
N070055 Grade III Oligoastrocytoma 18.0 ± 0.5 
N070314 Grade II Oligodendroglioma 19.6 ± 1 * 
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3.3.1.3 Sensitivity to Chemotherapeutic Drugs  
The same cell cohort was also tested for sensitivity to the chemotherapeutic drugs 
docetaxel and temozolomide. The IC50 values for docetaxel ranged in glioblastomas 
from 0.4 nM to 25.4 nM and the astrocytomas from 1.4 nM to 59.5 nM; both grade 
III oligoastrocytomas had an IC50 of 2.7 nM, and for grade II oligodendroglioma the 
IC50 for docetaxel was 24.8 nM. The IC50 values clearly demonstrate that sensitivity 
to docetaxel is not correlated with tumour type and grade. 11 out of 23 
glioblastomas and 1 grade III astrocytoma had an IC50 <2 nM for docetaxel (Table 
3.3.8, Fig. 3.3.15) and were responsive to one, two or three TKIs; this would 
indicate there might be a benefit from combing docetaxel and TKIs.  
     The IC50 values of temozolomide also did not correlate with tumour type and 
grade. They ranged in glioblastoma from 198.3 µM to 1146 µM, in astrocytoma from 
437.8 µM to 1037.8 µM, in grade III oligoastrocytomas from 417.2 µM to 852.4 
µM, and the IC50 value in the grade II oligodendroglioma was 939.9 µM (Table 
3.3.9, Fig. 3.3.16).  
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            Table 3.3.8 Docetaxel IC50 values of glioma Cultures.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
Standard deviations represent biological duplicate results calculated in Microsoft Excel.* 
Biologically triplicate results. ** Result of a single assay. N070788 is an outlier not included in 
Fig. 3.3.16. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3.16 The IC50 values of docetaxel in glioblastomas (a), and in other glioma 
cell cultures (b).
     Cell Culture Tumour Type Docetaxel  
(nM) 
 
N080923 Primary Glioblastoma 0.4 ± 0.05 * 
N070152 Primary Glioblastoma 
    0.5 ± 0.0 
N071271 Primary Glioblastoma 0.6 ± 0.02 * 
N080540 Primary Glioblastoma 0.7 ± 0.01 * 
N070454 Primary Glioblastoma 
    0.9 ± 0.2 
N060978 Primary Glioblastoma 
    1.0 ± 0.4 
N070701   Secondary Glioblastoma 
    1.1 ± 0.4 
N061007   Primary Glioblastoma     1.2 ** 
N060893  Secondary  Glioblastoma 
    1.6 ± 0.7 
N070201  Grade III Astrocytoma 
    1.4 ± 0.1 
N061092 Primary Glioblastoma 
    1.5 ± 0.4 
N070126 Primary Glioblastoma 
    1.4 ± 0.1 
N070859 Primary Glioblastoma 
    2.1 ± 0.1 
N060950  Grade III Oligoastrocytoma 
    2.7 ± 0.6 
N080533   Primary Glioblastoma 
    2.6 ± 1.6 
N070055  Grade III Oligoastrocytoma 
    2.7 ± 0.2 
N070865 Primary Glioblastoma 
    5.0 ± 1.7 
N060913 Primary Glioblastoma 
    5.6 ± 3.1 
N080501 Primary Glioblastoma 
    5.8 ± 0.5 * 
N071144 Primary Glioblastoma 
    6.4 ± 1.5 
N070450   Grade II Astrocytoma 
    8.3 ± 2.2 
N080943   Primary Glioblastoma 
    9.0 ± 1.2 
N070229   Grade III Astrocytoma 
          9.4 ± 1 * 
N070293   Primary Glioblastoma 
        13.0 ± 5.2 
N070237   Grade III Astrocytoma 
  16.4 ± 1 
N070314 Grade II Oligodendroglioma   24.8 * 
N080869 Primary Glioblastoma 
  19.0 ± 5.2 * 
N071026 Primary Glioblastoma 
  23.2 ± 4 * 
N080558 Primary Glioblastoma 
  25.4 ± 4.3 
N070788 
  Grade III Astrocytoma 
  59.5 ± 3.5 
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Table 3.3.9 Temozolomide IC50 values of glioma cell cultures.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
Data represents biologically triplicate assays. * Standard deviations are from biologically duplicate 
assays. ** result of a single assay.  
 
 
 
 
 
 
 
 
 
Fig. 3.3.17 The IC50 values of temozolomide in glioblastomas (a), and in other 
glioma cell cultures (b). 
Cell 
Culture 
Tumour Type Temozolomide  
(µM) 
 
 
N070126  Primary Glioblastoma 198.3 ± 10.8 * 
N080923  Primary Glioblastoma 322.9 ± 66.9 
N071271  Primary Glioblastoma 372.4 ± 44.8 
N070055  Grade III Oligoastrocytoma 417.2 ± 65.4 * 
N070201  Grade III Astrocytoma 437.8 ± 22 * 
N070152  Primary Glioblastoma 497.0 ± 98.4 * 
N070859  Primary Glioblastoma 502.2 ± 91.2 * 
N070788  Grade III Astrocytoma 515.0 ± 0 * 
N080805  Primary Glioblastoma 515.0 ** 
N061007  Primary Glioblastoma 566.6 ** 
N080540  Primary Glioblastoma 609.3 ± 90.7 
N061092  Primary Glioblastoma 618.0 ± 0 * 
N070454  Primary Glioblastoma 638.7 ± 284.3 * 
N071144  Primary Glioblastoma 638.7 ± 126.7 
N070865  Primary Glioblastoma 643.8 ± 182.3 * 
N080501  Primary Glioblastoma 700.5 ± 116.4 
N070237  Grade III Astrocytoma 713.4 ± 114.3 
N080533  Primary Glioblastoma 738.1 ±  136.5 
N071026  Primary Glioblastoma 738.1 ± 59.2 
N080869  Primary Glioblastoma 763.8 ± 147.8 
N070701  Secondary  Glioblastoma 772.6 ± 67 
N071057  Primary Glioblastoma 793.2 ± 320.4 * 
N060978  Primary Glioblastoma 810.2 ± 73.1 
N060950 Grade III Oligoastrocytoma 852.4 ± 18 * 
N080943  Primary Glioblastoma 877.3 ± 127.7 
N070450  Grade II Astrocytoma 888.5 ± 346.1* 
N070314  Grade II Oligodendroglioma 939.9 ± 127.2 * 
N080558  Primary Glioblastoma 940.5 ± 95.8 
N070293  Primary Glioblastoma 
    1004.4 ± 164.3 
N070229  Grade III Astrocytoma 
    1037.8 ± 25.2 ** 
     N060913  Primary Glioblastoma 
    1133.1 ± 145.8 * 
N060893  Secondary  Glioblastoma 
    1146.0 ± 91.2 * 
0
200
400
600
800
1000
1200
1400
25 35 45 55 65 75
% cell survival
u
M
(a)
0
200
400
600
800
1000
1200
25 35 45 55 65 75
% cell survival
u
M
(b)
 147 
3.3.1.4 Normal Human Astrocytes  
To evaluate the drug effects on normal cells, we tested cell proliferation of normal 
human astrocytes (NHAs) in the presence of TKIs and the chemotherapeutic drugs. 
NHAs were not responsive to erlotinib; however, they had IC50 values of 7.8 µM for 
gefitinib, and 16.9 µM for imatinib. We also found that the NHAs were not sensitive 
to chemotherapeutic drugs. IC50 values were 1228.4 µM for temozolomide and >124 
nM for docetaxel. The NHAs had higher IC50 values for both chemotherapeutic 
compounds than any glioma cell culture.  
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3.3.1.5 Accumulation of Gefitinib in Glioma Cells 
To test the accumulation of gefitinib in tumour cells we selected 4 glioma cell 
cultures according to their responsiveness to gefitinib: glioblastoma 1 and the 
oligoastrocytoma III as non-responders, and glioblastoma 2 and glioblastoma 3 as 
responders. The cell cultures were exposed to 2 µM gefitinib for 2 hours, followed 
by mass spectrometry analysis carried out by a Ph.D student in our centre, Sandra 
Roche. Glioblastoma 2 and glioblastoma 3 showed a 2 fold increased uptake of 
gefitinib in comparison to glioblastoma 1 (Fig. 3.3.17). Although the grade III 
oligoastrocytoma, was not a responder to gefitinib (IC50>10 µM) it showed a much 
higher drug uptake (1125.1 ng/million cells) than all three glioblastomas (136.2-
291.5 ng/million cells).  
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Fig. 3.3.18 Accumulation of gefitinib in three glioblastomas and one grade III 
oligoastrocytoma. Data represents triplicate samples. Standard deviations were 
generated from Microsoft excel software. 
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3.3.1.6 Expression at Protein Level of Growth Factor Receptors, ATP 
Transport Proteins, and Tyrosine Kinases 
Western blotting analysis was carried out on 26 cell cultures and on NHAs (Fig. 
3.3.18 (i) and (ii)), to analyse protein expression of Pgp and BCRP. The ATP-
transporter Pgp was expressed in all cultures except two, the glioblastoma lines 
N070152 and N080943. However, N070152, has a very low IC50 value for 
docetaxel, which does not fit with the low levels of Pgp expression. BCRP 
expression varied greatly between the cultures. 8 cultures showed very low BCRP 
expression (Fig. 3.3.18 (ii)), these blots were developed with enhanced 
chemiluminescence confirming the presence of BCRP in these cultures (Fig. 3.3.18 
(iii)).      
 
Table 3.3.10 Cell cultures analysed by western blotting in figure 3.3.18 (i) and  
(iii).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane Sample Tumour Type 
 
1    Positive control - 
2 N060893 Secondary Glioblastoma 
3 N060978 Primary Glioblastoma 
4 N070055       Grade III Oligoastrocytoma 
5 N070152 Primary Glioblastoma 
6 N070201 Grade III Astrocytoma 
7 N061092        Primary Glioblastoma 
8 N070126 Primary Glioblastoma 
9 N070293 Primary Glioblastoma 
10 N070314 Grade II Oligodendroglioma 
11 N070229  Grade III Astrocytoma  
12 N070701        Secondary Glioblastoma 
13 N070788  Grade III Astrocytoma 
14 N070859 Primary Glioblastoma 
15 N070865 Primary Glioblastoma 
16 N060913 Primary Glioblastoma 
17 N071026 Primary Glioblastoma 
18 N071271 Primary Glioblastoma 
19 N080501 Primary Glioblastoma 
20 N080533 Primary Glioblastoma 
21 N080540 Primary Glioblastoma 
22 N080869 Primary Glioblastoma 
23 N080923 Primary Glioblastoma 
24 N080943 Primary Glioblastoma 
25 NHA Normal Human Astrocytes 
26 N070450 Grade II Astrocytoma 
27 N061007 Primary Glioblastoma 
28 N071144 Primary Glioblastoma 
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Fig. 3.3.19 (i): Western blot analysis of the tyrosine kinases multidrug resistance 
proteins Pgp, and BCRP.  
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Fig. 3.3.19 (ii) Western blot analysis of the tyrosine kinases multidrug resistance 
proteins Pgp, and BCRP.  
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3.3.1.7 Specific Targets of Erlotinib and Gefitinib 
Western blot analysis was carried out on 26 cell cultures and NHAs, to examine the 
expression of EGFR. Both erlotinib and gefitinib specifically target EGFR. All cell 
cultures expressed EGFR (Fig. 3.3.19). 3 cultures were responsive to erlotinib alone, 
7 cultures were responsive to gefitinib alone, and 5 cultures were responsive to both 
erlotinib and gefitinib. One culture, N070152, expressed both EGFR and EGFRvIII, 
and was responsive to both erlotinib and gefitinib. 8 cultures did not respond to 
either drug. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
* Responsive to Erlotinib   * Responsive to Gefitinib 
 
Fig. 3.3.20 Expression of EGFR and EGFRvIII in the glioma cell cultures. 
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3.3.1.8 Specific Targets of Imatinib  
The expression of the specific targets of imatinib in the cell cultures was examined, 
including PDGFR-β, C-Abl and C-Kit. All cultures expressed PDGFR-β, however, 
N070152 had much lower expression in comparison to the other cultures (Fig. 
3.4.10 and 3.4.11). N070978 was the only culture not to express C-Abl and 
N070152 was the only culture not to express C-Kit (Fig. 3.4.11). Expression of 
these imatinib targets did not always correspond to responsiveness to imatinib. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Responsive to imatinib 
 
Fig. 3.3.21 (a) Expression of PDGFR-β, C-Abl and C-Kit in the cell cultures. 
PDGFR-β has 2 bands, C-Kit also has 2. 
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* Responsive to imatinib 
 
Fig. 3.3.21 (b) Expression of PDGFR-β, C-Abl and C-Kit in the cell cultures. 
PDGFR-β has 2 bands, C-Kit also has 2. 
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3.3 Discussion  
 
Characterization of newly Developed Glioma Cell Cultures 
 
Introduction 
Established immortalised glioma cell lines which have undergone several passages, 
involving clonal selection in vitro are homogeneous, their phenotype typically does 
not change, and may not represent the diversity of genetic abnormalities found in 
brain tumours (http://ehis.niehs.nih.gov/; Harry et al. 1998; Francis Ali-Osman 
2005). The experimental results obtained with these cell lines may be quite different 
from those obtained from studies using biopsy specimens. To maintain the cell 
heterogeneity typically found in a brain tumour, glioma cell cultures were developed 
from brain tumour biopsy samples and characterized at early passages (below 
passage 10) with regard to protein expression, sensitivity to TKIs and 
chemotherapeutic drugs, proliferation and invasion activity. In parallel the 
corresponding tissue had undergone immunohistochemical and molecular 
characterisation, which is subject of a different thesis.  
Out of 44 glioma biopsy samples 39 cell cultures were developed (Table 
3.3.2). The age of the patient cohort ranged from 22-78 years, with the majority of 
patients being aged between 50-78 years (Table 3.3.3). The average survival of 
patients with a glioblastoma in our cohort was 16 months with an average age of 
occurrence of 58 years (Table. 3.3.3), this is consistent with published data (Van 
Meir EG 2010). The average survival for patients with a lower grade glioma was 34 
months and the average age was 40 years (Table. 3.3.3), patients with lower grade 
gliomas tend to be younger and have a higher survival rate (Paul Kleihues 1997).  
Glioblastoma cell cultures were characterized by both elongated and rounded 
cells, depicting the heterogeneity seen in vivo. The grade III oligoastrocytoma had 
clusters of cells forming networks with other clusters, and the grade III astrocytoma 
showed a typical star-shaped cell structure. The grade III oligodendroglioma showed 
the typical fried egg cell structure reported by others (Paul Kleihues 1997).  
The dominating cell type found in the fast cultures was elongated, these are 
possibly the fast proliferating cells (Fig.3.3.3 to 3.3.4). The slow growing cultures 
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had more of a mixed and flattened cell type, while the cultures which slowed down 
in growth with less than 10 passages had more of a mixed cell type population, with 
larger flattened cells present (Fig.3.3.5 to 3.3.8). The cultures with fast growth 
originated from patients with an average survival time of 22 months, the slow 
growing cultures originated from patients with an average survival time of 25 
months, while the cultures which slowed down in culture originated from patients 
with an average survival time of 13 months. The culture which stopped growing was 
derived from a patient with greater than 36 months survival. It is possible that the 
culture which slowed down in growth contained more of a mixed cell population 
than the fast or slow growth cultures, and possibly even contain stem cell-like cells, 
which would explain the large cell types with large nuclei. 17 cultures were 
examined by ICC for GFAP and nestin expression, a low amount of GFAP was 
expressed, and nestin expression was higher in the lower proliferating cultures (Fig. 
3.3.14). This indicated that there was possibly undifferentiated stem cells present in 
the slower cultures, as nestin is a neuronal stem cell marker (Kawataki et al. 2010). 
 
Invasion and Proliferation of Newly Developed Glioma Cell Cultures 
The invasion and proliferation rate of each cell culture was examined. The majority 
of the glioblastomas were invasive, however the average invasion activity ranged 
from 6 µm/day to 50 µm/day (Fig. 3.3.10). Within the group of astroctyomas and 
mixed gliomas both invasive and non-invasive phenotypes were found. There was a 
large variation of proliferation rates in the cultures; there was no correlation between 
tumour grade and proliferation rate (Fig. 3.3.11 and. 3.4.12). There was no 
significant correlation between invasion and proliferation, i.e. a highly invasive 
culture was not necessarily a slow proliferating one, and a low amount of invasion 
did not always correlate with a fast proliferating culture (Fig. 3.3.13). Invasion and 
proliferation are dependent on substrate, no correlation may have been due to 
different substrates, proliferation assays were carried out with plastic and invasion 
with collagen. It would be possible to correlate invasion and proliferation if you 
used the MIB-1 antibody to the Ki-67 antigen, this antigen is expressed in cells in 
the proliferative phase of the cell cycle an is not expressed in cells at the resting 
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stage (Khoshyomn et al. 1999; Kogiku et al. 2008). Hagerstrand et al, established 20 
high-grade glioma primary cultures and also found large variation in growth rates 
among the cultures, the fastest growing culture displayed an 18-fold increase in cell 
number, the slowest growing cultures only showed a 1.2-fold increase in cell 
number over the 4-day culture period (Hagerstrand et al. 2006). While low-grade 
astrocytomas in vivo tend to be highly invasive, but slow proliferating, the 
proliferation rate of glial tumour cells and mixed gliomas seems to increase with the 
grade of malignancy (Francis Ali-Osman 2005).  
 These characteristics were not fully reflected in their in vitro behaviour. It 
is possible that the in vitro 3D collagen invasion assay was not suitable for each 
cell culture, some cultures did not form hanging drops, instead they remained as 
loose cell aggregates, other invasion assays such as the Boyden Chamber assay 
could have been used. However it is also thought that different sections of the 
tumour contain cells with specific functions, some may be specifically involved in 
proliferation and others in invasion, the biopsy section of the tumour could have 
determined the characteristics of the cell culture, i.e. a highly proliferative section 
of a tumour could have given rise to a cell culture with high proliferation, and a 
highly invasive section of a tumour could have resulted in a highly invasive cell 
culture. As all invasion and proliferation assays were carried out below passage 10 
with each culture, and large differences were seen with both characteristics this 
further supports the hypothesis that biopsy samples were taken from different 
sections of each tumour. With in vitro assays glioma spheroids have been shown to 
be organised adaptive biosystems, which carefully correlate the proliferative and 
invasive ratio within the spheroid to maximise cell number and spheroid expansion 
(Deisboeck et al. 2001; Huang et al. 2008), confirming that different sections of a 
tumour have different biological functions.  
With cultures of glioma cells Giese et al, have shown have shown a 
relationship between migratory and proliferative behaviour (Giese et al. 2003). 
Highly motile glioma cells tend to have lower proliferation rates, i.e. cells proliferate 
only when they do not move this is known as the or ‘Go or Grow’ mechanism (Giese 
et al. 1996). Biological evidence indicates that migratory and proliferative processes 
 157 
share common signalling pathways, suggesting a unique intracellular mechanism 
that regulates both behaviours (Giese et al. 2003; Godlewski et al. 2010; Hatzikirou 
et al. 2010). 
Machesparan et al, established 12 glioblastoma and 1 astrocytoma culture 
from biopsy samples, and found a much more heterogeneous migratory response 
from these samples in comparison to their previous work with established glioma 
cell lines (Mahesparan et al. 1999). They found that the ability to migrate in 
response to extracellular matrix (ECM) was specific to each biopsy specimen as 
opposed to any individual ECM component; in addition with immunohistochemical 
analysis they found anti-glial fibrillary acidic protein (GFAP) staining revealed both 
GFAP-positive and -negative migrating cells, further supporting the presence of 
different cell types in these samples (Mahesparan et al. 1999). It is possible that by 
altering the ECM there could have been differences in invasion.  
Poor prognosis in glioblastomas arises from invasive tumour cells which 
have escaped treatment. It has been shown that glioblastoma cells have the ability to 
switch between invasive and proliferative phenotypes (Godlewski et al. 2010; 
Molina et al. 2010). Molina et al, developed an in vivo model of human invasive 
glioblastoma in mouse brain from a human glioblastoma cell line, they showed an 
increase in tumourigenicity in vivo with increased invasion, and decreased 
proliferation in  vitro for invasive cells (Molina et al. 2010). They also found Akt 
activation was directly related to increased tumourigenicity, stemness and 
invasiveness, and MAPK activation correlated with proliferation; cross-talk was 
found between these two pathways (Molina et al. 2010). If this cross-talk in 
glioblastomas is a key regulator of survival, inhibitors of the PI3K/Akt pathway may 
activate the MAPK pathway and vice versa, allowing an internal phenotype control 
switch between proliferation and invasion activation. Liu et al, have shown that 
activation of Notch1 signalling represses both, PI3K/Akt and MAPK in endothelial 
cells (Liu et al. 2006) increasing Notch1 signalling may have an antitumourigenic 
effect in glioma. 
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Response of Glioma Cell Cultures to Tyrosine Kinases  
Specific tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor 
(EGFR) and the platelet derived growth factor receptor (PDGFR) have been used in 
the treatment of various cancer types where increased signalling is thought to 
contribute to tumour progression. Only subgroups of patients have been shown to 
response to each TKI. The molecular characteristics which determine a patients 
response to a TKI have yet to be fully defined. However EGFR kinase domain 
mutations were predictive of responsiveness of lung cancer patients to the EGFR 
TKIs erlotinib and gefitinib (Pao and Miller 2005). 
 Receptor tyrosine kinases, like EGFR and PDGFR, have been identified as 
therapeutic targets in glioblastoma; however, treatment success with inhibitors of 
these receptors is still debated since they are effective only in a limited number of 
patients (Omuro et al. 2007). It was thought that the expression of tyrosine kinases 
including EGFR, PDGFR, C-Abl, and C-Kit, which are specifically targeted by 
tyrosine kinase inhibitors, would be indicative of a responder or non-responder of 
each TKI in glioma. Each glioma cell culture was tested for sensitivity to three 
TKIs, erlotinib and gefitinib which target EGFR, and imatinib which targets 
PDGFR, C-Abl, and C-Kit. Using cut-off concentrations for IC50s, based on 
published data (Mellinghoff et al. 2005; Servidei et al. 2006; Hofer and Frei 2007; 
Zerbe et al. 2008) each cell line was classified as a responder or non-responder to 
each TKI (Table 3.3.4 – 3.3.7). 
 35% of the glioblastomas were responsive to erlotinib (Table 3.3.5) and 56% 
to gefitinib (Table 3.4.6). 26% of glioblastomas responded to two TKIs and 1 
responded to all 3 TKIs; the glioblastoma which responded to all 3 was a secondary 
glioblastoma, the other secondary glioblastoma tested was responsive to gefitinib, it 
is possible that secondary glioblastomas are more sensitive to TKIs; this would need 
to be further clarified with a larger number of secondary glioblastoma samples. 
Normal human astrocytes were not responsive to erlotinib, but were responsive to 
gefitinib and imatinib. 
 This response rate to EGFR-TKIs is high compared to the observations 
reported by Mellinghoff et al, (Mellinghoff et al. 2005). They found in their study 
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that only 10-20% of glioblastoma patients responded to erlotinib and gefitinib, with 
reduction of tumour size by 25%; however, a higher response is possible in vitro 
because of the absence of a BBB, allowing exposure to higher TKI concentrations. 
Mellinghoff et al, also analysed the tumour tissue of their patients and correlated co-
expression of EGFRvIII and PTEN in tumour cells with responsiveness to these 
EGFR kinase inhibitors (Mellinghoff et al. 2005). In a phase II trial with 110 
glioblastoma patients Van den Bent et al, found no correlation with EGFR, 
EGFRvIII expression and improved outcome with erlotinib; they also found 
insufficient single-agent activity in glioblastomas (van den Bent et al. 2009). 
Sarkaria et al, found 2 erlotinib sensitive glioblastoma tumours each with amplified 
EGFR and expressing wild-type PTEN, one of the tumours had truncated EGFRvIII, 
and the other had full length EGFR (Sarkaria et al. 2007). By western blot analysis 
only one cell culture N070152 had expression of EGFRvIII; therefore it was not 
possible to determine if expression of EGFRvIII was correlated with TKI response 
in the glioma cell cultures. It would have been necessary to examine the expression 
of PTEN in all cell cultures to identify its role in the response to these TKIs. 
 The majority of the cell cultures over-expressed wild-type EGFR in 
comparison to the NHAs regardless of tumour grade (Fig. 3.3.20); within this group 
32% of the cell cultures were responsive to erlotinib and 42% to gefitinib. 
Suggesting that responsiveness to erlotinib and gefitinib in vitro seems not to be 
directly correlated with EGFR expression. In the literature it is reported that EGFR 
is overexpressed in 50-60% of glioblastoma patients and amplification is often 
coupled with gene rearrangement (Omuro et al. 2007). The most common mutated 
form is EGFRvIII which is present in 24-67% of glioblastoma patients (Heimberger 
et al. 2005). Hwang et al, found that overexpression of EGFR is correlated with the 
grade of malignancy in tumour tissue; 67% in low-grade astrocytomas, 87% in 
anaplastic astrocytomas, and 100% in glioblastomas (Hwang et al. 1997). Torp et al, 
1991 also found that high-grade gliomas contain more EGFR positive tumour cells 
than low-grade gliomas, and that small neurons and normal glial cells did not 
express EGFR (Torp et al. 1991). Haas-Kogan et al, showed that the response to 
erlotinib treatment was higher in glioblastoma with high EGFR expression and low 
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phosphorylated protein kinase B (PKB)/Akt than those with low EGFR expression 
and high (PKB)/Akt levels (Haas-Kogan et al. 2005). Additionally, they found no 
correlation between EGFRvIII expression and response (Haas-Kogan et al. 2005). 
 Gefitinib has been shown to be effective in lung cancer patients carrying 
mutations in exons 19 and 21 of the EGFR tyrosine kinase domain. These mutations 
were not found in a study involving 95 gliomas including glioblastomas, anaplastic 
oligodendrogliomas, and low-grade gliomas, which might explain the limited 
success of gefitinib in glioma treatment (Marie et al. 2005). Using a multi-
institutional study with glioblastoma tissue and cell lines Lee et al, have shown that 
EGFR missence mutations and amino acid substitutions have an important role in 
determining sensitivity to EGFR small molecule inhibitors (Lee et al. 2006). 
Different mutations of EGFR found in gliomas in comparison to mutations of EGFR 
found in other cancers, may be responsible for resistance to gefitinib in glioma. To 
determine if response to gefitinib is directly related to mutations of EGFR, it would 
be necessary to screen all of the glioma cultures for these mutations. A PCR based 
GeneTailorTM/ QuickChange II site-directed high-throughput mutagenesis system 
could be used for that. 
 It appears that EGFR amplification and mutations together with the 
expression of functional PTEN are involved in glioma sensitivity to EGFR 
inhibition; additional factors influencing glioma sensitivity to EGFR have yet to be 
identified, such as other key pathways or mutations of downstream proteins of these 
pathways.  
Only 6 out of 23 glioblastomas responded to imatinib, whereas the response 
rate was higher within anaplastic astrocytomas and mixed gliomas. Haberler et al, 
found a 15.7% imatinib response rate in patients with glioblastoma (Haberler et al. 
2006). Hagerstrand et al, found a positive correlation in gliomas between PDGFR 
expression and imatinib sensitivity (Hagerstrand et al. 2006). The use of imatinib as 
a single agent in patients with recurrent malignant gliomas was successful only in a 
small group of patients, and only 3% had 6 months progression free survival (Wen 
et al. 2006). Phase II trials with imatinib alone in gliomas had very little effect (Wen 
et al. 2006; Raymond et al. 2008). It is uncertain whether this was due to poor 
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penetration of imatinib through the BBB to the target site. In the present study 
strong expression of C-Kit in 25 out of 26 cell cultures was found. In the literature 
the amount of C-Kit mRNA or protein expression in glioma cell lines varies 
between 50% and 100% (Hamel et al. 1992; Stanulla et al. 1995). The co-expression 
of the receptor kinase C-Kit and its ligand SCF, was found in glioma cell lines, 
suggesting it is involved in intracellular mechanisms for autocrine growth regulation 
of glioma cells (Stanulla et al. 1995). In the present study C-Abl expression was 
found in all cell cultures, with the exception of one, which was a non-responder to 
imatinib (Fig. 3.3.21). Jiang et al, found C-Abl to be overexpressed in glioblastomas 
compared to lower grade gliomas, and they suggest it is associated with poor 
survival (Jiang et al. 2006). 
One glioblastoma culture, N070152, a non-responder to imatinib showed 
very low expression of PDGFR-β and no C-Kit expression; on the other hand, 
EGFR and EGFRvIII were highly expressed (Fig. 3.3.20) and  the cells did respond 
to both EGFR inhibitors erlotinib and gefitinib. Another culture, N070701, 
expressed EGFR, PDGFR-β, C-Kit, and C-Abl and was sensitive to all three TKIs 
tested (Fig. 3.3.20 and 3.3.21). However, TKI target proteins was not indicative of a 
responder in the majority of the cultures.  
 Various other growth factor receptors are also activated in glioma including 
the vascular endothelial growth factor receptor (VEGFR), and the insulin-like 
growth factor (IGF) receptor; their inhibition can prevent tumour growth (Ziegler et 
al. 2008). It has been suggested that inhibition of multiple tyrosine kinases is 
necessary to effectively inhibit downstream signalling, as many tyrosine kinases 
involved in the PI3K signalling pathway are activated at the same time (Shingu et al. 
2009). Imatinib is an inhibitor of multiple tyrosine kinases including PDGFR and C-
Kit, which are associated with the PI3K/Akt pathway, but its effect as a single drug 
is minimal in glioma. 
 To date molecular targeted therapy has not translated into phase III trials for 
malignant glioma. The mechanisms of resistance to receptor tyrosine kinase (RTK) 
inhibition are not fully understood. New trials for gliomas are likely to involve a 
multiple target approach and combination with chemotherapy and/ or radiotherapy 
 162 
(Omuro et al. 2007). Many anti-apoptotic mechanisms are responsible for the 
resistance of glioblastoma cells to chemotherapy and radiotherapy, and it is 
suggested that these mechanisms are also responsible for resistance to RTK 
inhibition (Ziegler et al. 2008).  
The oncogenetic process in gliomas is regulated by differentially activated or 
silenced signalling pathways; which include PI3K/AKT/PTEN/MTOR, 
Ras/Raf/MAPK and protein kinase C signalling. Due to the large amount of cell 
heterogeneity in malignant gliomas and low prevalence of each genetic abnormality, 
it has been difficult to identify targets that act as key promoters of oncogenesis, with 
many studies reporting conflicting results. Several drugs have been tested for glioma 
therapy, including tyrosine kinase inhibitors erlotinib and gefitinib, the PDGFR-TKI 
imatinib, the mTOR inhibitors temsirolimus and everolimus, VEFGR, protein kinase 
C-beta inhibitors, and other angiogenesis pathway inhibitors such as vatalanib, 
bevacizumab, and enzataurin (Omuro et al. 2007). A new approach is involving the 
inhibition of multiple targets simultaneously with less specific, multi-targeting 
drugs, which can be the use of two or more single-targeted drugs, in combination 
with cytotoxic chemotherapy and/or radiotherapy. It may be necessary to target 
other key proteins in the PI3K/AKT and Ras/MAPK growth and survival pathways, 
in addition to the proteins targeted in this study, to find an effective treatment for 
gliomas.  
 
Sensitivity of Glioma Cell Cultures to Temozolomide 
Temozolomide is currently the standard drug for the treatment of newly diagnosed 
and recurrent glioblastoma (Dresemann 2010). An IC50 range for the glioma cultures 
of 198.3 µM-1146 µM for temozolomide was found (Table 3.3.9) (Fig. 3.3.17), 
which is much higher than the plasma concentration of 72 µM reported for 
malignant glioma patients (Ostermann et al. 2004). A 100 µM concentration of 
temozolomide was found in the brain tumour of a xenograft model (Kato et al. 
2010), which is still significantly lower than the IC50 range found with the cell 
cultures. A similar IC50 concentration range with melanoma cell lines was found in 
the NICB by Dr. Alex Eustace (between 223 µM and 791 µM). Normal human 
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astrocytes were found to have an IC50 of 1228.4 µM, showing that temozolomide has 
little toxicity to normal cells in vitro. Temozolomide is rapidly hydrolysed to its 
active metabolite 5-(3-methyltriazeno)-imidazole-4-carboxamide (MTIC) which can 
reach a plasma concentration of 276 ng/ml (Rudek et al. 2004). Under physiological 
conditions temozolomide has a short half life of 1.8 hours, which might explain the 
high concentrations needed in in vitro assays to see an effect. Another explanation 
could be that temozolomide is a substrate of the MDR pump Pgp, which is 
expressed in the majority of the cell cultures (Fig. 3.3.19) (Schaich et al. 2009). 
Akbar et al, have published a gel-matrix containing temozolomide which was placed 
directly at the tumour site in a rat intracranial resection model. This resulted in high 
levels of oncolytic activity towards glioma cells, and minimal cytotoxicity toward 
normal brain tissue, this could be a promising treatment for gliomas (Akbar et al. 
2009).  
  
Sensitivity of Glioma Cell Cultures to Docetaxel 
Docetaxel is a very successful drug in the treatment of a variety of solid tumours 
particularly in lung cancer (Burris et al. 1995). All IC50s for the glioma cell cultures 
were in the nanomolar range, (0.4 nM to 24.5 nM) 12 out of 22 glioblastomas had an 
IC50 < 2 nM (Table 3.3.8) (Fig. 3.3.16). There was no difference in sensitivity 
between glioblastomas and lower grade tumours (Fig. 3.3.16). One cell culture, a 
grade III astrocytoma, was not as sensitive to docetaxel (IC50 of 59.5 nM) (Table 
3.3.8), normal human astrocytes were not as sensitive to docetaxel (IC50 of >124 
nM) (Table 3.1). 24 out of 26 cell cultures expressed Pgp: with 2 glioblastomas 
being negative for Pgp expression. One of these was highly sensitive to docetaxel 
(IC50 of 0.5 nM) (Fig. 3.3.8). Fracasso et al, have found a plasma concentration of 
docetaxel of 0.5 nM in glioma patients and a CSF concentration of 0.05 nM 
(Fracasso et al. 2004), the two sensitive glioblastoma cultures had an IC50 for 
docetaxel (Table 3.3.8) within that found in plasma.  
Expression of the MDR pump BCRP was found in all cell cultures tested: 
one glioblastoma and one grade II oligodendroglioma showed particularly high 
expression of BCRP compared to the positive control (Fig. 3.3.19). One grade III 
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astrocytoma culture showed IC50 of 59.5 nM for docetaxel but not particularly high 
expression of both ABC pumps Pgp and BCRP (Fig. 3.3.19). Therefore, the lack of 
sensitivity to docetaxel by MDR pump expression could not be explained.  
Other ABC transporter pumps, such as MRP1 and MRP2 have been found in 
gliomas (Leslie et al. 2005), and might be involved in docetaxel resistance/ 
sensitivity in the cell cultures, this remains to be examined. Clinical trials using 
systemic docetaxel have not been effective in malignant gliomas probably due to 
poor penetration of drug through the BBB and into the tumour (Forsyth et al. 1996; 
Sanson et al. 2000; Kemper et al. 2003; Kemper et al. 2004). This can be addressed 
by convection-enhanced delivery (CED), a drug application method in which the 
drug is injected directly into the tumour avoiding the blockage through the BBB; 
this is being used in an ongoing clinical trial with paclitaxol with recurrent gliomas 
and is showing promising results (Chamberlain 2006). All glioblastomas with low 
docetaxel IC50 (< 2 nM) were also responsive to one, two, or three TKIs. These 
combinations could be useful in a clinical approach.  
 
Accumulation of TKIs in 4 Glioma Cell Cultures 
It was thought that response to TKIs may be directly related to the amount of drug 
accumulated in the cells. Therefore the accumulation of gefitinib in 4 glioma cell 
cultures was examined by mass spectrometry. The cultures were selected according 
to their responsiveness to gefitinib. The cells were exposed to 2 µM of gefitinib for 
2 hours. Glioblastoma cells which were responsive to gefitinib had a 2 fold increase 
in uptake of gefitinib compared to the non-responsive glioblastomas. The grade III 
oligoastrocytoma, however had a significantly higher uptake of gefitinib than all 3 
glioblastoma cultures although it was a non-responder to gefitinib. Therefore, the 
uptake of gefitinib seems not to predictive for responsiveness to the drug in the 
oligoastrocytoma cells.  
The accumulation of gefitinib to the brain is limited by the expression of Pgp 
and BCRP (Agarwal et al.). However, seen in the cultures analysed. There may be 
other membrane efflux pumps present  in these glioma cells such as MRP1 and 
MRP2 (Leslie et al. 2005). Bronger et al, have shown the membrane pumps ABCC4 
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and ABCC5, to be more strongly associated with oligoastrocytomas (Bronger et al. 
2005).  
 
3.3 Summary and Conclusion  
 
Characterization of Newly Developed Glioma Cell Cultures 
In collaboration with Beaumont hospital 31 glioma cell cultures were developed 
directly from tissue samples and characterized with regard to their invasion and 
proliferation rate. The majority of the glioblastoma cultures were invasive, however 
the average invasion activity varied between cultures. It was expected that all 
glioblastomas would be invasive, as is typically the case in vivo. Within the group of 
astroctyomas, and mixed gliomas both invasive and non-invasive phenotypes were 
found, while low-grade astrocytomas in vivo tend to be highly invasive. The 
proliferation rate of glial tumour cells and mixed gliomas seems to increase with the 
grade of malignancy in vivo. These invasive and proliferation characteristics are 
obviously not fully reflected in the in vitro behaviour. 
 
Response of Glioma Cell Cultures to Tyrosine Kinases  
Within the glioma cell culture cohort it was found that 35% of the glioblastomas 
were responsive to TKIs targeting EGFR, whereas anaplastic astrocytomas, mixed 
gliomas, and the oligodendroglioma responded better to imatinib, targeting PDGFR, 
C-Kit, and Bcr-Abl. However, in most cases the protein expression of the tyrosine 
kinases EGFR and PDGFR-β, C-Kit, and C-Abl, did not correlate with the 
responsiveness to the specific TKIs. Even though the cultures do express the target 
proteins of the TKIs, none of the cultures were sensitive to them; sensitivity to a TKI 
is usually seen with an IC50 of 1 µM or less, the lowest IC50 was 6.5 µM. The in 
vitro data indicated that individually the TKIs may not be a sufficient treatment for 
gliomas. 
 
Expression of Drug Efflux Pumps and Sensitivity to Chemotherapeutic Drugs 
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The expression of Pgp and BCRP did not always correlate to sensitivity to docetaxel 
or temozolomide. Therefore the expression levels of these pumps are not indicative 
of response to chemotherapeutic drugs. High concentrations of temzolomide were 
necessary to achieve an IC50 in the cultures. All glioblastomas, which were sensitive 
to docetaxel (IC50 < 2 nM) were also responsive to one or more TKIs, the 
combination treatment with docetaxel and one or two of these TKIs is potentially a 
good treatment option for these cases.  
 
Effect of TKIs and Chemotherapeutic Drugs on Invasion in Glioma 
As single drug treatments only docetaxel and imatinib were effective in inhibiting 
invasion activity. Unfortunately, their penetration through the BBB is limited. In 
general response rates of glioblastoma patients to TKIs which specifically target 
EGFR has been low, however the present study showed docetaxel and imatinib to  
be promising treatments for glioma. 
 
Accumulation of Gefitinib in Gliomas 
The intracellular accumulation of gefitinib was higher in gefitinib responsive 
glioblastomas than in non-responsive ones; however, a mixed glioma sample 
showed much higher up-take of TKI despite the fact that it was non-responsive to 
gefitinib. Further experiments have to be performed to explain this result.  
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3.4 Drug Effects in a 3D Invasion Assay  
The work in this section was carried out with my supervisor Dr Verena Amberger-
Murphy. Due to the highly infiltrative and invasive behaviour of gliomas, finding an 
effective drug to treat gliomas has proved difficult. The effect of TKIs and 2 
chemotherapy drugs on invasion in a 3D invasion assay was examind. The 
compounds tested included erlotinib (Erl), gefitinib (Gef) and imatinib (Imt), and the 
chemotherapeutic drugs temozolomide (Tmz) and docetaxel (Doc). The effect of 
each individual drug and the combination effect of TKIs with chemotherapy drugs 
was assessed. 16 invasive glioma cultures were examined, including: 11 primary 
glioblastomas, 2 secondary glioblastomas, 2 grade III astrocytomas and 1 
oligoastrocytoma.  
Spheroids of each culture were implanted into collagen type I gels and cells 
were left to invade for 4 days prior to drug treatment (Fig. 3.4.1) (see section 2.8). 
Invasion was then measured over 9-29 days in the presence and absence (Ctr) of 
drug. Drug concentrations were calculated as approximately twice the IC50 for each 
cell culture from the monolayer proliferation assay, as higher concentrations are 
typically required for spheroids; in some cases IC50 data were not available, and drug 
concentrations had to be estimated. The drug concentrations used for both 
proliferation and invasion are shown (Table 3.4.1 to 3.4.18). For each spheroid four 
measurements (in µm) were taken. Each condition was done in duplicate per 
experiment. Due to the slow proliferation rates of some cultures, repeated 
experiments were not always possible. Tables 3.4.12, 3.4.15 and 3.4.19 show the 
overall effect of drugs on the cultures.  
 
 
 
 
 
 
 
 
Fig. 3.4.1 A primary glioblastoma spheroid implanted into collagen gel, after 4 
days invasion, 10x magnification. 
 
400 µm
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3.4.1 Drug Effect on Invasion Activity of Primary Glioblastomas  
            Table 3.4.1 Drug concentrations N061007. 
Drug Invasion Assay 
Concentration 
IC50 
Concentration 
Proliferation 
Assay 
 
Erlotinib 18.3 µM 9.1 µM 
 
Gefitinib 20 µM >20 µM 
 
Imatinib 13.6 µM >20 µM 
 
Temozolomide 
 41.2 µM* 566.6 µM 
 
Docetaxel 13.9 nM 1.2 nM 
 
*: The invasion assay was carried out prior to the proliferation assay therefore the concentration used 
was too low. >: greater than the cut-off concentration (IC50 not determined). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
*: invasion increased. 
Fig. 3.4.2 (a) Average invasion per day over 13 days for N061007, (b) significance 
of combination effect of erlotinib and docetaxel compared to single drug effect. The 
deviations represent measurements over 13 days. Standard deviations were 
generated from Microsoft Excel software. 
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Surprisingly gefitinib alone and in combination with temozolomide and docetaxel 
increased invasion with N061007, single treatment with imatinib and docetaxel had 
a small inhibitory effect on invasion (Fig. 3.4.2 (a)).The combination of erlotinib 
and docetaxel had the strongest inhibitory effect  
(Fig. 3.4.2 (b)). 
 
                    Table 3.4.2 Drug concentrations N061092. 
Drug Invasion Assay 
Concentration 
IC50 Concentration 
Proliferation 
Assay 
 
Erlotinib 11.6 µM 9.3 µM 
 
Gefitinib 44.8 µM >20 µM 
 
Imatinib 67.8 µM >20 µM 
 
Temozolomide 1030 µM 618 µM 
 
Docetaxel 4.6 nM 1.5 nM 
 
         >: greater than cut-off concentration (IC50 not determined). 
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  *: increased invasion. 
Fig. 3.4.3 (a) Average invasion per day over 27 days for N061092, (b) significance 
of combination effect of imatinib and docetaxel compared to single drug effect. The 
deviations represent measurements over 27 days. Standard deviations were 
generated from Microsoft Excel software. 
 
Erlotinib, gefitinib, imatinib and docetaxel had a very strong inhibitory effect on the 
invasion of N061092, however, temozolomide showed an increase in invasion even 
though a high concentration was used (Fig. 3.4.3 (a)). The strongest inhibitory effect 
was with the combination of imatinib and docetaxel (Fig. 3.4.3 (b). 
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                  Table 3.4.3 Drug concentrations N070152. 
Drug Invasion Assay 
Concentration 
IC50 Concentration 
Proliferation 
Assay 
 
Erlotinib 11.6 µM 6.5 µM 
 
Gefitinib 44.8 µM 17 µM 
 
Imatinib 67.8 µM >20 µM 
 
Temozolomide 1030 µM 497 µM 
 
Docetaxel 4.6 nM 0.5 nM 
 
         >: greater than cut-off concentration (IC50 not determined). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4.4 (a) Average invasion per day over 27 days for N070152, (b) significance 
of combination effect gefitinib and docetaxel compared to single drug effect. The 
deviations represent measurements over 27 days. Standard deviations were 
generated from Microsoft Excel software. 
 
Erlotinib had a strong inhibitory effect on the invasion of N070152, imatinib, 
gefitinib and docetaxel had an even stronger effect (Fig. 3.4.4 (a)). The strongest 
effect was with the combination of docetaxel and gefitinib (Fig. 3.4.4 (b)).        
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                      Table 3.4.4 Drug concentrations N070454. 
 
 
 
 
 
 
 
 
 
  >: greater than cut-off concentration (IC50 not determined). 
 
 
 
 
 
 
 
 
 
    
 
                                                      
 
 
                                                                   
 
Fig. 3.4.5 (a) average invasion per day over 15 days in comparison to the control for 
the cell line N070454, (b) and (c) significance of combination effect compared to 
single drug effect. The deviations represent measurements over 15 days. Standard 
deviations were generated from Microsoft Excel software. 
Drug Invasion Assay 
Concentration 
IC50 
Concentration 
Proliferation 
Assay 
 
Erlotinib 46.5 µM >10 µM 
 
Gefitinib 44.8 µM >20 µM 
 
Imatinib 10.1 µM 16.7 µM 
 
Temozolomide 2472.3 µM 638.7 µM 
 
Docetaxel 11.6 nM 0.9 nM 
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All of the single drug treatments had an inhibitory effect on invasion for N070454, 
docetaxel had a very strong effect (Fig. 3.4.5 (a)). When erlotinib or gefitinib were 
combined with temozolomide a stronger inhibitory effect was seen (Fig. 3.4.5 (b)). 
 
Table 3.4.5 Drug concentrations N070859. 
Drug Invasion Assay 
Concentration 
IC50 
Concentration 
Proliferation 
Assay 
 
Erlotinib 18.6 µM >10 µM 
 
Gefitinib 40.3 µM >20 µM 
 
Imatinib 67.8 µM >20 µM 
 
Temozolomide 1287.6 µM 502.2 µM 
 
Docetaxel 11.6 nM 1.9 nM 
 
  >: greater than cut-off concentration (IC50 not determined). 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4.6 Average invasion per day over 9 days for N070859. The deviations 
represent measurements over 9 days. Standard deviations were generated from 
Microsoft Excel software. 
 
Temozolomide had a small inhibitory effect on the invasion of N070859, erlotinib, 
gefitinib had a stronger effect, imatinib and docetaxel had a very strong inhibitory 
effect (Fig. 3.4.6). 
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                         Table 3.4.6 Drug concentrations N070865. 
Drug Invasion Assay 
Concentration 
IC50 
Concentration 
Proliferation 
Assay 
 
Erlotinib 18.6 µM >10 µM 
 
Gefitinib 40.3 µM >20 µM 
 
Imatinib 67.8 µM >20 µM 
 
Temozolomide 1287.6 µM 772.6 µM 
 
Docetaxel 6.9 nM 5 nM 
 
  >: greater than cut-off concentration (IC50 not determined). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4.7 Average invasion per day over 9 days for N070865. The deviations 
represent measurements over 9 days. Standard deviations were generated from 
Microsoft Excel software. 
 
Erlotinib and temozolomide had a small inhibitory effect on the invasion of 
N070865, gefitinib, imatinib and docetaxel had a stronger effect; there was no 
increased effect with combination treatments (Fig. 3.4.7). 
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    Table 3.4.7 Drug concentrations N071026. 
Drug Invasion Assay 
Concentration 
IC50 
Concentration 
Proliferation 
Assay 
 
Erlotinib 23.2 µM >10 µM 
 
Gefitinib 40.3 µM >20 µM 
 
Imatinib 33.9 µM 19.6 µM 
 
Temozolomide 1442.1 µM 738.1 µM 
 
Docetaxel 46.1 nM 23.2 nM 
 
   >: greater than cut-off concentration (IC50 not determined). 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4.8 Average invasion per day over 14 days for N071026. The deviations 
represent measurements over 14 days. Standard deviations were generated from 
Microsoft Excel software. 
 
Erlotinib, gefitinib and temozolomide had a strong inhibitory effect on the invasion 
of N071026, docetaxel and imatinib had a very strong effect, the combination of 
imatinb and docetaxel had the strongest effect (Fig. 3.4.8). 
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                         Table 3.4.8 Drug concentrations N071144. 
Drug Invasion Assay 
Concentration 
IC50 
Concentration 
Proliferation 
Assay 
 
Erlotinib 18.6 µM 9.3 µM 
 
Gefitinib 44.8 µM 19.5 µM 
 
Imatinib 50.8 µM >20 µM 
 
Temozolomide 1514.3 µM 401.7 µM 
 
Docetaxel 8.3 nM 6.4 nM 
 
  >: greater than cut-off concentration (IC50 not determined). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4.9 (a) Average invasion per day over 16 days for N071144, (b)   significance 
of combination effect of gefitinib and docetaxel compared to single drug effect. The 
deviations represent measurements over 16 days. Standard deviations were 
generated from Microsoft Excel software. 
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Erlotinib and gefitinib had a small inhibitory effect on the invasion of N071144, 
temozolomide had no effect, imatinib and docetaxel had a very strong effect (Fig. 
3.4.9 (a)). A further significant inhibitory effect on invasion was seen with the 
combination of gefitinib and docetaxel with p-values of less than 0.05 (Fig. 3.4.9 
(b)). 
 
    Table 3.4.9 Drug concentrations N071271. 
Drug Invasion Assay 
Concentration 
IC50 
Concentration 
Proliferation 
Assay 
 
Erlotinib 23.2 µM >10 µM 
 
Gefitinib 35.8 µM 16.7 µM 
 
Imatinib 47.4 µM >20 µM 
 
Temozolomide 669.6 µM 372.4 µM 
 
Docetaxel 1.16 nM 0.6 nM 
 
  >: greater than cut-off concentration (IC50 not determined). 
 
 
 
 
 
 
 
 
 
 
          *: increased invasion.                  
      
Fig. 3.4.10 Average invasion per day over 15 days for N071271. The deviations 
represent measurements over 15 days. Standard deviations were generated from 
Microsoft Excel software. 
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Erlotinib had a small inhibitory effect on the invasion of N071271, docetaxel had a 
stronger effect, gefitinib had a very strong effect; both imatinib and temozolomide 
substantially increased invasion (Fig. 3.4.10). 
 
                  Table 3.4.10 Drug concentrations N080869. 
 
 
 
 
 
 
 
 
 
      >: greater than cut-off concentration (IC50 not determined). 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4.11 Average invasion per day over 15 days for N080869. The deviations 
represent measurements over 15 days. Standard deviations were generated from 
Microsoft Excel software. 
 
Gefitinib, imatinib and docetaxel had a strong inhibitory effect on the invasion of 
N080869, erlotinib and temozolomide had a small effect (Fig. 3.4.11). 
 
 
Drug Invasion Assay 
Concentration 
IC50 
Concentration 
Proliferation 
Assay 
 
Erlotinib 20 µM >10 µM 
 
Gefitinib 44.8 µM >20 µM 
 
Imatinib 40.7 µM 14 µM 
 
Temozolomide 1236.1 µM    763.8 µM 
 
Docetaxel 29 nM 19 nM 
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                         Table 3.4.11 Drug concentrations N080943. 
 
 
 
 
 
 
 
 
 
   >: greater than cut-off concentration (IC50 not determined). 
 
 
 
 
 
 
 
 
 
Fig. 3.4.12 Average invasion per day over 15 days for N080943. The deviations 
represent measurements over 15 days. Standard deviations were generated from 
Microsoft Excel software. 
 
Single drug treatments of gefitinib, imatinib and docetaxel had the strongest 
inhibitory effect on the invasion of N080943, erlotinib and temozolomide had a 
small effect (Fig. 3.4.12). 
Drug Invasion Assay 
Concentration 
IC50 
Concentration 
Proliferation 
Assay 
 
Erlotinib 20 µM >10 µM 
 
Gefitinib 44.8 µM >20 µM 
 
Imatinib 40.7 µM >20 µM 
 
Temozolomide 1854.2 µM 877.3 µM 
 
Docetaxel 13.9 nM 9 nM 
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Table 3.4.12 Summary of drug effects on invasion activity of primary 
glioblastomas. 
Cell 
Culture 
Erl Gef Imt Tmz Doc Erl/ 
Tmz 
 
Erl/ 
Doc 
Gef/ 
Tmz 
Gef/ 
Doc 
Imt/ 
Tmz 
Imt/ 
Doc 
 
 
N061007 0.9 1.9 0.7 1.0 0.8 0.9 0.6 1.4 1.2 0.9 0.6 
 
N061092 0.5 0.2 0.3 1.3 0.4 0.9 0.4 0.2 0.2 - 0.1 
 
N070152 0.7 0.3 0.3 0.9 0.4 - 0.4 0.3 0.2 - 0.3 
 
N070454 0.5 0.8 0.7 0.7 0.2 0.2 0.2 0.3 0.3 - 0.1 
 
N070859 0.7 0.5 0.2 0.8 0.4 0.8 0.4 0.9 0.4 0.5 0.2 
 
N070865 0.8 0.6 0.5 0.7 0.5 0.7 0.5 0.5 0.5 0.6 0.5 
 
N071026 0.6 0.5 0.4 0.7 0.3 0.8 0.4 0.5 0.3 0.3 0.2 
 
N071144 0.8 0.8 0.2 1.0 0.3 0.6 0.3 0.7 0.2 0.3 0.2 
 
N071271 0.8 0.3 1.4 1.3 0.6 - 0.8 - 0.5 - 0.8 
 
N080869 0.7 0.2 0.5 0.8 0.3 0.9 0.3 0.7 0.2 0.4 0.2 
 
N080943 0.7 0.5 0.3 0.7 0.3 0.8 0.3 0.5 0.3 0.3 0.3 
 
The effect of drug treatment on invasion activity was compared to the control (1.0). The most 
effective single drug treatments are highlighted in blue. The combination treatments which had an 
increased inhibitory effect on invasion in comparison to either drug alone are highlighted in red. Erl: 
erlotinib, Gef: gefitinb, Imt: imatinib, Tmz: temozolomide, Doc: docetaxel. 
 
Overall the most effective single drug treatment with the primary glioblastomas was 
imatinib. The most effective drug combination treatment was with imatinib and 
docetaxel. 
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3.4.2 Drug Effect on Invasion Activity of Secondary Glioblastomas 
 
                         Table 3.4.13 Drug concentrations N060893. 
Drug Invasion Assay 
Concentration 
IC50 
Concentration 
Proliferation 
Assay 
 
Erlotinib 15.3 µM >10 µM 
 
Gefitinib 33.5 µM 16.8µM 
 
Imatinib 49.4 µM >20 µM 
 
Temozolomide 2334.2 µM 1146 µM 
 
Docetaxel 1.6 nM 1.6 nM 
 
  >: greater than cut-off concentration (IC50 not determined). 
 
 
 
 
 
 
 
 
 
 
 
               *: increased invasion.               
 
Fig. 3.4.13 Average invasion per day over 26 days for N060893. The deviations 
represent measurements over 26 days. Standard deviations were generated from 
Microsoft Excel software. 
 
Imatinib and docetaxel had a strong inhibitory effect on the invasion of N060893, 
erlotinib had no effect, gefitinib increased invasion and temozolomide strongly 
increased invasion (Fig. 3.4.13). 
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    Table 3.4.14 Drug concentrations N070701. 
 
 
 
 
 
 
 
 
 
   >: greater than cut-off concentration (IC50 not determined). 
 
 
 
 
 
 
 
 
 
Fig. 3.4.14 Average invasion per day over 24 days for N070701. The deviations 
represent measurements over 24 days. Standard deviations were generated from 
Microsoft Excel software. 
 
Imatinib and docetaxel had the strongest inhibitory effect on the invasion of 
N070701, temozolomide had a small effect, gefitinib increased invasion.  
Drug Invasion Assay 
Concentration 
IC50 
Concentration 
Proliferation 
Assay 
 
Erlotinib 23.2 µM 7.9 µM 
 
Gefitinib 27.8 µM 16.7µM 
 
Imatinib 50.8 µM 14.4 µM 
 
Temozolomide 1545.2 µM 772.6 µM 
 
Docetaxel 1.6 nM 1 nM 
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Table 3.4.15 Drug effects on invasion activity of secondary glioblastomas. 
Cell 
Culture 
Erl Gef Imt Tmz Doc 
 
N060893 1.0 1.2 0.4 1.5 0.5 
 
N070701 1.0 1.1 0.2 0.8 0.5 
 
Drug treated spheroids were compared to the control (1.0), imatinib showed the most inhibition of 
invasion. The treatments which had the strongest inhibitory effect on invasion are highlighted in blue. 
Erl: erlotinib, Gef: gefitinb, Imt: imatinib, Tmz: temozolomide, Doc: docetaxel. 
 
 
 
Erlotinib had no effect on the invasion of both secondary glioblastomas; gefitinib 
increased invasion. Imatinib had a strong inhibitory effect with both secondary 
glioblastomas. 
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 3.4.3 Drugs Effect on Invasion Activity of Astrocytomas and an 
Oligoastrocytoma 
 
Table 3.4.16 Drug concentrations N070229 (grade III astrocytoma). 
 
 
 
 
 
 
 
 
 
   >: greater than cut-off concentration (IC50 not determined). 
Drug Invasion Assay 
Concentration 
IC50 
Concentration 
Proliferation 
Assay 
 
Erlotinib 79 µM >10 µM 
 
Gefitinib 58.3 µM >20 µM 
 
Imatinib 67.8 µM >20 µM 
 
Temozolomide 1030.1 µM 1055.9 µM 
 
Docetaxel 4.6 nM 9.4 nM 
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Fig. 3.4.15 (a) Average invasion per day over 15 days for N070229 (b) significance 
of combination effect of gefitinib and temozolomide compared to single drug effect. 
The deviations represent measurements over 15 days. Standard deviations were 
generated from Microsoft Excel software. 
 
 
Erlotinib, imatinib and docetaxel had a very strong inhibitory effect on the invasion 
of N070229, temozolomide had very little effect and gefitinib had no effect (Fig. 
3.4.15 (a)). The combination of gefitinib and temozolomide had increased inhibitory 
effect on invasion (Fig. 3.4.15 (b)). 
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Relative Invasion 1.000 1.059 0.946 0.590
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P<0.003
P<0.02
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Table 3.4.17 Drug concentrations N070450 (grade II astrocytoma). 
 
 
 
 
 
 
 
 
 
 
 >: greater than cut-off concentration (IC50 not determined). 
 
 
 
 
 
 
 
 
         *: increased invasion. 
 
 
 
 
 
 
 
 
Fig. 3.4.16 (a) Average invasion per day over 15 for N070450, (b) significance of 
combination effect of erlotinib and temozolomide compared to single drug effect. 
The deviations represent measurements over 15 days. Standard deviations were 
generated from Microsoft Excel software. 
Drug Invasion Assay 
Concentration 
IC50 
Concentration 
Proliferation 
Assay 
 
Erlotinib 23.2 µM >10 µM 
 
Gefitinib 44.8 µM >20 µM 
 
Imatinib 33.9 µM 15.8 µM 
 
Temozolomide 1287.6 µM 888.5 µM 
 
Docetaxel 11.6 nM 8.3 nM 
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Gefitinib and imatinib had a strong inhibitory effect on the invasion of N070450, 
docetaxel had a very strong effect (Fig. 3.4.16 (a)). The combination of erlotinib and 
temozolomide had an increased effect with significant p-values less than 0.05 (Fig. 
3.4.16 (b)). 
 
Table 3.4.18 Drug concentrations N070055 (grade III oligoastrocytoma). 
 
 
 
 
 
 
 
 
 
 >: greater than cut-off concentration (IC50 not determined). 
Drug Invasion Assay 
Concentration 
IC50 
Concentration 
Proliferation 
Assay 
 
Erlotinib 18.6 µM 9.3 µM 
 
Gefitinib 44.8 µM >20 µM 
 
Imatinib 33.9 µM 18 µM 
 
Temozolomide 1030.1 µM 417.2 µM 
 
Docetaxel 4.6 nM 2.7 nM 
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Fig. 3.4.17 (a) Average invasion per day over 29 days for N070055, (b) significance 
of combination effect of docetaxel and gefitinib compared to single drug effect. The 
deviations represent measurements over 29 days. Standard deviations were 
generated from Microsoft Excel software. 
 
Gefitinib and imatinib had a strong inhibitory effect on the invasion of N070055, 
docetaxel had the strongest effect (Fig. 3.4.17 (a)). The combination of gefitinib and 
docetaxel had an increased inhibitory effect with significant p-values less than 0.05 
(Fig. 3.4.17 (b)). 
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(a)
0
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Relative Invasion 1.000 0.204 0.214 0.069
Ctr Gef Doc Doc/Gef
P<0.0002
P<0.002
(b)
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Table 3.4.19 Drug effects on invasion activity of astrocytomas and an 
oligoastrocytoma. 
N070229 and N070450: grade III astrocytoma. N070055: Oligoastrocytoma. 
The inhibitory effect of each drug treatment on invasion was measured in comparison to the control 
(1.0), the most effective single drug treatments are highlighted in blue. The combination treatments 
which had an increased effect on invasion in comparison to either drug alone are highlighted in red. 
Erl: erlotinib, Gef: gefitinb, Imt: imatinib, Tmz: temozolomide, Doc: docetaxel. 
 
 
Imatinib and docetaxel were the most effective single drug treatments with the 
astrocytomas and the oligoastrocytoma, while the most effective combination 
treatment was imatinib and docetaxel (Table 3.4.19). 
 
Cell 
Culture 
Erl Gef Imt Tmz Doc Erl/ 
Tmz 
Erl/ 
Doc 
Gef/ 
Tmz 
Gef/ 
Doc 
Imt/ 
Tmz 
Imt/ 
Doc 
 
N070229 0.4 1.1 0.2 0.9 0.3 0.3 0.2 0.6 0.4 - 0.2 
 
N070450 1.3 0.5 0.6 0.8 0.3 0.4 0.3 0.4 0.2 - 0.1 
 
N070055 1.0 0.3 0.6 0.8 0.2 0.8 0.2 0.7 0.1 - 0.1 
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3.4 Discussion  
 
Effect of Tyrosine Kinase Inhibitors and Chemotherapeutic Drugs on Invasion 
in Glioma 
 
Introduction 
 
Very little information is available on the direct effect of TKIs and 
chemotherapeutic drugs on glioma invasion. Therefore the effect of these drugs 
individually and in combination on the newly established glioma cultures, was 
examined using a 3D collagen invasion assay. Some of the pathways known to be 
involved in glioma invasion include the RAS/MAPK pathway and the PI3K/Akt 
pathway. RAS is activated by receptor tyrosine kinases, including EGFR, PDGFR, 
other growth factor receptors and cytokines (Gullick 2008). Overactivation of the 
RAS/MAPK pathway can increase cellular proliferation, migration and 
differentiation in several types of cancers including gliomas (Schlessinger 1993). 
The PI3K/Akt pathway is also stimulated by the growth factor receptors, EGFR, 
PDGFR, fibroblast growth factor receptor (FGFR) and insulin-like growth factor 
receptor (IGFR) and promotes cell survival, regulates EGF-driven cell motility and 
invasion of glioma, breast, and bladder cancer cell lines (Schlessinger 2000). About 
50% of glioblastomas overexpress EGFR (Omuro et al. 2007). A mutated form, 
EGFRvIII, has been found in 24 to 67% of glioblastomas. EGFRvIII is 
constitutively activated in  and is involved in response to TKIs (Heimberger et al. 
2005) PDGFR is overexpresed in about 25% of glioblastoma and 60% of 
astrocytomas (Haberler et al. 2006). Besides inhibing growth factor signalling, TKIs 
reduce matrix metalloproteinase (MMP) expression and activity, which has a 
negative effect on the invasive and infiltrative behaviour of tumour cells (Newton 
2004). Tumour cell-secreted MMPs and serine proteinases degrade extracellular 
matrix (ECM) proteins and provide space for movement and infiltration. Which 
mediates invasion in glioma through the induction of membrane type 1-MMP (Van 
Meter et al. 2004).  
To date single drug treatments with TKIs or chemotherapeutic drugs has 
shown little improvement in glioma treatment, therefore combinations of TKIs and 
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chemotherapeutic drugs were tested in this project expecting an increased inhibitory 
effect on glioma invasion. The effect of TKIs on invasion of newly developed 
glioma cultures was examined using erlotinib and gefitinib, which specifically target 
EGFR, and imatinib which targets PDGFR/C-Kit/ and C-Abl.  
In a previous section it has been shown that imatinib and docetaxel acted 
synergistically on 3 out of 4 glioma cell cultures and significantly decreased 
invasion in a 3D spheroid invasion assay (Kinsella et al. 2010). This result, 
however, could not be reproduced in early passage glioma cultures using the same 
assay. This could be due to heterogeneity of early passage cultures, possibly 
including stem-like cells. 
Response rates of glioblastoma patients to TKIs which specifically target 
EGFR has been low, with 10-20% of glioblastoma patients responding to erlotinib 
and gefitinib (Mellinghoff et al. 2005). Haberler et al, found a 15.7% imatinib 
response rate in patients with glioblastoma (Haberler et al. 2006). There are ongoing 
clinical trials in glioblastoma patients with erlotinib and chemotherapeutic drugs , 
however it may also be necessary to look at the effectiveness of some multiple 
targeting TKIs such as sunitinib which is showing promising results in glioma cells 
(Giannopoulou et al. 2010). Sunitinib specifically targets the growth factors PDGFR 
and VEGFR, it has shown strong antiangiogenic and antitumour activity in renal 
gastrointestinal and neuroendrocrine cancer cell lines (Abrams et al. 2003; Adams 
and Leggas 2007; Cuneo et al. 2008). Dasatinib is another TKI which specifically 
targets EGFR and SRC, SRC plays a key role in invasion through focal adhesion 
kinase (FAK) in glioblastoma, Milano et al, have shown dasatinib to be more 
effective in glioblastoma that were PTEN negative (Milano et al. 2009). 
It is believed that by combining TKIs and chemotherapeutic drugs this might 
improve patient outcome in glioma. In a phase II study Prados et al, found that a 
combination of erlotinib and temozolomide together with radiotherapy in patients 
with glioblastoma and gliosarcoma; resulted in 19.3 months median survival in 
comparison to the control group with a median survival of 14.1 months (Prados et 
al. 2009). Longer survival was correlated with O6-methylguanine-DNA 
methyltransfease (MGMT) promotor methylation and functional PTEN (Prados et 
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al. 2009). Van den Bent et al, examined a phase II trial in 110 recurrent 
glioblastoma patients who received prior radiotherapy, looking at erlotinib treatment 
in comparison to temozolomide or carmustine (BCNU) (van den Bent et al. 2009). 
There was no increase in survival, with erlotinib treatment they found an 11.4% 6 
month progression free survival, and in the control arm it was 24%, only low 
phosphorylated Akt expression had a low correlation with improved outcome, and 
none of the patients with EGFRvIII mutant presence and PTEN expression had 6 
month progression free survival (van den Bent et al. 2009). However Mellinghoff et 
al, correlated co-expression of EGFRvIII and PTEN in tumour cells with 
responsiveness to EGFR kinase inhibitors, erlotinib and gefitinib (Mellinghoff et al. 
2005). There are several glioma therapies currently in clinical trial phase; a phase II 
trial involving the PDGFR kinase inhibitor nilotinib which targets BCR-ABL in 
recurrent malignant gliomas, a phase II trial involving the TKI dasatinib targeting 
PDGFR and SRC kinase in recurrent glioblastoma patients, and a phase III trial 
involving temozolomide in combination with bevacizumab, an antibody which 
targets VEGF in patients with newly diagnosed glioblastoma or gliosarcoma .  
 
Effect of Temozolomide on Glioma Invasion 
Temozolomide is an alkylating drug, which causes DNA methylation at the O6 
position of guanine and crosslinks between DNA strands, which results in cell death. 
Temozolomide is currently the first line chemotherapeutic drug for glioblastomas, 
resulting in a median survival of around 16 months (Stupp et al. 2002). However, 
tested on the majority of cell cultures it had a 10 to 30% inhibitory effect on glioma 
invasion (Figs. 3.4.2 to 3.4.17). Surprisingly, temozolomide increased invasion 
activity in 4 cell cultures (Figs. 3.4.2, 3.4.3, 3.4.10, 3.4.13), which needs to be 
further assessed. Improved clinical outcome after temozolomide treatment has been 
associated with promoter methylation of MGMT (or loss of MGMT) and Loss of 
Heterozygosity (LOH) of 1p and 19q in patients with glioblastoma, anaplastic 
astrocytoma and oligoastrocytomas. The DNA repair enzyme MGMT reverses the 
alkylating effect of temozolomide, resulting in increased resistance to temozolomide 
(Ishii et al. 2007). Temozolomide treatment in glioblastoma patients, who have the 
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methylated MGMT promoter has been promising, and has shown an increase in 
progression free survival (PFS), PFS and overall survival were longer in patients 
with tumours with MGMT promoter methylation (13.4 and 23.2 months) versus 
those without MGMT promoter methylation (3.4 and 13.1 months) (Stupp et al. 
2010). The allelic losses of 1p and 19q are associated with sensitivity of brain 
tumours to radiotherapy and chemotherapy (Ishii et al. 2007). In particular, LOH in 
1p and promoter methylation of MGMT was associated with longer progression free 
survival in glioma (Ishii et al. 2007). It is possible the glioblastomas whose invasion 
was not affected by temozolomide or in fact increased, could have expression of 
MGMT, allowing them to repair the DNA damage caused by temozolomide; the 
presence of MGMT needs to be tested in these cultures to clarify this. It is also 
possible that these early passage cultures contain populations of stem cells, these 
cells are known to be resistant to chemotherapy and radiation (as discussed in 
section 2) (Bao et al. 2006; Chua et al. 2008). The expression of MGMT and the 
detection of LOH of 1p19q in the glioma cell cultures may explain the resistance to 
temozolomide, it would also be interesting to check for the stem cell marker CD133, 
to check for the presence of stem cells in the cultures.  
Using an established glioma cell line, U87MG, Gunther et al, showed found 
an IC50 of 50 µM with temozolomide after 8 days (Gunther et al. 2003), in the 
present study an established cell line SNB-19 had an IC50 with temozolomide of 30 
µM after 7 days, and with the low passage glioma cultures the IC50 results for 
temozoloimde were much higher ranging from 198.3 to 1146 µM. It appears that 
early passage glioma cultures are a lot more resistant to temozolomide than glioma 
cell lines. This could explain why temozolomide treatment is not as clinically 
effective as in vitro results appear. 
Others have found an improvement with temozolomide treatment by 
combining it with other inhibitors. Demuth et al, 2007 found that inhibition of 
mitogen-activated protein kinase (MAPK) kinase 3 (MKK3) signalling through a 
novel treatment combination of p38 inhibitor plus temozolomide heightens the 
vulnerability of glioma to chemotherapy (Demuth et al. 2007). They also found that 
members of the MAPK family are strong promoters of tumour invasion, 
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progression, and therefore associated with poor patient survival (Demuth et al. 
2007). Dasatinib targets drug-resistant tumours with mutant BCR-ABL, KIT, and 
EGFR by blocking tyrosine phosphorylation sites that are critical in tumorigenesis. 
Milano et al, found that levels of phosphorylated SRC, AKT, and ribosomal protein 
S6 were decreased in cell lines treated with low nanomolar concentrations of 
dasatinib at baseline and following stimulation with EGF (Milano et al. 2009). An 
increased sensitivity to dasatinib was noted in glioma cells with functional PTEN 
(Milano et al. 2009) and their invasive potential was reduced in the presence of 
dasatinib. A combination of glioma cells with dasatinib and temozolomide resulted 
in a significant increase in cell cycle disruption and autophagic cell death (Milano et 
al. 2009).  
 
Effect of Docetaxel on Glioma Invasion 
Docetaxel strongly inhibited the invasion activity of most cell cultures (Fig. 3.4.2 to 
3.4.17). In a previous section it has also been shown that docetaxel also strongly 
inhibits proliferation in glioma, possibly showing docetaxel to be a very effective 
chemotherapeutic drug for treating glioma (section 3). Docetaxel is a cytotoxic 
taxane that inhibits depolymerisation of microtubules, thereby interrupting cell 
proliferation and inhibiting cell motility (Bissery et al. 1995). Docetaxel is used in 
the treatment of various forms of cancer and is one of the most effective 
chemotherapeutic agents for non-small cell lung cancer (Burris et al. 1995). As 
second line treatment in phase II trials in recurrent glioblastoma, systemic docetaxel 
showed very little response which is probably due to the poor penetration of the 
BBB (Forsyth et al. 1996; Kemper et al. 2003; Kemper et al. 2004). Local delivery 
of docetaxel in an animal model resulted in a significant improvement in survival 
(Sampath et al. 2006). 
 Kogashiwa et al, showed that docetaxel suppressed filopodia formation in 
head and neck cancer, and suppressed two-dimensional (2D) cell migration and 3D 
cell invasion by decreasing Cdc42 activities in HEp-2 cells (Kogashiwa et al. 2010). 
Actin filament polymerization, elongation, and contraction, are thought to provide 
the major driving forces for cell migration (Ridley et al. 2003). Cdc42 controls the 
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polarity of actin in the microtubules through distinct signal transduction pathways 
(Cau and Hall 2005). Abnormal tubulin bundles induced by docetaxel may lead to 
suppression of Cdc42 and decreased transport of Cdc42 to the plasma membrane 
(Kogashiwa et al. 2010). Decreased Cdc42 activity was likely to affect actin 
filament formation, resulting in decreased filopodia. These results suggest that 
docetaxel treatment has the benefit of reducing local invasion in addition to its 
ability to cause apoptosis. 
 
Effect of Erlotinib and Gefitinib on Glioma Invasion 
Overall erlotinib and gefitinib as a single drug treatments did not have a strong 
effect on invasion (Fig. 3.4.2 to 3.4.17), while in 3 cultures the combination of 
erlotinib with docetaxel (Fig. 3.4.2) or with temozolomide (Figs. 3.4.5 and 3.4.16) 
was more potent than each drug alone. Gefitinib even increased invasion in 4 high-
grade glioma cultures (Figs. 3.4.2, 3.4.13, 3.4.14, and 3.4.15). A combination of 
temozolomide and gefitinib inhibited invasion activity of 2 cultures by 43% and 
36% (Figs. 3.4.5 and 3.4.15); which might be due to the presence of methylated 
MGMT making them more sensitive to temozolomide.  
Inhibition of EGFR alone may not be sufficient to inhibit invasion in glioma. 
Mutated forms of EGFR, i.e. EGFRvIII (Haas-Kogan et al. 2005) and other growth 
factors such as PDGFR and VEGFR (Schlessinger 2000) may have a more 
significant role to play in cell survival and invasion. Bevacizumab, a monoclonal 
antibody targeting VEGFR is showing promising results in glioma (Friedman et al. 
2009; Kreisl et al. 2009). Erlotinib is currently being combined with dasatinib in a 
phase I/II clinical trial in advanced NSCLC patients (Haura et al. 2010). Dasatinib 
specifically targets Src family kinase (SFK) proteins which are activated in cancer 
and coordinate growth, survival, invasion, and angiogenesis. It is known that Src 
kinase and EGFR signalling is coordinated, therefore it may be more effective to 
target both pathways in patients with advanced non-small-cell lung cancer, and 
possibly also in other cancers including glioma. 
Guillamo et al, used a panel of six human malignant gliomas from 
established xenografts and showed that gefitinib reduced cell invasion in EGFR 
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amplified tumours and PTEN LOH seemed to be a determinant of resistance. They 
have also shown that inhibition of angiogenesis by gefitinib seems independent of 
EGFR (Guillamo et al. 2009). All cultures tested in this study express EGFR 
(section 3.4) and PTEN; however it is not clear if PTEN is mutated resulting in loss 
of function, making the cultures resistant to gefitinib. Mellinghoff et al, examined 
the effect of erlotinib and gefitinib in 49 patients with recurrent malignant glioma, 
and found only a 10-20% response which was correlated response with the co-
expression of EGFRvIII and PTEN (Mellinghoff et al. 2005). 
Gefitinib has been shown to be effective in lung cancer patients carrying 
mutations in exons 19 and 21 of the EGFR tyrosine kinase domain. These mutations 
were not found in a study involving 95 gliomas including glioblastomas, anaplastic 
oligodendrogliomas, and low-grade gliomas, which might explain the limited 
success of gefitinib in glioma treatment (Marie et al. 2005). There have been some 
encouraging results with TKIs and chemotherapeutic drugs in non-small cell lung 
cancer (NSCLC), however response appears to be due to specific activated EGFR 
mutations (Mack et al. 2009). Mack et al, have shown that activating mutations in 
the EGFR are associated with enhanced response to EGFR tyrosine kinase inhibitors 
in NSCLC, whereas KRAS mutations translate into poor patient outcomes (Mack et 
al. 2009). They found EGFR mutations in 10 of 49 patients (20%), six (12%) had 
single activating mutations in EGFR, associated with improved progression-free 
survival (median, 18.3 months), four patients had a de novo T790M resistance 
mutation (median progression-free survival, 3.9 months) (Mack et al. 2009). KRAS 
mutations were detected in two patients, both of whom had rapid progressive disease 
(Mack et al. 2009), which may not be present in all cancers.  
 
Effect of Imatinib on Glioma Invasion 
Most of the cultures tested express PDGFR-β, C-abl and C-Kit. Imatinib as a single 
drug had a strong inhibitory effect on invasion in most cell cultures (Fig. 3.4.2 to 
3.4.17), which is promising, imatinib blocks invasion through PDGFR inhibition 
(Aoki et al. 2007; Abouantoun and Macdonald 2009). It has been reported that small 
amounts of imatinib in the plasma can cross the BBB (Bihorel et al. 2007), this 
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could possibly be overcome by treatments such as convection enhanced delivery 
which bypasses the BBB (Chamberlain 2006). Imatinib combined with docetaxel 
decreased invasion by an additional 14% in one glioblastoma cell culture (Fig. 
3.4.3). In a previous section it has been shown that the combination of imatinib and 
docetaxel produces a strong apoptotic effect in glioma cell cultures as well as 
decreasing proliferation and invasion in glioma. Docetaxel causes G2/M cell cycle 
arrest (Gucluler and Baran 2009) and imatinib induces cell cycle arrest at the G0-G1 
or G2/M phase in glioma cells (Ren et al. 2009). As imatinib and docetaxel 
individually strongly inhibit invasion in these newly established glioma cell cultures, 
it would be interesting to see if a combined effect of both drugs would also strongly 
inhibit proliferation with each culture. 
Angiogenesis is an important hallmark of glioblastomas involving 
microvascular proliferation (Paul Kleihues 1997), this process is initiated by growth 
factors including VEGF, FGF and PDGF which activate several pathways 
controlling glioma formation. Abouantoun and Macdonald, have shown that 
PDGFRB tyrosine kinase activity is critical for migration and invasion of 
medulloblastoma cells possibly by transactivating EGFR (Abouantoun and 
Macdonald 2009). Aoki et al, have shown that PDGF-BB enhanced the invasive 
activity of malignant peripheral nerve sheath tumour cells schwannomas and 
neurofibromas through PDGFR phosphorylation which can be inhibited by imatinib 
(Aoki et al. 2007).  
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3.4 Summary and Conclusion 
Overall with the glioma cultures, there was not a strong increased effect on 
inhibition of invasion with the TKIs erlotinib, gefitinib and imatinib combined with 
the chemotherapeutic drugs docetaxel or temozolomide. Temozolomide showed 
some inhibition of invasion in some of the glioma cultures however, it was worrying 
to see that temozolomide increased invasion in 4 of the cultures. Docetaxel 
treatment on the other hand had a very strong inhibitory effect on invasion with the 
majority of the cultures. It was shown previously that docetaxel also inhibits 
proliferation in these cultures; possibly indicating that docetaxel would be a more 
effective chemotherapeutic drug for glioma than temozolomide. Erlotinib and 
gefitinib had a weak inhibitory effect on invasion of the cultures. Imatinib had a 
strong inhibitory effect on glioma cultures. 
 It is possible that single drug treatments of either imatinib or docetaxel may 
have a strong inhibitory effect on glioma invasion, using convection enhanced 
delivery to overcome the BBB.  
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3.5 Expression of Protein Targeted by TKIs in High-Grade Glioma, in relation 
to their response to these Inhibitors  
As previously mentioned glioma cultures were generated from tumour biopsy 
samples. In collaboration with Rachel Howley, a Ph.D student from Beaumont 
hospital, Dublin, 26 high-grade gliomas were choosen (20 glioblastomas, 2 
secondary glioblastomas, and 4 grade III astrocytomas) to analyse the correlation 
between responsiveness to TKIs and the expression of specific protein targets of the 
PI3K/Akt pathway which are targeted by tyrosine kinase inhibitors. Rachel carried 
out immunocytochemical analysis with each culture. The expression of these targets 
was examined in each individual culture (Figs. 3.5.6-28). The targets included 
PDGFR-α, PDGFR-β, phosphorylated C-Abl (p-C-Abl), phosphorylated C-Kit (p-
C-Kit), all of which are specific targets of imatinib; EGFR and EGFRvIII, specific 
targets of erlotinib and gefitinib; and some downstream targets of EGFR and 
PDGFR including phosphorylated Akt (p-Akt), the tumour suppressor gene PTEN 
and a downstream protein of MTOR phosphorylated p70S6K (p-p70S6K). The 
expression of each target protein was given an immunocytochemical score (see 
section 2.12.4). The overall expression levels in the cultures were 92.3% PDGFR-α 
and PDGFR-β, 61.5% for p-C-Abl, 61.5% for p-C-Kit, 88.4% for EGFR, 65.3% for 
p-Akt, 84.6% for p-p70S6K and 100% for PTEN.  
 The age profile of these patients was between 22 to 78 years, and survival 
ranged from 1 month to several years (Table 3.5.1). Figure 3.5.1 shows the Kaplan 
Meier graph for survival data. The lowest survival time was seen with the primary 
glioblastomas, the secondary glioblastomas and the grade III astrocytomas had a 
longer survival time. 
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    Table 3.5.1 Patient age, gender and survival time. 
      ?: we do not have the survival information for this patient post 12 months. >: greater than. 
     M: male. F: female. 
Cell Culture Tumour Type Age at 
onset 
Gender Survival 
Time 
(months) 
 
N060913 Primary Glioblastoma 67 F 10 
N060978 Primary Glioblastoma 54 F 3 
N061007 Primary Glioblastoma 75 M 1 
N061092 Primary Glioblastoma 78 M 6 
N070126 Primary Glioblastoma 56 M 28 
N070152 Primary Glioblastoma 52 M 5 
N070293 Primary Glioblastoma 38 M >36 
5070454 Primary Glioblastoma 73 F 3 
N070859 Primary Glioblastoma 55 M 12 
N070865 Primary Glioblastoma 70 M 5 
N071026 Primary Glioblastoma 46 M 10 
N071144 Primary Glioblastoma 53 M 8 
N071271 Primary Glioblastoma 59 M 11 
N080501 Primary Glioblastoma 60 M 18 
N080533 Primary Glioblastoma 55 F 15 
N080540 Primary Glioblastoma 51 M ?>12 
N080558 Primary Glioblastoma 64 M 5 
N080869 Primary Glioblastoma 54 F >20 
N080923 Primary Glioblastoma 61 M 15 
N080943 Primary Glioblastoma 62 F >19 
N060893 Secondary Glioblastoma 40 M >138 
N070701 Secondary Glioblastoma 39 F >56 
N070201 Grade III Astrocytoma  42 M >36 
N070229 Grade III Astrocytoma 22 M >36 
N070237 Grade III Astrocytoma 33 M 55 
N070788 Grade III Astrocytoma 38 F >31 
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Censored: still alive. 1o: Primary glioblastoma, 2o: Secondary glioblastoma, AA III: grade III 
anaplastic astrocytoma. Cum: cumulative. 
 
Fig. 3.5.1 Kaplan Meier graph showing the difference in survival time of the 
primary glioblastomas with secondary glioblastomas and grade III anaplastic 
astrocytomas used in our study. The cumulative survival was plotted on the y-axis 
with a value of 1 representing 100% of the cohort alive; with each death the line 
stepped down, a steeper drop represented a worse outcome. The vertical lines that 
cross each arm are patients still alive, and survival time is only known up to that 
point. 
 
Survival Time (months)
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3.5.1 Response of High-Grade Gliomas to the TKIs 
Using IC50 toxicity assays the cultures were classified as responders or non-
responders to Erlotinib, gefitinib, and imatinib (see section 3.2.2). TKI 
responsiveness was classified as follows: if the IC50 concentrations for the culture 
was less than or equal to 10 µM for erlotinib, and 20 µM for both gefitinib and 
imatinib these were responders, non-responders had IC50 values greater than these 
concentrations. Of the 26 high-grade glioma cultures, 7 were non-responders to any 
of the TKIs tested, 3 responded to erlotinib, 6 to gefitinib, and 3 to imatinib (Table 
3.5.2). There were also 4 which responded to both erlotinib and gefitinib, 1 to 
erlotinib and imatinib, 1 to gefitinib and imatinib, and 1 which responded to 
erlotinib, gefitinib and imatinib (Table 3.5.2). The ICC expression of specific 
protein targets of the PI3K/Akt pathway is shown for each individual culture; the 
cultures are grouped in regard to their TKI responsiveness (Figs. 3.5.29-44). 
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Table 3.5.2 Response of high-grade gliomas to the TKIs, erlotinib, gefitinib and 
imatinib. 
Cell Culture Tumour Type Response to TKIs 
 
 
N070229 Grade III Astrocytoma Non-responder 
N070237 Grade III Astrocytoma Non-responder 
N070788 Grade III Astrocytoma Non-responder 
N070859 Primary Glioblastoma Non-responder 
N070865 Primary Glioblastoma Non-responder 
N080558 Primary Glioblastoma Non-responder 
N080943 Primary Glioblastoma Non-responder 
N060913 Primary Glioblastoma Erlotinib 
N061007 Primary Glioblastoma Erlotinib 
N061092 Primary Glioblastoma Erlotinib 
N060893 Secondary Glioblastoma Gefitinib 
N070126 Primary Glioblastoma Gefitinib 
N070293 Primary Glioblastoma Gefitinib 
N071271 Primary Glioblastoma Gefitinib 
N080501 Primary Glioblastoma Gefitinib 
N080533 Primary Glioblastoma Gefitinib 
N060978 Primary Glioblastoma Erlotinib & Gefitinib 
N070152 Primary Glioblastoma Erlotinib & Gefitinib 
N071144 Primary Glioblastoma Erlotinib & Gefitinib 
N080923 Primary Glioblastoma Erlotinib & Gefitinib 
N070201 Grade III Astrocytoma Erlotinib & Imatinib 
N070454 Primary Glioblastoma Imatinib 
N071026 Primary Glioblastoma Imatinib 
N080869 Primary Glioblastoma Imatinib 
N080540 Primary Glioblastoma Gefitinib & Imatinib 
N070701 Secondary Glioblastoma 
 
Erlotinib, Gefitinib & 
Imatinib 
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3.5.1 Non-Responders to Tyrosine Kinase Inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5.2 PI3K/Akt pathway targets of 3 grade III astrocytomas N070229 (a), 
N070237 (b) and N070788 (c) which were non-responders to the TKIs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5.3 PI3K/Akt pathway targets for 4 primary glioblastoma cultures N070865 
(a), N080558 (b) N080943 (c) and N070859 (d) which were non-responders to the 
TKIs. 
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 3.5.2 Erlotinib responders  
 
Table 3.5.3 IC50 values of erlotinib for cultures which responded to erlotinib. 
Cell Culture IC50 for Erlotinib 
 
N060913 7.2 µM 
N061007 9.1 µM 
N061092 9.3 µM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5.4 PI3K/Akt pathway targets for 3 primary glioblastoma cultures N060913 
(a), N061007 (b) and N061092 (c) which responded to erlotinib. 
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3.5.3 Gefitinib Responders 
 
 
Table 3.5.4 IC50 values of gefitinib for cultures which responded to gefitinib. 
Cell Culture IC50 for Gefitinib 
 
N060893 16.8 µM 
N070126 20 µM 
N070293 18.3 µM 
N071271 16.7 µM 
N080501 16.9 µM 
N080533 16.7 µM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5.5 PI3K/Akt pathway targets for a secondary glioblastoma N060893 (a), and 
2 primary glioblastomas N070126 (b) and N070293 (c) which responded to 
gefitinib. 
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Fig. 3.5.6 PI3K/Akt pathway targets for 3 primary glioblastomas N071271 (a), 
N080501 (b), and N080533 (c) which responded to gefitinib. 
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3.5.4 Responders to Erlotinib and Gefitinib 
 
Table 3.5.5 IC50 values of gefitinib and erlotinib for cultures which responded to 
erlotinib and gefitinib. 
Cell Culture IC50 for Erlotinib IC50 for Gefitinib 
 
N060978 9.5 µM 17.2 µM 
N070152 6.5 µM 17 µM 
N071144 9.3 µM 19.5 µM 
N080923 7.2 µM 15.2 µM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5.7 PI3K/Akt pathway targets for 4 primary glioblastomas N060978 (a), 
N070152 (b), N071144 (c) and N080923 (d) which responded to both erlotinib and 
gefitinib. 
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3.5.5 Responders to Imatinib 
 
Table 3.5.6 IC50 values of imatinib for cell cultures which responded to imatinib.  
Cell Culture IC50 for Imatinib 
 
N070454 16.7 µM 
N071026 19.6 µM 
N080869 14 µM 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5.8 PI3K/Akt pathway targets for 3 primary glioblastomas N070454 (a), 
N071026 (b), and N080869 (c) which responded to imatinib. 
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3.5.6 Responder to Erlotinib and Imatinib 
 
                         Table 3.5.7 IC50 value of erlotinib and imatinib for N070201.  
Cell Culture IC50 for Erlotinib IC50 for Imatinib 
N070201 8.4 µM 20 µM 
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Fig. 3.5.9 PI3K/Akt pathway targets for a grade III astrocytoma N070201 which 
responded to both erlotinib and imatinib. 
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3.5.7 Responder to Gefitinib and Imatinib 
 
Table 3.5.8 IC50 value of gefitinib and imatinib for N080540.  
Cell Culture IC50 for Gefitinib IC50 for Imatinib 
N080540 18.5 µM 15.8 µM 
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Fig. 3.5.10 PI3K/Akt pathway targets for a primary glioblastoma N080540. 
 
 
3.5.8 Responder to Erlotinib, Gefitinib and Imatinib 
 
       Table 3.5.9 IC50 value of erlotinib, gefitinib, and imatinib for N070701. 
Cell Culture IC50 for Erlotinib IC50 for Gefitinib IC50 for Imatinib 
N070701 7.9 µM 16.7 µM 14.4 µM 
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Fig. 3.5.11 PI3K/Akt pathway targets for a secondary glioblastoma N070701. 
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3.5.9 PI3K/Akt Pathway Proteins Expression and Response to Tyrosine Kinase 
Inhibitors 
Receptor tyrosine kinases EGFR, PDGFR-α, PDGFR-β, C-Kit and a non-receptor 
tyrosine kinase C-Abl activate the PI3K/Akt pathway; the expression of these was 
examined by ICC.  
EGFR is a specific target of erlotinib and gefitinib. The gefitinib and 
erlotinib responders had the highest EGFR expression; and lower expression of 
EGFR was found in the non-responders and imatinib responders (Fig. 3.5.13) (Table 
3.5.10). 
PDGFR is specifically targeted by imatinib. The non-responders had higher 
expression of PDGFR-β whereas the imatinib responders had higher PDGFR-α 
expression (Fig. 3.5.13) (Table 3.5.10). The responders to erlotinib and gefitinib had 
similar expression levels of PDGFR-α and PDGFR-β (Fig. 3.5.13) (Table 3.5.10). 
KIT is a receptor tyrosine kinase which plays an important role in 
proliferation, differentiation, metastasis, and glioma development. C-Abl is an 
ubiquitously expressed non-receptor tyrosine kinase and is involved in cell cycle 
arrest and apoptosis. Overexpression of C-Abl in glioblastomas suggests an 
association with poor survival (Jiang et al. 2006). Overall, higher expression of p-C-
Abl and p-C-Kit was found in gefitinib responders compared to non-responders and 
erlotinib or imatinib responders (Fig. 3.5.13) (Table 3.5.10). 
PI3K/Akt pathway activation was examined by ICC expression of the 
tumour suppressor PTEN, p-Akt and p-p70S6K. PTEN is a tumour suppressor gene 
which inhibits cell growth, and negatively regulates the PI3K/Akt pathway. The 
PI3K/Akt pathway promotes cell survival and Akt promotes cell growth via MTOR 
signalling. MTOR also plays an important role in regulating protein translation 
through phosphorylation of p70S6K, a protein involved in ribosome biogenesis. 
Overall higher expression of p-Akt and p-p70S6K was found in the gefitinib 
responders (Figs. 3.5.14), (Table 3.5.11). 
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Fig. 3.5.12 Average ICC score of EGFR, PDGFR-α, PDGFR-β, p-C-Abl, and p-C-
Kit for non-responders, and for responders to erlotinib, gefitinib, and imatinib. The 
standard deviations represent the variance of the ICC score within each group. 
Standard deviations were generated from Microsoft Excel software. 
 
 
Table 3.5.10 Average ICC score of EGFR, PDFGR-α, PDGFR-β, p-C-Abl and p-C-
Kit in high-grade gliomas. 
Response 
to TKIs 
EGFR PDGFR-α PDGFR-β 
 
p-C-Abl p-C-Kit 
 
Non-
responder 
1.9 ± 2 2.9 ± 1.2 8 ± 4.1 1.7 ± 1.8 2.1 ± 3.1 
Erlotinib 
responder 
4.3 ± 2.3 3.7 ± 3.9 4.4 ± 3.8 1.2 ± 1.9 1.7 ± 1.8 
Gefitinib 
responder 
5.3 ± 3.2 4.4 ± 3.5 5.6 ± 4.2 4 ± 3.2 3.8 ± 3.6 
Imatinib 
responder 
2.3 ± 1.4 7.8 ± 3.1 5.8 ± 2.9 1.7 ± 1.2 0.7 ± 0.8 
        Highest average ICC score 
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Fig. 3.5.13 Average ICC score of PTEN, p-Akt, and p-p70S6K for non-responders, 
erlotinib, gefitinib, and imatinib responders. The standard deviations represent the 
variance of the ICC score within each group. Standard deviations were generated 
from Microsoft Excel software. 
 
Table 3.5.11 Average ICC score of PTEN, p-Akt and p-p70S6K in high-grade 
gliomas. 
Response 
to TKIs 
PTEN 
 
p-Akt p-p70S6K 
 
Non-
responder 
8 ± 3.3 1.7 ± 1.9 3.1 ± 3 
Erlotinib 
responder 
8.6 ± 4.4 2.7 ± 4 2.1 ± 3.4 
Gefitinib 
responder 
7 ± 4.4 3.5 ± 4.3 5.3 ± 3.7 
Imatinib 
responder 
9.7 ± 3.7 1 ± 0.9 3.8 ± 3.3 
      Highest average ICC score 
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3.5.10 Bioinformatic Analysis for PI3K/Akt Pathway Proteins in Non-
Responders and Responders to Tyrosine Kinase Inhibitors 
The statistical analysis was carried out by a bioinformatician Dr. Colin Clarke from 
the NICB. The cohort included 26 high-grade glioma samples. This dataset was too 
small for supervised analysis; therefore hierarchical clustering analysis (HCA) and 
principal components analysis (PCA) were employed for multivariate statistics.  
3.5.10.1 Hierarchical Clustering Analysis 
Statistical analysis was used to analyse the large amount of data which were 
generated through ICC analysis. To stratify samples corresponding to a clinical trait 
or response to drug, the Ward’s distance method with Euclidian was used (Lomo et 
al. 2008). HCA on cell culture ICC data resulted in two main groupings of samples; 
11 samples with high and 15 with low PTEN expression (Fig. 3.5.14 vertical 
grouping). Clustering the marker again resulted in two additional clusters: PDGFR-
α, PDGFR-β and PTEN grouped together; these markers contain the majority of 
high scores from the ICC analysis. The second cluster contains p-C-Kit, p-C-Abl, 
EGFRtot, EGFRvIII, p-p70S6K and p-Akt expression, and was defined by low ICC 
scores (Fig. 3.5.14 vertical grouping).  
 Cluster 1 had the highest PTEN and PDGFR-α expression. PDGFR-β 
expression was high in some of the cultures. Cluster 1 also had very little expression 
of EGFR, p-C-Kit, and p-C-Abl. There was low expression of downstream targets of 
the PI3K/Akt pathway, including p-p70S6K and p-Akt (Fig. 3.5.14) (Table 3.5.12).  
 Cluster 2 is characterized by higher PDGFR-β, EGFR, p-C-Kit and p-C-Abl 
expression as well as higher expression of downstream targets of the PI3K/Akt 
pathway including p-p70S6K and p-Akt (Fig. 3.5.14) (Table 3.5.13).  
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Bright green: high expression bright red: low expression black: in between. 
*: Anaplastic astrocytoma. *: secondary glioblastoma. Cluster 1 is highlighted with a gray arrow, 
cluster 2 with an orange arrow. 
 
Fig. 3.5.14 HCA and heatmap for cell culture ICC analysis of 26 high-grade glioma 
samples. The dendrogram depicts all cases individually in rows, and the 
interpretation of each protein in columns. PDGFR.A: PDGFRα; PDGFR.B: 
PDGFRβ; c.KIT.P: phosphorylated c-KIT; c.ABL.P: phosphorylated c-
ABL; P70S6K.P: phosphorylated p70S6K; AKT.P: phosphorylated AKT. 
 * * * * *  * 
Cluster 1 Cluster 2 
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Table 3.5.12 Characteristics of Cluster 1 
Cell 
Culture 
Tumour Grade Survival Time 
(months) 
Doubling 
Time (hrs) 
Invasion Erl Gef Imt 
N070293 Primary Glioblastoma 
 
>36 91.5 2 - + - 
N070201 Grade III Astrocytoma 
 
>36 59.4 0 + - + 
N080869 Primary Glioblastoma 
 
>20 115 2 - - + 
N061007 Primary Glioblastoma 
 
1 >168 1 + - - 
N070237 Grade III Astrocytoma 
 
55 88.45 0 - - - 
N060913 Primary Glioblastoma 
 
110 >168 1 + - - 
N080558 Primary Glioblastoma 
 
5 115.4 0 - - - 
N080943 Primary Glioblastoma 
 
>19 94.33 2 - - - 
N061092 Primary Glioblastoma 
 
6 100.5 2 + - - 
N070454 Primary Glioblastoma 
 
3 51.5 2 - - + 
N080540 Primary Glioblastoma 
 
>12 49.1 0 - + + 
Erl: erlotinib, Gef: gefitinib, Imt: imatinib. -: non-responder, +: responder. Invasion. 2: very invasive, 1: some invasion, 0: no invasion. 
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Table 3.5.13 Characteristics of Cluster 1 
Cell 
Culture 
Tumour Grade Survival Time 
(months) 
Doubling 
Time (hrs) 
Invasion Erl Gef Imt 
N080501 Primary Glioblastoma 
 
18 107 1 - + - 
N071144 Primary Glioblastoma 
 
8 77.7 2 + + - 
N080533 Primary Glioblastoma 
 
15 62.58 2 - + - 
N071271 Primary Glioblastoma 
 
11 59.2 2 - + - 
N080923 Primary Glioblastoma 
 
15 56.2 0 + + - 
N070152 Primary Glioblastoma 
 
5 48.8 2 + + - 
N070126 Primary Glioblastoma 
 
28 82.54 0 - + - 
N070229 Grade III Astrocytoma >36 72.46 2 - - - 
 
N060893 Secondary Glioblastoma 
 
>138 88.13 1 - + - 
N070788 Grade III Astrocytoma >31 65.9 0 - - - 
 
N070859 Primary Glioblastoma 
 
12 56 1 - - - 
N070865 Primary Glioblastoma 
 
5 37.3 2 - - - 
N060978 Primary Glioblastoma 
 
3 99.3 0 + + - 
N070701 Secondary Glioblastoma 
 
>56 71.8 1 + + + 
N071026 Primary Glioblastoma 
 
10 74.52 2 - - + 
Erl: erlotinib, Gef: gefitinib, Imt: imatinib. -: non-responder, +: responder. Invasion 2: very invasive, 1: some invasion, 0: no invasion
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3.5.2 Correlation of Patient Survival Time with Hierarchial Cluster Analysis 
Within the two main clusters received through HCA patient survival time was 
correlated with the expression of each protein from the PI3K/Akt pathway. Cluster 1 
had a lower proliferation rate overall in comparison to cluster 2 (Table 3.5.12 and 
3.5.13). Figures 3.5.15 to 3.5.22 show the relationship with each protein between the 
two clusters: cluster 2 had higher PDGFR-β expression than cluster 1; the majority 
of patients in cluster 2 with high PDGFR-β expression had a lower survival time 
(Fig. 3.5.15). There was significantly higher expression of PDGFR-β in cluster 2 (p 
= 0.05) (Table 3.5.14). PDGFR-α expression was not correlated with survival time 
in either cluster (Fig. 3.5.16). There was no significant difference in expression of 
PDGFR-α between the two clusters (p = 0.067) (Table 3.5.15).  
High expression of PTEN in cluster 1 appears to be related to longer survival 
in 3 patients; whereas there was no correlation with PTEN and survival in cluster 2 
(Fig. 3.5.17). There was higher expression of PTEN in cluster 1 than cluster 2, 
statistically significant (p = 2.86E-05) (Table 3.5.16).  
In cluster 1 there was very little expression of p-C-Kit, (4 out of 11 cultures 
had expression); high expression of p-C-Kit was found in cluster 2 and seemed to 
correlate with lower survival time (Fig. 3.5.18), with higher expression of p-C-Kit in 
cluster 2 (p = 0.0018) (Table 3.5.17).  
6 patients out of 11 in cluster 1 had no expression of p-C-Abl, while 13 out 
of 15 patients in cluster 2 expressed p-C-Abl and within this group 8 showed a 
correlation with lower survival (Fig. 3.5.19). There was no difference in expression 
of C-Abl between the clusters (p = 0.074) (Table 3.5.18).  
While levels of EGFRtot expression in cluster 1 were very low, EGFRtot 
expression was much higher in cluster 2 and correlated with lower survival time 
(Fig. 3.5.20), a difference in EGFRtot expression was found between the two 
clusters (p = 0.005) (Table 3.5.19).  
Very low expression of p-p70S6K was seen in cluster 1; 3 patients had no 
expression. In cluster 2 expression level of p-p70S6K was much higher and the 
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majority of the patients with high expression had a lower survival time (Fig. 3.5.21), 
(p = 0.0046) (Table 3.5.20).  
There was little p-Akt expression overall. In cluster 2 strong expression of p-
Akt was seen in two samples, which was accompanied with lower survival time 
(Fig. 3.5.22), there was no difference of expression of p-Akt between the two 
clusters (p = 0.239) (Table 3.5.21). 
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3.5.2.1 PDGFR-β Expression in Comparison to Patient Survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: Grade III astrocytoma. 20: secondary glioblastoma. *: patient still alive. PDGFRB: PDGFR-β. 
N060893 had greater than 138 months survival.  
 
Fig. 3.5.15 Survival time (months) of patients correlated with PDGFR-β ICC score 
in cluster 1 (a) and cluster 2 (b). 
 
Table 3.5.14 Anova analysis of PDGFR-β ICC score, with cluster 1 and cluster 2. 
Protein Average ICC Score 
Cluster 1 
Average ICC Score 
Cluster 2 
P Value 
 
 
PDGFR-β 4.5 ± 2.4 7.4 ± 4.4 0.05 
 
Standard deviations represent variance within each cluster. 
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3.5.2.2 PDGFR-α Expression in Comparison to Patient Survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: Grade III astrocytoma. 20: secondary glioblastoma. *: patient still alive. PDGFRA: PDGFR-α. 
N060893 had greater than 138 months survival 
 
Fig. 3.5.16 Survival time in months of patients correlated with PDGFR-α ICC score 
in cluster 1 (a) and cluster 2 (b). 
 
Table 3.5.15 Anova analysis of PDGFR-α ICC score, with cluster 1 and cluster 2. 
Protein Average ICC Score 
Cluster 1 
Average ICC Score 
Cluster 2 
P Value 
 
 
PDGFR-α 5.9 ± 4.0 3.5 ± 2.5 0.067 
 
Standard deviations represent variance within each cluster. 
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3.5.2.3 PTEN Expression in Comparison to Patient Survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: Grade III astrocytoma. 20: secondary glioblastoma. *: patient still alive. N060893 had   greater 
than 138 months survival. 
 
 
Fig. 3.5.17 Survival time in months of patients correlated with PTEN ICC score in 
cluster 1 (a) and cluster 2 (b). 
 
Table 3.5.16 Anova analysis of PDGFR-α ICC score, with cluster 1 and cluster 2. 
Protein Average ICC Score 
Cluster 1 
Average ICC Score 
Cluster 2 
P Value 
 
 
PTEN 11.6 ± 1.2 6.0 ± 3.5 2.86E-05 
 
Standard deviations represent variance within each cluster. 
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3.5.2.4 p-C-Kit Expression in Comparison with Patient Survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
A: Grade III astrocytoma. 20: secondary glioblastoma. *: patient still alive. P-C-Kit: phosphorylated 
C-Kit. N060893 had greater than 138 months survival. 
 
Fig. 3.5.18 Survival time in months of patients correlated with p-C-Kit ICC score in 
cluster 1 (a) and cluster 2 (b). 
 
Table 3.5.17 Anova analysis of PDGFR-α ICC score, with cluster 1 and cluster 2. 
Protein Average ICC Score 
Cluster 1 
Average ICC Score 
Cluster 2 
P Value 
 
 
C-Kit-P 0.5 ± 0.9 4.1 ± 3.3 0.0018 
 
Standard deviations represent variance within each cluster. 
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3.5.2.5 p-C-Abl Expression in Comparison with Patient Survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
A: Grade III astrocytoma. 20: secondary glioblastoma. *: patient still alive. P-C-Abl: phosphorylated 
C-Abl. N060893 had greater than 138 months survival 
 
 
Fig. 3.5.19 Survival time in months of patients correlated with p-C-Abl ICC score in 
cluster 1 (a) and cluster 2 (b). 
 
Table 3.5.18 Anova analysis of p-C-Abl ICC score, with cluster 1 and cluster 2. 
Protein Average ICC Score 
Cluster 1 
Average ICC Score 
Cluster 2 
P Value 
 
 
C-Abl-P 1.5 ± 2.0            3.4 ± 3.0 0.074 
 
Standard deviations represent variance within each cluster. 
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 3.5.2.6 EGFR Expression in Comparison with Patient Survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: Grade III astrocytoma. 20: secondary glioblastoma. *: patient still alive. EGFRtot: EGFR total. 
N060893 had greater than 138 months survival 
 
Fig. 3.5.20 Survival time in months of patients correlated with EGFRtot ICC score 
in cluster 1 (a) and cluster 2 (b). 
 
   Table 3.5.19 Anova analysis of EGFR ICC score, with cluster 1 and cluster 2. 
Protein Average ICC Score 
Cluster 1 
Average ICC Score 
Cluster 2 
P Value 
 
 
EGFRtot 1.8 ± 1.4 4.9 ± 3.1 0.005 
 
Standard deviations represent variance within each cluster. 
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3.5.2.7 p-p70S6K Expression in Comparison with Patient Survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: Grade III astrocytoma. 20: secondary glioblastoma. *: patient still alive. P-p70S6K: 
phosphorylated p70S6K. N060893 had greater than 138 months survival 
 
Fig. 3.5.21 Survival time in months of patients correlated with p-p70S6K ICC score 
in cluster 1 (a) and cluster 2 (b). 
 
Table 3.5.20 Anova analysis of p-p70S6K ICC score, with cluster 1 and cluster 2. 
Protein Average ICC Score 
Cluster 1 
Average ICC Score 
Cluster 2 
P Value 
 
 
p-p70S6K 1.7 ± 1.8 5.3 ± 3.5 0.0046 
 
Standard deviations represent variance within each cluster. 
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3.5.2.8 p-Akt Expression in Comparison with Patient survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
 
 
 
A: Grade III astrocytoma. 20: secondary glioblastoma. *: patient still alive. P-Akt: phosphorylated 
Akt. N060893 had greater than 138 months survival 
 
Fig. 3.5.22 Survival time in months of patients correlated with p-Akt ICC score in 
cluster 1 (a) and cluster 2 (b). 
 
 
Table 3.5.21 Anova analysis of p-Akt ICC score, with cluster 1 and cluster 2. 
Protein Average ICC Score 
Cluster 1 
Average ICC Score 
Cluster 2 
P Value 
 
 
p-Akt 1.5 ± 2.0 3.4 ± 4.0 0.23 
 
Standard deviations represent variance within each cluster. 
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3.5.11 Unsupervised Principal Components Analysis of Pathway Proteins 
response to Tyrosine Kinase Inhibitors 
Unsupervised Principal components analysis (PCA) was applied to the ICC data to 
see if expression of certain proteins is associated with response to TKIs. 55 % of the 
variance in the dataset was retained in the first two principal components (Fig. 
3.5.23). The biplot represents the grouping of the cell cultures in principle 
component space in relation to their expression of the proteins (Fig. 3.5.23). 
Figure 3.5.24 shows the PCA score plot for responders (R) and non-
responders to Erlotinib (NR). Fig 3.5.24 showed that there was a definitive 
separation between responders and non-responders to erlotinib treatment. The 
majority of responders cluster to the top right of the plots, suggesting that these 
samples were not influenced by the analysed proteins (Fig. 3.5.24). Most of the 
NR’s cluster to the lower right of the plots associated with higher expression of 
PTEN and PDGFR-α. 
With gefitinib there was stratification between responders and non-
responders, with the latter clustering toward the right of the plot (Fig. 3.5.25). Again 
the NRs were associated with higher expression of PTEN and PDGFR-α. Within the 
responders to gefitinib one group clustered to the top right not being influenced by 
the protein tested; another group clustered to the bottom left characterized by high 
expression of the target proteins, p-p70S6K,p-C-Kit, p-Akt and p-C-Abl (Fig. 
3.5.25). 
Imatinib responders clustered toward the bottom right hand corner of the 
plot, which shows a strong influence by PTEN and PDGFR-α (Fig. 3.5.26).  
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Fig. 3.5.23 Unsupervised PCA of 26 cell cultures. 55% of the variance in the dataset 
is retained in the first two principal components. The biplot represents the grouping 
of cell cultures in principle component space. The red arrows correspond to the 
influence of protein staining values on the separation of the samples. Each protein is 
labelled in red and each glioma cell culture is labelled in black. Each culture is 
positioned closest to the protein they had the highest expression of. The cultures 
which had little or no expression of the proteins lie to the right hand side of the 
arrows.
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Determination of variable influence on response/non-response 
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R: responder, NR: non-responder. PC1: principle component 1. PC2 : principle component 2. 
 
Fig. 3.5.24 PCA scores plot of cell culture ICC. Samples are labelled according to 
their responsiveness to erlotinib. This plot is a replicate of figure 3.5.23, with the 
cultures labelled as responders or non-responders to erlotinib. The main cluster of 
erlotinib responders is circled in red, which is at the top right hand side of the plot, 
showing that responsiveness to erlotinib is not associated with expression of the 
proteins. 
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R: responder, NR: non-responder. PC1: principle component 1. PC2: principle component 2. 
 
Fig. 3.5.25 PCA scores plot of of cell culture ICC. Samples were labelled according 
to their responsiveness to gefitinib. This plot has the same layout as figure 3.5.23, 
with the cultures labelled as responders or non-responders to gefitinib. The 2 main 
clusters of gefitinib responders are circled in red. There was a cluster of gefitinib 
responders that had high expression of some of the proteins (bottom left hand side) 
and a cluster which did not (top right hand side). 
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Fig. 3.5.26 PCA scores plot of PC1 versus PC2 of cell culture ICC. Samples are 
labelled according to their response to imatinib. The cultures are labelled as 
responders or non-responders to imatinib and have the same grouping as figure 
3.5.23. The majority of the imatinib responders are circled in red. The cluster of 
imatinib responders was at the bottom right hand side of the plot, this was due to the 
high expression of PTEN and PDGFR-α. 
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3.5 Discussion:  
 
Expression of Proteins targeted by TKIs in High-Grade Glioma, in relation to 
their Response to these Inhibitors.  
Overexpression of EGFR and PDGFR is frequently found in glioblastoma, which 
results in the activation of downstream kinases including phosphatidylinositol 3′-
kinase (PI3K), Akt, and the mammalian target of rapamycin (MTOR). MTOR is a 
nutrient sensor which regulates cell growth and many cellular functions such as 
mRNA translation and metabolism (Shaw and Cantley 2006). MTOR has been 
shown to play a key role in tumour progression in various types of cancer including 
glioma (Seeliger et al. 2007), where it is activated by Akt (Riemenschneider et al. 
2006). MTOR phosphorylates p70S6K, which regulates protein synthesis and has 
been shown to cause glioblastoma formation in mice (Holland et al. 2000), while its 
inhibition causes apoptosis (Hu et al. 2005). It was hypothesized that the expression 
of specific proteins targeted by TKIs in glioma cell cultures would correlate with 
their response to tyrosine kinase inhibitors. 26 newly developed high-grade glioma 
cell cultures were analysed by immunocytochemistry (ICC) (Table 3.5.1). The ICC 
work was carried out by a Ph.D student, Rachel Howley, in Beaumont Hospital, 
Dublin. The cell cultures were classified as responders or non-responders to the 
TKIs, erlotinib, gefitinib, and imatinib (Table 3.5.2) (see section 3.3.2).  
EGFR was expressed in 88.4%, and EGFRvIII in 26.9% of the cultures. P-
Akt was expressed in 65.3% and PTEN in 100% of the cultures. A similar 
expression level of Akt was found in glioblastoma cells by others where Akt was 
activated in 70% of gliomas (Alessi et al. 1996; Haas-Kogan et al. 1998). The 
expression of EGFR by ICC varied in the cultures; it was low in the non-responders 
and imatinib responders, and high in erlotinib and gefitinib responders (Fig. 3.5.12) 
(Table 3.5.10). PTEN expression did not appear to be a determinant of TKI 
responsiveness. Mellinghoff et al, found the inhibition of EGFR was successful in a 
sub-group of recurrent glioblastomas (Mellinghoff et al. 2005). Response was 
correlated with co-expression of the mutated form of EGFRvIII and PTEN; 
however, the detailed mechanism of action is still unknown (Mellinghoff et al. 
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2005). Sordella et al, found that in lung cancer cells EGFRvIII activates PI3K/AKT 
signalling and can sensitize cells to the EGFR inhibitor, gefitinib (Sordella et al. 
2004); this has not been shown yet for glioblastomas. Overall a low amount of 
EGFRvIII was found in the cultures, 2 primary glioblastomas and 2 grade III 
astrocytomas had low EGFRvIII expression and PTEN expression, 1 of the primary 
glioblastomas was a gefitinib responder and 1 of these grade III astrocytomas was an 
erlotinib responder (Figs 3.5.2, 3.5.3 3.5.5 and 3.5.9). There were 2 primary 
glioblastomas with higher EGFRvIII expression who also expressed PTEN; both 
were responders to gefitinib (Fig. 3.5.6). It is thought that the loss of PTEN might 
promote resistance to EGFR kinase inhibitors (Bianco et al. 2003). High expression 
of PTEN was found in the majority of the cultures; however, it is unclear if it is 
functional. PTEN can be mutated with loss of function, which has been reported for 
about 30% of glioblastomas (Kleihues and Ohgaki 2000).  
 
PDGFR-α Expression in Relation to Imatinib Responders in High-grade 
Glioma Cultures 
PDGFR-α and PDGFR-β was expressed in 92.3% of the glioma cultures, p-C-Abl in 
61.5%, and p-C-Kit in 61.5%. Non-responders had higher expression of PDGFR-β 
in comparison to the responders (Fig. 3.5.12) (Table 3.5.10). While PDGFR-α and 
PDGFR-β levels were similar in the responders to erlotinib and gefitinib (Fig. 
3.5.12) (Table 3.5.10). The imatinib responders had higher PDGFR-α expression in 
comparison to the non-responders, erlotinib and gefitinib responders (Fig. 3.5.12) 
(Table 3.5.10). Responsiveness to imatinib in gliomas appears to correlate with high 
PDGFR-α expression; it may be possible to base imatinib treatment on PDGFR-α 
expression in glioma patients. Amplification of the PDGFR-α gene and/or 
overexpression of the receptor at the protein level, has been found in high-grade 
gliomas (Fleming et al. 1992; Kumabe et al. 1992; Smith et al. 2000), and in 
astrocytomas (Guha et al. 1995; Saxena et al. 1999). Therefore, this receptor may 
play a more generalized role in glioma formation, as it is not exclusive to 
glioblastomas, and non-responders had higher PDGFR-β expression indicating that 
PDGFR-β may be associated with a more resistant phenotype. 
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P-Akt, p-p70S6K, p-C-Abl and p-C-Kit Expression in Relation to Gefitinib 
Responders in High-Grade Glioma Cultures 
A downstream protein of MTOR, p-p70S6K was expressed in 84.6% of the cultures 
and p-Akt in 65.3%. Li et al, found in a cohort of 36 glioblastoma patients 
expression levels of p-Akt (36.1%), p-MTOR (44.4%), and p-p70S6K (41.7%); in 
addition they found levels correlated with grade of malignancy (Li et al. 2010). 
Annovazzi et al, found mTOR, p-p70S6K, p-Akt expression in 64 malignant 
gliomas, and found the expression which was increased in higher grades of 
malignancy (Annovazzi et al. 2009).  
In our cohort higher expression of p-p70S6K was found in the gefitinib 
responders, and lower expression in non-responders, erlotinib and imatinib 
responders (Fig. 3.5.13) (Table 3.5.11). MTOR can be regulated independently of 
PI3K (Tang et al. 2003), the MTOR-p70S6K pathway may play a more critical role 
in tumourigenesis, this would explain the higher expression of p-p70S6K in gefitinib 
responders. Gefitinib responders had a slightly lower PTEN expression in 
comparison to the other groups; PTEN may have loss of function in gefitinib 
responders. 
In addition higher expression of p-C-Abl and p-C-Kit was found with 
gefitinib responders than with the non-responders, erlotinib or imatinib responders 
(Fig. 3.5.12) (Table 3.5.10). Jiang et al, showed that the over-expression of C-Abl 
has been found in glioblastomas compared but not in lower grade gliomas, 
suggesting an association with poor survival (Jiang et al. 2006). Stanulla et al, 
showed that the expression of C-Kit was found in the cytoplasm of glioma cell lines, 
suggesting its involvement in the autocrine growth regulation of glioma cells 
(Stanulla et al. 1995). It may also be that gliomas expressing higher levels of p-C-
Kit and p-C-Abl are more responsive to gefitinib, because higher levels of 
expression of the phosphorylated protein targets of the PI3K/Akt pathway were 
found in the gefitinib responders indicated that the pathway was more active in 
gefitinib responders. 
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Bioinformatic Analysis of Proteins of the PI3K/Akt Pathway in Relation to 
Response to Tyrosine Kinase Inhibitors in High-Grade Glioma 
Using hierarchical cluster analysis (HCA) and unsupervised principal components 
analysis (PCA) two distinct clusters of samples were found within the cohort. It is 
possible that the 2 clusters represent 2 different subgroups of high-grade gliomas. 
Brennan et al, took a cohort of 27 glioma samples and carried out proteomic 
analysis, to examine signal transduction pathways (Brennan et al. 2009). They 
compared their results with The Cancer Genome Atlas (Brennan et al. 2009), which 
contains expression data of 243 glioblastoma samples; 3 subclasses of glioblastoma 
emerged, one with high EGFR activation, another with high PDGFR activation, and 
a third had loss of the RAS regulator Neurofibromatosis type I (NF1) (Brennan et al. 
2009). The EGFR signalling class had high notch pathway activation, the PDGF 
class had high levels of PDGFB ligand and phosphorylation of PDGFR-β and NF-
kappa-B (NFκ-B). The class with loss of NF1 had lower MAPK and PI3K activation 
(Brennan et al. 2009). Cluster 2 from the present study may correspond to class 2, 
because it is characterized by high PDGFR-β expression (Brennan et al. 2009). It 
would be interesting to check the samples for NF1 loss and notch signalling by 
proteomic analysis to see if any of the samples correspond to the third class 
mentioned (Brennan et al. 2009). If glioma samples become classified into more 
specific subgroups based on protein expression and pathway signalling, a patient’s 
treatment could become tailored with specific drugs to suit each individual, and 
possibly result in more effective treatment.  
High expression of PTEN and PDGFR-α was characterized for cluster 1 (11 
samples), while PDGFR-β, EGFR, p-C-Kit and p-C-Abl expression was 
predominant in cluster 2 (15 samples) (Fig. 3.5.14).  
 High EGFR and p-Akt expression correlated with low survival time in 
cluster 2 in glioblastomas (Figs. 3.5.20 and 3.5.22); these 2 biomarkers have been 
previously associated with poor prognosis in glioma (Shinojima et al. 2003). 
PDGFR-β, PDGFR-α, p-C-Kit and p-C-Abl expression did not correlate with 
survival in either cluster (Figs. 3.5.15, 3.5.16, 3.5.18 and 3.5.19). High expression of 
PTEN was found in all samples in cluster 1 (Fig. 3.5.17) the average doubling time 
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for cluster 1 was 100 hours whereas for cluster 2 it was 70 hours (Tables 3.5.12 and 
3.5.13), this indicated that a loss of PTEN resulted in a higher proliferation rate. 
There were 10 gefitinib responders in cluster 2 (Table 3.5.13). P-C-Abl had no effect 
on survival in cluster 1; in cluster 2, 8 out of 15 patients with C-Abl expression had 
less than 20 months survival (Fig. 3.5.19). Overexpression of C-Abl has been found 
in glioblastomas compared to lower grade gliomas, suggesting an association with 
poor survival (Jiang et al. 2006). Higher levels of p-C-Kit expression have been 
associated with lower survival times in high-grade glioma (Sun et al. 2006). P-
p70S6K expression in cluster 2 was found in 5 patients with survival of 10 months 
or less, and 4 patients with less than 20 months survival; it was not associated with 
survival in cluster 1 (Fig. 3.5.21). Higher expression of p70S6K in glioblastoma is 
associated with poor prognosis (Pelloski et al. 2006). P-Akt expression in cluster 1 
was found in 5 patients with less than 12 months survival, and 4 patients who had no 
expression had greater than 19 months survival; with cluster 2, 4 patients with p-Akt 
expression had survival of 10 months or less, and 4 had less than 20 months survival 
(Fig. 3.5.22). The activation of Akt seems to be a consequence of the loss of PTEN 
function (Wu et al. 1998). 
Amplification of the PDGFR-α gene and/or overexpression of the receptor at 
the protein level, has been found in high-grade gliomas (Fleming et al. 1992; 
Kumabe et al. 1992; Smith et al. 2000). Expression and amplification of the 
PDGFR-α gene have also been found in astrocytomas (Guha et al. 1995; Saxena et 
al. 1999). However, PDFGR-α expression did not have any effect on survival time 
in either cluster (Fig. 3.5.16). In addition PTEN also had no effect on survival (Fig. 
3.5.17). 
Unsupervised PCA of the culture data captures 55% of the variance in the 
dataset showing PTEN, PGDFR-α and PGDFR-β loading vectors in approximately 
the same direction (Fig. 3.5.23). All drug responses were separated using PCA based 
on the expression of various target proteins (Fig. 3.5.23). Non-responders and 
responders to erlotinib and gefitinib showed lower expression of PDGFR-α (Fig. 
3.5.24 and 3.5.25); in contrast, higher expression was found in imatinib responders 
(Fig. 3.5.26). The majority of gefitinib responders were influenced by the proteins of 
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the PI3K/Akt pathway (Fig. 3.5.25); while erlotinib response may be characterised 
by lack of expression of those markers (Fig. 3.5.24), suggesting that erlotinib 
responsiveness may not be reliant on the PI3K/Akt pathway.   
 
PI3K/Akt Pathway in High-Grade Glioma 
In high-grade gliomas was examined; other pathways, and downstream proteins 
seem to be involved in glioma tumourigenesis, e.g. RAS/RAF signalling is found in 
gliomas (Jeuken et al. 2007). Copy number gains in the oncogenes BRAF, NRAS, 
KRAS, and HRAS and in growth factors EGF, PDGF, IGF, FGF, TGF have been 
found in 44% and 53% of gliomas, respectively (Jeuken et al. 2007). These copy 
number gains were most frequently found in WHO grade III and IV gliomas; 
phosphorylated MAPK, the activated downstream compound of the RAS/RAF 
pathway, was detected in most cases (Jeuken et al. 2007). Fan et al, found protein 
kinase C (PKC) to be a mediator of EGFR signalling to MTOR independently of 
Akt in glioma, separating MTOR from the Akt-signalling cascade (Fan et al. 2009). 
They used erlotinib to inhibit EGFR signalling, and found a correlation with 
decreased levels of phosphorylated MTOR (p-MTOR) and p70S6K in cells which 
expressed the wild type for PTEN (Fan et al. 2009). EGFR inhibition did not affect 
cells which expressed p-MTOR, p70S6K and mutant PTEN; the amount of p-Akt 
decreased with EGFR inhibition, however, Akt levels did not correlate with MTOR 
signalling (Fan et al. 2009). Activated MTOR correlated with the presence of 
activated Akt, in glioblastoma, MTOR is thought to have a stimulatory effect on 
PI3K/Akt (Choe et al. 2003). They identified an Akt-independent pathway, linking 
EGFR to MTOR which was dependent on PKC (Fan et al. 2009). They showed that 
by blocking or activating Akt there was no effect on proliferation or response to 
erlotinib in glioma, and the levels of EGFR correlated with p-p70S6K and PKC in 
glioblastoma, and but not with Akt (Fan et al. 2009). Furthermore the inhibition of 
PKC decreased the viability of glioma cells independently of EGFR or PTEN 
expression levels (Fan et al. 2009). Perhaps PKC is a more important signalling 
pathway in glioma; PKC inhibitors need to be examined in glioma and may have 
more promising results than PI3K/Akt inhibitors. In relation to TKI responsiveness 
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there is a need to look at all of the different pathways to gain a better understanding 
of cross talk between pathways, and biomarkers for responsiveness to TKIs. 
 
3. 5 Summary and Conclusion  
With 26 high-grade gliomas cultures correlation of expression of proteins from the 
PI3K/Akt pathway, resulted in statistically significant separation of responders and 
non-responders to TKIs. High PDGFR-α and PTEN expression correlated with 
imatinib responders. Higher expression of p-Akt, p-p70S6K, p-C-Abl and p-C-Kit 
was found with gefitinib responders. Possibly indicating that gefitinib responders 
have a more active PI3K/Akt pathway. Erlotinib  responders and non-responders had 
much lower expression of the proteins from the PI3K/Akt pathway. They may be 
more dependent on other pathways for survival, such as the RAS/MAPK or PKC 
pathway.  
There was a correlation with low survival and high EGFR and p-Akt 
expression, this was not surprising as over expression of EGFR and high levels of p-
Akt have been reported to be associated with a poor prognosis in glioma. 
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3.6 MicroRNA  
 
3.6.1 Taqman Low Density Array (TLDA) Analysis of Two Subsets of Primary 
Glioma Cultures 
Within the cohort of primary glioblastoma cultures there were large differences in 
proliferation rate and invasive behaviour. The objective of this part of the project 
was to look for miRNAs that regulate proliferation and invasion in glioblastomas. 
Therefore, two pools were formed: pool 1 consisted of two invasive glioblastoma 
cultures with a high proliferation rate, and pool 2 contained two glioblastoma 
cultures with very little invasion activity and a much lower proliferation rate (Tables 
3.6.1 and 3.6.2). TLDA analysis (section 2.14.1) was carried out on both pools, the 
expression of 365 miRNAs was measured. From the TLDA data miRNA expression 
was compared in pool 1 (fast, invasive) with pool 2 (slow, non-invasive). 
Proliferation rate was previously measured based on the doubling time of the 
cultures (see section 2.4.2); invasion was measured with the 3D spheroid invasion 
assay (see section 2.8). Previously with pool 2 biospheres (tissue pieces) (Fig. 
3.3.10) of N070978 were found to be invasive, however, when the culture of 
N070978 was tested for invasion using the 3D collagen invasion assay it was non-
invasive. Not all biospheres of N060913 were invasive, the cell culture of N060913 
was not tested for invasion as it stopped proliferating. For clarity, pool 2 is referred 
to as non-invasive. 
Pool 1 miRNA expression was designated as 100%. Using a cycle threshold 
(Ct) cut off of 34, out of 365 miRNAs, 82 were upregulated in Pool 2, and 34 were 
downregulated; of which 19 have been reported in the literature to be associated 
with glioma proliferation or invasion (Table 3.6.3). A fold change cut off of 2 or 
greater was then applied, this resulted in 62 miRNAs identified as upregulated in 
pool 2, and 13 downregulated in pool 2 in comparison to pool 1. 
The Ct (section 2.14.2) cut off was 34, therefore anything at 34 or above was 
defined as not expressed or to have very low levels of a miRNA expressed. 13 
miRNAs were undetected or present at very low levels in pool 1 (fast, invasive) in 
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comparison to pool 2 (slow, non-invasive) (Table 3.6.5). 13 miRNAs were 
undetected or present at very low levels in pool 2 in comparison to pool 1 (Table 
3.6.6). 
 
 
Table 3.6.1 TLDA plate with the fast, invasive Pool 1, with 2 invasive primary 
glioblastoma cultures with a fast proliferation rate. 
 
 
 
 
 
 
 
 
Table 3.6.2 TLDA plate with the slow non-invasive Pool 2, with 2 primary 
glioblastoma cultures, one non-invasive, and one slightly-invasive, both with a 
slow proliferation rate. 
Cell 
Culture 
Tumour 
Type 
Doubling 
Time (hrs) 
Invasive 
Behaviour 
 
Patient 
Survival 
Time 
(months) 
Age 
N060978 Primary 
Glioblastoma 
98.33 Non-invasive 
 
3 54 
N060913 Primary 
Glioblastoma 
>168 Poorly-
invasive 
 
110 67 
 
Cell 
Culture 
Tumour 
Type 
Doubling 
Time (hrs) 
Invasive 
Behaviour 
 
Patient 
Survival 
Time 
(months) 
Age 
N070152 Primary 
Glioblastoma 
55 Invasive 
 
5 52 
N070859 Primary 
Glioblastoma 
55.98 Invasive 
 
12 55 
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Table 3.6.3 Deregulated miRNAs identified in primary glioblastomas in the 
present study (in comparison to pool 1) and in other studies. 
MiRNA Our TLDA Analysis Deregulation in 
Glioblastomas 
 
MiR-125b ↑P2 ↑ (Ciafre et al. 2005) 
 
MiR-328 ↑P2 ↓ (Silber et al. 2008) 
 
MiR-31 ↑P2 ↓ (Silber et al. 2008) 
 
MiR-155 ↓P2 ↑ (Silber et al. 2008) 
 
MiR-19a ↓P2 ↑ (Malzkorn et al. 2010) 
 
Mir-146b ↓P2 ↓ (Xia et al. 2009) 
 
MiR-323* ↑P2 ↓ (Silber et al. 2008) 
 
MiR-101* ↑P2 ↓ (Silber et al. 2008) 
 
MiR-181b* ↑P2 ↓ (Ciafre et al. 2005) 
 
MiR-218* ↑P2 ↓ (Godlewski et al. 2008) 
 
MiR-25* ↑P2 ↓ (Ciafre et al. 2005) 
 
MiR-330 ↑P2 ↑ (Gal et al. 2008) 
 
MiR-34a ↑P2 ↓ (Li et al. 2009) 
 
MiR-107 Low P2 ↑ (Gal et al. 2008) 
 
MiR-9 Low P2 ↑ (Malzkorn et al. 2010) 
 
MiR-221* ↓P2 ↑ (Zhang et al. 2009) 
 
MiR-222* ↓P2 ↑ (Zhang et al. 2009) 
 
MiR-296* ↓P2 ↑ (Wurdinger et al. 2008) 
 
MiR-132* ↓P2 ↓ (Silber et al. 2008) 
 
↑: upregulated, ↓: downregulated. *: less than 2 fold dysregulated. P2: Pool 2 (slow, non-
invasive glioblastomas). Low: very low levels detected or undetected. 
 
MiRNAs previously reported in the literature to be associated with invasion or 
proliferation in glioblastoma, also found to be deregulated in the present study. 
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3.6.1.1 MiRNAs Upregulated in Pool 2 in Comparison to Pool 1 
MiR-143 was the most highly upregulated miRNA in pool 2, with a 7.6-fold 
increase in expression in pool 2 in comparison to pool 1. Of the 62 miRNAs that 
were upregulated in pool 2 in comparison to pool 1, 20 of these miRNAs were 
greater than 3 fold upregulated (Fig. 3.6.1); 18 were greater than 2 fold upregulated 
in pool 2 (Fig. 3.6.2).  
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Fig. 3.6.1 20 MiRNAs greater than 3 fold upregulated in pool 2 in comparison to 
pool 1. 
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Table 3.6.4 miRNAs upregulated greater than 3 fold in pool 2 (slow, non-invasive) 
compared to pool 1 (fast, invasive), genes/function/cancer they are associated with. 
miRNA Fold 
Upregulated 
Genes/Function/Cancer associated with  
 
 
miR-143 7.59 ERK5: apoptosis (Akao et al. 2009). DNMT3A: (Ng et al. 2009) 
FNDC3B: invasion/migration & metastasis (Zhang et al. 2009) 
KRAS: growth (Chen et al. 2009). ABL2: C-Abl  
 
miR-99a 5.67 SAMSN1 and USP25:  (Yamada et al. 2008). Downregulated in 
ovarian cancer (Nam et al. 2008) 
 
miR-146a 5.37 BRMS1: invasion, migration and metastasis (Hurst et al. 2009) 
proliferation (Wang et al. 2008). MMPs: migration and invasion (Xia 
et al. 2009) 
 
miR-134 5.36 Developmental in brain (Schratt et al. 2006) 
 
miR-23b 5.31 UPA & C-MET: migration & proliferation (Salvi et al. 2009) 
 
miR-23a 5.14 Apoptosis (Chhabra et al. 2009) 
 
miR-127 4.80 E2F3, NOTCH1, BCL6, ZFHX1B, and BCL2: apoptosis, 
proliferation, cell-to-cell connection (Tryndyak et al. 2009) 
 
miR-485-
3p 
4.65 ? 
 
miR-15a 4.61 Cell cycle arrest (Bandi et al. 2009). Proliferation (Calin et al. 2008)  
 
Let-7c 4.61 Prostate cancer (Ozen et al. 2008) 
 
miR-432 4.50 Muscle development and growth (McDaneld et al. 2009) 
 
miR-382 4.30 ? 
 
miR-411 3.90 ? 
 
miR-145 3.88 TP53: apoptosis (Spizzo et al. 2009) 
 
miR-152 3.79 ? 
 
miR-100 3.42 Oral cancer (Henson et al. 2009) 
 
miR-193a 3.40 Tumour suppressor (Kozaki et al. 2008) 
 
miR-29c 3.39 TP53: (Mraz et al. 2009) 
 
miR-125b 3.15 ErbB2: proliferation and migration (Hofmann et al. 2009)  
 
miR-487b 3.04 ? 
 
?: no information available on this. Genes are highlighted in bold. References are in parenthesis.  
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Fig. 3.6.2 18 miRNAs greater than 2 fold upregulated in pool 2 in comparison to 
pool 1. 
 
3.6.1.2 MiRNAs Downregulated in Pool 2 in Comparison to Pool 1 
13 miRNAs were 2 fold or greater downregulated in pool 2 (slow, non-invasive) in 
comparison to pool 1 (fast, invasive) (Fig. 3.6.3).  
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Fig. 3.6.3 13 miRNAs 2 fold or greater downregulated in pool 2 in comparison to 
pool 1. 
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Table 3.6.5 miRNAs downregulated 2 fold or greater in pool 2 (slow, non-
invasive) compared to pool 1 (fast, invasive), genes/function/cancer they are 
associated with. 
miRNA Fold 
Downregulated 
Genes/Function/Cancer associated with  
 
 
miR-155 3.6 Targets the tumour suppressor genes:TP53INP1 (Yeung 
et al. 2008), FUS1 (Du et al. 2009), 
BCL11B (Karlsson et al. 2007), PTPRD (Veeriah et al. 
2009), (Solomon et al. 2008), 
CDKN1A (Petrocca et al. 2008) 
 
miR-93 4.6 TP53INP1 (Gironella et al. 2007) 
JARID2: cell cycle regulator (Bolisetty et al. 2009) 
 
miR-660 3.1 RAB3GAP2: neurodevelopment (Aligianis et al. 2006) 
 
miR-137 
     2.8 High expression found in lymph node metastasis of 
colorectal cancer (Huang et al. 2009) 
 
miR-345 
     2.5 Targets the tumour suppressor CDKN2A (Guled et al. 
2009) 
 
miR-423 
     2.4 Targets the tumour suppressor CDKN2A (Guled et al. 
2009) 
 
miR-20a 
     2.3 Promotes proliferation and invasion by targeting amyloid 
precursor protein (APP) in ovarian cancer (Fan et al. 
2010) 
 
miR-17-5p 
     2.3 Promotes breast cancer migration and invasion by 
suppression of HBP1 (Li et al. 2010) 
 
miR-106b 
     2.2 Functions as an oncogene by suppressing p21 and BIM 
(Kan et al. 2009) 
 
miR-19a 
     2.2 Involved in the malignant progression in glioma (Malzkorn 
et al. 2010) 
 
miR-197 
     2.1 Regulates the expression of the tumour suppression gene 
FUS1 (Du et al. 2009) 
 
miR-146b 
     2.0 Highly expressed in thyroid carcinoma (Chou et al. 2010) 
 
miR-449b 
     2.0 ? 
 
?: no information available on this. Genes are highlighted in bold. References are in parenthesis.  
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3.6.1.3 MiRNAs Detected in the TLDA as Off or Very Low Levels Detected 
The Ct cut off was 34 and above, therefore the closer the Ct was to 34 the lower the 
level of miRNA detected and the more likely for the miRNA to be off. 13 miRNAs 
were undetected or very low levels (Ct>33) detected in pool 1 (fast, invasive) in 
comparison to pool 2 (slow, non-invasive) (Table 3.6.6). 13 miRNAs were 
undetected or very low levels detected in pool 2 in comparison to pool 1 (Table 
3.6.7).  
 
Table 3.6.6 13 miRNAs off or very low levels detected in Pool 1 (fast, 
invasive) in comparison to Pool 2 (slow, non-invasive), genes/function/cancer 
they are associated with. 
miRNA         Cycle        
    Threshold 
Pool 2, Pool 1  
Genes/Function/Cancer 
associated with 
 
 
     miR-193b 
    33.25, 33.97 UPA: invasion (Li et al. 2009) 
 
     miR-213 
    33.28, 33.97 ? 
 
     miR-302b 
    32.29, 33.97 CYCLIN D2: pluripotency of embryonic 
stem cells (Lee et al. 2008) 
 
     miR-30e-
5p 
    32.94, 34.67 ? 
 
     miR-330 
    31.79, 33.94 E2F1: growth and apoptosis (Lee et al. 
2009) 
 
     miR-433 
    32.40, 33.96 Gastric carcinoma (Luo et al. 2009) 
 
     miR-497 
    33.38, 36.94 Breast cancer (Yan et al. 2008) 
 
     miR-518f 
    31.96, undet ? 
 
     miR-564 
    32.93, 34.02 ? 
 
     miR-646 
    32.96, undet ? 
 
     miR-654 
    32.99, undet ? 
 
     miR-34a 
 
    32.11, 33.96 C-MET and NOTCH: growth (Li et al. 
2009) 
     miR-485-
5p 
    32.49, 33.99 ? 
 
?: no information available on this. Genes are highlighted in bold. References are in  
parenthesis. Undet: undetermined. 
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Table 3.6.7 13 miRNAs off or very low levels detected in Pool 2 (slow, non-
invasive) in comparison to Pool 1 (fast, invasive), genes/function/cancer they are 
associated with. 
miRNA Cycle    
Threshold 
Pool 1, Pool 2 
Genes/Function/Cancer associated with 
 
 
miR-10a 
    29.9, undet HOXB1 and HOXB3: metastasis (Weiss et al. 
2009) 
 
miR-219 
    32.9, undet ? 
 
miR-501 
    32.9, undet ? 
 
miR-107 
    29.3, 35.98 Head and neck cancer (Liu et al. 2009) 
 
miR-589 
    32.9, undet ? 
 
miR-9 
    28.3, 36.01 CBX7: (tumour suppressor) in glioma (Chao et 
al. 2008) 
 
miR-182 
    30.4, 35.95 FOXO3: metastasis (Segura et al. 2009) 
 
miR-18a 
    32.9, 33.99 Hepatocellular carcinoma (Liu et al. 2009) 
 
miR-32 
    32.9, 34.26 PTEN, BCL11B: (tumour suppressor genes)  
 
miR-424 
    32.5, 34.97 BCL2L2: antiapoptotic protein  
 
miR-449 
    31.7, 36.99 ? 
 
miR-532 
    30.7, 33.96 ? 
 
miR-550 
    31.3, 35.97 ? 
 
?: no information available on this. Genes are highlighted in bold. References are in parenthesis. 
Undet: undetermined. 
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3.6.2 Predicted Genes for miRNA Groups 
To date biological experiments have uncovered only a small fraction of all miRNA 
targeted genes (miTGs); therefore computational target prediction remains one of the 
key means to analyze the role of miRNAs in biological processes. 20 miRNAs were 
selected which were the most upregulated in pool 2 in comparison to pool 1 (Fig. 
3.6.1) and a search was performed with this group of miRNAs using the DIANA 
LAB database (http://diana.cslab.ece.ntua.gr/?sec=software) (DNA intelligent 
analysis), which uses an algorithm to predict target genes for a group of miRNAs. 
The top ten genes predicted to be targeted by the 20 miRNAs most upregulated in 
pool 2 in comparison to pool 1 are listed; the target prediction is grouped by mRNA, 
ordered by descending number of expected sites for any of the selected miRNAs 
(Tables 3.6.8 (a) and (b)). In addition the 20 most upregulated miRNAs in pool 1 
were selected (Tables 3.6.9 (a) and (b)), the top ten genes predicted to be targeted by 
this group of miRNAs are listed. 
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Table 3.6.8 (a) Top 10 predicted target genes using the DIANA LAB database 
(http://diana.cslab.ece.ntua.gr/?sec=software) for 20 miRNAs most upregulated in 
pool 2 (slow, non-invasive) in comparison to pool 1 (fast, invasive). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Name Expected 
Number of 
miRNA binding 
sites 
 
ONECUT2 One cut homeobox 2 18.4 
 
 
TNRC6B Trinucleotide repeat 
containing 6B 
16.0 
 
 
SH3TC2 SH3 domain and 
tetratricopeptide 
repeats 2 
15.7 
 
 
 
FLJ25778 Hypothetical protein 
FLJ25778 
12.9 
 
 
IGF1R Insulin-like growth 
factor 1 receptor 
12.4 
 
 
BNC2 Basonuclin 2  zinc 
finger protein 
basonuclin 
12.0 
 
 
 
CC5 Chloride channel 5 
(nephrolithiasis 2, X-
linked 
11.9 
 
 
 
FLJ20309 Hypothetical protein 11.9 
 
ACVR2B Activin A receptor, type 
IIB 
11.5 
 
 
YOD1OTU Deubiquinating enzyme 
1 homolog (S. 
cerevisiae) 
11.2 
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Table 3.6.8 (b) Published information for the top 10 predicted target genes with the 
DIANA LAB database (http://diana.cslab.ece.ntua.gr/?sec=software) for 20 
miRNAs most upregulated in pool 2 (slow, non-invasive) in comparison to pool 1 
(fast, invasive). 
 
? no information available on this. References are in parenthesis. 
Gene Published information 
 
ONECUT2 Methylated in lymphoma (Pike et al. 2008), and lung cancer (Rauch et 
al. 2006) 
 
TNRC6B Associated with aggressive prostate cancer risk (Sun et al. 2009) 
 
SH3TC2 Mutations in this gene result in autosomal recessive Charcot-Marie-
Tooth disease type 4C (Lupo et al. 2009) 
 
FLJ25778 Cell cycle regulator (Balaji et al. 2009) 
 
IGF1R IGF-I modulates proliferation and strongly stimulates migration of 
glioma cell lines in vitro (Schlenska-Lange et al. 2008) 
 
BNC2 ? 
 
CC5 ? 
 
FLJ20309 ? 
 
ACVR2B An activin type 2 receptor. Activins are dimeric growth and 
differentiation factors which belong to the transforming growth factor-
beta (TGF-beta) superfamily of structurally related signaling proteins 
(Ishikawa et al. 1998) 
 
YOD1 OTU ? 
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Table 3.6.9 (a) Top 10 predicted target genes with the DIANA LAB database 
(http://diana.cslab.ece.ntua.gr/?sec=software) for 20 miRNAs most upregulated in 
pool 2 (slow, non-invasive) in comparison to pool 1 (fast, invasive). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene     Name Expected 
Number of  
miRNA binding 
sites 
 
ATXN1 Ataxin 1 11.2 
 
TNRC6B Trinucleotide repeat 
containing 6B 
10.2 
 
 
BNC2 Basonuclin 2 Zinc finger 
protein basonuclin-2 
8.4 
 
 
 
SH3TC2 SH3 domain and 
tetratricopeptide 
repeats 2 
8.2 
 
 
 
KLF12 Kruppel-like factor 12 8.2 
 
 
TCF4 Transcription factor 4 7.7 
 
 
FLJ25778 Hypothetical protein 7.2 
 
AAK1 AP2 associated kinase 
1 
7.1 
 
 
MECP2 Methyl CpG binding 
protein 2 (Rett 
syndrome) 
6.9 
 
 
 
NFIB Nuclear factor I/B 6.5 
 
 254 
Table 3.6.9 (b) Published information for the top 10 predicted target genes with the 
DIANA LAB database (http://diana.cslab.ece.ntua.gr/?sec=software) for 20 
miRNAs most upregulated in pool 1 (fast, invasive) in comparison to pool 2 (slow, 
non-invasive). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            ? no information available on this. References are in parenthesis. 
 
 
 
 
 
Gene Published information 
 
ATXN1 Ataxin-1 mediates neurodegeneration (Tsuda et al. 2005) 
 
TNRC6B Required for miRNA function (Baillat and Shiekhattar 2009) 
 
BNC2 Has the potential to generate nearly 90,000 mRNA isoforms 
encoding over 2000 different proteins (Vanhoutteghem and Djian 
2007). Expressed in glioblastoma, a tumour suppressor gene 
(Nord et al. 2009). 
 
SH3TC2 Mutations in this gene result in autosomal recessive Charcot-
Marie-Tooth disease type 4C, a childhood-onset 
neurodegenerative disease characterized by demyelination of 
motor and sensory neurons (Lupo et al. 2009). 
 
KLF12 Activator protein-2 alpha (AP-2 alpha) is a developmentally-
regulated transcription factor and important regulator of gene 
expression during vertebrate development and carcinogenesis.  
 
TCF4 Associated with the pathogenesis of colorectal cancer (Goel and 
Boland 2010). 
 
FLJ25778 Cell-cycle regulator (Balaji et al. 2009). 
 
AAK1 ? 
 
MECP2 Contributes to apoptosis (Bracaglia et al. 2009).  
 
NFIB ? 
 
 255 
3.6.3 Top Ten miRNA Targets 
From the TLDA data comparing pool 1 (fast, invasive) to pool 2 (slow, non-
invasive) the top ten most interesting miRNA targets were selected (Table 3.6.10). 
In relation to pool 1, 3 miRNAs were chosen that were upregulated and 5 
downregulated, 1 off in pool 1, and 1 off in pool 2 for functional analysis. 
 
 
Table 3.6.10 Top ten most interesting miRNA targets differentially expressed in 
pool 1 (fast, invasive) in comparison to pool 2 (slow, non-invasive) from the TLDA 
analysis. 
* Ct: 31.96, ** Ct: 29.96, Ct: cycle threshold, Off:Ct>34. ↓ downregulated in pool 2, ↑ upregulated 
in pool 2. Genes are highlighted in bold. ? no information available on this. References are in 
parenthesis. 
 
miRNA Comparison Gene targets/ Function 
 
miR-93 3.6 fold ↓  Targets the tumour suppressor genes:TP53INP1 (Yeung et 
al. 2008), FUS1 (Du et al. 2009), BCL11B (Karlsson et al. 
2007), PTPRD (Veeriah et al. 2009), (Solomon et al. 
2008),CDKN1A (Petrocca et al. 2008) 
 
miR-155 4.6 fold ↓ TP53INP1 (Gironella et al. 2007) 
JARID2: cell cycle regulator (Bolisetty et al. 2009) 
miR-660 3.1 fold ↓ RAB3GAP2: neurodevelopment (Aligianis et al. 2006) 
 
miR-143 7.6 fold ↑ ERK5: apoptosis (Akao et al. 2009). DNMT3A: growth (Ng 
et al. 2009) 
FNDC3B: invasion/migration and metastasis (Zhang et al. 
2009) 
KRAS: growth (Chen et al. 2009). ABL2: growth   
 
miR-99a 5.7  fold ↑ SAMSN1 and USP25 (Yamada et al. 2008) 
 
miR-
146a 
 
5.4  fold ↑ BRMS1: metastasis, invasion and migration (Hurst et al. 
2009) 
Growth (Wang et al. 2008). MMPs: glioma migration and 
invasion by (Xia et al. 2009) 
 
miR-134 5.4  fold ↑ Developmental in brain (Coolen and Bally-Cuif 2009) 
 
miR-23b 5.3  fold ↑ UPA and C-MET: migration and proliferation (Salvi et al. 
2009) 
 
miR-518f Off P1 V P2 (*) ? 
 
miR-10a Off P2 V P1 (**) HOXB1 and HOXB3: metastasis (Weiss et al. 2009) 
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3.6.3.1 Expression of miR-155 in Glioma Cultutres and Normal Human 
Astrocytes 
The TLDA result identified that MiR-155 was 4.6 fold upregulated in pool 1 (fast, 
invasive) in comparison to pool 2 (slow, non-invasive). The presence of miR-155 
was measured by qRT-PCR in normal human astrocytes, 5 primary glioblastomas, 1 
grade II astrocytoma II culture, and one established glioblastoma cell line SNB-19 
(Fig. 3.6.4 (a)) (Table 3.6.11). As a calibrator N070152A was used and this was set 
to 100% expression of miR-155. N070152 and N070859 were included in pool 1 
and N060978 and N060913 in pool 2 of the TLDA analysis, which gave 4.6 fold 
downregulation of miR-155 in pool 2 in comparison to pool 1 (Fig. 3.6.4). However, 
N070859 showed downregulation of miR-155 in comparison to N070152, when 
miR-155 was expected to also be upregulated in N070859. In addition high 
expression of miR-155 was found in the normal human astrocytes, and very low 
expression of miR-155 in the established glioblastoma cell line SNB-19; the 
opposite effect was expected as miR-155 was found to be upregulated in the 
invasive pool with high proliferation. 
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         Invasive (blue), Non-invasive/poorly-invasive (green). *: doubling time >168 hrs. 
 
Fig. 3.6.4 (a) MiR-155 expression by qRT-PCR in normal human astrocytes, 5 
primary glioblastomas and 1 grade II astrocytoma II culture and one established 
glioblastoma cell line (SNB-19). N070152A was a calibrator sample taken as 100% 
expression of miR-155. Samples (with the exception of N060913, measured in 
technical triplicate (n=3)) were measured in technical and biological triplicate 
(n=3x3). (b) Doubling time of 3 invasive cultures and 3 cultures with less invasion; 
all of which have been measured for miR-155 expression. Standard deviations were 
generated using Microsoft excel software. 
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Table 3.6.11 Characteristics of primary glioma cultures validated with miR-155. 
    * SNB-19 is an established cell line known to have a fast proliferation rate. 
 
 
 
 
Cell Culture Tumour 
Type 
Doubling 
Time (hrs) 
Invasive 
Behaviour 
 
% Expression of 
miR-155 
 
N070152 Primary 
Glioblastoma 
55 Invasive 98.2 
 
N070859 Primary 
Glioblastoma 
56 Invasive 35.8 
 
N070450 Grade II 
Astrocytoma 
65.1 Invasive 37.8 
 
N060893 Secondary 
Glioblastoma 
88.1 Poorly-invasive 29.6 
 
N060978 Primary 
Glioblastoma 
98.3 Non-invasive 16.6 
 
N060913 Primary 
Glioblastoma 
>168 Poorly-invasive 11.1 
 
SNB-19* Glioblastoma - Invasive 1.7 
 
NHA - - Invasive 127.7 
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3.6.3.2 Expression of miR-93 in Glioma Cultures and Normal Human 
Astrocytes 
MiR-93 was 3.6 fold upregulated in Pool 1 (fast, invasive) compared to Pool 2 
(slow, non-invasive) in the TLDA analysis (Fig. 3.6.5). The presence of miR-93 was 
validated by qRT-PCR in one established glioblastoma cell line SNB-19, 12 glioma 
cultures (8 glioblastomas, 2 grade III astrocytomas, 1 grade III oligoastrocytoma, 1 
grade II oligodendroglioma), and in normal human astrocytes (Table 3.6.12). 
N070152A was used as a calibrator and taken as 100% expression of miR-93. 
N070152 was an invasive primary glioblastoma culture with a high proliferation 
rate, which was included in pool 1 of the TLDA analysis. 3 biological repeats of 
each culture were included with the exception of N060913 and N070314; these 
cultures had very slow proliferation rate and only one RNA sample was obtained 
from them. Cell cultures with high proliferation showed high expression levels of 
miR-93, 3 of the cultures with high miR-93 expression were also invasive (Fig. 3.6.5 
(a)). Conversely miR-93 was down-regulated in cultures with lower proliferation 
and invasion rate, and in normal human astrocytes (Fig. 3.6.5 (a)). N070152 and 
N070859 were included in pool 1, and N060978 and N060913 in pool 2.  
These results indicated that expression of miR-93 positively correlates with 
invasive gliomas with a high proliferation rate. Some of the cultures with high 
expression of miR-93 also had a low doubling time, i.e. a low proliferation rate, and 
some of the cultures with low expression of miR-93 had a high doubling time, i.e. a 
low proliferation rate (Fig. 3.6.5 (b)). Most of the cultures with low expression of 
miR-93 showed little or no invasion (Table 3.6.12).  
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     Invasive (blue), Non-invasive/poorly-invasive (green). *: doubling time >168 hrs. 
 
Fig. 3.6.5 (a) Percentage expression of miR-93 in an established glioblastoma cell 
line SNB-19, normal human astrocytes (NHAs), and glioma cultures, N070152A 
was a calibrator sample taken as 100% expression of miR-93. Most cultures were 
measured in technical and biological triplicate (n=3x3) with the exception of 
N060913 and N070314, which were measured in technical triplicate only (n=3). (b) 
doubling time in glioma cultures. Standard deviations were generated using excel 
software. 
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Table 3.6.12 Doubling time and invasive behaviour of glioma cultures validated for 
miR-93 expression. 
* SNB-19 is an established cell line known to have a fast proliferation rate. 
Cell 
Culture 
Tumour Type Doubling 
Time (hrs) 
Invasive 
Behaviour 
Percentage 
Expression of 
miR-93 
 
 
SNB-19* Primary Glioblastoma -      Invasive 200.9 
 
N070152 Primary Glioblastoma 55.0 Invasive   129.6 
 
N070865 Primary Glioblastoma 37.3 Invasive     98.2 
 
N070859 Primary Glioblastoma 56.0 Invasive     64.9 
 
N070126 Primary Glioblastoma 82.5 Non-invasive   55.6 
 
   NHA - -       Invasive 52 
 
N070055 Grade III 
Oligoastrocytoma 
68.5 Invasive      34.4 
 
N070788 Grade III Astrocytoma 65.7 Non-invasive     32.8 
 
N070201 Grade III Astrocytoma 60.2 Non-invasive     31.0 
 
N060978 Primary Glioblastoma 98.3 Non-invasive     30.6 
 
N060913 Primary Glioblastoma >168 Poorly-invasive     26.3 
 
N070314 Grade II 
Oligodendroglioma 
71.5 -     15.6 
 
N060893 Secondary 
Glioblastoma 
88.1 Poorly -invasive       5.9 
 
N061007 Primary Glioblastoma >168 Poorly -invasive               5.9 
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3.6.3.3 Functional Validation of miR-93: Transfection of anti-miR-93 and pre-
miR-93 into an Established Glioblastoma Cell Line 
The established glioblastoma cell line SNB-19, an invasive cell line with a high 
proliferation rate showed upregulation of miR-93 (Fig. 3.6.5 (a)). SNB-19 was 
transiently transfected with anti-miR-93 and pre-miR-93 to examine the effect on 
proliferation when miR-93 expression was both decreased with anti-miR-93 and 
increased with pre-miR-93. The cells were seeded at 1X10E5/ ml, 1 ml per well in a 
6 well plate for 3 days; with 2 µl of Neofx transfection reagent, and 30 nM of 
miRNA, negative pre-miR, negative anti-miR and siRNA (against kinesin). The 
media was changed 8 hours post- transfection. The cell numbers were then measured 
using the acid phosphatase assay (see section 2.4.1 B). Anti-miR-93 decreased 
proliferation by 13.2%; pre-miR-93 had no effect on proliferation (Fig. 3.6.6).  
 
 
0
20
40
60
80
100
120
% cell survival 100 69.4 100 86.8 100 96.7
Cells 
only Kinesin
Neg Ant-
miR
Anti-miR-
93
Neg Pre-
miR
Pre-miR-
93
 
Fig. 3.6.6 Transient transfection of anti-miR-93 and pre-miR-93 into an established 
glioblastoma cell line SNB-19. 30 nM of miRNA, negative pre-miR, negative anti-
miR and siRNA (against kinesin) with 2 µl of Neofx over a 3 day assay. Standard 
deviations were from 3 biologically individual assays (n=2X3). Standard deviations 
were generated using excel software. 
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3.6.3.4 Protein Targets of miR-93 
We have shown miR-93 to be highly expressed in invasive glioblastomas with high 
proliferation, and low expression of miR-93 in non-invasive glioblastomas with low 
proliferation and in normal human astrocytes (Fig. 3.6.5 (a)).  
Using the database microRNA.org  
(http://www.microrna. org/microrna/home.do) 4 tumour suppressor genes were 
identified which are targets of miR-93, tumour protein 53 inducible nuclear protein 
1 (TP53INP1), B-cell CLL/lymphoma 11B (BCL11B), protein tyrosine phosphatase 
receptor type D (PTPRD), and cyclin-dependent kinase inhibitor 1A (CDKN1A) 
(Table 3.6.13). It was hypothesised that overexpression of miR-93 may decrease the 
expression of these tumour suppressor genes, resulting in increased proliferation and 
invasion in glioma cell cultures. 
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Table 3.6.13 Tumour suppressor genes targets predicted for miR-93 using the 
database microRNA.org (http://www.microrna.org/microrna/home.do). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Name Background Number of 
mRNA target 
sites for 
miR-93 
 
TP53INP1 Tumour protein 53 
inducible nuclear 
protein 1 
Induces G1 arrest and 
increases p53-mediated 
apoptosis in leukaemia 
(Gironella et al. 2007; Yeung 
et al. 2008; Cano et al. 2009). 
4 
 
 
 
 
 
BCL11B B-cell 
CL/lymphoma 11B 
(zinc finger 
protein) 
Bcl11b functions as a tumour 
suppressor in myelogenous 
leukaemia, also found in brain 
tissue (Karlsson et al. 2007). 
4 
 
 
 
 
 
PTPRD Protein tyrosine 
phosphatase, 
receptor type, D 
Tumour suppressor gene 
found in GBM & leukaemia 
(Solomon et al. 2008; Veeriah 
et al. 2009). 
3 
 
 
 
 
CDKN1A Cyclin-dependent 
kinase inhibitor 1A 
(P21 Cip1) 
Impairs TGF beta tumour 
suppressor in gastric cancer 
(Petrocca et al. 2008). 
1 
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Fast (blue), slow (green), normal human astrocytes (violet). Mut: mutated form of BCL11B, WT: 
wild type BCL11B. 
 
Fig. 3.6.7 Expression of BCL11B in glioma cell lines and normal human astrocytes. 
 
The first target gene of miR-93 to be examined in the cultures was BCL11B. 
BCL11B was expressed in 5 out of 8 of the fast glioma cultures tested, the 4 fast 
cultures with the highest expression (lanes 2, 3, 4 and 8) were also invasive, while 
the fast culture with the lowest expression (lane 10) was non-invasive. Whereas 
BCL11B appeared to have lower expression in slower, non-invasive cell cultures 
with 3 out of 5 having expression 1 with high expression (lane 14) and 2 with lower 
expression (lanes 11 and 15) (Fig. 3.6.7). 
 
 
 
1      2        3      4      5      6 7 8        9     10 11    12 13  14 15
Mut
WTβ-actin
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Table 3.6.14 Characteristics of glioma cultures and normal human astrocytes of   
which have been tested for BCL11B expression in figure 3.6.7. 
Lane Sample Origin Doubling 
Time 
(Hours) 
Invasive 
Behaviour 
 
1 Positive control Jurkat nuclear lysate 
(leukaemia cell line) 
- - 
 
 
2 SNB-19* Primary Glioblastoma - Invasive 
 
3 N070152 Primary Glioblastoma 55 Invasive 
 
4 N070865 Primary Glioblastoma 37.3 Invasive 
 
5 N070859 Primary Glioblastoma 56 Invasive 
 
6 N070126 Primary Glioblastoma 82.5 Non-invasive 
 
7 NHA Normal Human Astrocytes - Invasive 
 
8 N070055 Grade III Oligoastrocytoma 
 
68.5 Invasive 
9 N070788 Grade III Astrocytoma 65.7 Non-invasive 
 
10 N070201 Grade III Astrocytoma 60.2 Non-invasive 
 
11 N060978 Primary Glioblastoma 98.3 Non-invasive 
 
12 N060913 Primary Glioblastoma >168 Poorly 
invasive 
 
13 N070314 Grade II Oligodendroglioma 
 
71.5 - 
14 N060893 Primary Glioblastoma 88.1 Non-invasive 
 
15 N061007 Primary Glioblastoma >168 Poorly-
invasive 
 
* SNB-19 is an established cell line known to have a fast proliferation rate. 
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3.6.3.5 Expression of miR-23b in Glioma Cell Cultures and Normal Human 
Astrocytes 
To further examine miR-23b expression in glioma using qRT-PCR we measured the 
expression of miR-23b in 4 glioma cell lines and in normal human astrocytes. 
N070152 and N070859 were the two cultures included in pool 1 of the TLDA 
analysis and N060978 and N060913 were included in pool 2. N070152 and 
N070859 (fast, invasive cultures from pool 1) had much lower expression of miR-
23b in comparison to N060978 and N0600913 (slow, non-invasive cultures from 
pool 2); over twice as much miR-23b was expressed in the slow non-invasive 
cultures. N070152 had lower expression of miR-23b in comparison to the NHAs; 
however N070859 had a similar expression level of miR-23b to that of the NHAs 
(Fig. 3.6.8). 
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NHA: normal human astrocytes (violet), Invasive high proliferation rate (blue), Non-invasive  
low proliferation rate (green). 
 
Fig. 3.6.8 Percentage expression measured by qRT-PCR of miR-23b in glioma 
cultures and normal human astrocytes. N070152A was taken as a calibrator sample 
as 100% expression of miR-23b. Each sample was measured in technical triplicate 
(n=3); in addition N070152 and NHAs were measured biological triplicate (n=3x3), 
N070859 and N060978 in biological duplicate (n=3x2). Standard deviations were 
generated using excel software. 
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3.6.3.6 Functional Validation of miR-23b: Transfection of pre-miR-23b with an 
Established Glioblastoma Cell Line 
MiR-23b was 5.3 fold upregulated in pool 2 (slow, non-invasive) in comparison to 
pool 1 (fast, invasive) of the TLDA analysis. It was thought that by increasing the 
expression of miR-23b in glioma cells this would decrease proliferation. Therefore 
SNB-19 was transiently transfected with pre-miR-23b. Pre-miR-23b decreased 
proliferation by 30% (Fig. 3.6.9). The cells were seeded at 1X10E5/ ml, 1 ml per 
well, in a 6 well plate for 3 days with 2 µl of lipofectamine 2000 transfection 
reagent. 50 nM of miRNA, negative pre-miR, negative and siRNA (against kinesin) 
was used. The media was changed 8 hours post-transfection. The cell number was 
then measured using the acid phosphatase assay (see section 2.4.1 B). It was decided 
to examine if the effect on proliferation with pre-miR-23b could be further 
increased, therefore the assay length was increased to 5 days; the concentration of 
the cells was decreased to 2X10E4/ ml so that the control would not become 
confluent, proliferation was decreased by 40% compared to the negative pre-miR 
control (Fig. 3.6.10). 
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Fig. 3.6.9 Transient transfection of SNB-19 with pre-miR-23b in comparison to the 
negative pre-miR control, with 2 µl of lipofectamine 2000. 50 nM of miRNA, 
negative pre-miR or siRNA (against kinesin) were used. Standard deviations were of 
three biologically individual assays (n=2x3). Standard deviations were generated 
using excel software. 
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Fig. 3.6.10 Transient transfection of SNB-19 with pre-miR-23b in comparison to the 
negative pre-miR control, with 2 µl of lipofectamine. 50 nM of miRNA, negative 
pre-miR and siRNA (against kinesin) were used. Standard deviations were of two 
biologically individual assays (n=2x2). Standard deviations were generated using 
excel software. 
 
3.6.3.7 Expression of miR-23b in SNB-19 Cells Post Transfection 
After transient transfection of the glioma cell line SNB-19 with pre-miR-23b RNA 
was extracted from the cells to measure the amount of miR-23b in the cells post-
transfection (see section 2.14.3). miR-23b expression was analysed by qRT-PCR. 
There was much higher levels (over twice as much) of miR-23b in the cells 
transfected with pre-miR-23b in comparison to the control cells and the cells 
transfected with the negative pre-miR (Fig. 3.6.11).  
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Fig. 3.6.11 Expression of miR-23b by qRT-PCR in SNB-19, post transfection with 
pre-miR-23b. Negative pre-miR was used as a control. Each sample was measured 
in technical triplicate (n=2). Standard deviations were generated using excel 
software.
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3.6.3.8 Gene Targets of miR-23b 
By increasing expression of miR-23b in the glioma cell line SNB-19 strong 
inhibition of proliferation was found. It was decided to look for target genes of miR-
23b using 3 different databases, TargetScan (http://www.targetscan.org/), 
MicroRNA.org (http://www.microrna.org/) and DIANA LAB 
 (http://diana.cslab.ece.ntua.gr/). In addition the literature was checked for 
information on these genes to find the most likely candidates. The genes chosen 
were associated with a malignant phenotype, i.e. miR-23b inhibition of the gene 
would be advantageous to glioma progression. The selection was also based on the 
best alignment of the miR-23b sequence with the target gene, and the most mRNA 
sites. In total 15 strong potential target genes were found for miR-23b, and 7 were 
chosen for further examination (Tables 3.6.15 - 3.6.17). Using the website 
(http://blast.ncbi.nlm.nih.gov/ ) primers were designed for the following genes 
SEMaphorin 6D (SEMA6D), X-linked Inhibitor of Apoptosis (XIAP), SMAD 
family member 5 (SMAD5), Mitogen-Activated Protein Kinase Kinase Kinase 
Kinase 4 (MAP4K4), B-cell CLL/Lymphoma 2 (BCL2), MNNG (N-Methyl-N'-
nitro-N-nitroso-guanidine) HOS Tranforming gene (MET), and Platelet Derived 
Growth Factor Alpha (PDGFA) (see Table 2.14.12). The expression of these 7 genes 
was examined by qRT-PCR in SNB-19 cells which had been transfected with pre-
miR-23b. A small bit of genomic DNA carried over from the RNA extraction, which 
resulted in PCR product in the negative control (no enzyme included in the RT 
reaction). This made it difficult to determine the difference between significant PCR 
product and product derived from genomic DNA (Fig. 3.6.12-3.6.25). However with 
XIAP there was a large difference between PCR product cycle number and genomic 
DNA cycle number for us to clearly identify product (Fig. 3.6.14). There was a 
65.3% knockdown of XIAP after transfecting SNB-19 with pre-miR-23b (Fig. 
3.6.15). The PCR amplicons were ran out on a 2.5% agarose gel to check for primer-
dimers (PD); none were found (Fig. 3.6.26).  
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Table 3.6.15 Potential target genes found for miR-23b using the Target Scan 
database (http://www.targetscan.org/). 
 
 
 
? no information available on this. References are in parenthesis.  
Number of 
conserved 
mRNA 
sites  
Gene 
 
Function Publications 
 
 
 
3 SEMA6D Regulates proliferation and invasion. (Toyofuku et al. 
2004; Kinsella et al. 
2011) 
 
2 RAB39B RAS oncogene family 
involved in early pathogenetic events 
of neoplastic germ cell formation. 
(Biermann et al. 
2007) 
 
 
2 MAP4K4 Expression associated with worse 
prognosis in pancreatic cancer. 
Associated with lymph node 
metastasis in colorectal cancer. 
Overexpressed in pancreatic cancer. 
Promigratory kinase in ovarian 
cancer. 
Upregulated in glioma. 
(Liang et al. 2008) 
 
(Hao et al. 2010) 
 
(Badea et al. 2008) 
(Collins et al. 2006) 
 
(Ramnarain et al. 
2006) 
 
2 XIAP Inhibits apoptosis. 
 
Expressed in glioma. 
(Dubrez-Daloz et al. 
2008) 
(Wagenknecht et al. 
1999) 
 
1 MAP3K9 May play a role in esophageal cancer. (Chen et al. 2008) 
 
 
1 TGFA Transforming growth factor alpha. 
Upregulated in glioma. 
(Ramnarain et al. 
2006) 
 
 
 
1 PDGFA Overexpressed in glioma increases 
proliferation. 
(Martinho et al. 
2009) 
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Table 3.6.16 Potential target genes found for miR-23b using the MicroRNA.org  
database (http://www.microrna.org/microrna/home.do). 
? no information available on this. References are in parenthesis. 
Number 
of 
conserve
d mRNA 
sites 
Gene 
 
Function Publications 
 
 
 
 
3 SMAD5 TGFbeta-stimulated Smad1/5 
phosphorylation mediates the pro-
migratory TGFbeta switch in 
mammary epithelial cells (breast 
cancer) 
Increased expression in HCC 
(Liu et al. 2009) 
 
 
 
 
(Zimonjic et al. 2003) 
 
3 XIAP/BIR
C4 
Inhibits apoptosis 
 
Expressed in glioma 
(Dubrez-Daloz et al. 
2008) 
(Wagenknecht et al. 
1999) 
 
2 MAP3K7I
P3 
? ? 
 
2 MET Regulates migration and 
proliferation 
(Salvi et al. 2009) 
 
 
2 MAP4K4 Expression associated with worse 
prognosis in pancreatic cancer. 
Associated with lymph node 
metastasis in colorectal cancer. 
Overexpressed in pancreatic 
cancer. 
Promigratory kinase in ovarian 
cancer. 
(Liang et al. 2008) 
(Hao et al. 2010) 
 
 
(Badea et al. 2008) 
 
(Collins et al. 2006) 
 
 
2 BCL2 Causes brain tumours resistance 
to chemotherapy. 
Increases proliferation in glioma. 
(Tyagi et al. 2002) 
 
(Roth et al. 2000) 
 
2 SEMA6D Regulates proliferation and 
invasion. 
(Toyofuku et al. 2004) 
 
1 TGFA Transforming growth factor alpha 
Upregulated in glioma. 
(Ramnarain et al. 2006) 
 
1 PDGFA Overexpressed in glioma increase 
proliferation. 
(Martinho et al. 2009) 
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Table 3.6.17 Potential target genes found for miR-23b using the DIANA LAB 
database (http://diana.cslab.ece.ntua.gr/?sec=software).  
MiTG score Gene 
 
Function Publications 
 
 
19.7 SEMA6D Regulates proliferation and invasion. (Toyofuku et al. 
2004) 
 
19 XIAP/BIRC4 Inhibits apoptosis. 
Expressed in glioma. 
(Dubrez-Daloz et al. 
2008) 
(Wagenknecht et al. 
1999) 
 
16.7 MAP3K1 ? ? 
 
11.9 MYCT1 c-myc overexpressed in cancer. (Dang 2010) 
 
11.4 MAP3K7IP3 ? ? 
 
10.4 BCL2 Makes brain tumours resistant to 
chemotherapy. 
Increases proliferation in glioma. 
(Tyagi et al. 2002) 
 
(Roth et al. 2000) 
 
10.3 TGFBR3 ? ? 
 
9.2 SMAD5 TGFbeta-stimulated Smad1/5 
phosphorylation mediates the pro-
migratory TGFbeta switch in 
mammary epithelial cells (breast 
cancer). 
Increased expression in HCC. 
(Liu et al. 2009) 
 
 
 
 
(Zimonjic et al. 2003) 
 
9 MET Regulates migration and 
proliferation. 
(Salvi et al. 2009) 
 
8.8 MAP4K3 ? ? 
 
? no information available on this. References are in parenthesis. 
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Fig. 3.6.12 Cycle numbers of the expression of SEMA6D measured by qRT-PCR in 
SNB-19 cells (RT+) and in the negative RT control (RT-). Each sample was 
measured in triplicate (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6.13 Expression of SEMA6D measured by qRT-PCR in SNB-19 cells 
transfected with pre-miR-23b. Negative pre-miR was used as a control; each sample 
was measured in technical triplicate (n=3). Standard deviations were generated with 
SDS applied biosystem. 
Negative Pre-miR Pre-miR-23b
RT +
RT -
Baseline Noise 
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Fig. 3.6.14 Cycle numbers of the expression of XIAP measured by qRT-PCR in 
SNB-19 cells (RT+) and in the negative RT control (RT-). Each sample was 
measured in technical triplicate (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6.15 Expression of XIAP measured by qRT-PCR in SNB-19 cells transfected 
with pre-miR-23b. Negative pre-miR was used as a control; each sample was 
measured in technical triplicate (n=3). Standard deviations were generated with SDS 
applied biosystem software. 
 
Neg-pre-miR Pre-miR-23b
RT +
RT -
Baseline Noise 
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Fig. 3.6.16 Cycle numbers of the expression of SMAD5 measured by qRT-PCR in 
SNB-19 cells (RT+) and in the negative RT control (RT-). Each sample was 
measured in technical triplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6.17 Expression of SMAD5 measured by qRT-PCR in SNB-19 cells 
transfected with pre-miR-23b. Negative pre-miR was used as a control; each sample 
was measured in technical triplicate (n=3). Standard deviations were generated with 
SDS applied biosystem software. 
 
Neg-pre-miR Pre-miR-23b
RT +
RT -
Baseline Noise 
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Fig. 3.6.18 Cycle numbers of the expression of MAP4K4 measured by qRT-PCR in 
SNB-19 cells (RT+) and in the negative RT control (RT-). Each sample was 
measured in technical triplicate (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6.19 Expression of MAP4K4 measured by qRT-PCR in SNB-19 cells 
transfected with pre-miR-23b. Negative pre-miR was used as a control; each sample 
was measured in technical triplicate (n=3). Standard deviations were generated with 
SDS applied biosystem software. 
 
Neg-pre-miR Pre-miR-23b
RT +
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Baseline Noise 
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Fig. 3.6.20 Cycle numbers of the expression of BCL2 measured by qRT-PCR in 
SNB-19 cells (RT+) and in the negative RT control (RT-). Each sample was 
measured in technical triplicate (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6.21 Expression of BCL2 measured by qRT-PCR in SNB-19 cells transfected 
with pre-miR-23b. Negative pre-miR was used as a control, each samples was 
measured in technical triplicate (n=3). Standard deviations were generated with SDS 
applied biosystem software. 
 
Neg-pre-miR Pre-miR-23b
RT +
RT -
Baseline Noise 
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Fig. 3.6.22 Cycle numbers of the expression of MET measured by qRT-PCR in 
SNB-19 cells (RT+) and in the negative RT control (RT-). Each sample was 
measured in technical triplicate (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6.23 Expression of MET measured by qRT-PCR in SNB-19 cells transfected 
with pre-miR-23b. Negative pre-miR was used as a control; each sample was 
measured in technical triplicate (n=3). Standard deviations were generated with SDS 
applied biosystem software. 
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Fig. 3.6.24 Cycle numbers of the expression of PDGFA measured by qRT-PCR in 
SNB-19 cells (RT+) and in the negative RT control (RT-). Each sample was 
measured in technical triplicate (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6.25 Expression of PDGFA measured by qRT-PCR in SNB-19 cells 
transfected with pre-miR-23b. Negative pre-miR was used as a control, each 
samples was measured in technical triplicate (n=3). Standard deviations were 
generated with SDS applied biosystem software. 
 
Neg-pre-miR Pre-miR-23b
RT +
RT -
Baseline Noise 
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Fig. 3.6.26 PCR amplicons run on a 2.5% agarose gel. First lane contains marker. 
Lane 1-4 of each gene has (1) control (cells only), (2) negative pre-miR, (3) pre-
miR-23b, (4) negative control for RT reaction (no enzyme). Where there is no band 
present in lane 4 there was very little DNA contamination during the RNA 
extraction. 
SEMAD6 SMAD5 MAP4K4XIAP
BCL2 MET PDGFA β-actin
200bp
100bp
200bp
100bp
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3.6.3.9 Effect of miR-93 and miR-23b on Invasion Activity of Glioma 
MiR-93 had higher expression in fast, invasive glioma cultures. The effect of anti-
miR-93 was tested on the invasion activity of the established glioma cell line SNB-
19 after they had been transfected with anti-miR-93 (see section 2.14.3), to see if by 
decreasing the expression of miR-93 we could also decrease invasion. There was no 
decrease in invasion activity in cells transfected with anti-miR-93 in comparison to 
the negative anti-miR control. The transfection reagent, lipofectamine had a strong 
inhibitory effect on invasion (Fig. 3.6.27). We also looked at the effect of pre-miR-
23b on invasion activity (see section 2.9) of SNB-19; to see if by increasing the 
amount of miR-23b in the cells would decrease invasion. It did not appear that miR-
23b had any specific effect on invasion; however the cells were very sensitive to the 
negative pre-miR control which had a strong inhibitory effect on invasion (Fig. 
3.6.28). 
 
        
0
50
100
150
200
%
 
Ce
ll 
In
v
as
io
n
Series1 128.0 100.0 95.1 58.9
Cells only Negative Ant-
miR Anti-miR-93 Lipofectamine 
 
Fig. 3.6.27 Invasion of SNB-19 post transfection with anti-miR-93. 3 biologically 
individual assays were carried out (n=2x3). Standard deviations were generated 
using excel software. 
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Fig. 3.6.28 Invasion of SNB-19 post transfection with pre-miR-23b. 3 biologically 
individual assays were carried out (n=2x3). Standard deviations were generated 
using excel software. 
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3.6 Discussion  
 
MiRNA Expression in Gliomas  
 
Introduction 
As miRNAs control important processes such as differentiation, cell growth and cell 
death, they hold great promise for targeted cancer therapy. MiRNAs are small non-
coding regulatory RNA fragments of 20-22 nucleotides. 721 human miRNAs have 
been identified and thought to regulate at least 30% of genes (Lewis et al. 2005). 
They bind mRNA through partial homology and can potentially regulate the 
expression of multiple targets, most of which are still largely unknown. MiRNAs are 
thought to act as master regulators, which orchestrate networks of gene signalling. 
Every type of analysed tumour has shown significantly different miRNA profiles in 
comparison to normal cells from the same tissue. 
Several miRNAs have already been reported to regulate glioma proliferation 
and invasion. Knockdown of miR-221/222 has reduced growth and invasion in 
glioma cells due to downregulation of the anti-apoptotic gene BCL2 and the 
upregulation of negative regulators of the cell cycle including connexin43, p27, p57, 
PUMA, caspase-3, PTEN, TIPM3 and Bax (Gillies and Lorimer 2007; Medina et al. 
2008; Zhang et al. 2009; Zhang et al. 2009). Mir-21 also plays a key role in glioma 
and other cancers as an anti-apoptotic factor (Chan et al. 2005; Chen et al. 2008; 
Ohno et al. 2009). MiR-181a and miR-181b act as tumour suppressors in glioma 
leading to growth inhibition, apoptosis and invasion inhibition (Shi et al. 2008). 
Very little is known about miRNA interactions with cellular pathways in 
brain tumours; however, some miRNAs have been shown to be directly involved in 
pathway regulation in glioma. MiRNAs have been associated with the Notch 
pathway, which plays key roles in nervous system development and in brain 
tumours (Kefas et al. 2009). A neuronally expressed miRNA, miR-326 was 
upregulated following Notch-1 knockdown, and was not only suppressed by Notch 
but also inhibited Notch proteins and activity, indicating a feedback loop (Kefas et 
al. 2009). Transfection of miR-326 into both established and stem cell-like glioma 
lines and in vivo in a xenograft model was cytotoxic, and rescue was obtained with 
 285 
Notch restoration (Kefas et al. 2009). MiR-326 partially mediated the toxic effects 
of Notch knockdown (Kefas et al. 2009). MiR-34a is a transcriptional target of p53, 
and is down-regulated in some cancer cell lines (Li et al. 2009). Transfection of 
miR-34a down-regulated c-Met in human glioma and medulloblastoma cells and 
Notch-1, Notch-2, and CDK6 protein expressions in glioma and stem cells, and 
strongly inhibited in vivo glioma xenograft growth (Li et al. 2009). MiR-34a in 
glioma and medulloblastoma cell lines strongly inhibited cell proliferation, cell 
cycle progression, survival, and invasion (Li et al. 2009). MiR-34a suppresses brain 
tumour growth by targeting c-Met and Notch in glioma cells and stem cells (Li et al. 
2009).  
MiR-21 is an important oncogene that targets a network of p53, TGF-beta, 
and tumour suppressor genes in glioblastoma cells (Zhu et al. 2007; 
Papagiannakopoulos et al. 2008). Type I interferons (IFNs) are involved in double-
stranded RNA responses. IFN-beta treatment reduced miR-21 expression in glioma 
cells, and IFN-beta suppressed the growth of glioma-initiating cell-derived 
intracranial tumours; downregulation of miR-21 contributes to the antitumor effects 
of IFN-beta and miR-21 expression is negatively regulated by STAT3 activation 
(Ohno et al. 2009), it also inhibits the EGFR pathway independently of PTEN status 
(Zhou et al.). 
The most common genetic alterations found in glioblastoma include EGFR 
activation and AKT pathways (Wong et al. 1987; Haas-Kogan et al. 1998). In 
glioblastoma cells, transfection of miR-7 decreased the level of EGFR and upstream 
regulators of the AKT pathway, insulin receptor substrate 1 (IRS1) and insulin 
receptor substrate 2 (IRS2); these cells had increased apoptosis and reduced invasion 
(Kefas et al. 2008). This would suggest that miR-7 regulates the EGFR and AKT 
pathways. MiR-7 is a potential tumour suppressor in glioblastoma targeting critical 
cancer pathways. MiR-7 decreased viability and invasiveness of primary 
glioblastoma lines and is a regulator of major cancer pathways suggesting that it has 
therapeutic potential for glioblastoma (Kefas et al. 2008). 
MiR-26a is a direct regulator of PTEN expression and is frequently 
amplified in human glioma, most often in association with monoallelic PTEN loss 
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(Huse et al. 2009). MiR-26a-mediated PTEN repression in a murine glioma model 
both enhances de novo tumour formation and precludes loss of heterozygosity and 
the PTEN locus (Huse et al. 2009). 
 
TLDA Screening of MiRNAs in Glioma 
The expression of 365 miRNAs in 2 sets of primary glioblastomas was screened by 
TLDA, one set contained 2 primary invasive glioblastoma cultures with a high 
proliferation rate (pool 1) (Table 3.6.1), and one contained 2 non-invasive 
glioblastomas with a low proliferation rate (pool 2) (Table 3.6.2). The most extreme 
characteristics were chosen from the newly developed glioma cultures, i.e. the most 
invasive with the highest proliferation rate, and the least invasive with the lowest 
proliferation rate. It is thought that glioma cells favour one phenotype, that is they 
are either highly invasive or highly proliferative, known as the go or grow 
hypothesis, however some of the glioma samples in the present study had both high 
proliferation and were also invasive. There was no significant correlation between 
invasion and proliferation within the cohort of glioma cultures, i.e. a highly invasive 
culture was not necessarily a slow proliferating one, and a low amount of invasion 
did not always correlate with a fast proliferating culture. These characteristics may 
have been determined by the section of the tumour that the biopsy sample was 
removed from, i.e. a highly invasive section which would have resulted in an 
invasive cell population, or a highly proliferative section which would have given a 
highly proliferative population, as brain tumours contain a very heterogeneous 
population, and each section of a tumour has been shown to have specific functions 
(Deisboeck et al. 2001; Huang et al. 2008). It is possible that the glioblastoma 
cultures in pool 1 contained cells from a highly invasive area as well as cells from a 
highly proliferative area of the tumour, and the cultures in pool 2 may have 
contained cells from a low invasive and low proliferative areas. 
From the TLDA data it was found that 62 miRNAs were upregulated in pool 
2 (Fig. 3.6.1 and 3.6.2) (Table 3.6.4), and 13 were downregulated in pool 2 in 
comparison to pool 1 (Fig 3.6.3) (Table 3.6.5). 13 miRNAs were also found to be off 
 287 
or have very low levels of detection in pool 1 in comparison to pool 2 (Table 3.6.6), 
and 13 in pool 2 in comparison to pool 1 (Table 3.6.7). 
Godlewski et al, identified MiRNA-451 as a conditional switch controlling glioma 
cell proliferation and migration (Godlewski et al. 2010). MiR-451 levels were 
regulated by glucose, with abundant energy miR-451 expression is high (Godlewski 
et al. 2010). MiR-451 suppresses AMP-activated protein kinase (AMPK) signalling, 
which leads to high proliferation rates in cells with continual MTOR activation 
(Godlewski et al. 2010). With low amounts of glucose present, miR-451 
downregulation is necessary for AMPK pathway activation, leading to suppressed 
proliferation rates, increased cell survival, and migration (Godlewski et al. 2010). 
This is known as the “go or grow hypothesis” (Hatzikirou et al. 2010), it is possible 
that miR-451 levels are lower in pool 2 cell lines and this could explain their low 
proliferation rate. 
Silber et al, looked at 192 human miRNAs in anaplastic astrocytomas and 
primary glioblastomas, from human tissue samples in comparison to normal brain 
tissue, and found 4 upregulated and 25 miRNAs downregulated in glioma (Silber et 
al. 2008). They found that transfection of miR-124 or miR-137 induced G1 cell 
cycle arrest in glioblastoma cells, which was associated with decreased expression 
of cyclin-dependent kinase 6 and phosphorylated retinoblastoma (pSer 807/811) 
proteins (Silber et al. 2008). Ciafre et al, examined the expression of 245 miRNAs 
in glioblastoma tissue and cell lines in comparison to normal brain by microarray, 
and found 9 upregulated and 4 downregulated miRNAs (Ciafre et al. 2005). They 
found miR-221 to be strongly upregulated in glioblastoma, and miR-128, miR-181a, 
miR-181b, and miR-181c were downregulated (Ciafre et al. 2005). Godlewski et al, 
looked at miRNA expression with a microarray using glioblastoma tissue in 
comparison to normal brain and found 8 upregulated and 11 downregulated 
miRNAs (Godlewski et al. 2008). They found that miR-128 targeted the Bmi-1 
oncogene/stem cell renewal factor and inhibited glioma proliferation and self 
renewal (Godlewski et al. 2008). 19 of the miRNAs dysregulated in our study have 
been reported in the literature to be associated with glioma proliferation or invasion 
(Table 3.6.3). A high number of miRNAs were upregulated in pool 2, i.e. 
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downregulated in pool 1 the fast, invasive phenotype. Most of the miRNA profiling 
studies on glioblastomas have focused on comparing normal brain with 
glioblastomas; however the present study differs in that it related fast, invasive 
glioblastomas to slow, non-invasive glioblastomas and examined the deregulation of 
miRNAs between these phenotypes. To our knowledge this type of study has not 
been carried out before. 
MiR-143 was the highest upregulated miRNA in pool 2 in comparison to 
pool 1 (over 7 fold) (Fig. 3.6.1) (Table 3.6.4). Ng et al, found overexpression of 
miR-143 is significant in suppressing colorectal cancer cell growth through 
inhibition of translation of the oncogene KRAS (Chen et al. 2009), and DNA 
methyltranferase 3A (Ng et al. 2009). Clape et al, have shown that increased 
expression of miR-143 in prostate cancer inhibited cell proliferation this was partly 
due to the inhibition of extracellular signal-regulated kinase-5 (ERK5) activity 
(Clape et al. 2009). The expression of miR-143 has also been shown to suppress 
growth and induce apoptosis in leukaemia (Akao et al. 2009) and B-cell lymphoma 
(Akao et al. 2007). Unfortunately, no effect was seen on proliferation with miR-143 
in a transient transfection, however miR-143 is known to cluster with miR-145 
(Parmacek 2009), therefore it may be necessary for these 2 miRNAs to function at 
the same time (i.e. to transfect both miR-143 and miR-145 at the same time); miR-
145 was also upregulated in pool 2 (3.8 fold) (Table 3.6.4). 
 
Predicted Genes for miRNA Groups from TLDA Analysis 
Based on the hypothesis that groups of differentially expressed miRNAs may 
regulate the same genes the algorithm from the DIANA LAB database was applied 
(http://diana.cslab.ece.ntua.gr/?sec=software), to identify potential genes targeted by 
the 20 most upregulated miRNAs in Pool 1 and in Pool 2. With Pool 1 the top 2 
targeted genes were ataxin 1 (ATXN1) and trinucleotide repeat containing 6B 
(TNRC6B) (Table 3.6.8). Tsuda et al, found that ATXN1 mediates 
neurodegeneration through its interaction with Gfi-1/Senseless proteins (Tsuda et al. 
2005), Crespo-Barreto et al, found that partial loss of ATXN1 function contributes 
to the pathogenesis of Spinocerebellar ataxia type 1 (SCA1), an inherited 
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neurodegenerative disease caused by expansion of a CAG repeat that encodes a 
polyglutamine tract in ATXN1 (Crespo-Barreto et al. 2010). Sun et al, found that 
TNRC6B is associated with aggressive prostate cancer, Balliat et al, discovered that 
a single nucleotide polymorphism at 22q13 located within the TNRC6B gene has 
been associated with prostate cancer risk  (Sun et al. 2009); TNRC6B is required for 
miRNA-mediated mRNA degradation function (Baillat and Shiekhattar 2009). With 
Pool 2 the top 2 targeted genes were one cut homeobox 2 (ONECUT2) and again 
TNRC6B (Table 3.6.9); Pike et al, found ONECUT2 to be methylated in lymphoma 
(Pike et al. 2008) and Rauch et al, found it methylated in lung cancer (Rauch et al. 
2006) and it may also play a role in glioma. TNRC6B appears to be targeted by both 
pools and could possibly be significant in regulating miRNA function in glioma.  
 
miR-155 Expression in Glioma 
From the TLDA analysis miR-155 was found to be downregulated in slow, non-
invasive glioblastomas in comparison to fast, invasive glioblastomas (Fig. 3.6.3) 
(Table 3.6.5). High expression of miR-155 was found in the normal human 
astrocytes, and low expression in the established glioblastoma cell line SNB-19; 1 
primary glioblastoma (N070152) had high expression of miR-155 and all of the 
other cell lines had low expression of miR-155 (Fig. 3.6.4) (Table 3.6.11). It was 
expected that miR-155 would have had high expression in all fast, invasive cultures; 
this was not the case as the highest expression was found in NHAs. As there were 2 
pooled cell cultures in the fast, invasive pool, and miR-155 expression in N070152 
was more than twice that of N070859, this diluted out the low miR-155 expression 
in N070859.  
With high miR-155 expression in NHA’s, and 1 out of 4 fast, invasive 
glioma cultures, it was decided that miR-155 would not be an ideal miRNA target to 
follow up in fast, invasive glioblastomas. Yeung et al, showed miR-155 binds to the 
mRNA of TP53INP1, which regulates P53 activity, a known tumour suppressor 
gene which functions in glioma (Yeung et al. 2008), and may be over-expressed in a 
number of glioblastomas with low P53 activity, but not in all glioblastomas.  
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miR-93 Expression in Glioma 
From the TLDA analysis miR-93 was found to be 3.6 fold downregulated in slow, 
non-invasive glioblastomas in comparison to fast, invasive glioblastomas (Fig. 
3.6.3) (Table 3.6.5). The expression of miR-93 was validated by qRT-PCR in one 
established glioblastoma cell line SNB-19, 12 glioma cultures including 8 primary 
glioblastomas, 1 secondary glioblastoma, 1 grade III oligoastrocytoma and 1 grade 
II oligodendroglioma, and in NHAs (Fig. 3.6.5) (Table 3.6.12). As expected miR-93 
was upregulated in all 3 fast, proliferating and invasive cultures and was 
downregulated in all non-invasive, slow proliferating cultures as well as in NHAs 
(Fig. 3.6.5). This indicated that miR-93 might play an important role in regulating 
invasion and proliferation in gliomas. Yeung et al, have also shown that miR-93 
binds to the mRNA of TP53INP1, which regulates P53 activity (Yeung et al. 2008), 
and may also be over-expressed in a number of glioblastomas with low P53 activity.  
 
Functional Validation of miR-93 in an Established Glioblastoma Cell Line 
As miR-93 was found to be overexpressed in fast invasive glioma cells by qRT-
PCR, the functional effect of miR-93 was then examined in an established 
glioblastoma cell line SNB-19. SNB-19 was transiently transfected with anti-miR-
93, and a 13.2% decrease in proliferation was found (Fig. 3.6.6). The effect of anti-
miR-93 on invasion activity needs to be examined in SNB-19. 
It was hypothesized that the overexpression of miR-93 in fast proliferating 
invasive glioma cells results in a downregulation of TP53INP1, and an increase in 
proliferation. TP53INP1 regulates P53 activity; a tumour suppressor gene which 
functions in glioma. Increased miR-93 expression would lead to downregulation of 
P53 and increased proliferation. Using the microRNA.org database 
(http://www.microrna.org/microrna/home.do) 4 tumour suppressor genes were 
identified which are potential targets of miR-93: tumour protein 53 inducible nuclear 
protein 1 (TP53INP1), B-cell CLL/lymphoma 11B (BCL11B), protein tyrosine 
phosphatase receptor type D (PTPRD), and cyclin-dependent kinase inhibitor 1A 
(CDKN1A) (Table 3.6.13). Yeung et al, found that knockdown the expression of 
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both miR-93 and miR-130b resulted in enhanced TP53INP1 expression causing 
apoptosis in leukaemia (Yeung et al. 2008). Cano et al, have shown that TP53INP1 
induces p53-driven oxidative stress response, that possesses both a p53-independent 
intracellular reactive oxygen species regulatory function, and a p53-dependent 
transcription regulatory function (Cano et al. 2009). Gironella et al, found 
dramatically reduced expression of TP53INP1 in pancreatic cancer (Gironella et al. 
2007). Karlsson et al, found BCL11B to be a tumour suppressor in leukaemia 
(Karlsson et al. 2007); and Veeriah et al, and Solomon et al, also found PTPRD to 
function as a tumour suppressor gene in leukaemia (Solomon et al. 2008; Veeriah et 
al. 2009). Petrocca et al, showed that CDKN1A acts as a tumour suppressor in 
gastric cancer by inhibiting TGF beta (Petrocca et al. 2008).  
The expression of BCL11B, a target of miR-93 was examined by western 
blot. It was found that BCL11B was expressed in all cultures tested. 5 out of 8 of the 
fast glioblastoma cultures had high expression of BCL11B. 1 out of 4 slow cultures 
had high expression of BCL11B (Fig. 3.6.7) (Table 3.6.14). Higher expression of 
miR-93 in fast, invasive glioma cultures correlates with higher expression of 
BCL11B (Fig. 3.6.5). Inhibition of this tumour suppressor gene favours glioma 
progression. Western blot analysis of the other tumour suppressor genes, including 
TP53INP1, CDKN1A, and PTPRD would confirm if these genes are expressed in 
the cultures. It would be interesting to analyse the expression of all 4 tumour 
suppressor genes after SNB-19 cells had been transfected with anti-miR-93, to see if 
the expression of these genes is increased when miR-93 expression is decreased. 
 
Functional Validation of miR-23b in an Established Glioblastoma Cell Line 
From the TLDA analysis miR-23b was found to be 5.3 fold upregulated in pool 2 
(slow, non-invasive), that is it was downregulated in pool 1 (fast, invasive) (Fig. 
3.6.1) (Table 3.6.4). The expression of miR-23b was also examined by qRT-PCR in 
4 glioma cell cultures, 2 of which were included in pool 1 (fast, invasive) of the 
TLDA analysis, and 2 which were in pool 2 (slow, non-invasive); in addition the 
expression of miR-23b was examined in NHAs. Twice as much miR-23b was 
expressed in pool 2 cultures as in pool 1 cultures. The pool 1 cultures had a similar 
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expression level of miR-23b to that of the NHAs (Fig. 3.6.8). It was previously 
shown that NHAs are invasive. 
By increasing the expression of miR-23b in a transient transfection assay 
pre-miR-23b decreased proliferation by 30% in a glioma cell line over 3 days, and 
by up to 40% in a 5 day assay. This is a strong inhibition of proliferation for one 
miRNA with a transient transfection over a short period of time. The expression of 
miR-23b was examined by qRT-PCR in SNB-19 cells post transfection with pre-
miR-23b, this confirmed very high levels of miR-23b in the cells in comparison to 
the non-transfected parental cell line. This confirmed the inhibition of proliferation 
was due to the increase in the amount of miR-23b transfected into the cells.  
As such a strong effect was observed the next step included finding target 
genes of miR-23b using 3 different databases, TargetScan (http://www.targetscan. 
org/), MicroRNA.org (http://www.microrna.org/microrna/home.do) and DIANA 
LAB (http://diana.cslab.ece.ntua.gr/?sec=software). These databases predict 
thousands of potential gene targets for each individual miRNA, and although they 
predict target genes based on target sequence conservation homology and/or with 
miRNAs, there is no guarantee that these genes are in fact targets of these miRNAs.  
In addition the literature was examined for information on these genes, particularly 
information which supported the malignant glioma phenotype i.e. invasion and 
proliferation; by increasing miR-23b expression and downregulating the target gene 
that would be advantageous to glioma progression. The selection was based on the 
best alignment and the most potential mRNA sites of the miR-23b sequence within 
the target gene. The list was comprised of 15 potential target genes for miR-23b, and 
7 genes were chosen for further examination.  
Using the website http://blast.ncbi.nlm.nih.gov/Blast.cgi primers were 
designed for the 7 genes: semaphorin 6D (SEMA6D), X-linked inhibitor of 
apoptosis (XIAP), SMAD family member 5 (SMAD5), mitogen-activated protein 
kinase kinase kinase kinase 4 (MAP4K4), B-cell lymphoma 2 (BCL2), met proto-
oncogene (hepatocyte growth factor receptor) (MET), and platelet-derived growth 
factor subunit A (PDGFA) (Table 3.8.15). Toyofuku et al, have shown SEMAD6 to 
be involved in cardiac morphogenesis, and to have a migration-promoting activity 
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on outgrowing cells of cardiac explants (Toyofuku et al. 2004). XIAP is known to 
inhibit apoptosis in many cancer types (Dubrez-Daloz et al. 2008). Liu et al, have 
found that SMAD5 mediates the pro-migratory TGF-beta switch in breast cancer 
mammary epithelial cells (Liu et al. 2009), Zimonjic et al, found increased 
expression of SMAD5 in human hepatocellular carcinoma (Zimonjic et al. 2003). 
Liang et al, and Badae et al, found MAP4K4 expression to be associated with poor 
prognosis in pancreatic cancer (Badea et al. 2008; Liang et al. 2008). Hao et al, 
found MAP4K4 to be associated with metastasis in colorectal cancer (Hao et al. 
2010). BCL2 is an anti-apoptotic gene, Tygai et al, found that BCL2 was involved 
in brain tumour resistance to chemotherapy (Tyagi et al. 2002), and Roth et al, 
showed that overexpression of BCL2 increased proliferation in glioma (Roth et al. 
2000). Salvi et al, found that overexpression of miR-23b led to decreased migration 
and proliferation abilities of human hepatocellular carcinoma cells (Salvi et al. 
2009). 
QRT-PCR was then carried out for each of the 7 target genes in SNB-19 
cells which had been transfected with pre-miR-23b. Due to a small amount of 
genomic DNA contamination during the RNA extraction, it was only possible to 
measure the PCR product from MAP4K4 and XIAP, as there was sufficient 
separation of the cycle threshold number from amplicons generated from RNA and 
that of the genomic DNA.  
The PCR amplicons were resolved on a 2.5% agarose gel to check for 
additional bands including primer-dimers (PD), there were none present. A PD is a 
potential by-product in PCR, it consists of primer molecules that have attached to 
each other due to strings of complementary bases in the primers. No bands were 
expected in lane 4 for each gene (RT negative control), which was the case with 
XIAP, SMAD5, MAP4K4, and MET; however bands derived from genomic DNA 
were present in the gel for BCL2, PDGFA and B-actin, which were not as strong as 
lanes 1 to 3, but the band in lane 4 for SEMAD6 was strong. The presence of a band 
in lane 4 indicated the presence of genomic DNA in our PCR reaction. However 
with the exception of SEMAD6 the fourth band was either absent or fainter than the 
other bands, confirming that sufficient amplicons were amplified specifically for the 
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target genes. To prevent DNA contamination the extracted RNA could have been 
treated with DNase (an enzyme which digests DNA) to remove any DNA carried 
over in the RNA extraction. 
 QRT-PCR showed that a 65.3% knockdown of XIAP was achieved with 
overexpression of miR-23b in the glioma cell line SNB-19. This was a very strong 
inhibitory effect with a single miRNA. The ability of cancer cells to resist apoptosis 
is crucial for development, progression, and treatment resistance. XIAP is the most 
potent member of the inhibitor of apoptosis (IAP) family (Deveraux and Reed 
1999). XIAP is a direct inhibitor of cell death proteases, it directly inhibits caspase-3 
and 7; these caspases are highly conserved throughout the animal kingdom 
(Deveraux et al. 1997). These have a protective effect against irradiation and anti-
cancer drugs (LaCasse et al. 1998). Shi et al, have shown miR-21 to also target 
caspase-3 in addition to targeting caspase-9 in glioma, leading to cell growth 
suppression and invasion reduction (Shi et al. 2008). XIAP could potentially play a 
very significant role in glioma progression. As the present study has shown miR-23b 
to be decreased in invasive glioblastoma with a high proliferation rate, it is possible 
that a decrease of miR-23b expression in glioblastomas and subsequent unregulated 
expression of XIAP, has led to the ability of glioblastomas to evade apoptosis, 
which has possibly contributed to resistance and malignant progression in 
glioblastoma.  
 Future work will include the confirmation by western blot, of decreased 
protein levels of XIAP in SNB-19 cells overexpressing miR-23b. Further 
confirmation of XIAP as a target gene for miR-23b would include cloning of 3 
stably transfected plasmids (Fig. 4.12.3) each containing an XIAP 3’UTR with one 
of the 3 potential binding sites for miR-23b (Fig. 4.12.2), downstream of a reporter 
gene e.g. luciferase or GFP; this could then be transfected into glioblastoma cells 
with pre-miR negative and pre-miR-23b. MiR-23b would then bind to the 3’ UTR of 
the XIAP gene, and downregulate the gene. Binding of miR-23b would reduce 
luciferase expression levels if XIAP is a specific target of miR-23b in glioma cells. 
This would confirm XIAP as a target of miR-23b, and also determine the exact 
binding site of miR-23b on the XIAP gene. 
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 It would also be interesting to check the presence of miR-23b in the lower 
grade tumours, as it has only been examined in the higher grade tumours. This 
would indicate if miR-23b is associated with malignant progression in glioma.  
 
58 -  aucacauugccagggauuacc - 78 
 
         (http://mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000439) 
 
Fig 4.12.1 Mature sequence of hsa-miR-23b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            (www.microrna.org)  
Fig. 4.12.2 Three predicted binding sites of miR-23b in the coding sequence for the 
XIAP gene. 
3' ccAUU--AGGGACC---GUUACACUa 5' hsa-miR-23b
| | |    | :  :  :  | | |       | | |  |  |  |  | | 
999:5' guUAACCUUUUUGGUGCCAAUGUGAa 3' XIAP 
3' ccauuagggaccGUUACACUa 5' hsa-miR-23b
:  | |  | |  |  | | 
3102:   5' agugaguguauaUAAUGUGAu 3' XIAP 
3' ccauuagggaccGUUACACUa 5' hsa-miR-23b
|  | |  | |  |  | | 
4634:5' auacaguuaacaCAAUGUGAa 3' XIAP 
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CMV: cytomegalovirus. XIAP: X-linked inhibitor of apoptosis 3’UTR: 3 prime  
untranslated region. 
 
Fig. 4.12.3 Plasmid containing XIAP 3’UTR, and the reporter gene luciferase. 
 
Effect of miR-93 and miR-23b on Invasion Activity of Glioma 
The effect of anti-miR-93 was examined on the invasion activity of SNB-19 to see if 
by decreasing the expression of miR-93 that this could also decrease invasion. No 
effect on invasion was found (Fig. 3.8.27). Increasing the expression of miR-23b 
with pre-miR-23b to try to decrease invasion in SNB-19 had no effect (Fig. 3.8.28). 
Unfortunately the cell line SNB-19 was sensitive to the transfection reagent 
lipofectamine 2000; this alone had a strong inhibitory effect on invasion. In addition 
the negative control for pre-miR had an even stronger inhibitory effect on invasion; 
this made it difficult to accurately measure invasion activity when SNB-19 was 
transfected with miR-93 and miR-23b. However, as miR-93 and miR-23b have 
previously been shown to directly inhibit proliferation it is possible they may also 
inhibit invasion, as it has been discussed that glioma cells can switch from a 
proliferative to an invasive state and vice versa depending on environmental 
influences. Unfortunately it was not possible to measure invasion with SNB-19 post 
transfection with the reagent lipofectamine 2000. It may have damaged the 
membrane of the cells irreversibly and prevented invasion activity. Other methods of 
transfection need to be examined that leave the cell membrane intact, such as 
different transfection reagents or sonication. 
CMV Luciferase XIAP 3’UTR
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3.6 Summary and Conclusion  
 
miRNA Expression in Gliomas 
(1) From the TLDA analysis 62 miRNAs were upregulated in non-invasive 
glioblastomas with slow proliferation and 13 were downregulated in 
comparison to invasive glioblastomas with fast proliferation.  
(2) MiR-155 was 4.6 fold downregulated in slow, non-invasive glioblastomas; 
however, its expression did not correlate with a fast invasive phenotype. 
(3) MiR-93 was 3.59 fold downregulated in slow, non-invasive glioblastomas in 
comparison to fast invasive glioblastomas. MiR-93 overexpression 
correlated with high proliferation and invasiveness in 12 glioma cultures, 1 
established cell line, and in normal human astrocytes. Anti-miR-93 
downregulated proliferation by 13.2 % in an established glioblastoma cell 
line, SNB-19. MiR-93 plays a role in proliferation in gliomas.  
(4) High expression of the tumour suppressor gene BCL11B, in fast invasive 
glioma cultures correlated with high expression of miR-93, suggesting that 
miR-93 targets BCL11B. 
(5) MiR-23b was 5.3 fold upregulated in slow, non-invasive glioblastomas. 
Overexpression of miR-23b resulted in a 30% decrease of proliferation over 
3 days, and 40% over 5 days. Twice as much miR-23b expression was found 
in the slow, non-invasive glioblastoma pool in comparison to the fast, 
invasive glioblastoma pool. Overexpression of miR-23b resulted in a 65% 
knockdown at mRNA level of XIAP, the most potent human inhibitor of 
apoptosis, which is responsible for resistance to treatment in a variety of 
cancer types. Therefore, miR-23b might be a promising candidate for the 
development of new targeted treatment options.  
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4.1 The Effect of Imatinib and Docetaxel on Glioma 
(1) It is possible that this study identified a mutated form of BCR-Abl in the 
established glioma cell line SNB-19, which accounts for the resistance of this 
cell line to imatinib. This mutated protein should be analysed further by mass 
spectrometry. In addition, it would be interesting to screen the newly developed 
glioma cultures for this mutation.  
(2) The strongly synergistic effect of the combination of imatinib and docetaxel 
shown in glioma cells should be validated in the newly developed primary 
cultures.  
 
4.2 Temozolomide Resistant Cell Line SNB-19 
The temozolomide resistant cell line SNB-19-Tmz, developed in this study should 
be further characterized with regard to its proliferation and invasion behaviour and 
its expression profile of the glial marker GFAP, and the stem cell markers nestin and 
CD133. It would also be interesting to examine the MGMT and the P53 status, as 
both are playing a role in drug resistance. By searching for possible mutations or 
deletions in proteins of the PI3K/Akt pathway it would enable us to explore another 
mechanism of resistance in this temozolomide resistant cell line. 
  
4.3 Response of Glioma Cell Lines to Tyrosine Kinases  
(1) As the response to TKIs with the glioma cultures was not correlated with specific 
targets of the TKIs, it would be interesting to look at single nucleotide 
polymorphism (SNP) analysis in each culture to identify mutations indicative of 
responders or non-responders to TKIs.  
(2) The expression of targets involved in the PI3K/Akt pathway was examined in 
relation to responders and non-responders to TKIs. By examining other 
pathways, which might be involved in glioma tumourigenesis, such as the PKC, 
and MAPK pathways, this would give a better idea of glioma dependency on 
such pathways. 
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4.4 MiRNA 
(1) Validation of other miRNAs identified in the TLDA analysis in all newly 
developed glioma cultures and the NHAs, to identify additional miRNAs   
involved in the regulation of proliferation and invasion in glioma.  
 
(2) Western blot analysis of XIAP in SNB-19 cells post transfection with pre- miR- 
23b, to measure the amount of protein knockdown with miR-23b. 
 
(3) Investigation of the phenotypical effect resulting from miRNA-23b   
overexpression by using a stable transfection system. By cloning a plasmid 
containing the XIAP 3’UTR containing binding sites for miR-23b, and a 
luciferase reporter gene into glioma cells, this would allow us to identify if XIAP 
is a specific target of miR-23b. 
 301 
 
 
 
 
 
 
 
 
 
 
 
Section 5.0 References 
 302 
 
 
 
ABTA. American Brain tumour Association, 2009 American Brain tumour 
Association. 
NCRI. National cancer registry Ireland, © National Cancer Registry, 2006. 
Abouantoun, T. J. and T. J. Macdonald (2009). "Imatinib blocks migration and 
invasion of medulloblastoma cells by concurrently inhibiting activation of 
platelet-derived growth factor receptor and transactivation of epidermal 
growth factor receptor." Mol Cancer Ther 8(5): 1137-47. 
Abrams, T. J., L. J. Murray, E. Pesenti, V. W. Holway, T. Colombo, L. B. Lee, J. M. 
Cherrington and N. K. Pryer (2003). "Preclinical evaluation of the tyrosine 
kinase inhibitor SU11248 as a single agent and in combination with 
"standard of care" therapeutic agents for the treatment of breast cancer." Mol 
Cancer Ther 2(10): 1011-21. 
Adams, V. R. and M. Leggas (2007). "Sunitinib malate for the treatment of 
metastatic renal cell carcinoma and gastrointestinal stromal tumors." Clin 
Ther 29(7): 1338-53. 
Adnane, J., P. Gaudray, C. A. Dionne, G. Crumley, M. Jaye, J. Schlessinger, P. 
Jeanteur, D. Birnbaum and C. Theillet (1991). "BEK and FLG, two receptors 
to members of the FGF family, are amplified in subsets of human breast 
cancers." Oncogene 6(4): 659-63. 
Agarwal, S., R. Sane, J. L. Gallardo, J. R. Ohlfest and W. F. Elmquist (2010). 
"Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) 
and breast cancer resistance protein (ABCG2)-mediated active efflux." J 
Pharmacol Exp Ther 334(1): 147-55. 
Akao, Y., Y. Nakagawa, A. Iio and T. Naoe (2009). "Role of microRNA-143 in Fas-
mediated apoptosis in human T-cell leukemia Jurkat cells." Leuk Res 33(11): 
1530-8. 
Akao, Y., Y. Nakagawa, Y. Kitade, T. Kinoshita and T. Naoe (2007). 
"Downregulation of microRNAs-143 and -145 in B-cell malignancies." 
Cancer Sci 98(12): 1914-20. 
Akbar, U., T. Jones, J. Winestone, M. Michael, A. Shukla, Y. Sun and C. Duntsch 
(2009). "Delivery of temozolomide to the tumor bed via biodegradable gel 
matrices in a novel model of intracranial glioma with resection." J 
Neurooncol 94(2): 203-12. 
Albini, A., I. Paglieri, G. Orengo, S. Carlone, M. G. Aluigi, R. DeMarchi, C. 
Matteucci, A. Mantovani, F. Carozzi, S. Donini and R. Benelli (1997). "The 
beta-core fragment of human chorionic gonadotrophin inhibits growth of 
Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma 
cell line." Aids 11(6): 713-21. 
Alessi, D. R., F. B. Caudwell, M. Andjelkovic, B. A. Hemmings and P. Cohen 
(1996). "Molecular basis for the substrate specificity of protein kinase B; 
comparison with MAPKAP kinase-1 and p70 S6 kinase." FEBS Lett 399(3): 
333-8. 
 303 
Ali, I. U., L. M. Schriml and M. Dean (1999). "Mutational spectra of 
PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity." J 
Natl Cancer Inst 91(22): 1922-32. 
Aligianis, I. A., N. V. Morgan, M. Mione, C. A. Johnson, E. Rosser, R. C. 
Hennekam, G. Adams, R. C. Trembath, D. T. Pilz, N. Stoodley, A. T. Moore, 
S. Wilson and E. R. Maher (2006). "Mutation in Rab3 GTPase-activating 
protein (RAB3GAP) noncatalytic subunit in a kindred with Martsolf 
syndrome." Am J Hum Genet 78(4): 702-7. 
Allikmets, R., L. M. Schriml, A. Hutchinson, V. Romano-Spica and M. Dean 
(1998). "A human placenta-specific ATP-binding cassette gene (ABCP) on 
chromosome 4q22 that is involved in multidrug resistance." Cancer Res 
58(23): 5337-9. 
Amberger, V. R., V. Avellana-Adalid, T. Hensel, A. Baron-van Evercooren and M. 
E. Schwab (1997). "Oligodendrocyte-type 2 astrocyte progenitors use a 
metalloendoprotease to spread and migrate on CNS myelin." Eur J Neurosci 
9(1): 151-62. 
Ambion www.ambion.com. 
Annovazzi, L., M. Mellai, V. Caldera, G. Valente, L. Tessitore and D. Schiffer 
(2009). "mTOR, S6 and AKT expression in relation to proliferation and 
apoptosis/autophagy in glioma." Anticancer Res 29(8): 3087-94. 
Aoki, H., Y. Takada, S. Kondo, R. Sawaya, B. B. Aggarwal and Y. Kondo (2007). 
"Evidence that curcumin suppresses the growth of malignant gliomas in vitro 
and in vivo through induction of autophagy: role of Akt and extracellular 
signal-regulated kinase signaling pathways." Mol Pharmacol 72(1): 29-39. 
Aoki, M., K. Nabeshima, K. Koga, M. Hamasaki, J. Suzumiya, K. Tamura and H. 
Iwasaki (2007). "Imatinib mesylate inhibits cell invasion of malignant 
peripheral nerve sheath tumor induced by platelet-derived growth factor-
BB." Lab Invest 87(8): 767-79. 
Auger, N., J. Thillet, K. Wanherdrick, A. Idbaih, M. E. Legrier, B. Dutrillaux, M. 
Sanson and M. F. Poupon (2006). "Genetic alterations associated with 
acquired temozolomide resistance in SNB-19, a human glioma cell line." 
Mol Cancer Ther 5(9): 2182-92. 
Badea, L., V. Herlea, S. O. Dima, T. Dumitrascu and I. Popescu (2008). "Combined 
gene expression analysis of whole-tissue and microdissected pancreatic 
ductal adenocarcinoma identifies genes specifically overexpressed in tumor 
epithelia." Hepatogastroenterology 55(88): 2016-27. 
Baehrecke, E. H. (2003). "miRNAs: micro managers of programmed cell death." 
Curr Biol 13(12): R473-5. 
Baillat, D. and R. Shiekhattar (2009). "Functional dissection of the human TNRC6 
(GW182-related) family of proteins." Mol Cell Biol 29(15): 4144-55. 
Balaji, S., L. M. Iyer and L. Aravind (2009). "HPC2 and ubinuclein define a novel 
family of histone chaperones conserved throughout eukaryotes." Mol Biosyst 
5(3): 269-75. 
Bandi, N., S. Zbinden, M. Gugger, M. Arnold, V. Kocher, L. Hasan, A. Kappeler, T. 
Brunner and E. Vassella (2009). "miR-15a and miR-16 are implicated in cell 
 304 
cycle regulation in a Rb-dependent manner and are frequently deleted or 
down-regulated in non-small cell lung cancer." Cancer Res 69(13): 5553-9. 
Bao, S., Q. Wu, R. E. McLendon, Y. Hao, Q. Shi, A. B. Hjelmeland, M. W. 
Dewhirst, D. D. Bigner and J. N. Rich (2006). "Glioma stem cells promote 
radioresistance by preferential activation of the DNA damage response." 
Nature 444(7120): 756-60. 
Bartolovic, K., S. Balabanov, U. Hartmann, M. Komor, A. M. Boehmler, H. J. 
Buhring, R. Mohle, D. Hoelzer, L. Kanz, W. K. Hofmann and T. H. 
Brummendorf (2004). "Inhibitory effect of imatinib on normal progenitor 
cells in vitro." Blood 103(2): 523-9. 
Bauer, G. (2000). "Reactive oxygen and nitrogen species: efficient, selective, and 
interactive signals during intercellular induction of apoptosis." Anticancer 
Res 20(6B): 4115-39. 
Baumann, N. and D. Pham-Dinh (2001). "Biology of oligodendrocyte and myelin in 
the mammalian central nervous system." Physiol Rev 81(2): 871-927. 
Benbest www.benbest.com/nutrceut/AntiOxidants.html. 
Bianco, R., I. Shin, C. A. Ritter, F. M. Yakes, A. Basso, N. Rosen, J. Tsurutani, P. 
A. Dennis, G. B. Mills and C. L. Arteaga (2003). "Loss of 
PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the 
antitumor action of EGFR tyrosine kinase inhibitors." Oncogene 22(18): 
2812-22. 
Biermann, K., L. C. Heukamp, K. Steger, H. Zhou, F. E. Franke, I. Guetgemann, V. 
Sonnack, R. Brehm, J. Berg, P. J. Bastian, S. C. Muller, L. Wang-Eckert, H. 
Schorle and R. Buttner (2007). "Gene expression profiling identifies new 
biological markers of neoplastic germ cells." Anticancer Res 27(5A): 3091-
100. 
Bihorel, S., G. Camenisch, M. Lemaire and J. M. Scherrmann (2007). "Influence of 
breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the 
transport of imatinib mesylate (Gleevec) across the mouse blood-brain 
barrier." J Neurochem 102(6): 1749-57. 
Bihorel, S., G. Camenisch, M. Lemaire and J. M. Scherrmann (2007). "Modulation 
of the brain distribution of imatinib and its metabolites in mice by valspodar, 
zosuquidar and elacridar." Pharm Res 24(9): 1720-8. 
Bissery, M. C., G. Nohynek, G. J. Sanderink and F. Lavelle (1995). "Docetaxel 
(Taxotere): a review of preclinical and clinical experience. Part I: Preclinical 
experience." Anticancer Drugs 6(3): 339-55, 363-8. 
Blom, T., H. Fox, A. Angers-Loustau, K. Peltonen, L. Kerosuo, K. Wartiovaara, M. 
Linja, O. A. Janne, P. Kovanen, H. Haapasalo and N. N. Nupponen (2008). 
"KIT overexpression induces proliferation in astrocytes in an imatinib-
responsive manner and associates with proliferation index in gliomas." Int J 
Cancer 123(4): 793-800. 
Boddy, A. V., J. Sludden, M. J. Griffin, C. Garner, J. Kendrick, P. Mistry, C. 
Dutreix, D. R. Newell and S. G. O'Brien (2007). "Pharmacokinetic 
investigation of imatinib using accelerator mass spectrometry in patients with 
chronic myeloid leukemia." Clin Cancer Res 13(14): 4164-9. 
 305 
Bohler, T., J. Waiser, H. Hepburn, J. Gaedeke, C. Lehmann, P. Hambach, K. Budde 
and H. H. Neumayer (2000). "TNF-alpha and IL-1alpha induce apoptosis in 
subconfluent rat mesangial cells. Evidence for the involvement of hydrogen 
peroxide and lipid peroxidation as second messengers." Cytokine 12(7): 986-
91. 
Bolisetty, M. T., G. Dy, W. Tam and K. L. Beemon (2009). "Reticuloendotheliosis 
virus strain T induces miR-155, which targets JARID2 and promotes cell 
survival." J Virol 83(23): 12009-17. 
Bracaglia, G., B. Conca, A. Bergo, L. Rusconi, Z. Zhou, M. E. Greenberg, N. 
Landsberger, S. Soddu and C. Kilstrup-Nielsen (2009). "Methyl-CpG-
binding protein 2 is phosphorylated by homeodomain-interacting protein 
kinase 2 and contributes to apoptosis." EMBO Rep 10(12): 1327-33. 
Brennan, C., H. Momota, D. Hambardzumyan, T. Ozawa, A. Tandon, A. Pedraza 
and E. Holland (2009). "Glioblastoma subclasses can be defined by activity 
among signal transduction pathways and associated genomic alterations." 
PLoS One 4(11): e7752. 
Bronger, H., J. Konig, K. Kopplow, H. H. Steiner, R. Ahmadi, C. Herold-Mende, D. 
Keppler and A. T. Nies (2005). "ABCC drug efflux pumps and organic anion 
uptake transporters in human gliomas and the blood-tumor barrier." Cancer 
Res 65(24): 11419-28. 
Broniscer, A., J. C. Panetta, M. O'Shaughnessy, C. Fraga, F. Bai, M. J. Krasin, A. 
Gajjar and C. F. Stewart (2007). "Plasma and cerebrospinal fluid 
pharmacokinetics of erlotinib and its active metabolite OSI-420." Clin 
Cancer Res 13(5): 1511-5. 
Brunner, T. B., S. M. Hahn, A. K. Gupta, R. J. Muschel, W. G. McKenna and E. J. 
Bernhard (2003). "Farnesyltransferase inhibitors: an overview of the results 
of preclinical and clinical investigations." Cancer Res 63(18): 5656-68. 
Burris, H. A., 3rd, S. Fields and N. Peacock (1995). "Docetaxel (Taxotere) in 
combination: a step forward." Semin Oncol 22(6 Suppl 13): 35-40. 
Cai, X. M., B. B. Tao, L. Y. Wang, Y. L. Liang, J. W. Jin, Y. Yang, Y. L. Hu and X. 
L. Zha (2005). "Protein phosphatase activity of PTEN inhibited the invasion 
of glioma cells with epidermal growth factor receptor mutation type III 
expression." Int J Cancer 117(6): 905-12. 
Calatozzolo, C., M. Gelati, E. Ciusani, F. L. Sciacca, B. Pollo, L. Cajola, C. Marras, 
A. Silvani, L. Vitellaro-Zuccarello, D. Croci, A. Boiardi and A. Salmaggi 
(2005). "Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 
and GST-pi in human glioma." J Neurooncol 74(2): 113-21. 
Calin, G. A., A. Cimmino, M. Fabbri, M. Ferracin, S. E. Wojcik, M. Shimizu, C. 
Taccioli, N. Zanesi, R. Garzon, R. I. Aqeilan, H. Alder, S. Volinia, L. 
Rassenti, X. Liu, C. G. Liu, T. J. Kipps, M. Negrini and C. M. Croce (2008). 
"MiR-15a and miR-16-1 cluster functions in human leukemia." Proc Natl 
Acad Sci U S A 105(13): 5166-71. 
Cano, C. E., J. Gommeaux, S. Pietri, M. Culcasi, S. Garcia, M. Seux, S. Barelier, S. 
Vasseur, R. P. Spoto, M. J. Pebusque, N. J. Dusetti, J. L. Iovanna and A. 
Carrier (2009). "Tumor protein 53-induced nuclear protein 1 is a major 
mediator of p53 antioxidant function." Cancer Res 69(1): 219-26. 
 306 
Cappuzzo, F., E. Magrini, G. L. Ceresoli, S. Bartolini, E. Rossi, V. Ludovini, V. 
Gregorc, C. Ligorio, A. Cancellieri, S. Damiani, A. Spreafico, C. T. Paties, 
L. Lombardo, C. Calandri, G. Bellezza, M. Tonato and L. Crino (2004). "Akt 
phosphorylation and gefitinib efficacy in patients with advanced non-small-
cell lung cancer." J Natl Cancer Inst 96(15): 1133-41. 
Cau, J. and A. Hall (2005). "Cdc42 controls the polarity of the actin and microtubule 
cytoskeletons through two distinct signal transduction pathways." J Cell Sci 
118(Pt 12): 2579-87. 
Cemeus, C., T. T. Zhao, G. M. Barrett, I. A. Lorimer and J. Dimitroulakos (2008). 
"Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of 
EGFRvIII and PTEN status." J Neurooncol 90(1): 9-17. 
Chamberlain, M. C. (2006). "Treatment options for glioblastoma." Neurosurg Focus 
20(4): E2. 
Chan, J. A., A. M. Krichevsky and K. S. Kosik (2005). "MicroRNA-21 is an 
antiapoptotic factor in human glioblastoma cells." Cancer Res 65(14): 6029-
33. 
Chao, T. F., Y. Zhang, X. Q. Yan, B. Yin, Y. H. Gong, J. G. Yuan, B. Q. Qiang and 
X. Z. Peng (2008). "[MiR-9 regulates the expression of CBX7 in human 
glioma]." Zhongguo Yi Xue Ke Xue Yuan Xue Bao 30(3): 268-74. 
Chemblink www.chemblink.com. 
Chen, J., L. Guo, D. A. Peiffer, L. Zhou, O. T. Chan, M. Bibikova, E. Wickham-
Garcia, S. H. Lu, Q. Zhan, J. Wang-Rodriguez, W. Jiang and J. B. Fan 
(2008). "Genomic profiling of 766 cancer-related genes in archived 
esophageal normal and carcinoma tissues." Int J Cancer 122(10): 2249-54. 
Chen, M. Y., R. R. Lonser, P. F. Morrison, L. S. Governale and E. H. Oldfield 
(1999). "Variables affecting convection-enhanced delivery to the striatum: a 
systematic examination of rate of infusion, cannula size, infusate 
concentration, and tissue-cannula sealing time." J Neurosurg 90(2): 315-20. 
Chen, X., X. Guo, H. Zhang, Y. Xiang, J. Chen, Y. Yin, X. Cai, K. Wang, G. Wang, 
Y. Ba, L. Zhu, J. Wang, R. Yang, Y. Zhang, Z. Ren, K. Zen, J. Zhang and C. 
Y. Zhang (2009). "Role of miR-143 targeting KRAS in colorectal 
tumorigenesis." Oncogene 28(10): 1385-92. 
Chen, Y., W. Liu, T. Chao, Y. Zhang, X. Yan, Y. Gong, B. Qiang, J. Yuan, M. Sun 
and X. Peng (2008). "MicroRNA-21 down-regulates the expression of tumor 
suppressor PDCD4 in human glioblastoma cell T98G." Cancer Lett 272(2): 
197-205. 
Chhabra, R., Y. K. Adlakha, M. Hariharan, V. Scaria and N. Saini (2009). 
"Upregulation of miR-23a approximately 27a approximately 24-2 cluster 
induces caspase-dependent and -independent apoptosis in human embryonic 
kidney cells." PLoS One 4(6): e5848. 
Choe, G., S. Horvath, T. F. Cloughesy, K. Crosby, D. Seligson, A. Palotie, L. Inge, 
B. L. Smith, C. L. Sawyers and P. S. Mischel (2003). "Analysis of the 
phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in 
vivo." Cancer Res 63(11): 2742-6. 
Chou, C. K., R. F. Chen, F. F. Chou, H. W. Chang, Y. J. Chen, Y. F. Lee, K. D. 
Yang, J. T. Cheng, C. C. Huang and R. T. Liu (2010). "miR-146b is highly 
 307 
expressed in adult papillary thyroid carcinomas with high risk features 
including extrathyroidal invasion and the BRAF(V600E) mutation." Thyroid 
20(5): 489-94. 
Chou, T. C. and P. Talalay (1984). "Quantitative analysis of dose-effect 
relationships: the combined effects of multiple drugs or enzyme inhibitors." 
Adv Enzyme Regul 22: 27-55. 
Chua, C., N. Zaiden, K. H. Chong, S. J. See, M. C. Wong, B. T. Ang and C. Tang 
(2008). "Characterization of a side population of astrocytoma cells in 
response to temozolomide." J Neurosurg 109(5): 856-66. 
Ciafre, S. A., S. Galardi, A. Mangiola, M. Ferracin, C. G. Liu, G. Sabatino, M. 
Negrini, G. Maira, C. M. Croce and M. G. Farace (2005). "Extensive 
modulation of a set of microRNAs in primary glioblastoma." Biochem 
Biophys Res Commun 334(4): 1351-8. 
Clape, C., V. Fritz, C. Henriquet, F. Apparailly, P. L. Fernandez, F. Iborra, C. 
Avances, M. Villalba, S. Culine and L. Fajas (2009). "miR-143 interferes 
with ERK5 signaling, and abrogates prostate cancer progression in mice." 
PLoS One 4(10): e7542. 
Collins, C. S., J. Hong, L. Sapinoso, Y. Zhou, Z. Liu, K. Micklash, P. G. Schultz and 
G. M. Hampton (2006). "A small interfering RNA screen for modulators of 
tumor cell motility identifies MAP4K4 as a promigratory kinase." Proc Natl 
Acad Sci U S A 103(10): 3775-80. 
Coolen, M. and L. Bally-Cuif (2009). "MicroRNAs in brain development and 
physiology." Curr Opin Neurobiol 19(5):461-70. 
Crespo-Barreto, J., J. D. Fryer, C. A. Shaw, H. T. Orr and H. Y. Zoghbi (2010). 
"Partial loss of ataxin-1 function contributes to transcriptional dysregulation 
in spinocerebellar ataxia type 1 pathogenesis." PLoS Genet 6(7): e1001021. 
Cui, J. G., Y. Zhao, P. Sethi, Y. Y. Li, A. Mahta, F. Culicchia and W. J. Lukiw 
(2009). "Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma 
targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell 
proliferation." J Neurooncol 98(3): 297-304. 
Cui, Q., Z. Yu, E. O. Purisima and E. Wang (2006). "Principles of microRNA 
regulation of a human cellular signaling network." Mol Syst Biol 2: 46. 
Cuneo, K. C., L. Geng, A. Fu, D. Orton, D. E. Hallahan and A. B. Chakravarthy 
(2008). "SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic 
effects of ionizing radiation." Int J Radiat Oncol Biol Phys 71(3): 873-9. 
Dahmane, N., P. Sanchez, Y. Gitton, V. Palma, T. Sun, M. Beyna, H. Weiner and A. 
Ruiz i Altaba (2001). "The Sonic Hedgehog-Gli pathway regulates dorsal 
brain growth and tumorigenesis." Development 128(24): 5201-12. 
Dang, C. V. (2010). "Rethinking the Warburg effect with Myc micromanaging 
glutamine metabolism." Cancer Res 70(3): 859-62. 
Debinski, W. (2002). "Local treatment of brain tumors with targeted chimera 
cytotoxic proteins." Cancer Invest 20(5-6): 801-9. 
Decleves, X., S. Bihorel, M. Debray, S. Yousif, G. Camenisch and J. M. Scherrmann 
(2008). "ABC transporters and the accumulation of imatinib and its active 
metabolite CGP74588 in rat C6 glioma cells." Pharmacol Res 57(3): 214-22. 
 308 
Deisboeck, T. S., M. E. Berens, A. R. Kansal, S. Torquato, A. O. Stemmer-
Rachamimov and E. A. Chiocca (2001). "Pattern of self-organization in 
tumour systems: complex growth dynamics in a novel brain tumour spheroid 
model." Cell Prolif 34(2): 115-34. 
Del Duca, D., T. Werbowetski and R. F. Del Maestro (2004). "Spheroid preparation 
from hanging drops: characterization of a model of brain tumor invasion." J 
Neurooncol 67(3): 295-303. 
Demayo, F., P. Minoo, C. G. Plopper, L. Schuger, J. Shannon and J. S. Torday 
(2002). "Mesenchymal-epithelial interactions in lung development and 
repair: are modeling and remodeling the same process?" Am J Physiol Lung 
Cell Mol Physiol 283(3): L510-7. 
Demeule, M., D. Shedid, E. Beaulieu, R. F. Del Maestro, A. Moghrabi, P. B. Ghosn, 
R. Moumdjian, F. Berthelet and R. Beliveau (2001). "Expression of 
multidrug-resistance P-glycoprotein (MDR1) in human brain tumors." Int J 
Cancer 93(1): 62-6. 
Demuth, T., L. B. Reavie, J. L. Rennert, M. Nakada, S. Nakada, D. B. Hoelzinger, 
C. E. Beaudry, A. N. Henrichs, E. M. Anderson and M. E. Berens (2007). 
"MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and 
p38 drive glioma invasion and progression and predict patient survival." Mol 
Cancer Ther 6(4): 1212-22. 
Deveraux, Q. L. and J. C. Reed (1999). "IAP family proteins--suppressors of 
apoptosis." Genes Dev 13(3): 239-52. 
Deveraux, Q. L., R. Takahashi, G. S. Salvesen and J. C. Reed (1997). "X-linked IAP 
is a direct inhibitor of cell-death proteases." Nature 388(6639): 300-4. 
Diana lab "http://www.diana.cslab." 
Dresemann, G. (2010). "Temozolomide in malignant glioma." Onco Targets Ther 
7(3): 139-46. 
Druker, B. J. (2001). "Current treatment approaches for chronic myelogenous 
leukemia." Cancer J 7 Suppl 1: S14-8. 
Du, L., J. J. Schageman, M. C. Subauste, B. Saber, S. M. Hammond, L. Prudkin, 
Wistuba, II, L. Ji, J. A. Roth, J. D. Minna and A. Pertsemlidis (2009). "miR-
93, miR-98, and miR-197 regulate expression of tumor suppressor gene 
FUS1." Mol Cancer Res 7(8): 1234-43. 
Dubrez-Daloz, L., A. Dupoux and J. Cartier (2008). "IAPs: more than just inhibitors 
of apoptosis proteins." Cell Cycle 7(8): 1036-46. 
Duesberg, P., R. Stindl and R. Hehlmann (2001). "Origin of multidrug resistance in 
cells with and without multidrug resistance genes: chromosome 
reassortments catalyzed by aneuploidy." Proc Natl Acad Sci U S A 98(20): 
11283-8. 
Dziadziuszko, R., S. E. Witta, F. Cappuzzo, S. Park, K. Tanaka, P. V. Danenberg, A. 
E. Baron, L. Crino, W. A. Franklin, P. A. Bunn, Jr., M. Varella-Garcia, K. D. 
Danenberg and F. R. Hirsch (2006). "Epidermal growth factor receptor 
messenger RNA expression, gene dosage, and gefitinib sensitivity in non-
small cell lung cancer." Clin Cancer Res 12(10): 3078-84. 
Endersby, R. and S. J. Baker (2008). "PTEN signaling in brain: neuropathology and 
tumorigenesis." Oncogene 27(41): 5416-30. 
 309 
Evers, R., M. Kool, A. J. Smith, L. van Deemter, M. de Haas and P. Borst (2000). 
"Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 
on MDR1 Pgp-, MRP1- and MRP2-mediated transport." Br J Cancer 83(3): 
366-74. 
Fan, Q. W., C. Cheng, Z. A. Knight, D. Haas-Kogan, D. Stokoe, C. D. James, F. 
McCormick, K. M. Shokat and W. A. Weiss (2009). "EGFR signals to 
mTOR through PKC and independently of Akt in glioma." Sci Signal 2(55): 
ra4. 
Fan, X., Y. Liu, J. Jiang, Z. Ma, H. Wu, T. Liu, M. Liu, X. Li and H. Tang (2010). 
"miR-20a promotes proliferation and invasion by targeting APP in human 
ovarian cancer cells." Acta Biochim Biophys Sin (Shanghai) 42(5): 318-24. 
Fleming, T. P., A. Saxena, W. C. Clark, J. T. Robertson, E. H. Oldfield, S. A. 
Aaronson and I. U. Ali (1992). "Amplification and/or overexpression of 
platelet-derived growth factor receptors and epidermal growth factor receptor 
in human glial tumors." Cancer Res 52(16): 4550-3. 
Forsyth, P., G. Cairncross, D. Stewart, M. Goodyear, N. Wainman and E. 
Eisenhauer (1996). "Phase II trial of docetaxel in patients with recurrent 
malignant glioma: a study of the National Cancer Institute of Canada Clinical 
Trials Group." Invest New Drugs 14(2): 203-6. 
Fracasso, P. M., L. J. Goldstein, D. P. de Alwis, J. S. Rader, M. A. Arquette, S. A. 
Goodner, L. P. Wright, C. L. Fears, R. J. Gazak, V. A. Andre, M. F. Burgess, 
C. A. Slapak and J. H. Schellens (2004). "Phase I study of docetaxel in 
combination with the P-glycoprotein inhibitor, zosuquidar, in resistant 
malignancies." Clin Cancer Res 10(21): 7220-8. 
Francis Ali-Osman, D. (2005). Brain Tumors. Durham, Humana Press Inc, 999 
Riverview Drive, Suite 208, Totowa, New Jersey 07512. 
Franke, T. F., S. I. Yang, T. O. Chan, K. Datta, A. Kazlauskas, D. K. Morrison, D. 
R. Kaplan and P. N. Tsichlis (1995). "The Protein-Kinase Encoded by the 
Akt Protooncogene Is a Target of the Pdgf-Activated Phosphatidylinositol 3-
Kinase." Cell 81(5): 727-736. 
Frankel, R. H., W. Bayona, M. Koslow and E. W. Newcomb (1992). "p53 mutations 
in human malignant gliomas: comparison of loss of heterozygosity with 
mutation frequency." Cancer Res 52(6): 1427-33. 
Frederick, L., X. Y. Wang, G. Eley and C. D. James (2000). "Diversity and 
frequency of epidermal growth factor receptor mutations in human 
glioblastomas." Cancer Res 60(5): 1383-7. 
Friedman, H. S., M. D. Prados, P. Y. Wen, T. Mikkelsen, D. Schiff, L. E. Abrey, W. 
K. Yung, N. Paleologos, M. K. Nicholas, R. Jensen, J. Vredenburgh, J. 
Huang, M. Zheng and T. Cloughesy (2009). "Bevacizumab alone and in 
combination with irinotecan in recurrent glioblastoma." J Clin Oncol 27(28): 
4733-40. 
Furukawa, K., Y. Kumon, H. Harada, S. Kohno, S. Nagato, M. Teraoka, S. Fujiwara, 
K. Nakagawa, K. Hamada and T. Ohnishi (2006). "PTEN gene transfer 
suppresses the invasive potential of human malignant gliomas by regulating 
cell invasion-related molecules." Int J Oncol 29(1): 73-81. 
 310 
Gal, H., G. Pandi, A. A. Kanner, Z. Ram, G. Lithwick-Yanai, N. Amariglio, G. 
Rechavi and D. Givol (2008). "MIR-451 and Imatinib mesylate inhibit tumor 
growth of Glioblastoma stem cells." Biochem Biophys Res Commun 376(1): 
86-90. 
Galceran, J., C. Sustmann, S. C. Hsu, S. Folberth and R. Grosschedl (2004). "LEF1-
mediated regulation of Delta-like1 links Wnt and Notch signaling in 
somitogenesis." Genes Dev 18(22): 2718-23. 
Geoerger, B., K. Kerr, C. B. Tang, K. M. Fung, B. Powell, L. N. Sutton, P. C. 
Phillips and A. J. Janss (2001). "Antitumor activity of the rapamycin analog 
CCI-779 in human primitive neuroectodermal tumor/medulloblastoma 
models as single agent and in combination chemotherapy." Cancer Res 
61(4): 1527-32. 
Giannopoulou, E., K. Dimitropoulos, A. A. Argyriou, A. K. Koutras, F. 
Dimitrakopoulos and H. P. Kalofonos (2010). "An in vitro study, evaluating 
the effect of sunitinib and/or lapatinib on two glioma cell lines." Invest New 
Drugs 28(5): 554-60. 
Giese, A., R. Bjerkvig, M. E. Berens and M. Westphal (2003). "Cost of migration: 
invasion of malignant gliomas and implications for treatment." J Clin Oncol 
21(8): 1624-36. 
Giese, A., M. A. Loo, N. Tran, D. Haskett, S. W. Coons and M. E. Berens (1996). 
"Dichotomy of astrocytoma migration and proliferation." Int J Cancer 67(2): 
275-82. 
Gilg, A. G., S. L. Tye, L. B. Tolliver, W. G. Wheeler, R. P. Visconti, J. D. Duncan, 
F. V. Kostova, L. N. Bolds, B. P. Toole and B. L. Maria (2008). "Targeting 
hyaluronan interactions in malignant gliomas and their drug-resistant 
multipotent progenitors." Clin Cancer Res 14(6): 1804-13. 
Gillies, J. K. and I. A. Lorimer (2007). "Regulation of p27Kip1 by miRNA 221/222 
in glioblastoma." Cell Cycle 6(16): 2005-9. 
Gironella, M., M. Seux, M. J. Xie, C. Cano, R. Tomasini, J. Gommeaux, S. Garcia, 
J. Nowak, M. L. Yeung, K. T. Jeang, A. Chaix, L. Fazli, Y. Motoo, Q. Wang, 
P. Rocchi, A. Russo, M. Gleave, J. C. Dagorn, J. L. Iovanna, A. Carrier, M. 
J. Pebusque and N. J. Dusetti (2007). "Tumor protein 53-induced nuclear 
protein 1 expression is repressed by miR-155, and its restoration inhibits 
pancreatic tumor development." Proc Natl Acad Sci U S A 104(41): 16170-5. 
Glass, T. L., T. J. Liu and W. K. Yung (2000). "Inhibition of cell growth in human 
glioblastoma cell lines by farnesyltransferase inhibitor SCH66336." Neuro 
Oncol 2(3): 151-8. 
Godlewski, J., A. Bronisz, M. O. Nowicki, E. A. Chiocca and S. Lawler (2010). 
"microRNA-451: A conditional switch controlling glioma cell proliferation 
and migration." Cell Cycle 9(14): 2742-8. 
Godlewski, J., M. O. Nowicki, A. Bronisz, S. Williams, A. Otsuki, G. Nuovo, A. 
Raychaudhury, H. B. Newton, E. A. Chiocca and S. Lawler (2008). 
"Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-
128 inhibits glioma proliferation and self-renewal." Cancer Res 68(22): 
9125-30. 
 311 
Goel, A. and C. R. Boland (2010). "Recent insights into the pathogenesis of 
colorectal cancer." Curr Opin Gastroenterol 26(1): 47-52. 
Golembieski, W. A., S. L. Thomas, C. R. Schultz, C. K. Yunker, H. M. McClung, N. 
Lemke, S. Cazacu, T. Barker, E. H. Sage, C. Brodie and S. A. Rempel 
(2008). "HSP27 mediates SPARC-induced changes in glioma morphology, 
migration, and invasion." Glia 56(10): 1061-75. 
Gucluler, G. and Y. Baran (2009). "Docetaxel enhances the cytotoxic effects of 
imatinib on Philadelphia positive human chronic myeloid leukemia cells." 
Hematology 14(3): 139-44. 
Guha, A., K. Dashner, P. M. Black, J. A. Wagner and C. D. Stiles (1995). 
"Expression of PDGF and PDGF receptors in human astrocytoma operation 
specimens supports the existence of an autocrine loop." Int J Cancer 60(2): 
168-73. 
Guha, A., D. Glowacka, R. Carroll, K. Dashner, P. M. Black and C. D. Stiles (1995). 
"Expression of platelet derived growth factor and platelet derived growth 
factor receptor mRNA in a glioblastoma from a patient with Li-Fraumeni 
syndrome." J Neurol Neurosurg Psychiatry 58(6): 711-4. 
Guillamo, J. S., S. de Bouard, S. Valable, L. Marteau, P. Leuraud, Y. Marie, M. F. 
Poupon, J. J. Parienti, E. Raymond and M. Peschanski (2009). "Molecular 
mechanisms underlying effects of epidermal growth factor receptor 
inhibition on invasion, proliferation, and angiogenesis in experimental 
glioma." Clin Cancer Res 15(11): 3697-704. 
Guled, M., L. Lahti, P. M. Lindholm, K. Salmenkivi, I. Bagwan, A. G. Nicholson 
and S. Knuutila (2009). "CDKN2A, NF2, and JUN are dysregulated among 
other genes by miRNAs in malignant mesothelioma -A miRNA microarray 
analysis." Genes Chromosomes Cancer 48(7): 615-23. 
Gullick, J. D. H. a. W. J. (2008). EGFR Signaling Networks in cancer Therapy, 
Humana Press, c/o Springer Science + Business Media, LLC, 233 Spring 
Street, New York, NY 10013, USA. 
Gunther, W., E. Pawlak, R. Damasceno, H. Arnold and A. J. Terzis (2003). 
"Temozolomide induces apoptosis and senescence in glioma cells cultured as 
multicellular spheroids." Br J Cancer 88(3): 463-9. 
Haas-Kogan, D., N. Shalev, M. Wong, G. Mills, G. Yount and D. Stokoe (1998). 
"Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to 
mutation of the tumor suppressor PTEN/MMAC." Curr Biol 8(21): 1195-8. 
Haas-Kogan, D. A., M. D. Prados, T. Tihan, D. A. Eberhard, N. Jelluma, N. D. 
Arvold, R. Baumber, K. R. Lamborn, A. Kapadia, M. Malec, M. S. Berger 
and D. Stokoe (2005). "Epidermal growth factor receptor, protein kinase 
B/Akt, and glioma response to erlotinib." J Natl Cancer Inst 97(12): 880-7. 
Haberler, C., E. Gelpi, C. Marosi, K. Rossler, P. Birner, H. Budka and J. A. 
Hainfellner (2006). "Immunohistochemical analysis of platelet-derived 
growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in 
glioblastoma: possible implications for patient selection for imatinib 
mesylate therapy." J Neurooncol 76(2): 105-9. 
Hagerstrand, D., G. Hesselager, S. Achterberg, U. Wickenberg Bolin, M. Kowanetz, 
M. Kastemar, C. H. Heldin, A. Isaksson, M. Nister and A. Ostman (2006). 
 312 
"Characterization of an imatinib-sensitive subset of high-grade human 
glioma cultures." Oncogene 25(35): 4913-22. 
Hamel, W., M. Westphal and H. M. Shepard (1992). "Protooncogene Expression in 
Human Glioma Derived Cell-Lines." International Journal of Oncology 1(6): 
673-682. 
Hao, J. M., J. Z. Chen, H. M. Sui, X. Q. Si-Ma, G. Q. Li, C. Liu, J. L. Li, Y. Q. Ding 
and J. M. Li (2010). "A five-gene signature as a potential predictor of 
metastasis and survival in colorectal cancer." J Pathol 220(4): 475-89. 
Harry, G. J., M. Billingsley, A. Bruinink, I. L. Campbell, W. Classen, D. C. 
Dorman, C. Galli, D. Ray, R. A. Smith and H. A. Tilson (1998). "In vitro 
techniques for the assessment of neurotoxicity." Environ Health Perspect 
106 Suppl 1: 131-58. 
Hatzikirou, H., D. Basanta, M. Simon, K. Schaller and A. Deutsch (2010). "'Go or 
Grow': the key to the emergence of invasion in tumour progression?" Math 
Med Biol epub ahead of print. 
Haura, E. B., T. Tanvetyanon, A. Chiappori, C. Williams, G. Simon, S. Antonia, J. 
Gray, S. Litschauer, L. Tetteh, A. Neuger, L. Song, B. Rawal, M. J. Schell 
and G. Bepler (2010). "Phase I/II study of the Src inhibitor dasatinib in 
combination with erlotinib in advanced non-small-cell lung cancer." J Clin 
Oncol 28(8): 1387-94. 
Heimberger, A. B., R. Hlatky, D. Suki, D. Yang, J. Weinberg, M. Gilbert, R. 
Sawaya and K. Aldape (2005). "Prognostic effect of epidermal growth factor 
receptor and EGFRvIII in glioblastoma multiforme patients." Clin Cancer 
Res 11(4): 1462-6. 
Henson, B. J., S. Bhattacharjee, D. M. O'Dee, E. Feingold and S. M. Gollin (2009). 
"Decreased expression of miR-125b and miR-100 in oral cancer cells 
contributes to malignancy." Genes Chromosomes Cancer 48(7): 569-82. 
Hermanson, M., K. Funa, M. Hartman, L. Claesson-Welsh, C. H. Heldin, B. 
Westermark and M. Nister (1992). "Platelet-derived growth factor and its 
receptors in human glioma tissue: expression of messenger RNA and protein 
suggests the presence of autocrine and paracrine loops." Cancer Res 52(11): 
3213-9. 
Hesselager, G. and E. C. Holland (2003). "Using mice to decipher the molecular 
genetics of brain tumors." Neurosurgery 53(3): 685-94; discussion 695. 
NIH      http://ehis.niehs.nih.gov/.  
Hirsch, F. R., M. Varella-Garcia, J. McCoy, H. West, A. C. Xavier, P. Gumerlock, 
P. A. Bunn, Jr., W. A. Franklin, J. Crowley and D. R. Gandara (2005). 
"Increased epidermal growth factor receptor gene copy number detected by 
fluorescence in situ hybridization associates with increased sensitivity to 
gefitinib in patients with bronchioloalveolar carcinoma subtypes: a 
Southwest Oncology Group Study." J Clin Oncol 23(28): 6838-45. 
Hirschmann-Jax, C., A. E. Foster, G. G. Wulf, J. G. Nuchtern, T. W. Jax, U. Gobel, 
M. A. Goodell and M. K. Brenner (2004). "A distinct "side population" of 
cells with high drug efflux capacity in human tumor cells." Proc Natl Acad 
Sci U S A 101(39): 14228-33. 
 313 
Hofer, S. and K. Frei (2007). "Gefitinib concentrations in human glioblastoma 
tissue." J Neurooncol 82(2): 175-6. 
Hofmann, M. H., J. Heinrich, G. Radziwil and K. Moelling (2009). "A short hairpin 
DNA analogous to miR-125b inhibits C-Raf expression, proliferation, and 
survival of breast cancer cells." Mol Cancer Res 7(10): 1635-44. 
Holland, E. C., J. Celestino, C. Dai, L. Schaefer, R. E. Sawaya and G. N. Fuller 
(2000). "Combined activation of Ras and Akt in neural progenitors induces 
glioblastoma formation in mice." Nat Genet 25(1): 55-7. 
Hu, X., P. P. Pandolfi, Y. Li, J. A. Koutcher, M. Rosenblum and E. C. Holland 
(2005). "mTOR promotes survival and astrocytic characteristics induced by 
Pten/AKT signaling in glioblastoma." Neoplasia 7(4): 356-68. 
Huang, S., D. Vader, Z. Wang, A. Stemmer-Rachamimov, D. A. Weitz, G. Dai, B. 
R. Rosen and T. S. Deisboeck (2008). "Using magnetic resonance 
microscopy to study the growth dynamics of a glioma spheroid in collagen I: 
A case study." BMC Med Imaging 8: 3. 
Huang, Z. M., J. Yang, X. Y. Shen, X. Y. Zhang, F. S. Meng, J. T. Xu, B. F. Zhang 
and H. J. Gao (2009). "MicroRNA expression profile in non-cancerous 
colonic tissue associated with lymph node metastasis of colon cancer." J Dig 
Dis 10(3): 188-94. 
Hurst, D. R., M. D. Edmonds, G. K. Scott, C. C. Benz, K. S. Vaidya and D. R. 
Welch (2009). "Breast cancer metastasis suppressor 1 up-regulates miR-146, 
which suppresses breast cancer metastasis." Cancer Res 69(4): 1279-83. 
Huse, J. T., C. Brennan, D. Hambardzumyan, B. Wee, J. Pena, S. H. Rouhanifard, C. 
Sohn-Lee, C. le Sage, R. Agami, T. Tuschl and E. C. Holland (2009). "The 
PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and 
facilitates gliomagenesis in vivo." Genes Dev 23(11): 1327-37. 
Hwang, S. L., C. Y. Chai, H. J. Lin and S. L. Howng (1997). "Expression of 
epidermal growth factor receptors and c-erbB-2 proteins in human astrocytic 
tumors." Kaohsiung J Med Sci 13(7): 417-24. 
Hynes, N. E. and H. A. Lane (2005). "ERBB receptors and cancer: the complexity of 
targeted inhibitors." Nat Rev Cancer 5(5): 341-54. 
Ishii, D., A. Natsume, T. Wakabayashi, H. Hatano, Y. Asano, H. Takeuchi, S. 
Shimato, M. Ito, M. Fujii and J. Yoshida (2007). "Efficacy of temozolomide 
is correlated with 1p loss and methylation of the deoxyribonucleic acid repair 
gene MGMT in malignant gliomas." Neurol Med Chir (Tokyo) 47(8): 341-9; 
discussion 350. 
Ishikawa, S., M. Kai, Y. Murata, M. Tamari, Y. Daigo, T. Murano, M. Ogawa and 
Y. Nakamura (1998). "Genomic organization and mapping of the human 
activin receptor type IIB (hActR-IIB) gene." J Hum Genet 43(2): 132-4. 
Jemal, A., T. Murray, E. Ward, A. Samuels, R. C. Tiwari, A. Ghafoor, E. J. Feuer 
and M. J. Thun (2005). "Cancer statistics, 2005." CA Cancer J Clin 55(1): 
10-30. 
Jeuken, J., C. van den Broecke, S. Gijsen, S. Boots-Sprenger and P. Wesseling 
(2007). "RAS/RAF pathway activation in gliomas: the result of copy number 
gains rather than activating mutations." Acta Neuropathol 114(2): 121-33. 
 314 
Jiang, R., C. Mircean, I. Shmulevich, D. Cogdell, Y. Jia, I. Tabus, K. Aldape, R. 
Sawaya, J. M. Bruner, G. N. Fuller and W. Zhang (2006). "Pathway 
alterations during glioma progression revealed by reverse phase protein 
lysate arrays." Proteomics 6(10): 2964-71. 
Johnston, R. J. and O. Hobert (2003). "A microRNA controlling left/right neuronal 
asymmetry in Caenorhabditis elegans." Nature 426(6968): 845-9. 
Kan, T., F. Sato, T. Ito, N. Matsumura, S. David, Y. Cheng, R. Agarwal, B. C. Paun, 
Z. Jin, A. V. Olaru, F. M. Selaru, J. P. Hamilton, J. Yang, J. M. Abraham, Y. 
Mori and S. J. Meltzer (2009). "The miR-106b-25 polycistron, activated by 
genomic amplification, functions as an oncogene by suppressing p21 and 
Bim." Gastroenterology 136(5): 1689-700. 
Kanakaraj, P., S. Raj, S. A. Khan and S. Bishayee (1991). "Ligand-induced 
interaction between alpha- and beta-type platelet-derived growth factor 
(PDGF) receptors: role of receptor heterodimers in kinase activation." 
Biochemistry 30(7): 1761-7. 
Kanda, Y., K. Mitani, M. Kurokawa, T. Yamagata, Y. Yazaki and H. Hirai (1998). 
"Overexpression of the MEN/ELL protein, an RNA polymerase II elongation 
factor, results in transformation of Rat1 cells with dependence on the lysine-
rich region." J Biol Chem 273(9): 5248-52. 
Karlsson, A., A. Nordigarden, J. I. Jonsson and P. Soderkvist (2007). "Bcl11b 
mutations identified in murine lymphomas increase the proliferation rate of 
hematopoietic progenitor cells." BMC Cancer 7: 195. 
Kato, Y., D. A. Holm, B. Okollie and D. Artemov (2010). "Noninvasive detection of 
temozolomide in brain tumor xenografts by magnetic resonance 
spectroscopy." Neuro Oncol 12(1): 71-9. 
Katz, D., A. Segal, Y. Alberton, O. Jurim, P. Reissman, R. Catane and N. I. Cherny 
(2004). "Neoadjuvant imatinib for unresectable gastrointestinal stromal 
tumor." Anticancer Drugs 15(6): 599-602. 
Kawataki, T., E. Sato, T. Sato and H. Kinouchi (2010). "Anaplastic ganglioglioma 
with malignant features in both neuronal and glial components--case report." 
Neurol Med Chir (Tokyo) 50(3): 228-31. 
Kefas, B., L. Comeau, D. H. Floyd, O. Seleverstov, J. Godlewski, T. Schmittgen, J. 
Jiang, C. G. diPierro, Y. Li, E. A. Chiocca, J. Lee, H. Fine, R. Abounader, S. 
Lawler and B. Purow (2009). "The neuronal microRNA miR-326 acts in a 
feedback loop with notch and has therapeutic potential against brain tumors." 
J Neurosci 29(48): 15161-8. 
Kefas, B., J. Godlewski, L. Comeau, Y. Li, R. Abounader, M. Hawkinson, J. Lee, H. 
Fine, E. A. Chiocca, S. Lawler and B. Purow (2008). "microRNA-7 inhibits 
the epidermal growth factor receptor and the Akt pathway and is down-
regulated in glioblastoma." Cancer Res 68(10): 3566-72. 
Kemper, E. M., A. E. van Zandbergen, C. Cleypool, H. A. Mos, W. Boogerd, J. H. 
Beijnen and O. van Tellingen (2003). "Increased penetration of paclitaxel 
into the brain by inhibition of P-Glycoprotein." Clin Cancer Res 9(7): 2849-
55. 
 315 
Kemper, E. M., M. Verheij, W. Boogerd, J. H. Beijnen and O. van Tellingen (2004). 
"Improved penetration of docetaxel into the brain by co-administration of 
inhibitors of P-glycoprotein." Eur J Cancer 40(8): 1269-74. 
Khoshyomn, S., S. Lew, J. DeMattia, E. B. Singer and P. L. Penar (1999). "Brain 
tumor invasion rate measured in vitro does not correlate with Ki-67 
expression." J Neurooncol 45(2): 111-6. 
Khvorova, A., A. Reynolds and S. D. Jayasena (2003). "Functional siRNAs and 
miRNAs exhibit strand bias." Cell 115(2): 209-16. 
Kilic, T., J. A. Alberta, P. R. Zdunek, M. Acar, P. Iannarelli, T. O'Reilly, E. 
Buchdunger, P. M. Black and C. D. Stiles (2000). "Intracranial inhibition of 
platelet-derived growth factor-mediated glioblastoma cell growth by an 
orally active kinase inhibitor of the 2-phenylaminopyrimidine class." Cancer 
Res 60(18): 5143-50. 
Kinsella, P., M. Clynes and V. Amberger-Murphy (2011). "Imatinib and docetaxel 
in combination can effectively inhibit glioma invasion in an in vitro 3D 
invasion assay." J Neurooncol 101(2): 189-98. 
Kitange, G. J., B. L. Carlson, M. A. Schroeder, P. A. Decker, B. W. Morlan, W. Wu, 
K. V. Ballman, C. Giannini and J. N. Sarkaria (2010). "Expression of CD74 
in high grade gliomas: a potential role in temozolomide resistance." J 
Neurooncol 100(2): 177-86. 
Kleihues, P. and H. Ohgaki (2000). "Phenotype vs genotype in the evolution of 
astrocytic brain tumors." Toxicol Pathol 28(1): 164-70. 
Kogashiwa, Y., H. Sakurai, T. Kimura and N. Kohno (2010). "Docetaxel suppresses 
invasiveness of head and neck cancer cells in vitro." Cancer Sci 101(6): 
1382-6. 
Kogiku, M., I. Ohsawa, K. Matsumoto, Y. Sugisaki, H. Takahashi, A. Teramoto and 
S. Ohta (2008). "Prognosis of glioma patients by combined immunostaining 
for survivin, Ki-67 and epidermal growth factor receptor." J Clin Neurosci 
15(11): 1198-203. 
Kolenda, J., S. S. Jensen, C. Aaberg-Jessen, K. Christensen, C. Andersen, N. 
Brunner and B. W. Kristensen (2010). "Effects of hypoxia on expression of a 
panel of stem cell and chemoresistance markers in glioblastoma-derived 
spheroids." J Neurooncol epub ahead of print. 
Komatsu, M., T. Takahashi, T. Abe, I. Takahashi, H. Ida and G. Takada (2001). 
"Evidence for the association of ultraviolet-C and H(2)O(2)-induced 
apoptosis with acid sphingomyelinase activation." Biochim Biophys Acta 
1533(1): 47-54. 
Koukourakis, M. I., A. Giatromanolaki, S. Schiza, S. Kakolyris and V. Georgoulias 
(1999). "Concurrent twice-a-week docetaxel and radiotherapy: a dose 
escalation trial with immunological toxicity evaluation." Int J Radiat Oncol 
Biol Phys 43(1): 107-14. 
Kozaki, K., I. Imoto, S. Mogi, K. Omura and J. Inazawa (2008). "Exploration of 
tumor-suppressive microRNAs silenced by DNA hypermethylation in oral 
cancer." Cancer Res 68(7): 2094-105. 
Kreisl, T. N., L. Kim, K. Moore, P. Duic, C. Royce, I. Stroud, N. Garren, M. 
Mackey, J. A. Butman, K. Camphausen, J. Park, P. S. Albert and H. A. Fine 
 316 
(2009). "Phase II trial of single-agent bevacizumab followed by bevacizumab 
plus irinotecan at tumor progression in recurrent glioblastoma." J Clin Oncol 
27(5): 740-5. 
Krol, J., K. Sobczak, U. Wilczynska, M. Drath, A. Jasinska, D. Kaczynska and W. J. 
Krzyzosiak (2004). "Structural features of microRNA (miRNA) precursors 
and their relevance to miRNA biogenesis and small interfering RNA/short 
hairpin RNA design." J Biol Chem 279(40): 42230-9. 
Kumabe, T., Y. Sohma, T. Kayama, T. Yoshimoto and T. Yamamoto (1992). 
"Overexpression and amplification of alpha-PDGF receptor gene lacking 
exons coding for a portion of the extracellular region in a malignant glioma." 
Tohoku J Exp Med 168(2): 265-9. 
Laban, C., S. A. Bustin and P. J. Jenkins (2003). "The GH-IGF-I axis and breast 
cancer." Trends Endocrinol Metab 14(1): 28-34. 
LaCasse, E. C., S. Baird, R. G. Korneluk and A. E. MacKenzie (1998). "The 
inhibitors of apoptosis (IAPs) and their emerging role in cancer." Oncogene 
17(25): 3247-59. 
le Coutre, P., K. A. Kreuzer, S. Pursche, M. Bonin, T. Leopold, G. Baskaynak, B. 
Dorken, G. Ehninger, O. Ottmann, A. Jenke, M. Bornhauser and E. Schleyer 
(2004). "Pharmacokinetics and cellular uptake of imatinib and its main 
metabolite CGP74588." Cancer Chemother Pharmacol 53(4): 313-23. 
Lee, J. C., I. Vivanco, R. Beroukhim, J. H. Huang, W. L. Feng, R. M. DeBiasi, K. 
Yoshimoto, J. C. King, P. Nghiemphu, Y. Yuza, Q. Xu, H. Greulich, R. K. 
Thomas, J. G. Paez, T. C. Peck, D. J. Linhart, K. A. Glatt, G. Getz, R. 
Onofrio, L. Ziaugra, R. L. Levine, S. Gabriel, T. Kawaguchi, K. O'Neill, H. 
Khan, L. M. Liau, S. F. Nelson, P. N. Rao, P. Mischel, R. O. Pieper, T. 
Cloughesy, D. J. Leahy, W. R. Sellers, C. L. Sawyers, M. Meyerson and I. K. 
Mellinghoff (2006). "Epidermal growth factor receptor activation in 
glioblastoma through novel missense mutations in the extracellular domain." 
PLoS Med 3(12): e485. 
Lee, K. H., Y. L. Chen, S. D. Yeh, M. Hsiao, J. T. Lin, Y. G. Goan and P. J. Lu 
(2009). "MicroRNA-330 acts as tumor suppressor and induces apoptosis of 
prostate cancer cells through E2F1-mediated suppression of Akt 
phosphorylation." Oncogene 28(38): 3360-70. 
Lee, N. S., J. S. Kim, W. J. Cho, M. R. Lee, R. Steiner, A. Gompers, D. Ling, J. 
Zhang, P. Strom, M. Behlke, S. H. Moon, P. M. Salvaterra, R. Jove and K. S. 
Kim (2008). "miR-302b maintains "stemness" of human embryonal 
carcinoma cells by post-transcriptional regulation of Cyclin D2 expression." 
Biochem Biophys Res Commun 377(2): 434-40. 
Lee, Y., C. Ahn, J. Han, H. Choi, J. Kim, J. Yim, J. Lee, P. Provost, O. Radmark, S. 
Kim and V. N. Kim (2003). "The nuclear RNase III Drosha initiates 
microRNA processing." Nature 425(6956): 415-9. 
Lee, Y., K. Jeon, J. T. Lee, S. Kim and V. N. Kim (2002). "MicroRNA maturation: 
stepwise processing and subcellular localization." Embo J 21(17): 4663-70. 
Leslie, E. M., R. G. Deeley and S. P. Cole (2005). "Multidrug resistance proteins: 
role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue 
defense." Toxicol Appl Pharmacol 204(3): 216-37. 
 317 
Levav-Cohen, Y., Z. Goldberg, V. Zuckerman, T. Grossman, S. Haupt and Y. Haupt 
(2005). "C-Abl as a modulator of p53." Biochem Biophys Res Commun 
331(3): 737-49. 
Lewis, B. P., C. B. Burge and D. P. Bartel (2005). "Conserved seed pairing, often 
flanked by adenosines, indicates that thousands of human genes are 
microRNA targets." Cell 120(1): 15-20. 
Lewis, B. P., I. H. Shih, M. W. Jones-Rhoades, D. P. Bartel and C. B. Burge (2003). 
"Prediction of mammalian microRNA targets." Cell 115(7): 787-98. 
Li, H., C. Bian, L. Liao, J. Li and R. C. Zhao (2010). "miR-17-5p promotes human 
breast cancer cell migration and invasion through suppression of HBP1." 
Breast Cancer Res Treat epub ahead of print. 
Li, L. and T. Xie (2005). "Stem cell niche: structure and function." Annu Rev Cell 
Dev Biol 21: 605-31. 
Li, X. F., P. J. Yan and Z. M. Shao (2009). "Downregulation of miR-193b 
contributes to enhance urokinase-type plasminogen activator (uPA) 
expression and tumor progression and invasion in human breast cancer." 
Oncogene 28(44): 3937-48. 
Li, X. Y., L. Q. Zhang, X. G. Zhang, X. Li, Y. B. Ren, X. Y. Ma, X. G. Li and L. X. 
Wang (2010). "Association between AKT/mTOR signalling pathway and 
malignancy grade of human gliomas." J Neurooncol epub ahead of print. 
Li, Y., F. Guessous, Y. Zhang, C. Dipierro, B. Kefas, E. Johnson, L. Marcinkiewicz, 
J. Jiang, Y. Yang, T. D. Schmittgen, B. Lopes, D. Schiff, B. Purow and R. 
Abounader (2009). "MicroRNA-34a inhibits glioblastoma growth by 
targeting multiple oncogenes." Cancer Res 69(19): 7569-76. 
Liang, J. J., H. Wang, A. Rashid, T. H. Tan, R. F. Hwang, S. R. Hamilton, J. L. 
Abbruzzese and D. B. Evans (2008). "Expression of MAP4K4 is associated 
with worse prognosis in patients with stage II pancreatic ductal 
adenocarcinoma." Clin Cancer Res 14(21): 7043-9. 
Lindroos, P. M., P. G. Coin, A. Badgett, D. L. Morgan and J. C. Bonner (1997). 
"Alveolar macrophages stimulated with titanium dioxide, chrysotile asbestos, 
and residual oil fly ash upregulate the PDGF receptor-alpha on lung 
fibroblasts through an IL-1beta-dependent mechanism." Am J Respir Cell 
Mol Biol 16(3): 283-92. 
Liu, I. M., S. H. Schilling, K. A. Knouse, L. Choy, R. Derynck and X. F. Wang 
(2009). "TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 
L45 loop and mediates the pro-migratory TGFbeta switch." Embo J 28(2): 
88-98. 
Liu, W. H., S. H. Yeh, C. C. Lu, S. L. Yu, H. Y. Chen, C. Y. Lin, D. S. Chen and P. 
J. Chen (2009). "MicroRNA-18a prevents estrogen receptor-alpha 
expression, promoting proliferation of hepatocellular carcinoma cells." 
Gastroenterology 136(2): 683-93. 
Liu, X., Z. Chen, J. Yu, J. Xia and X. Zhou (2009). "MicroRNA Profiling and Head 
and Neck Cancer." Comp Funct Genomics: 837514. 
Liu, Z. J., M. Xiao, K. Balint, A. Soma, C. C. Pinnix, A. J. Capobianco, O. C. 
Velazquez and M. Herlyn (2006). "Inhibition of endothelial cell proliferation 
 318 
by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt 
pathways and requires MAML1." Faseb J 20(7): 1009-11. 
Livak, K. J., S. J. Flood, J. Marmaro, W. Giusti and K. Deetz (1995). 
"Oligonucleotides with fluorescent dyes at opposite ends provide a quenched 
probe system useful for detecting PCR product and nucleic acid 
hybridization." PCR Methods Appl 4(6): 357-62. 
Lokker, N. A., C. M. Sullivan, S. J. Hollenbach, M. A. Israel and N. A. Giese 
(2002). "Platelet-derived growth factor (PDGF) autocrine signaling regulates 
survival and mitogenic pathways in glioblastoma cells: evidence that the 
novel PDGF-C and PDGF-D ligands may play a role in the development of 
brain tumors." Cancer Res 62(13): 3729-35. 
Lomo, L., M. R. Nucci, K. R. Lee, M. C. Lin, M. S. Hirsch, C. P. Crum and G. L. 
Mutter (2008). "Histologic and immunohistochemical decision-making in 
endometrial adenocarcinoma." Mod Pathol 21(8): 937-42. 
Lorenzi, P. L., W. C. Reinhold, S. Varma, A. A. Hutchinson, Y. Pommier, S. J. 
Chanock and J. N. Weinstein (2009). "DNA fingerprinting of the NCI-60 cell 
line panel." Mol Cancer Ther 8(4): 713-24. 
Lund, E., S. Guttinger, A. Calado, J. E. Dahlberg and U. Kutay (2004). "Nuclear 
export of microRNA precursors." Science 303(5654): 95-8. 
Luo, H., H. Zhang, Z. Zhang, X. Zhang, B. Ning, J. Guo, N. Nie, B. Liu and X. Wu 
(2009). "Down-regulated miR-9 and miR-433 in human gastric carcinoma." 
J Exp Clin Cancer Res 28: 82. 
Lupo, V., M. I. Galindo, D. Martinez-Rubio, T. Sevilla, J. J. Vilchez, F. Palau and 
C. Espinos (2009). "Missense mutations in the SH3TC2 protein causing 
Charcot-Marie-Tooth disease type 4C affect its localization in the plasma 
membrane and endocytic pathway." Hum Mol Genet 18(23): 4603-14. 
Ma, J., M. Murphy, P. J. O'Dwyer, E. Berman, K. Reed and J. M. Gallo (2002). 
"Biochemical changes associated with a multidrug-resistant phenotype of a 
human glioma cell line with temozolomide-acquired resistance." Biochem 
Pharmacol 63(7): 1219-28. 
Mack, P. C., W. S. Holland, R. A. Burich, R. Sangha, L. J. Solis, Y. Li, L. A. 
Beckett, P. N. Lara, Jr., A. M. Davies and D. R. Gandara (2009). "EGFR 
mutations detected in plasma are associated with patient outcomes in 
erlotinib plus docetaxel-treated non-small cell lung cancer." J Thorac Oncol 
4(12): 1466-72. 
Maher, E. A., F. B. Furnari, R. M. Bachoo, D. H. Rowitch, D. N. Louis, W. K. 
Cavenee and R. A. DePinho (2001). "Malignant glioma: genetics and biology 
of a grave matter." Genes Dev 15(11): 1311-33. 
Mahesparan, R., B. B. Tysnes, T. A. Read, P. O. Enger, R. Bjerkvig and M. Lund-
Johansen (1999). "Extracellular matrix-induced cell migration from 
glioblastoma biopsy specimens in vitro." Acta Neuropathol 97(3): 231-9. 
Malzkorn, B., M. Wolter, F. Liesenberg, M. Grzendowski, K. Stuhler, H. E. Meyer 
and G. Reifenberger (2010). "Identification and functional characterization 
of microRNAs involved in the malignant progression of gliomas." Brain 
Pathol 20(3): 539-50. 
 319 
Marie, Y., A. F. Carpentier, A. M. Omuro, M. Sanson, J. Thillet, K. Hoang-Xuan 
and J. Y. Delattre (2005). "EGFR tyrosine kinase domain mutations in 
human gliomas." Neurology 64(8): 1444-5. 
Marroni, M., N. Marchi, L. Cucullo, N. J. Abbott, K. Signorelli and D. Janigro 
(2003). "Vascular and parenchymal mechanisms in multiple drug resistance: 
a lesson from human epilepsy." Curr Drug Targets 4(4): 297-304. 
Martinho, O., A. Longatto-Filho, M. B. Lambros, A. Martins, C. Pinheiro, A. Silva, 
F. Pardal, J. Amorim, A. Mackay, F. Milanezi, N. Tamber, K. Fenwick, A. 
Ashworth, J. S. Reis-Filho, J. M. Lopes and R. M. Reis (2009). "Expression, 
mutation and copy number analysis of platelet-derived growth factor receptor 
A (PDGFRA) and its ligand PDGFA in gliomas." Br J Cancer 101(6): 973-
82. 
McDaneld, T. G., T. P. Smith, M. E. Doumit, J. R. Miles, L. L. Coutinho, T. S. 
Sonstegard, L. K. Matukumalli, D. J. Nonneman and R. T. Wiedmann 
(2009). "MicroRNA transcriptome profiles during swine skeletal muscle 
development." BMC Genomics 10: 77. 
Medina, R., S. K. Zaidi, C. G. Liu, J. L. Stein, A. J. van Wijnen, C. M. Croce and G. 
S. Stein (2008). "MicroRNAs 221 and 222 bypass quiescence and 
compromise cell survival." Cancer Res 68(8): 2773-80. 
Mellinghoff, I. K., M. Y. Wang, I. Vivanco, D. A. Haas-Kogan, S. Zhu, E. Q. Dia, 
K. V. Lu, K. Yoshimoto, J. H. Huang, D. J. Chute, B. L. Riggs, S. Horvath, 
L. M. Liau, W. K. Cavenee, P. N. Rao, R. Beroukhim, T. C. Peck, J. C. Lee, 
W. R. Sellers, D. Stokoe, M. Prados, T. F. Cloughesy, C. L. Sawyers and P. 
S. Mischel (2005). "Molecular determinants of the response of glioblastomas 
to EGFR kinase inhibitors." N Engl J Med 353(19): 2012-24. 
Miele, L. and B. Osborne (1999). "Arbiter of differentiation and death: Notch 
signaling meets apoptosis." J Cell Physiol 181(3): 393-409. 
Milano, V., Y. Piao, T. LaFortune and J. de Groot (2009). "Dasatinib-induced 
autophagy is enhanced in combination with temozolomide in glioma." Mol 
Cancer Ther 8(2): 394-406. 
Molina, J. R., Y. Hayashi, C. Stephens and M. M. Georgescu (2010). "Invasive 
glioblastoma cells acquire stemness and increased Akt activation." Neoplasia 
12(6): 453-63. 
Mondy, J. S., V. Lindner, J. K. Miyashiro, B. C. Berk, R. H. Dean and R. L. Geary 
(1997). "Platelet-derived growth factor ligand and receptor expression in 
response to altered blood flow in vivo." Circ Res 81(3): 320-7. 
Mraz, M., K. Malinova, J. Kotaskova, S. Pavlova, B. Tichy, J. Malcikova, K. Stano 
Kozubik, J. Smardova, Y. Brychtova, M. Doubek, M. Trbusek, J. Mayer and 
S. Pospisilova (2009). "miR-34a, miR-29c and miR-17-5p are downregulated 
in CLL patients with TP53 abnormalities." Leukemia 23(6): 1159-63. 
Myer, M. S., G. Joone, M. R. Chasen and C. E. van Rensburg (1999). "The 
chemosensitizing potential of GF120918 is independent of the magnitude of 
P-glycoprotein-mediated resistance to conventional chemotherapeutic agents 
in a small cell lung cancer line." Oncol Rep 6(1): 217-8. 
 320 
Nagane, M., H. Lin, W. K. Cavenee and H. J. Huang (2001). "Aberrant receptor 
signaling in human malignant gliomas: mechanisms and therapeutic 
implications." Cancer Lett 162 Suppl: S17-S21. 
Nagar, B. (2007). "c-Abl tyrosine kinase and inhibition by the cancer drug imatinib 
(Gleevec/STI-571)." J Nutr 137(6 Suppl 1): 1518S-1523S; discussion 1548S. 
Nakagawa, T., K. Ido, T. Sakuma, H. Takeuchi, K. Sato and T. Kubota (2009). 
"Prognostic significance of the immunohistochemical expression of O6-
methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug 
resistance protein-1 in glioblastomas." Neuropathology 29(4): 379-88. 
Nakanishi, T., J. E. Karp, M. Tan, L. A. Doyle, T. Peters, W. Yang, D. Wei and D. 
D. Ross (2003). "Quantitative analysis of breast cancer resistance protein and 
cellular resistance to flavopiridol in acute leukemia patients." Clin Cancer 
Res 9(9): 3320-8. 
Nam, E. J., H. Yoon, S. W. Kim, H. Kim, Y. T. Kim, J. H. Kim, J. W. Kim and S. 
Kim (2008). "MicroRNA expression profiles in serous ovarian carcinoma." 
Clin Cancer Res 14(9): 2690-5. 
Narayana, A., J. G. Golfinos, I. Fischer, S. Raza, P. Kelly, E. Parker, E. A. Knopp, 
P. Medabalmi, D. Zagzag, P. Eagan and M. L. Gruber (2008). "Feasibility of 
using bevacizumab with radiation therapy and temozolomide in newly 
diagnosed high-grade glioma." Int J Radiat Oncol Biol Phys 72(2): 383-9. 
Narayana, A., P. Kelly, J. Golfinos, E. Parker, G. Johnson, E. Knopp, D. Zagzag, I. 
Fischer, S. Raza, P. Medabalmi, P. Eagan and M. L. Gruber (2009). 
"Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: 
impact on local control and patient survival." J Neurosurg 110(1): 173-80. 
Nelson, P., M. Kiriakidou, A. Sharma, E. Maniataki and Z. Mourelatos (2003). "The 
microRNA world: small is mighty." Trends Biochem Sci 28(10): 534-40. 
Neshat, M. S., I. K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen, P. 
Frost, J. J. Gibbons, H. Wu and C. L. Sawyers (2001). "Enhanced sensitivity 
of PTEN-deficient tumors to inhibition of FRAP/mTOR." Proc Natl Acad 
Sci U S A 98(18): 10314-9. 
Newton, H. B. (2003). "Molecular neuro-oncology and development of targeted 
therapeutic strategies for brain tumors. Part 1: Growth factor and Ras 
signaling pathways." Expert Rev Anticancer Ther 3(5): 595-614. 
Newton, H. B. (2004). "Molecular neuro-oncology and the development of targeted 
therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness." 
Expert Rev Anticancer Ther 4(5): 803-21. 
Ng, E. K., W. P. Tsang, S. S. Ng, H. C. Jin, J. Yu, J. J. Li, C. Rocken, M. P. Ebert, 
T. T. Kwok and J. J. Sung (2009). "MicroRNA-143 targets DNA 
methyltransferases 3A in colorectal cancer." Br J Cancer 101(4): 699-706. 
Nies, A. T. (2007). "The role of membrane transporters in drug delivery to brain 
tumors." Cancer Lett 254(1): 11-29. 
Nister, M., L. Claesson-Welsh, A. Eriksson, C. H. Heldin and B. Westermark 
(1991). "Differential expression of platelet-derived growth factor receptors in 
human malignant glioma cell lines." J Biol Chem 266(25): 16755-63. 
Nord, H., C. Hartmann, R. Andersson, U. Menzel, S. Pfeifer, A. Piotrowski, A. 
Bogdan, W. Kloc, J. Sandgren, T. Olofsson, G. Hesselager, E. Blomquist, J. 
 321 
Komorowski, A. von Deimling, C. E. Bruder, J. P. Dumanski and T. Diaz de 
Stahl (2009). "Characterization of novel and complex genomic aberrations in 
glioblastoma using a 32K BAC array." Neuro Oncol 11(6): 803-18. 
Norden, A. D., J. Drappatz and P. Y. Wen (2008). "Antiangiogenic therapy in 
malignant gliomas." Curr Opin Oncol 20(6): 652-61. 
Ogiso, H., R. Ishitani, O. Nureki, S. Fukai, M. Yamanaka, J. H. Kim, K. Saito, A. 
Sakamoto, M. Inoue, M. Shirouzu and S. Yokoyama (2002). "Crystal 
structure of the complex of human epidermal growth factor and receptor 
extracellular domains." Cell 110(6): 775-87. 
Ohno, M., A. Natsume, Y. Kondo, H. Iwamizu, K. Motomura, H. Toda, M. Ito, T. 
Kato and T. Wakabayashi (2009). "The modulation of MicroRNAs by type I 
IFN through the activation of signal transducers and activators of 
transcription 3 in human glioma." Mol Cancer Res 7(12): 2022-30. 
Omuro, A. M., S. Faivre and E. Raymond (2007). "Lessons learned in the 
development of targeted therapy for malignant gliomas." Mol Cancer Ther 
6(7): 1909-19. 
Ostermann, S., C. Csajka, T. Buclin, S. Leyvraz, F. Lejeune, L. A. Decosterd and R. 
Stupp (2004). "Plasma and cerebrospinal fluid population pharmacokinetics 
of temozolomide in malignant glioma patients." Clin Cancer Res 10(11): 
3728-36. 
Ozen, M., C. J. Creighton, M. Ozdemir and M. Ittmann (2008). "Widespread 
deregulation of microRNA expression in human prostate cancer." Oncogene 
27(12): 1788-93. 
Paez, J. G., P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. 
Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, 
W. R. Sellers, B. E. Johnson and M. Meyerson (2004). "EGFR mutations in 
lung cancer: correlation with clinical response to gefitinib therapy." Science 
304(5676): 1497-500. 
Pan E, P. M. (2004). "Translational research in neuro-oncology." In: Perry MC, ed. 
Educational Book of the 40th Annual American Society of Clinical Oncology 
Meeting. 
Pao, W. and V. A. Miller (2005). "Epidermal growth factor receptor mutations, 
small-molecule kinase inhibitors, and non-small-cell lung cancer: current 
knowledge and future directions." J Clin Oncol 23(11): 2556-68. 
Papagiannakopoulos, T., A. Shapiro and K. S. Kosik (2008). "MicroRNA-21 targets 
a network of key tumor-suppressive pathways in glioblastoma cells." Cancer 
Res 68(19): 8164-72. 
Parmacek, M. S. (2009). "MicroRNA-modulated targeting of vascular smooth 
muscle cells." J Clin Invest 119(9): 2526-8. 
Pasquinelli, A. E., B. J. Reinhart, F. Slack, M. Q. Martindale, M. I. Kuroda, B. 
Maller, D. C. Hayward, E. E. Ball, B. Degnan, P. Muller, J. Spring, A. 
Srinivasan, M. Fishman, J. Finnerty, J. Corbo, M. Levine, P. Leahy, E. 
Davidson and G. Ruvkun (2000). "Conservation of the sequence and 
temporal expression of let-7 heterochronic regulatory RNA." Nature 
408(6808): 86-9. 
 322 
Paul Kleihues, W. K. C. (1997). Pathology and Genetics of tumours of the Nervous 
System. Lyon, International Agency for Research on Cancer, 150 Cours 
Albert Thomas, 69372 Lyon, France. 
Pelloski, C. E., E. Lin, L. Zhang, W. K. Yung, H. Colman, J. L. Liu, S. Y. Woo, A. 
B. Heimberger, D. Suki, M. Prados, S. Chang, F. G. Barker, 3rd, G. N. Fuller 
and K. D. Aldape (2006). "Prognostic associations of activated mitogen-
activated protein kinase and Akt pathways in glioblastoma." Clin Cancer Res 
12(13): 3935-41. 
Perry, J. R., K. Belanger, W. P. Mason, D. Fulton, P. Kavan, J. Easaw, C. Shields, S. 
Kirby, D. R. Macdonald, D. D. Eisenstat, B. Thiessen, P. Forsyth and J. F. 
Pouliot (2010). "Phase II trial of continuous dose-intense temozolomide in 
recurrent malignant glioma: RESCUE study." J Clin Oncol 28(12): 2051-7. 
Petrocca, F., R. Visone, M. R. Onelli, M. H. Shah, M. S. Nicoloso, I. de Martino, D. 
Iliopoulos, E. Pilozzi, C. G. Liu, M. Negrini, L. Cavazzini, S. Volinia, H. 
Alder, L. P. Ruco, G. Baldassarre, C. M. Croce and A. Vecchione (2008). 
"E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest 
and apoptosis in gastric cancer." Cancer Cell 13(3): 272-86. 
Pike, B. L., T. C. Greiner, X. Wang, D. D. Weisenburger, Y. H. Hsu, G. Renaud, T. 
G. Wolfsberg, M. Kim, D. J. Weisenberger, K. D. Siegmund, W. Ye, S. 
Groshen, R. Mehrian-Shai, J. Delabie, W. C. Chan, P. W. Laird and J. G. 
Hacia (2008). "DNA methylation profiles in diffuse large B-cell lymphoma 
and their relationship to gene expression status." Leukemia 22(5): 1035-43. 
Pinzani, M., S. Milani, H. Herbst, R. DeFranco, C. Grappone, A. Gentilini, A. 
Caligiuri, G. Pellegrini, D. V. Ngo, R. G. Romanelli and P. Gentilini (1996). 
"Expression of platelet-derived growth factor and its receptors in normal 
human liver and during active hepatic fibrogenesis." Am J Pathol 148(3): 
785-800. 
Pitman, M., B. Emery, M. Binder, S. Wang, H. Butzkueven and T. J. Kilpatrick 
(2004). "LIF receptor signaling modulates neural stem cell renewal." Mol 
Cell Neurosci 27(3): 255-66. 
Piva, R., P. Cavalla, S. Bortolotto, S. Cordera, P. Richiardi and D. Schiffer (1997). 
"p27/kip1 expression in human astrocytic gliomas." Neurosci Lett 234(2-3): 
127-30. 
Plosker, G. L. and M. Hurst (2001). "Paclitaxel: a pharmacoeconomic review of its 
use in non-small cell lung cancer." Pharmacoeconomics 19(11): 1111-34. 
Ponten, A., X. Li, P. Thoren, K. Aase, T. Sjoblom, A. Ostman and U. Eriksson 
(2003). "Transgenic overexpression of platelet-derived growth factor-C in 
the mouse heart induces cardiac fibrosis, hypertrophy, and dilated 
cardiomyopathy." Am J Pathol 163(2): 673-82. 
Prados, M. D., S. M. Chang, N. Butowski, R. DeBoer, R. Parvataneni, H. Carliner, 
P. Kabuubi, J. Ayers-Ringler, J. Rabbitt, M. Page, A. Fedoroff, P. K. Sneed, 
M. S. Berger, M. W. McDermott, A. T. Parsa, S. Vandenberg, C. D. James, 
K. R. Lamborn, D. Stokoe and D. A. Haas-Kogan (2009). "Phase II study of 
erlotinib plus temozolomide during and after radiation therapy in patients 
with newly diagnosed glioblastoma multiforme or gliosarcoma." J Clin 
Oncol 27(4): 579-84. 
 323 
Qin, Y., S. Chen, B. Jiang, Q. Jiang, H. Jiang, J. Li, L. Li, Y. Lai, Y. Liu and X. 
Huang (2010). "Characteristics of BCR-ABL kinase domain point mutations 
in Chinese imatinib-resistant chronic myeloid leukemia patients." Ann 
Hematol Epub ahead of print. 
Rabi, T. and A. Bishayee (2009). "d -Limonene sensitizes docetaxel-induced 
cytotoxicity in human prostate cancer cells: Generation of reactive oxygen 
species and induction of apoptosis." J Carcinog 8: 9. 
Ragel, B. T., W. T. Couldwell, D. L. Gillespie, M. M. Wendland, K. Whang and R. 
L. Jensen (2008). "A comparison of the cell lines used in meningioma 
research." Surg Neurol 70(3): 295-307; discussion 307. 
Ramnarain, D. B., S. Park, D. Y. Lee, K. J. Hatanpaa, S. O. Scoggin, H. Otu, T. A. 
Libermann, J. M. Raisanen, R. Ashfaq, E. T. Wong, J. Wu, R. Elliott and A. 
A. Habib (2006). "Differential gene expression analysis reveals generation of 
an autocrine loop by a mutant epidermal growth factor receptor in glioma 
cells." Cancer Res 66(2): 867-74. 
Rauch, T., H. Li, X. Wu and G. P. Pfeifer (2006). "MIRA-assisted microarray 
analysis, a new technology for the determination of DNA methylation 
patterns, identifies frequent methylation of homeodomain-containing genes 
in lung cancer cells." Cancer Res 66(16): 7939-47. 
Raymond, E., A. A. Brandes, C. Dittrich, P. Fumoleau, B. Coudert, P. M. Clement, 
M. Frenay, R. Rampling, R. Stupp, J. M. Kros, M. C. Heinrich, T. Gorlia, D. 
Lacombe and M. J. van den Bent (2008). "Phase II study of imatinib in 
patients with recurrent gliomas of various histologies: a European 
Organisation for Research and Treatment of Cancer Brain Tumor Group 
Study." J Clin Oncol 26(28): 4659-65. 
Reinhart, B. J., F. J. Slack, M. Basson, A. E. Pasquinelli, J. C. Bettinger, A. E. 
Rougvie, H. R. Horvitz and G. Ruvkun (2000). "The 21-nucleotide let-7 
RNA regulates developmental timing in Caenorhabditis elegans." Nature 
403(6772): 901-6. 
Ren, H., X. Tan, Y. Dong, A. Giese, T. C. Chou, N. Rainov and B. Yang (2009). 
"Differential effect of imatinib and synergism of combination treatment with 
chemotherapeutic agents in malignant glioma cells." Basic Clin Pharmacol 
Toxicol 104(3): 241-52. 
Ridley, A. J., M. A. Schwartz, K. Burridge, R. A. Firtel, M. H. Ginsberg, G. Borisy, 
J. T. Parsons and A. R. Horwitz (2003). "Cell migration: integrating signals 
from front to back." Science 302(5651): 1704-9. 
Riemenschneider, M. J., R. A. Betensky, S. M. Pasedag and D. N. Louis (2006). 
"AKT activation in human glioblastomas enhances proliferation via TSC2 
and S6 kinase signaling." Cancer Res 66(11): 5618-23. 
Risau, W., H. Drexler, V. Mironov, A. Smits, A. Siegbahn, K. Funa and C. H. 
Heldin (1992). "Platelet-derived growth factor is angiogenic in vivo." 
Growth Factors 7(4): 261-6. 
Rivera, A. L., C. E. Pelloski, M. R. Gilbert, H. Colman, C. De La Cruz, E. P. 
Sulman, B. N. Bekele and K. D. Aldape (2010). "MGMT promoter 
methylation is predictive of response to radiotherapy and prognostic in the 
 324 
absence of adjuvant alkylating chemotherapy for glioblastoma." Neuro Oncol 
12(2): 116-21. 
Rooprai, H. K., T. E. van Meter, S. D. Robinson, A. King, G. J. Rucklidge and G. J. 
Pilkington (2003). "Expression of MMP-2 and -9 in short-term cultures of 
meningioma: influence of histological subtype." Int J Mol Med 12(6): 977-
81. 
Roth, W., C. Grimmel, L. Rieger, H. Strik, S. Takayama, S. Krajewski, R. 
Meyermann, J. Dichgans, J. C. Reed and M. Weller (2000). "Bag-1 and Bcl-
2 gene transfer in malignant glioma: modulation of cell cycle regulation and 
apoptosis." Brain Pathol 10(2): 223-34. 
Rudek, M. A., R. C. Donehower, P. Statkevich, V. K. Batra, D. L. Cutler and S. D. 
Baker (2004). "Temozolomide in patients with advanced cancer: phase I and 
pharmacokinetic study." Pharmacotherapy 24(1): 16-25. 
Rxlist http://www.rxlist.com. 
Salvi, A., C. Sabelli, S. Moncini, M. Venturin, B. Arici, P. Riva, N. Portolani, S. M. 
Giulini, G. De Petro and S. Barlati (2009). "MicroRNA-23b mediates 
urokinase and c-met downmodulation and a decreased migration of human 
hepatocellular carcinoma cells." Febs J 276(11): 2966-82. 
Sampath, P., L. D. Rhines, F. DiMeco, B. M. Tyler, M. C. Park and H. Brem (2006). 
"Interstitial docetaxel (Taxotere), carmustine and combined interstitial 
therapy: a novel treatment for experimental malignant glioma." Journal of 
Neuro-Oncology 80(1): 9-17. 
Sampson, J. H., G. Akabani, G. E. Archer, D. D. Bigner, M. S. Berger, A. H. 
Friedman, H. S. Friedman, J. E. Herndon, 2nd, S. Kunwar, S. Marcus, R. E. 
McLendon, A. Paolino, K. Penne, J. Provenzale, J. Quinn, D. A. Reardon, J. 
Rich, T. Stenzel, S. Tourt-Uhlig, C. Wikstrand, T. Wong, R. Williams, F. 
Yuan, M. R. Zalutsky and I. Pastan (2003). "Progress report of a Phase I 
study of the intracerebral microinfusion of a recombinant chimeric protein 
composed of transforming growth factor (TGF)-alpha and a mutated form of 
the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of 
malignant brain tumors." J Neurooncol 65(1): 27-35. 
Sanger "www.microrna.sanger.ac.uk/sequences." 
Sanson, M., M. Napolitano, R. Yaya, F. Keime-Guibert, P. Broet, K. Hoang-Xuan 
and J. Y. Delattre (2000). "Second line chemotherapy with docetaxel in 
patients with recurrent malignant glioma: a phase II study." J Neurooncol 
50(3): 245-9. 
Sarkaria, J. N., L. Yang, P. T. Grogan, G. J. Kitange, B. L. Carlson, M. A. 
Schroeder, E. Galanis, C. Giannini, W. Wu, E. B. Dinca and C. D. James 
(2007). "Identification of molecular characteristics correlated with 
glioblastoma sensitivity to EGFR kinase inhibition through use of an 
intracranial xenograft test panel." Mol Cancer Ther 6(3): 1167-74. 
Sasayama, T., M. Nishihara, T. Kondoh, K. Hosoda and E. Kohmura (2009). 
"MicroRNA-10b is overexpressed in malignant glioma and associated with 
tumor invasive factors, uPAR and RhoC." Int J Cancer 125(6): 1407-13. 
 325 
Saxena, A., L. M. Shriml, M. Dean and I. U. Ali (1999). "Comparative molecular 
genetic profiles of anaplastic astrocytomas/glioblastomas multiforme and 
their subsequent recurrences." Oncogene 18(6): 1385-90. 
Schaich, M., L. Kestel, M. Pfirrmann, K. Robel, T. Illmer, M. Kramer, C. Dill, G. 
Ehninger, G. Schackert and D. Krex (2009). "A MDR1 (ABCB1) gene single 
nucleotide polymorphism predicts outcome of temozolomide treatment in 
glioblastoma patients." Ann Oncol 20(1): 175-81. 
Schlenska-Lange, A., H. Knupfer, T. J. Lange, W. Kiess and M. Knupfer (2008). 
"Cell proliferation and migration in glioblastoma multiforme cell lines are 
influenced by insulin-like growth factor I in vitro." Anticancer Res 28(2A): 
1055-60. 
Schlessinger, J. (1993). "How Receptor Tyrosine Kinases Activate Ras." Trends in 
Biochemical Sciences 18(8): 273-275. 
Schlessinger, J. (2000). "Cell signaling by receptor tyrosine kinases." Cell 103(2): 
211-25. 
Schmelzle, T. and M. N. Hall (2000). "TOR, a central controller of cell growth." 
Cell 103(2): 253-62. 
Schratt, G. M., F. Tuebing, E. A. Nigh, C. G. Kane, M. E. Sabatini, M. Kiebler and 
M. E. Greenberg (2006). "A brain-specific microRNA regulates dendritic 
spine development." Nature 439(7074): 283-9. 
Schwarz, D. S., G. Hutvagner, T. Du, Z. Xu, N. Aronin and P. D. Zamore (2003). 
"Asymmetry in the assembly of the RNAi enzyme complex." Cell 115(2): 
199-208. 
Seeliger, H., M. Guba, A. Kleespies, K. W. Jauch and C. J. Bruns (2007). "Role of 
mTOR in solid tumor systems: a therapeutical target against primary tumor 
growth, metastases, and angiogenesis." Cancer Metastasis Rev 26(3-4): 611-
21. 
Segura, M. F., D. Hanniford, S. Menendez, L. Reavie, X. Zou, S. Alvarez-Diaz, J. 
Zakrzewski, E. Blochin, A. Rose, D. Bogunovic, D. Polsky, J. Wei, P. Lee, I. 
Belitskaya-Levy, N. Bhardwaj, I. Osman and E. Hernando (2009). "Aberrant 
miR-182 expression promotes melanoma metastasis by repressing FOXO3 
and microphthalmia-associated transcription factor." Proc Natl Acad Sci U S 
A 106(6): 1814-9. 
Semenza, G. L. (2003). "Targeting HIF-1 for cancer therapy." Nat Rev Cancer 
3(10): 721-32. 
Servidei, T., A. Riccardi, M. Sanguinetti, C. Dominici and R. Riccardi (2006). 
"Increased sensitivity to the platelet-derived growth factor (PDGF) receptor 
inhibitor STI571 in chemoresistant glioma cells is associated with enhanced 
PDGF-BB-mediated signaling and STI571-induced Akt inactivation." J Cell 
Physiol 208(1): 220-8. 
Shaw, R. J. and L. C. Cantley (2006). "Ras, PI(3)K and mTOR signalling controls 
tumour cell growth." Nature 441(7092): 424-30. 
Sherbenou, D. W. and B. J. Druker (2007). "Applying the discovery of the 
Philadelphia chromosome." J Clin Invest 117(8): 2067-74. 
Sherbenou, D. W., O. Hantschel, I. Kaupe, S. Willis, T. Bumm, L. P. Turaga, T. 
Lange, K. H. Dao, R. D. Press, B. J. Druker, G. Superti-Furga and M. W. 
 326 
Deininger (2010). "BCR-ABL SH3-SH2 domain mutations in chronic 
myeloid leukemia patients on imatinib." Blood 116(17): 3278-85. 
Shi, L., Z. Cheng, J. Zhang, R. Li, Y. You and Z. Fu (2008). "[The mechanism of 
apoptosis in human U87 glioma cells induced by miR-21 antisense 
oligonucleotide]." Zhonghua Yi Xue Yi Chuan Xue Za Zhi 25(5): 497-501. 
Shi, L., Z. Cheng, J. Zhang, R. Li, P. Zhao, Z. Fu and Y. You (2008). "hsa-mir-181a 
and hsa-mir-181b function as tumor suppressors in human glioma cells." 
Brain Res 1236: 185-93. 
Shingu, T., K. Fujiwara, O. Bogler, Y. Akiyama, K. Moritake, N. Shinojima, Y. 
Tamada, T. Yokoyama and S. Kondo (2009). "Inhibition of autophagy at a 
late stage enhances imatinib-induced cytotoxicity in human malignant glioma 
cells." Int J Cancer 124(5): 1060-71. 
Shinojima, N., K. Tada, S. Shiraishi, T. Kamiryo, M. Kochi, H. Nakamura, K. 
Makino, H. Saya, H. Hirano, J. Kuratsu, K. Oka, Y. Ishimaru and Y. Ushio 
(2003). "Prognostic value of epidermal growth factor receptor in patients 
with glioblastoma multiforme." Cancer Res 63(20): 6962-70. 
Shlens, J. (2009). A Tutorial on Principal Component Analysis: 
http://www.snl.salk.edu/~shlens/pca.pdf. 
Shteper, P. J. and D. Ben-Yehuda (2001). "Molecular evolution of chronic myeloid 
leukaemia." Semin Cancer Biol 11(4): 313-23. 
Silber, J., D. A. Lim, C. Petritsch, A. I. Persson, A. K. Maunakea, M. Yu, S. R. 
Vandenberg, D. G. Ginzinger, C. D. James, J. F. Costello, G. Bergers, W. A. 
Weiss, A. Alvarez-Buylla and J. G. Hodgson (2008). "miR-124 and miR-137 
inhibit proliferation of glioblastoma multiforme cells and induce 
differentiation of brain tumor stem cells." BMC Med 6: 14. 
Smalheiser, N. R. (2003). "EST analyses predict the existence of a population of 
chimeric microRNA precursor-mRNA transcripts expressed in normal 
human and mouse tissues." Genome Biol 4(7): 403. 
Smith, J. S., X. Y. Wang, J. Qian, S. M. Hosek, B. W. Scheithauer, R. B. Jenkins 
and C. D. James (2000). "Amplification of the platelet-derived growth factor 
receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV 
anaplastic features." J Neuropathol Exp Neurol 59(6): 495-503. 
Solomon, D. A., J. S. Kim, J. C. Cronin, Z. Sibenaller, T. Ryken, S. A. Rosenberg, 
H. Ressom, W. Jean, D. Bigner, H. Yan, Y. Samuels and T. Waldman 
(2008). "Mutational inactivation of PTPRD in glioblastoma multiforme and 
malignant melanoma." Cancer Res 68(24): 10300-6. 
Sordella, R., D. W. Bell, D. A. Haber and J. Settleman (2004). "Gefitinib-sensitizing 
EGFR mutations in lung cancer activate anti-apoptotic pathways." Science 
305(5687): 1163-7. 
Spizzo, R., M. S. Nicoloso, L. Lupini, Y. Lu, J. Fogarty, S. Rossi, B. Zagatti, M. 
Fabbri, A. Veronese, X. Liu, R. Davuluri, C. M. Croce, G. Mills, M. Negrini 
and G. A. Calin (2009). "miR-145 participates with TP53 in a death-
promoting regulatory loop and targets estrogen receptor-alpha in human 
breast cancer cells." Cell Death Differ 17(2): 246-54. 
 327 
Stanulla, M., K. Welte, M. R. Hadam and T. Pietsch (1995). "Coexpression of stem 
cell factor and its receptor c-Kit in human malignant glioma cell lines." Acta 
Neuropathol 89(2): 158-65. 
Stokvis, E., H. Rosing, R. C. Causon, J. H. Schellens and J. H. Beijnen (2004). 
"Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) 
in human and dog plasma using liquid chromatography with tandem mass 
spectrometric detection." J Mass Spectrom 39(10): 1122-30. 
Stupp, R., P. Y. Dietrich, S. Ostermann Kraljevic, A. Pica, I. Maillard, P. Maeder, R. 
Meuli, R. Janzer, G. Pizzolato, R. Miralbell, F. Porchet, L. Regli, N. de 
Tribolet, R. O. Mirimanoff and S. Leyvraz (2002). "Promising survival for 
patients with newly diagnosed glioblastoma multiforme treated with 
concomitant radiation plus temozolomide followed by adjuvant 
temozolomide." J Clin Oncol 20(5): 1375-82. 
Stupp, R., M. E. Hegi, B. Neyns, R. Goldbrunner, U. Schlegel, P. M. Clement, G. G. 
Grabenbauer, A. F. Ochsenbein, M. Simon, P. Y. Dietrich, T. Pietsch, C. 
Hicking, J. C. Tonn, A. C. Diserens, A. Pica, M. Hermisson, S. Krueger, M. 
Picard and M. Weller (2010). "Phase I/IIa study of cilengitide and 
temozolomide with concomitant radiotherapy followed by cilengitide and 
temozolomide maintenance therapy in patients with newly diagnosed 
glioblastoma." J Clin Oncol 28(16): 2712-8. 
Stupp, R., W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, 
K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. 
Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, 
E. Eisenhauer and R. O. Mirimanoff (2005). "Radiotherapy plus concomitant 
and adjuvant temozolomide for glioblastoma." N Engl J Med 352(10): 987-
96. 
Sun, J., S. L. Zheng, F. Wiklund, S. D. Isaacs, G. Li, K. E. Wiley, S. T. Kim, Y. 
Zhu, Z. Zhang, F. C. Hsu, A. R. Turner, P. Stattin, W. Liu, J. W. Kim, D. 
Duggan, J. Carpten, W. Isaacs, H. Gronberg, J. Xu and B. L. Chang (2009). 
"Sequence variants at 22q13 are associated with prostate cancer risk." 
Cancer Res 69(1): 10-5. 
Sun, L., A. M. Hui, Q. Su, A. Vortmeyer, Y. Kotliarov, S. Pastorino, A. Passaniti, J. 
Menon, J. Walling, R. Bailey, M. Rosenblum, T. Mikkelsen and H. A. Fine 
(2006). "Neuronal and glioma-derived stem cell factor induces angiogenesis 
within the brain." Cancer Cell 9(4): 287-300. 
Swaisland, H. C., R. P. Smith, A. Laight, D. J. Kerr, M. Ranson, C. H. Wilder-Smith 
and T. Duvauchelle (2005). "Single-dose clinical pharmacokinetic studies of 
gefitinib." Clin Pharmacokinet 44(11): 1165-77. 
Takano, S., T. Yamashita and O. Ohneda (2010). "Molecular therapeutic targets for 
glioma angiogenesis." J Oncol: 351908. 
Tang, X., L. Wang, C. G. Proud and C. P. Downes (2003). "Muscarinic receptor-
mediated activation of p70 S6 kinase 1 (S6K1) in 1321N1 astrocytoma cells: 
permissive role of phosphoinositide 3-kinase." Biochem J 374(Pt 1): 137-43. 
Torp, S. H., E. Helseth, A. Dalen and G. Unsgaard (1991). "Epidermal growth factor 
receptor expression in human gliomas." Cancer Immunol Immunother 33(1): 
61-4. 
 328 
Toth, K., M. M. Vaughan, N. S. Peress, H. K. Slocum and Y. M. Rustum (1996). 
"MDR1 P-glycoprotein is expressed by endothelial cells of newly formed 
capillaries in human gliomas but is not expressed in the neovasculature of 
other primary tumors." Am J Pathol 149(3): 853-8. 
Toyofuku, T., H. Zhang, A. Kumanogoh, N. Takegahara, F. Suto, J. Kamei, K. Aoki, 
M. Yabuki, M. Hori, H. Fujisawa and H. Kikutani (2004). "Dual roles of 
Sema6D in cardiac morphogenesis through region-specific association of its 
receptor, Plexin-A1, with off-track and vascular endothelial growth factor 
receptor type 2." Genes Dev 18(4): 435-47. 
Tryndyak, V. P., S. A. Ross, F. A. Beland and I. P. Pogribny (2009). "Down-
regulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver 
during hepatocarcinogenesis induced by a methyl-deficient diet." Mol 
Carcinog 48(6): 479-87. 
Tsuda, H., H. Jafar-Nejad, A. J. Patel, Y. Sun, H. K. Chen, M. F. Rose, K. J. 
Venken, J. Botas, H. T. Orr, H. J. Bellen and H. Y. Zoghbi (2005). "The 
AXH domain of Ataxin-1 mediates neurodegeneration through its interaction 
with Gfi-1/Senseless proteins." Cell 122(4): 633-44. 
Tyagi, D., B. S. Sharma, S. K. Gupta, D. Kaul, R. K. Vasishta and V. K. Khosla 
(2002). "Expression of Bcl2 proto-oncogene in primary tumors of the central 
nervous system." Neurol India 50(3): 290-4. 
Ulasov, I. V., S. Nandi, M. Dey, A. M. Sonabend and M. S. Lesniak (2010). 
"Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of 
CD133(+) glioma stem cells to temozolomide therapy." Mol Med Epub 
ahead of print. 
Valera, E. T., A. K. Lucio-Eterovic, L. Neder, C. A. Scrideli, H. R. Machado, C. G. 
Carlotti-Junior, R. G. Queiroz, F. J. Motta and L. G. Tone (2007). 
"Quantitative PCR analysis of the expression profile of genes related to 
multiple drug resistance in tumors of the central nervous system." J 
Neurooncol 85(1): 1-10. 
van den Bent, M. J., A. A. Brandes, R. Rampling, M. C. Kouwenhoven, J. M. Kros, 
A. F. Carpentier, P. M. Clement, M. Frenay, M. Campone, J. F. Baurain, J. P. 
Armand, M. J. Taphoorn, A. Tosoni, H. Kletzl, B. Klughammer, D. Lacombe 
and T. Gorlia (2009). "Randomized phase II trial of erlotinib versus 
temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor 
group study 26034." J Clin Oncol 27(8): 1268-74. 
van den Heuvel-Eibrink, M. M., B. van der Holt, A. K. Burnett, W. U. Knauf, M. F. 
Fey, G. E. Verhoef, E. Vellenga, G. J. Ossenkoppele, B. Lowenberg and P. 
Sonneveld (2007). "CD34-related coexpression of MDR1 and BCRP 
indicates a clinically resistant phenotype in patients with acute myeloid 
leukemia (AML) of older age." Ann Hematol 86(5): 329-37. 
Van Meir EG, H. C., Norden AD, Shu HK, Wen PY, Olson JJ. (2010). "Exciting 
new advances in neuro-oncology: the avenue to a cure for malignant 
glioma." CA Cancer J Clin. 60(3): 166-93. 
Van Meter, T. E., W. C. Broaddus, H. K. Rooprai, G. J. Pilkington and H. L. 
Fillmore (2004). "Induction of membrane-type-1 matrix metalloproteinase by 
 329 
epidermal growth factor-mediated signaling in gliomas." Neuro Oncol 6(3): 
188-99. 
Vanhoutteghem, A. and P. Djian (2007). "The human basonuclin 2 gene has the 
potential to generate nearly 90,000 mRNA isoforms encoding over 2000 
different proteins." Genomics 89(1): 44-58. 
Veeriah, S., C. Brennan, S. Meng, B. Singh, J. A. Fagin, D. B. Solit, P. B. Paty, D. 
Rohle, I. Vivanco, J. Chmielecki, W. Pao, M. Ladanyi, W. L. Gerald, L. 
Liau, T. C. Cloughesy, P. S. Mischel, C. Sander, B. Taylor, N. Schultz, J. 
Major, A. Heguy, F. Fang, I. K. Mellinghoff and T. A. Chan (2009). "The 
tyrosine phosphatase PTPRD is a tumor suppressor that is frequently 
inactivated and mutated in glioblastoma and other human cancers." Proc Natl 
Acad Sci U S A 106(23): 9435-40. 
Virtua trials www.virtualtrials.com. 
Vollmann, A., H. P. Vornlocher, T. Stempfl, G. Brockhoff, R. Apfel and U. 
Bogdahn (2006). "Effective silencing of EGFR with RNAi demonstrates 
non-EGFR dependent proliferation of glioma cells." Int J Oncol 28(6): 1531-
42. 
Wagenknecht, B., T. Glaser, U. Naumann, S. Kugler, S. Isenmann, M. Bahr, R. 
Korneluk, P. Liston and M. Weller (1999). "Expression and biological 
activity of X-linked inhibitor of apoptosis (XIAP) in human malignant 
glioma." Cell Death Differ 6(4): 370-6. 
Wang, J., X. Wang, S. Jiang, P. Lin, J. Zhang, Y. Wu, Z. Xiong, J. J. Ren and H. 
Yang (2008). "Partial biological characterization of cancer stem-like cell line 
(WJ(2)) of human glioblastoma multiforme." Cell Mol Neurobiol 28(7): 991-
1003. 
Wang, X., S. Tang, S. Y. Le, R. Lu, J. S. Rader, C. Meyers and Z. M. Zheng (2008). 
"Aberrant expression of oncogenic and tumor-suppressive microRNAs in 
cervical cancer is required for cancer cell growth." PLoS One 3(7): e2557. 
Weiss, F. U., I. J. Marques, J. M. Woltering, D. H. Vlecken, A. Aghdassi, L. I. 
Partecke, C. D. Heidecke, M. M. Lerch and C. P. Bagowski (2009). 
"Retinoic acid receptor antagonists inhibit miR-10a expression and block 
metastatic behavior of pancreatic cancer." Gastroenterology 137(6): 2136-45 
e1-7. 
Wen, P. Y., W. K. Yung, K. R. Lamborn, P. L. Dahia, Y. Wang, B. Peng, L. E. 
Abrey, J. Raizer, T. F. Cloughesy, K. Fink, M. Gilbert, S. Chang, L. Junck, 
D. Schiff, F. Lieberman, H. A. Fine, M. Mehta, H. I. Robins, L. M. 
DeAngelis, M. D. Groves, V. K. Puduvalli, V. Levin, C. Conrad, E. A. 
Maher, K. Aldape, M. Hayes, L. Letvak, M. J. Egorin, R. Capdeville, R. 
Kaplan, A. J. Murgo, C. Stiles and M. D. Prados (2006). "Phase I/II study of 
imatinib mesylate for recurrent malignant gliomas: North American Brain 
Tumor Consortium Study 99-08." Clin Cancer Res 12(16): 4899-907. 
Westermark, B., C. H. Heldin and M. Nister (1995). "Platelet-derived growth factor 
in human glioma." Glia 15(3): 257-63. 
Wilcox, J. N., K. M. Smith, L. T. Williams, S. M. Schwartz and D. Gordon (1988). 
"Platelet-derived growth factor mRNA detection in human atherosclerotic 
plaques by in situ hybridization." J Clin Invest 82(3): 1134-43. 
 330 
Wong, A. J., S. H. Bigner, D. D. Bigner, K. W. Kinzler, S. R. Hamilton and B. 
Vogelstein (1987). "Increased expression of the epidermal growth factor 
receptor gene in malignant gliomas is invariably associated with gene 
amplification." Proc Natl Acad Sci U S A 84(19): 6899-903. 
Wong, M. L., A. H. Kaye and C. M. Hovens (2007). "Targeting malignant glioma 
survival signalling to improve clinical outcomes." J Clin Neurosci 14(4): 
301-8. 
Wong, S. and O. N. Witte (2004). "The BCR-ABL story: bench to bedside and 
back." Annu Rev Immunol 22: 247-306. 
Woods, S. A., E. Marmor, M. Feldkamp, N. Lau, A. J. Apicelli, G. Boss, D. H. 
Gutmann and A. Guha (2002). "Aberrant G protein signaling in nervous 
system tumors." J Neurosurg 97(3): 627-42. 
Wu, X., K. Senechal, M. S. Neshat, Y. E. Whang and C. L. Sawyers (1998). "The 
PTEN/MMAC1 tumor suppressor phosphatase functions as a negative 
regulator of the phosphoinositide 3-kinase/Akt pathway." Proc Natl Acad Sci 
U S A 95(26): 15587-91. 
Wurdinger, T., B. A. Tannous, O. Saydam, J. Skog, S. Grau, J. Soutschek, R. 
Weissleder, X. O. Breakefield and A. M. Krichevsky (2008). "miR-296 
regulates growth factor receptor overexpression in angiogenic endothelial 
cells." Cancer Cell 14(5): 382-93. 
Xia, H., Y. Qi, S. S. Ng, X. Chen, S. Chen, M. Fang, D. Li, Y. Zhao, R. Ge, G. Li, 
Y. Chen, M. L. He, H. F. Kung, L. Lai and M. C. Lin (2009). "MicroRNA-
15b regulates cell cycle progression by targeting cyclins in glioma cells." 
Biochem Biophys Res Commun 380(2): 205-10. 
Xia, H., Y. Qi, S. S. Ng, X. Chen, D. Li, S. Chen, R. Ge, S. Jiang, G. Li, Y. Chen, 
M. L. He, H. F. Kung, L. Lai and M. C. Lin (2009). "microRNA-146b 
inhibits glioma cell migration and invasion by targeting MMPs." Brain Res 
1269: 158-65. 
Xia, H. F., T. Z. He, C. M. Liu, Y. Cui, P. P. Song, X. H. Jin and X. Ma (2009). 
"MiR-125b expression affects the proliferation and apoptosis of human 
glioma cells by targeting Bmf." Cell Physiol Biochem 23(4-6): 347-58. 
Xie, D., D. Yin, H. J. Wang, G. T. Liu, R. Elashoff, K. Black and H. P. Koeffler 
(2004). "Levels of expression of CYR61 and CTGF are prognostic for tumor 
progression and survival of individuals with gliomas." Clin Cancer Res 
10(6): 2072-81. 
Yamada, H., K. Yanagisawa, S. Tokumaru, A. Taguchi, Y. Nimura, H. Osada, M. 
Nagino and T. Takahashi (2008). "Detailed characterization of a 
homozygously deleted region corresponding to a candidate tumor suppressor 
locus at 21q11-21 in human lung cancer." Genes Chromosomes Cancer 
47(9): 810-8. 
Yamamoto, N., A. Horiike, Y. Fujisaka, H. Murakami, T. Shimoyama, Y. Yamada 
and T. Tamura (2008). "Phase I dose-finding and pharmacokinetic study of 
the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-
8231 (erlotinib) in Japanese patients with solid tumors." Cancer Chemother 
Pharmacol 61(3): 489-96. 
 331 
Yan, L. X., X. F. Huang, Q. Shao, M. Y. Huang, L. Deng, Q. L. Wu, Y. X. Zeng and 
J. Y. Shao (2008). "MicroRNA miR-21 overexpression in human breast 
cancer is associated with advanced clinical stage, lymph node metastasis and 
patient poor prognosis." Rna 14(11): 2348-60. 
Yeung, M. L., J. Yasunaga, Y. Bennasser, N. Dusetti, D. Harris, N. Ahmad, M. 
Matsuoka and K. T. Jeang (2008). "Roles for microRNAs, miR-93 and miR-
130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in 
cell growth dysregulation by human T-cell lymphotrophic virus 1." Cancer 
Res 68(21): 8976-85. 
Yi, R., Y. Qin, I. G. Macara and B. R. Cullen (2003). "Exportin-5 mediates the 
nuclear export of pre-microRNAs and short hairpin RNAs." Genes Dev 
17(24): 3011-6. 
Yoh, K., G. Ishii, T. Yokose, Y. Minegishi, K. Tsuta, K. Goto, Y. Nishiwaki, T. 
Kodama, M. Suga and A. Ochiai (2004). "Breast cancer resistance protein 
impacts clinical outcome in platinum-based chemotherapy for advanced non-
small cell lung cancer." Clin Cancer Res 10(5): 1691-7. 
Zandi, R., A. B. Larsen, P. Andersen, M. T. Stockhausen and H. S. Poulsen (2007). 
"Mechanisms for oncogenic activation of the epidermal growth factor 
receptor." Cell Signal 19(10): 2013-23. 
Zerbe, L. K., L. D. Dwyer-Nield, J. M. Fritz, E. F. Redente, R. J. Shroyer, E. 
Conklin, S. Kane, C. Tucker, S. G. Eckhardt, D. L. Gustafson, K. K. Iwata 
and A. M. Malkinson (2008). "Inhibition by erlotinib of primary lung 
adenocarcinoma at an early stage in male mice." Cancer Chemother 
Pharmacol 62(4): 605-20. 
Zhang, C., C. Kang, Y. You, P. Pu, W. Yang, P. Zhao, G. Wang, A. Zhang, Z. Jia, 
L. Han and H. Jiang (2009). "Co-suppression of miR-221/222 cluster 
suppresses human glioma cell growth by targeting p27kip1 in vitro and in 
vivo." Int J Oncol 34(6): 1653-60. 
Zhang, C. Z., C. S. Kang, P. Y. Pu, G. X. Wang, Z. F. Jia, A. L. Zhang, L. Han and 
P. Xu (2009). "[Inhibitory effect of knocking down microRNA-221 and 
microRNA-222 on glioma cell growth in vitro and in vivo]." Zhonghua 
Zhong Liu Za Zhi 31(10): 721-6. 
Zhang, X., S. Liu, T. Hu, Y. He and S. Sun (2009). "Up-regulated microRNA-143 
transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis 
by repressing fibronectin expression." Hepatology 50(2): 490-9. 
Zhang, Y., T. Chao, R. Li, W. Liu, Y. Chen, X. Yan, Y. Gong, B. Yin, B. Qiang, J. 
Zhao, J. Yuan and X. Peng (2009). "MicroRNA-128 inhibits glioma cells 
proliferation by targeting transcription factor E2F3a." J Mol Med 87(1): 43-
51. 
Zhou, X., Y. Ren, L. Moore, M. Mei, Y. You, P. Xu, B. Wang, G. Wang, Z. Jia, P. 
Pu, W. Zhang and C. Kang (2010) "Downregulation of miR-21 inhibits 
EGFR pathway and suppresses the growth of human glioblastoma cells 
independent of PTEN status." Lab Invest 90(2): 144-55. 
Zhu, S., M. L. Si, H. Wu and Y. Y. Mo (2007). "MicroRNA-21 targets the tumor 
suppressor gene tropomyosin 1 (TPM1)." J Biol Chem 282(19): 14328-36. 
 332 
Zhuo, Y., J. Zhang, M. Laboy and J. A. Lasky (2004). "Modulation of PDGF-C and 
PDGF-D expression during bleomycin-induced lung fibrosis." Am J Physiol 
Lung Cell Mol Physiol 286(1): L182-8. 
Ziegler, D. S., R. D. Wright, S. Kesari, M. E. Lemieux, M. A. Tran, M. Jain, L. 
Zawel and A. L. Kung (2008). "Resistance of human glioblastoma 
multiforme cells to growth factor inhibitors is overcome by blockade of 
inhibitor of apoptosis proteins." J Clin Invest 118(9): 3109-22. 
Zimonjic, D. B., M. E. Durkin, C. L. Keck-Waggoner, S. W. Park, S. S. 
Thorgeirsson and N. C. Popescu (2003). "SMAD5 gene expression, 
rearrangements, copy number, and amplification at fragile site FRA5C in 
human hepatocellular carcinoma." Neoplasia 5(5): 390-6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
